[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmizQz7MdIkAsY1xuSj2oTVI-wJvL6nZkJhHEJll20uM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"University of Colorado, Denver",[4],1514,false,378,49,2302784,154,1035,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Obesity",70,{"name":18,"count":19},"Type 1 Diabetes",30,{"name":21,"count":22},"Breast Cancer",28,{"name":24,"count":25},"Type 2 Diabetes",23,{"name":27,"count":28},"Aging",20,{"name":30,"count":31},"Parkinson Disease",18,{"name":33,"count":34},"Diabetes",17,{"name":36,"count":37},"Multiple Sclerosis",16,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04650321","Home Based Infusions for Ocrelizumab","2021-08-31","Ocrelizumab at home",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT02955394","Preoperative Fulvestrant With or Without Enzalutamide in ER+\u002FHer2- Breast Cancer","2023-02-17","Enzalutamide",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05498103","Use of Methazolamide to Lower Intraocular Pressure","2023-09-14","Methazolamide 25 MG",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT02653092","Reprometabolic Syndrome Mediates Subfertility in Obesity","2023-12-11","Insulin",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT03273413","Statin Therapy in Patients With Early Stage ADPKD","2024-03-25","Pravastatin",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT03970226","Tocilizumab in Children With ACP","2024-05-26","Tocilizumab",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04149470","Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)","2024-08","Omeprazole 20mg BID",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04925193","Personalized Selinexor-based Therapy for Relapsed\u002FRefractory Multiple Myeloma","2024-08-06","Selinexor",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06565572","Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1","2024-08-21","nL-FLVC-001",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT05057546","Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)","2024-09-18","GnRH antagonist",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,147,197,234,268,295,321,340,366,391,419,440,465,489,515,533,554,572,599,617,690,741,789,847,878,900,993,1077,1106,1147,1175,1193,1211,1229,1247,1265,1291,1309,1336,1360,1386,1411,1437,1478,1547,1586,1679,1731,1780,1837,1874,1905,2003,2085,2122,2159,2191,2229,2255,2292,2314,2354,2391,2416,2434,2461,2485,2509,2532,2558,2576,2594,2621,2643,2667,2690,2708,2759,2777,2795,2813,2831,2849,2874,2892,2910,2934,2952,2970,2996,3022,3040,3063,3081,3104,3131,3149,3167,3185,3203,3221,3239,3257,3281,3299,3317,3341,3363,3381,3406,3448,3490,3524,3557,3586,3632,3656,3674,3699,3724,3742,3764,3790,3818,3845,3863,3888,3906,3924,3942,3966,3990,4008,4034,4052,4072,4093,4117,4147,4203,4230,4269,4293,4318,4341,4359,4386,4411,4429,4447,4465,4483,4510,4528,4546,4584,4612,4647,4675,4706,4740,4774,4797,4815,4845,4863,4890,4908,4934,4952,4976,4994,5017,5041,5066,5089,5117,5135,5159,5183,5201,5219,5246,5264,5289,5307,5333,5358,5376,5399,5424,5442,5466,5490,5514,5539,5557,5581,5602,5625,5649,5667,5695,5713,5731,5758,5776,5794,5819,5837,5855,5873,5891,5909,5933,5958,5976,6001,6019,6043,6061,6085,6109,6132,6150,6173,6197,6222,6249,6274,6298,6316,6338,6364,6382,6400,6425,6447,6472,6490,6514,6532,6553,6576,6599,6624,6655,6678,6696,6714,6737,6763,6781,6806,6824,6852,6870,6888,6911,6935,6953,6975,7002,7020,7038,7061,7084,7108,7130,7148,7171,7189,7212,7238,7282,7322,7348,7376,7406,7441,7463,7493,7515,7543,7567,7589,7610,7634,7657,7680,7698,7716,7734,7758,7782,7800,7825,7843,7865,7889,7907,7934,7952,7975,7998,8022,8040,8058,8076,8094,8118,8143,8161,8179,8197,8215,8233,8256,8274,8297,8322,8345,8367,8391,8419,8437,8461,8486,8511,8529,8554,8581,8599,8617,8640,8658,8681,8707,8729,8751,8782,8800,8825,8848,8866,8890,8908,8931,8953,8975,8996,9021,9039,9057,9075,9099,9122,9148,9166,9188,9206,9224,9246,9272,9298,9316,9338,9360,9384,9405,9429,9455,9473,9497,9525,9543,9561,9587,9605,9632,9658,9676,9698,9716,9742,9765,9783,9806,9829,9847,9870,9894,9930,9964,9999,10033,10051,10069,10090,10112,10136,10160,10182,10205,10223,10246,10264,10290,10308,10326,10344,10369,10392,10414,10436,10454,10472,10490,10513,10531,10554,10572,10595,10620,10638,10662,10685,10710,10733,10751,10769,10787,10811,10835,10858,10884,10902,10929,10947,10965,10983,11001,11023,11047,11072,11095,11117,11141,11159,11177,11200,11218,11243,11261,11285,11307,11330,11353,11371,11397,11421,11445,11475,11499,11553,11586,11612,11643,11672,11700,11735,11760,11793,11824,11853,11875,11900,11928,11950,11979,12002,12026,12044,12069,12095,12119,12137,12159,12177,12201,12219,12243,12266,12290,12311,12335,12353,12376,12401,12424,12442,12467,12489,12510,12534,12555,12578,12596,12614,12637,12658,12682,12700,12718,12736,12758,12782,12800,12823,12841,12864,12882,12904,12922,12944,12962,12986,13004,13026,13047,13070,13092,13116,13134,13156,13181,13199,13217,13235,13258,13276,13297,13315,13340,13358,13376,13397,13419,13440,13461,13483,13507,13525,13543,13568,13586,13608,13626,13644,13668,13686,13704,13722,13747,13765,13788,13810,13833,13857,13875,13896,13919,13943,13968,13991,14009,14033,14051,14069,14087,14109,14127,14145,14168,14186,14211,14229,14251,14273,14291],{"intervention":98,"totalTrials":99,"cells":100},"Montelukast",3,{"EARLY_PHASE1":101,"PHASE1":115,"PHASE2":118,"PHASE3":120,"PHASE4":133,"NA":145},{"trials":102,"activeCount":114,"soonestReadout":108},[103],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT07409714","SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 Diabetes","NOT_YET_RECRUITING",[90],"2030-02","2026-07",50,[24],[98,113],"Montelukast Placebo",1,{"trials":116,"activeCount":117},[],0,{"trials":119,"activeCount":117},[],{"trials":121,"activeCount":117},[122],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT05362474","Targeting Leukotrienes in Kidney Disease","TERMINATED",[93],"2023-06-20","2022-07-01",6,[131],"Diabetic Kidney Disease",[98],{"trials":134,"activeCount":114,"soonestReadout":140},[135],{"nctId":136,"briefTitle":137,"status":138,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":110,"conditions":142,"interventions":144},"NCT05498116","Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes","RECRUITING",[94],"2025-10","2023-01-26",[143],"Albuminuria",[98],{"trials":146,"activeCount":117},[],{"intervention":63,"totalTrials":99,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":169,"NA":195},{"trials":150,"activeCount":117},[],{"trials":152,"activeCount":117},[],{"trials":154,"activeCount":117},[],{"trials":156,"activeCount":117},[157],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":167},"NCT00456365","Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","COMPLETED",[93],"2012-10","2006-11",110,[166],"Polycystic Kidney, Autosomal Dominant",[168],"pravastatin",{"trials":170,"activeCount":114,"soonestReadout":62},[171,185],{"nctId":172,"briefTitle":173,"status":160,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":182},"NCT00630734","Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir\u002FRitonavir and Pravastatin",[94],"2009-10","2010-09","2008-02",32,[180,181],"HIV Infections","Hyperlipidemia",[63,183,184,63],"Darunavir","Ritonavir",{"nctId":60,"briefTitle":61,"status":186,"phases":187,"primaryCompletion":62,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":194},"ACTIVE_NOT_RECRUITING",[94],"2025-09-30","2017-08-31",150,[192,193],"ADPKD","Autosomal Dominant Polycystic Kidney",[63],{"trials":196,"activeCount":117},[],{"intervention":198,"totalTrials":199,"cells":200},"Omalizumab",2,{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":232},{"trials":202,"activeCount":117},[],{"trials":204,"activeCount":117},[],{"trials":206,"activeCount":117},[],{"trials":208,"activeCount":117},[],{"trials":210,"activeCount":114,"soonestReadout":215},[211,221],{"nctId":212,"briefTitle":213,"status":186,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT04774315","Molecular Endotypes of Chronic Idiopathic Urticaria",[94],"2025-03","2022-01-01",15,[219],"Chronic Urticaria, Idiopathic",[198],{"nctId":222,"briefTitle":223,"status":160,"phases":224,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT01701583","Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria",[94],"2016-04","2017-10","2013-04",10,[230],"Chronic Urticaria",[198],{"trials":233,"activeCount":117},[],{"intervention":235,"totalTrials":199,"cells":236},"Etonogestrel implant",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":266},{"trials":238,"activeCount":117},[],{"trials":240,"activeCount":117},[],{"trials":242,"activeCount":117},[],{"trials":244,"activeCount":117},[],{"trials":246,"activeCount":114,"soonestReadout":251},[247,257],{"nctId":248,"briefTitle":249,"status":138,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT05237141","Etonogestrel Implant as Emergency Contraception",[94],"2026-12","2022-04-01",12,[255],"Contraception",[235],{"nctId":258,"briefTitle":259,"status":160,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":265},"NCT04463693","Shoulder Contraceptive Implant Study",[94],"2022-02-15","2020-10-14",5,[255],[235],{"trials":267,"activeCount":117},[],{"intervention":269,"totalTrials":114,"cells":270},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":293},{"trials":272,"activeCount":117},[],{"trials":274,"activeCount":117},[],{"trials":276,"activeCount":117},[],{"trials":278,"activeCount":117},[],{"trials":280,"activeCount":114,"soonestReadout":285},[281],{"nctId":282,"briefTitle":283,"status":138,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":292},"NCT06140537","Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients",[94],"2028-10-31","2028-12-31","2024-02-01",80,[290,291,33],"Kidney Transplant; Complications","Vascular Diseases",[269],{"trials":294,"activeCount":117},[],{"intervention":296,"totalTrials":114,"cells":297},"Ozanimod",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":319},{"trials":299,"activeCount":117},[],{"trials":301,"activeCount":117},[],{"trials":303,"activeCount":117},[],{"trials":305,"activeCount":117},[],{"trials":307,"activeCount":114,"soonestReadout":312},[308],{"nctId":309,"briefTitle":310,"status":138,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":318},"NCT06529406","Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod",[94],"2028-08-01","2029-08-01","2024-07-29",100,[317],"Relapsing Multiple Sclerosis",[296],{"trials":320,"activeCount":117},[],{"intervention":43,"totalTrials":114,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":338},{"trials":324,"activeCount":117},[],{"trials":326,"activeCount":117},[],{"trials":328,"activeCount":117},[],{"trials":330,"activeCount":117},[],{"trials":332,"activeCount":114,"soonestReadout":42},[333],{"nctId":40,"briefTitle":41,"status":138,"phases":334,"primaryCompletion":42,"completion":42,"start":335,"enrollment":164,"conditions":336,"interventions":337},[94],"2021-03-01",[36],[43],{"trials":339,"activeCount":117},[],{"intervention":341,"totalTrials":114,"cells":342},"Efgartigimod",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":364},{"trials":344,"activeCount":117},[],{"trials":346,"activeCount":117},[],{"trials":348,"activeCount":117},[],{"trials":350,"activeCount":117},[],{"trials":352,"activeCount":114,"soonestReadout":357},[353],{"nctId":354,"briefTitle":355,"status":138,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":28,"conditions":359,"interventions":363},"NCT06860633","Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod",[94],"2026-12-31","2025-03-06",[360,361,362],"Myasthenia Gravis Crisis","Myasthenia Gravis Exacerbations","AChR Myasthenia Gravis",[341],{"trials":365,"activeCount":117},[],{"intervention":367,"totalTrials":114,"cells":368},"fenfluramine",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":389},{"trials":370,"activeCount":117},[],{"trials":372,"activeCount":117},[],{"trials":374,"activeCount":117},[],{"trials":376,"activeCount":117},[],{"trials":378,"activeCount":114,"soonestReadout":251},[379],{"nctId":380,"briefTitle":381,"status":138,"phases":382,"primaryCompletion":251,"completion":383,"start":384,"enrollment":263,"conditions":385,"interventions":388},"NCT06598449","Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age",[94],"2027-07","2024-10-22",[386,387],"Dravet Syndrome (DS)","Children Under 2 Years",[367],{"trials":390,"activeCount":117},[],{"intervention":392,"totalTrials":114,"cells":393},"Levonorgestrel\u002Fethinyl estradiol",{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":402,"NA":417},{"trials":395,"activeCount":117},[],{"trials":397,"activeCount":117},[],{"trials":399,"activeCount":117},[],{"trials":401,"activeCount":117},[],{"trials":403,"activeCount":114,"soonestReadout":408},[404],{"nctId":405,"briefTitle":406,"status":138,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":416},"NCT05058872","Contraceptive Hormone and Reward Measurement (CHARM Study)",[94],"2027-03-31","2021-10-01",144,[412,413,414,415],"Oral Hormonal Contraceptive Use","Neural Activity","Mood","Hedonic Function",[392],{"trials":418,"activeCount":117},[],{"intervention":73,"totalTrials":114,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":438},{"trials":422,"activeCount":117},[],{"trials":424,"activeCount":117},[],{"trials":426,"activeCount":117},[],{"trials":428,"activeCount":117},[],{"trials":430,"activeCount":114,"soonestReadout":72},[431],{"nctId":70,"briefTitle":71,"status":186,"phases":432,"primaryCompletion":72,"completion":72,"start":433,"enrollment":434,"conditions":435,"interventions":437},[94],"2020-10-07",90,[436],"Eosinophilic Esophagitis",[73],{"trials":439,"activeCount":117},[],{"intervention":441,"totalTrials":114,"cells":442},"NSAIDs",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":463},{"trials":444,"activeCount":117},[],{"trials":446,"activeCount":117},[],{"trials":448,"activeCount":117},[],{"trials":450,"activeCount":117},[],{"trials":452,"activeCount":114,"soonestReadout":457},[453],{"nctId":454,"briefTitle":455,"status":138,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":288,"conditions":459,"interventions":462},"NCT06860711","Safety of Short-course of NSAIDs in Pediatric Patients With CKD",[94],"2027-06","2025-07-22",[460,461],"Chronic Kidney Disease","Pediatric Urology",[441],{"trials":464,"activeCount":117},[],{"intervention":466,"totalTrials":114,"cells":467},"Vericiguat",{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":476,"NA":487},{"trials":469,"activeCount":117},[],{"trials":471,"activeCount":117},[],{"trials":473,"activeCount":117},[],{"trials":475,"activeCount":117},[],{"trials":477,"activeCount":114,"soonestReadout":482},[478],{"nctId":479,"briefTitle":480,"status":186,"phases":481,"primaryCompletion":482,"completion":408,"start":483,"enrollment":19,"conditions":484,"interventions":486},"NCT05704478","Impact of Vericiguat on Hemodynamics of Heart Failure",[94],"2026-03-31","2024-01-01",[485],"Heart Failure",[466],{"trials":488,"activeCount":117},[],{"intervention":490,"totalTrials":114,"cells":491},"Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":513},{"trials":493,"activeCount":117},[],{"trials":495,"activeCount":117},[],{"trials":497,"activeCount":117},[],{"trials":499,"activeCount":117},[],{"trials":501,"activeCount":114,"soonestReadout":506},[502],{"nctId":503,"briefTitle":504,"status":106,"phases":505,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":509,"interventions":511},"NCT07424378","Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)",[94],"2028-11","2026-02",66,[510],"Frostbite",[490,512],"Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum",{"trials":514,"activeCount":117},[],{"intervention":512,"totalTrials":114,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":531},{"trials":518,"activeCount":117},[],{"trials":520,"activeCount":117},[],{"trials":522,"activeCount":117},[],{"trials":524,"activeCount":117},[],{"trials":526,"activeCount":114,"soonestReadout":506},[527],{"nctId":503,"briefTitle":504,"status":106,"phases":528,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":529,"interventions":530},[94],[510],[490,512],{"trials":532,"activeCount":117},[],{"intervention":53,"totalTrials":114,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":541,"PHASE4":543,"NA":552},{"trials":536,"activeCount":117},[],{"trials":538,"activeCount":117},[],{"trials":540,"activeCount":117},[],{"trials":542,"activeCount":117},[],{"trials":544,"activeCount":114,"soonestReadout":52},[545],{"nctId":50,"briefTitle":51,"status":186,"phases":546,"primaryCompletion":52,"completion":547,"start":47,"enrollment":19,"conditions":548,"interventions":550},[94],"2024-12",[549],"Glaucoma, Open-Angle",[53,551],"Methazolamide 50 MG",{"trials":553,"activeCount":117},[],{"intervention":551,"totalTrials":114,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":570},{"trials":557,"activeCount":117},[],{"trials":559,"activeCount":117},[],{"trials":561,"activeCount":117},[],{"trials":563,"activeCount":117},[],{"trials":565,"activeCount":114,"soonestReadout":52},[566],{"nctId":50,"briefTitle":51,"status":186,"phases":567,"primaryCompletion":52,"completion":547,"start":47,"enrollment":19,"conditions":568,"interventions":569},[94],[549],[53,551],{"trials":571,"activeCount":117},[],{"intervention":573,"totalTrials":114,"cells":574},"Faricimab",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":597},{"trials":576,"activeCount":117},[],{"trials":578,"activeCount":117},[],{"trials":580,"activeCount":117},[],{"trials":582,"activeCount":117},[],{"trials":584,"activeCount":114,"soonestReadout":251},[585],{"nctId":586,"briefTitle":587,"status":588,"phases":589,"primaryCompletion":251,"completion":590,"start":591,"enrollment":315,"conditions":592,"interventions":595},"NCT06191094","Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy","ENROLLING_BY_INVITATION",[94],"2028-01","2024-07-12",[593,594],"Diabetic Retinopathy","Vitreous Hemorrhage Due to Diabetes Mellitus",[573,596],"sham treatment",{"trials":598,"activeCount":117},[],{"intervention":596,"totalTrials":114,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":615},{"trials":602,"activeCount":117},[],{"trials":604,"activeCount":117},[],{"trials":606,"activeCount":117},[],{"trials":608,"activeCount":117},[],{"trials":610,"activeCount":114,"soonestReadout":251},[611],{"nctId":586,"briefTitle":587,"status":588,"phases":612,"primaryCompletion":251,"completion":590,"start":591,"enrollment":315,"conditions":613,"interventions":614},[94],[593,594],[573,596],{"trials":616,"activeCount":117},[],{"intervention":618,"totalTrials":129,"cells":619},"Sodium bicarbonate",{"EARLY_PHASE1":620,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":663},{"trials":621,"activeCount":117},[622],{"nctId":623,"briefTitle":624,"status":160,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":632},"NCT04600323","Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD",[90],"2023-08-30","2021-02-01",34,[630,460,631],"Metabolic Acidosis","Cognitive Dysfunction",[633],"Sodium Bicarbonate",{"trials":635,"activeCount":117},[],{"trials":637,"activeCount":117},[],{"trials":639,"activeCount":117},[],{"trials":641,"activeCount":114,"soonestReadout":658},[642,654],{"nctId":643,"briefTitle":644,"status":160,"phases":645,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT02502071","Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes",[94],"2017-07","2017-08","2017-01",45,[18,651,131],"Diabetic Nephropathy",[653],"sodium bicarbonate",{"nctId":655,"briefTitle":656,"status":138,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":662},"NCT05005793","Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients",[94],"2026-08-31","2021-12-01",120,[630,290,291],[618],{"trials":664,"activeCount":117},[665,673,681],{"nctId":666,"briefTitle":667,"status":160,"phases":668,"primaryCompletion":669,"completion":669,"start":670,"enrollment":28,"conditions":671,"interventions":672},"NCT03428464","Bicarbonate Administration in Kidney Transplant Recipients",[95],"2020-03-25","2018-12-05",[290,630],[633],{"nctId":674,"briefTitle":675,"status":160,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":28,"conditions":679,"interventions":680},"NCT02031770","Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease",[95],"2016-03","2014-01",[630,460],[618],{"nctId":682,"briefTitle":683,"status":160,"phases":684,"primaryCompletion":685,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":689},"NCT02915601","Bicarbonate Administration in CKD",[95],"2022-05-19","2017-01-15",109,[460,630],[618],{"intervention":88,"totalTrials":99,"cells":691},{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":698,"PHASE4":700,"NA":725},{"trials":693,"activeCount":117},[],{"trials":695,"activeCount":117},[],{"trials":697,"activeCount":117},[],{"trials":699,"activeCount":117},[],{"trials":701,"activeCount":114,"soonestReadout":87},[702,712],{"nctId":85,"briefTitle":86,"status":186,"phases":703,"primaryCompletion":87,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":711},[94],"2025-07-28","2021-11-22",55,[708,709,710,27],"Menopause","Estrogen Deficiency","Women",[88],{"nctId":713,"briefTitle":714,"status":715,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":723},"NCT04043520","Bioenergetic Effects of Aging and Menopause (BEAM)","UNKNOWN",[94],"2024-08-31","2019-09-24",57,[708,721,27,722],"Obesity, Abdominal","Weight Gain",[88,724],"Estrogen Product",{"trials":726,"activeCount":117},[727],{"nctId":728,"briefTitle":729,"status":160,"phases":730,"primaryCompletion":731,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":738},"NCT03289559","Effects of Testosterone and Fat Utilization",[95],"2011-01-01","2014-01-01","2006-01-01",13,[736,737],"Healthy","Volunteers",[88,739,740],"Aromatase Inhibitors","Testosterone gel",{"intervention":742,"totalTrials":99,"cells":743},"Dalbavancin",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":750,"PHASE4":765,"NA":776},{"trials":745,"activeCount":117},[],{"trials":747,"activeCount":117},[],{"trials":749,"activeCount":117},[],{"trials":751,"activeCount":117},[752],{"nctId":753,"briefTitle":754,"status":125,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":764},"NCT04847921","Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition",[92,93],"2023-10-05","2021-04-30",11,[760,761,762,763],"Gram-Positive Bacterial Infections","Gram-Positive Bacteraemia","Substance Use Disorders","Intravenous Substance Abuse",[742],{"trials":766,"activeCount":114,"soonestReadout":771},[767],{"nctId":768,"briefTitle":769,"status":138,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":315,"conditions":774,"interventions":775},"NCT06266494","Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis",[94],"2026-05","2026-08","2024-03-01",[510],[742],{"trials":777,"activeCount":117},[778],{"nctId":779,"briefTitle":780,"status":125,"phases":781,"primaryCompletion":782,"completion":783,"start":784,"enrollment":199,"conditions":785,"interventions":788},"NCT04624451","Evaluation of Intravenous Dalbavancin for Peritonitis",[],"2023-12-31","2024-01-31","2020-06-01",[786,787],"Peritonitis","Peritonitis Bacterial",[742],{"intervention":790,"totalTrials":99,"cells":791},"Degarelix",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":817,"PHASE4":819,"NA":833},{"trials":793,"activeCount":117},[],{"trials":795,"activeCount":117},[],{"trials":797,"activeCount":117},[798],{"nctId":799,"briefTitle":800,"status":160,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":811},"NCT02278185","Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer",[92],"2019-04-10","2024-07-18","2015-11-11",19,[807,808,809,810],"Adenocarcinoma of the Prostate","Recurrent Prostate Cancer","Stage III Prostate Cancer","Stage IV Prostate Cancer",[48,812,813,814,815,816],"leuprolide acetate","goserelin acetate","histrelin acetate","triptorelin","degarelix",{"trials":818,"activeCount":117},[],{"trials":820,"activeCount":114,"soonestReadout":825},[821],{"nctId":822,"briefTitle":823,"status":138,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":315,"conditions":828,"interventions":830},"NCT06264882","Cardiometabolic Consequences of the Loss of Ovarian Function",[94],"2028-05-31","2028-08-31","2024-06-01",[708,709,27,829],"Adiposity",[790,831,832],"Transdermal Estradiol Patch","Transdermal Placebo Patch",{"trials":834,"activeCount":117},[835],{"nctId":836,"briefTitle":837,"status":160,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":844},"NCT02478775","Dysregulation of FSH in Obesity: Functional and Statistical Analysis",[95],"2021-06-30","2015-07",99,[15,843],"Fertility",[790,845,846],"recombinant FSH","Cetrorelix",{"intervention":831,"totalTrials":199,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":857,"NA":863},{"trials":850,"activeCount":117},[],{"trials":852,"activeCount":117},[],{"trials":854,"activeCount":117},[],{"trials":856,"activeCount":117},[],{"trials":858,"activeCount":114,"soonestReadout":825},[859],{"nctId":822,"briefTitle":823,"status":138,"phases":860,"primaryCompletion":825,"completion":826,"start":827,"enrollment":315,"conditions":861,"interventions":862},[94],[708,709,27,829],[790,831,832],{"trials":864,"activeCount":117},[865],{"nctId":866,"briefTitle":867,"status":160,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":874},"NCT00608062","Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women",[95],"2012-10-25","2007-03",155,[873,27,708],"Arterial Stiffening",[875,876,877],"GnRHant - Ganirelix acetate","Transdermal estradiol patch","Transdermal placebo patch",{"intervention":832,"totalTrials":199,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":894},{"trials":881,"activeCount":117},[],{"trials":883,"activeCount":117},[],{"trials":885,"activeCount":117},[],{"trials":887,"activeCount":117},[],{"trials":889,"activeCount":114,"soonestReadout":825},[890],{"nctId":822,"briefTitle":823,"status":138,"phases":891,"primaryCompletion":825,"completion":826,"start":827,"enrollment":315,"conditions":892,"interventions":893},[94],[708,709,27,829],[790,831,832],{"trials":895,"activeCount":117},[896],{"nctId":866,"briefTitle":867,"status":160,"phases":897,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":898,"interventions":899},[95],[873,27,708],[875,876,877],{"intervention":901,"totalTrials":902,"cells":903},"Metformin",7,{"EARLY_PHASE1":904,"PHASE1":916,"PHASE2":918,"PHASE3":929,"PHASE4":958,"NA":991},{"trials":905,"activeCount":114,"soonestReadout":910},[906],{"nctId":907,"briefTitle":908,"status":138,"phases":909,"primaryCompletion":910,"completion":911,"start":912,"enrollment":315,"conditions":913,"interventions":915},"NCT05515978","Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients",[90],"2035-10-20","2036-11-06","2022-10-10",[914],"Prostate Cancer",[901],{"trials":917,"activeCount":117},[],{"trials":919,"activeCount":117},[920],{"nctId":921,"briefTitle":922,"status":160,"phases":923,"primaryCompletion":924,"completion":924,"start":925,"enrollment":926,"conditions":927,"interventions":928},"NCT02903511","Feasibility Study of Metformin Therapy in ADPKD",[92],"2020-08-17","2016-11",56,[166],[901],{"trials":930,"activeCount":114,"soonestReadout":935},[931,949],{"nctId":932,"briefTitle":933,"status":138,"phases":934,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":939,"interventions":943},"NCT06975111","Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",[92,93],"2029-10-31","2030-10-01","2026-03-01",200,[708,940,941,942],"Menopause Hot Flashes","Menopause Related Conditions","Cardiovascular",[901,944,945,946,947,948],"semaglutide","Anti-hypertensives","Lipid Lowering Medication","Fezolinetant","Hormonal therapy",{"nctId":950,"briefTitle":951,"status":160,"phases":952,"primaryCompletion":953,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":957},"NCT01808690","EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes",[93],"2016-12-02","2013-03",52,[18],[901],{"trials":959,"activeCount":117},[960,971,978],{"nctId":961,"briefTitle":962,"status":160,"phases":963,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":970},"NCT01775813","The Health Influences of Puberty (HIP) Study",[94],"2018-05-31","2011-06",104,[15,968,969,24],"Insulin Resistance","Gonadal Dysfunction",[901],{"nctId":972,"briefTitle":973,"status":160,"phases":974,"primaryCompletion":975,"completion":975,"start":965,"enrollment":25,"conditions":976,"interventions":977},"NCT01813929","Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes",[94],"2017-03-24",[18],[901],{"nctId":979,"briefTitle":980,"status":160,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT02463357","Three New Ideas to Protect Special Forces From the Stress of High Altitude",[94],"2016-09","2015-08",148,[986],"Mountain Sickness",[988,989,901,990],"Nifedipine extended release","Methazolamide","Nitrite",{"trials":992,"activeCount":117},[],{"intervention":994,"totalTrials":902,"cells":995},"Cannabidiol",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1062,"PHASE4":1073,"NA":1075},{"trials":997,"activeCount":117},[],{"trials":999,"activeCount":117},[],{"trials":1001,"activeCount":114,"soonestReadout":1045},[1002,1013,1022,1032,1041,1052],{"nctId":1003,"briefTitle":1004,"status":160,"phases":1005,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1012},"NCT05299944","Reducing Pain and Opioid Use With CBD",[92],"2025-07-29","2025-08-19","2022-03-08",126,[1011],"Opioid Use Disorder",[994],{"nctId":1014,"briefTitle":1015,"status":160,"phases":1016,"primaryCompletion":1017,"completion":1017,"start":1018,"enrollment":1019,"conditions":1020,"interventions":1021},"NCT03582137","A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease",[92],"2022-01-04","2018-09-05",74,[30],[994],{"nctId":1023,"briefTitle":1024,"status":160,"phases":1025,"primaryCompletion":1026,"completion":1026,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1031},"NCT05632627","Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial",[92],"2025-07-07","2023-04-11",43,[1030],"Brain Injuries, Traumatic",[994],{"nctId":1033,"briefTitle":1034,"status":160,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":649,"conditions":1038,"interventions":1040},"NCT04873453","CBD for the Treatment of Alcohol Use Disorder",[92],"2023-05-31","2021-08-30",[1039],"Alcohol Use Disorder",[994],{"nctId":1042,"briefTitle":1043,"status":138,"phases":1044,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1051},"NCT05822362","CBD for Individuals at Risk for Alzheimer's Disease",[92],"2028-04","2029-04","2024-01-19",236,[1050],"Mild Cognitive Impairment",[994],{"nctId":1053,"briefTitle":1054,"status":160,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":734,"conditions":1058,"interventions":1060},"NCT02818777","A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease",[92],"2017-11","2016-10",[1059],"Parkinson's Disease",[1061],"cannabidiol",{"trials":1063,"activeCount":114,"soonestReadout":1068},[1064],{"nctId":1065,"briefTitle":1066,"status":138,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1072},"NCT05613608","Alcohol Use Disorder and Cannabidiol",[92,93],"2027-04","2023-04-30",180,[1039],[994],{"trials":1074,"activeCount":117},[],{"trials":1076,"activeCount":117},[],{"intervention":944,"totalTrials":199,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1091,"NA":1104},{"trials":1080,"activeCount":117},[],{"trials":1082,"activeCount":117},[],{"trials":1084,"activeCount":117},[],{"trials":1086,"activeCount":114,"soonestReadout":935},[1087],{"nctId":932,"briefTitle":933,"status":138,"phases":1088,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":1089,"interventions":1090},[92,93],[708,940,941,942],[901,944,945,946,947,948],{"trials":1092,"activeCount":117},[1093],{"nctId":1094,"briefTitle":1095,"status":160,"phases":1096,"primaryCompletion":1097,"completion":1097,"start":216,"enrollment":1098,"conditions":1099,"interventions":1102},"NCT04979130","Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)",[94],"2024-10-16",69,[24,1100,1101],"Chronic Inflammation","Intestinal Permeability",[1103],"Semaglutide",{"trials":1105,"activeCount":117},[],{"intervention":1107,"totalTrials":199,"cells":1108},"Shingrix",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1131,"NA":1145},{"trials":1110,"activeCount":117},[],{"trials":1112,"activeCount":117},[],{"trials":1114,"activeCount":117},[],{"trials":1116,"activeCount":114,"soonestReadout":1121},[1117],{"nctId":1118,"briefTitle":1119,"status":138,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1130},"NCT04128189","Shingrix in Renal Transplant Recipients",[93],"2029-06","2023-03-02",132,[1125,1126,1127,1128,1129],"Kidney Transplant Recipient Response to Shingrix Vaccine","Kidney Failure","Kidney Failure, Chronic","Kidney Transplantation","Herpes Zoster (HZ)",[1107],{"trials":1132,"activeCount":117},[1133],{"nctId":1134,"briefTitle":1135,"status":160,"phases":1136,"primaryCompletion":1137,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1143},"NCT04169009","Persistence of Protection by Shingrix",[94],"2023-03-31","2024-06-13","2020-07-28",105,[1142],"Herpes Zoster",[1144,1107],"Zostavax",{"trials":1146,"activeCount":117},[],{"intervention":1148,"totalTrials":114,"cells":1149},"Granisetron",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1171,"NA":1173},{"trials":1151,"activeCount":117},[],{"trials":1153,"activeCount":117},[],{"trials":1155,"activeCount":117},[],{"trials":1157,"activeCount":114,"soonestReadout":1162},[1158],{"nctId":1159,"briefTitle":1160,"status":186,"phases":1161,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1166,"interventions":1168},"NCT03817970","Cisplatin Disposition and Kidney Injury",[93],"2027-09-30","2027-12-31","2019-11-15",72,[1167],"Nephrotoxicity",[1148,1169,1170],"Ondansetron","Palonosetron",{"trials":1172,"activeCount":117},[],{"trials":1174,"activeCount":117},[],{"intervention":1170,"totalTrials":114,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":117},[],{"trials":1180,"activeCount":117},[],{"trials":1182,"activeCount":117},[],{"trials":1184,"activeCount":114,"soonestReadout":1162},[1185],{"nctId":1159,"briefTitle":1160,"status":186,"phases":1186,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1187,"interventions":1188},[93],[1167],[1148,1169,1170],{"trials":1190,"activeCount":117},[],{"trials":1192,"activeCount":117},[],{"intervention":945,"totalTrials":114,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":117},[],{"trials":1198,"activeCount":117},[],{"trials":1200,"activeCount":117},[],{"trials":1202,"activeCount":114,"soonestReadout":935},[1203],{"nctId":932,"briefTitle":933,"status":138,"phases":1204,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":1205,"interventions":1206},[92,93],[708,940,941,942],[901,944,945,946,947,948],{"trials":1208,"activeCount":117},[],{"trials":1210,"activeCount":117},[],{"intervention":946,"totalTrials":114,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1225,"NA":1227},{"trials":1214,"activeCount":117},[],{"trials":1216,"activeCount":117},[],{"trials":1218,"activeCount":117},[],{"trials":1220,"activeCount":114,"soonestReadout":935},[1221],{"nctId":932,"briefTitle":933,"status":138,"phases":1222,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":1223,"interventions":1224},[92,93],[708,940,941,942],[901,944,945,946,947,948],{"trials":1226,"activeCount":117},[],{"trials":1228,"activeCount":117},[],{"intervention":947,"totalTrials":114,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1243,"NA":1245},{"trials":1232,"activeCount":117},[],{"trials":1234,"activeCount":117},[],{"trials":1236,"activeCount":117},[],{"trials":1238,"activeCount":114,"soonestReadout":935},[1239],{"nctId":932,"briefTitle":933,"status":138,"phases":1240,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":1241,"interventions":1242},[92,93],[708,940,941,942],[901,944,945,946,947,948],{"trials":1244,"activeCount":117},[],{"trials":1246,"activeCount":117},[],{"intervention":948,"totalTrials":114,"cells":1248},{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1255,"PHASE4":1261,"NA":1263},{"trials":1250,"activeCount":117},[],{"trials":1252,"activeCount":117},[],{"trials":1254,"activeCount":117},[],{"trials":1256,"activeCount":114,"soonestReadout":935},[1257],{"nctId":932,"briefTitle":933,"status":138,"phases":1258,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":1259,"interventions":1260},[92,93],[708,940,941,942],[901,944,945,946,947,948],{"trials":1262,"activeCount":117},[],{"trials":1264,"activeCount":117},[],{"intervention":1266,"totalTrials":114,"cells":1267},"THC\u002FCBD",{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1287,"NA":1289},{"trials":1269,"activeCount":117},[],{"trials":1271,"activeCount":117},[],{"trials":1273,"activeCount":117},[],{"trials":1275,"activeCount":114,"soonestReadout":457},[1276],{"nctId":1277,"briefTitle":1278,"status":138,"phases":1279,"primaryCompletion":457,"completion":457,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1285},"NCT05052541","Safety and Efficacy of Oral Cannabis in Chronic Spine Pain",[93],"2026-01",157,[1283,1284],"Back Pain","Neck Pain",[1266,1286],"THC",{"trials":1288,"activeCount":117},[],{"trials":1290,"activeCount":117},[],{"intervention":1286,"totalTrials":114,"cells":1292},{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1299,"PHASE4":1305,"NA":1307},{"trials":1294,"activeCount":117},[],{"trials":1296,"activeCount":117},[],{"trials":1298,"activeCount":117},[],{"trials":1300,"activeCount":114,"soonestReadout":457},[1301],{"nctId":1277,"briefTitle":1278,"status":138,"phases":1302,"primaryCompletion":457,"completion":457,"start":1280,"enrollment":1281,"conditions":1303,"interventions":1304},[93],[1283,1284],[1266,1286],{"trials":1306,"activeCount":117},[],{"trials":1308,"activeCount":117},[],{"intervention":1310,"totalTrials":114,"cells":1311},"Varenicline",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1332,"NA":1334},{"trials":1313,"activeCount":117},[],{"trials":1315,"activeCount":117},[],{"trials":1317,"activeCount":117},[],{"trials":1319,"activeCount":114,"soonestReadout":1324},[1320],{"nctId":1321,"briefTitle":1322,"status":138,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1331},"NCT05786547","V+PSF-M for Tobacco Cessation in HIV Care in India",[93],"2026-07-22","2024-01-02",400,[1328,1329,1330],"Human Immunodeficiency Virus","Smoking Cessation","Smoking, Tobacco",[1310],{"trials":1333,"activeCount":117},[],{"trials":1335,"activeCount":117},[],{"intervention":1337,"totalTrials":114,"cells":1338},"Semaglutide 1.7mg subcutaneous",{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1356,"NA":1358},{"trials":1340,"activeCount":117},[],{"trials":1342,"activeCount":117},[],{"trials":1344,"activeCount":117},[],{"trials":1346,"activeCount":114,"soonestReadout":1351},[1347],{"nctId":1348,"briefTitle":1349,"status":106,"phases":1350,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":660,"conditions":1353,"interventions":1355},"NCT07021937","Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity",[93],"2031-04-30","2026-05-01",[1354],"Obesity\u002FTherapy",[1337],{"trials":1357,"activeCount":117},[],{"trials":1359,"activeCount":117},[],{"intervention":1361,"totalTrials":114,"cells":1362},"Semaglutide Pen Injector",{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1369,"PHASE4":1382,"NA":1384},{"trials":1364,"activeCount":117},[],{"trials":1366,"activeCount":117},[],{"trials":1368,"activeCount":117},[],{"trials":1370,"activeCount":114,"soonestReadout":1375},[1371],{"nctId":1372,"briefTitle":1373,"status":138,"phases":1374,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1381},"NCT05819138","Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes",[93],"2027-10-01","2027-12-01","2023-06-21",60,[1380],"Diabetes Mellitus, Type 1",[1361],{"trials":1383,"activeCount":117},[],{"trials":1385,"activeCount":117},[],{"intervention":1387,"totalTrials":114,"cells":1388},"Essential Amino Acid Supplement by Amino Co",{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1393,"PHASE3":1395,"PHASE4":1407,"NA":1409},{"trials":1390,"activeCount":117},[],{"trials":1392,"activeCount":117},[],{"trials":1394,"activeCount":117},[],{"trials":1396,"activeCount":114,"soonestReadout":658},[1397],{"nctId":1398,"briefTitle":1399,"status":138,"phases":1400,"primaryCompletion":658,"completion":658,"start":1401,"enrollment":706,"conditions":1402,"interventions":1406},"NCT05935826","Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)",[93],"2024-06-18",[1403,1404,1405],"Hepatic Steatosis","NAFLD","Adolescent Obesity",[1387],{"trials":1408,"activeCount":117},[],{"trials":1410,"activeCount":117},[],{"intervention":1412,"totalTrials":114,"cells":1413},"Semaglutide Injectable Product",{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1420,"PHASE4":1433,"NA":1435},{"trials":1415,"activeCount":117},[],{"trials":1417,"activeCount":117},[],{"trials":1419,"activeCount":117},[],{"trials":1421,"activeCount":114,"soonestReadout":1426},[1422],{"nctId":1423,"briefTitle":1424,"status":138,"phases":1425,"primaryCompletion":1426,"completion":1427,"start":1428,"enrollment":288,"conditions":1429,"interventions":1432},"NCT05819853","Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome",[93],"2028-02-01","2028-06-30","2023-11-03",[1430,1431],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","Obese",[1412],{"trials":1434,"activeCount":117},[],{"trials":1436,"activeCount":117},[],{"intervention":1169,"totalTrials":99,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":117},[],{"trials":1442,"activeCount":117},[],{"trials":1444,"activeCount":117},[],{"trials":1446,"activeCount":114,"soonestReadout":1162},[1447],{"nctId":1159,"briefTitle":1160,"status":186,"phases":1448,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1449,"interventions":1450},[93],[1167],[1148,1169,1170],{"trials":1452,"activeCount":117},[],{"trials":1454,"activeCount":117},[1455,1465],{"nctId":1456,"briefTitle":1457,"status":160,"phases":1458,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":1461,"conditions":1462,"interventions":1464},"NCT00387556","Ondansetron Reduce Vomiting Associated With Ketamine PSA",[95],"2006-12","2002-12",268,[1463],"Conscious Sedation",[1169],{"nctId":1466,"briefTitle":1467,"status":160,"phases":1468,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1475},"NCT01859715","Emergency Department (ED) Drug Interaction in Emergency Department Patients",[95],"2013-01","2013-02","2012-06",502,[1474],"Drug Interactions",[1476,1477,1169],"Oxycodone","Hydrocodone",{"intervention":1479,"totalTrials":263,"cells":1480},"Azacitidine",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1498,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1482,"activeCount":117},[],{"trials":1484,"activeCount":114,"soonestReadout":251},[1485],{"nctId":1486,"briefTitle":1487,"status":138,"phases":1488,"primaryCompletion":251,"completion":1489,"start":1490,"enrollment":19,"conditions":1491,"interventions":1495},"NCT06429449","Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia",[91],"2027-11","2024-07-21",[1492,1493,1494],"Leukemia","Myeloid Leukemia","Monocytic Leukemia",[1496,1479,1497],"Venetoclax","Mitoxantrone",{"trials":1499,"activeCount":99,"soonestReadout":1516},[1500,1512,1521,1531],{"nctId":1501,"briefTitle":1502,"status":160,"phases":1503,"primaryCompletion":1504,"completion":1505,"start":1506,"enrollment":1507,"conditions":1508,"interventions":1510},"NCT01743859","Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia",[92],"2016-04-27","2016-08-03","2012-12-06",37,[1509],"Acute Myeloid Leukemia",[1479,1511],"Lenalidomide",{"nctId":1513,"briefTitle":1514,"status":186,"phases":1515,"primaryCompletion":1516,"completion":457,"start":1517,"enrollment":1518,"conditions":1519,"interventions":1520},"NCT03573024","Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia",[92],"2025-04-14","2018-11-28",36,[1509],[1479,1496],{"nctId":1522,"briefTitle":1523,"status":138,"phases":1524,"primaryCompletion":1525,"completion":1526,"start":1527,"enrollment":28,"conditions":1528,"interventions":1529},"NCT06232655","Cladribine Venetoclax in Monocytic AML",[92],"2026-10","2027-10","2024-02-08",[1509],[1530,1496,1479],"Cladribine",{"nctId":1532,"briefTitle":1533,"status":186,"phases":1534,"primaryCompletion":1535,"completion":457,"start":1536,"enrollment":22,"conditions":1537,"interventions":1539},"NCT03564873","Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS",[91,92],"2025-10-07","2018-09-17",[1538],"High Grade Myelodysplastic Syndromes",[1540,1479,1540,1479],"Omacetaxine",{"trials":1542,"activeCount":117},[],{"trials":1544,"activeCount":117},[],{"trials":1546,"activeCount":117},[],{"intervention":1496,"totalTrials":1548,"cells":1549},4,{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1570,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1551,"activeCount":117},[],{"trials":1553,"activeCount":199,"soonestReadout":251},[1554,1566],{"nctId":1555,"briefTitle":1556,"status":138,"phases":1557,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":1561,"conditions":1562,"interventions":1564},"NCT05287568","CC-486 and Venetoclax for Acute Myeloid Leukemia",[91],"2027-03-23","2029-03","2022-12-19",35,[1563],"AML",[1496,1565],"CC-486",{"nctId":1486,"briefTitle":1487,"status":138,"phases":1567,"primaryCompletion":251,"completion":1489,"start":1490,"enrollment":19,"conditions":1568,"interventions":1569},[91],[1492,1493,1494],[1496,1479,1497],{"trials":1571,"activeCount":199,"soonestReadout":1516},[1572,1576],{"nctId":1513,"briefTitle":1514,"status":186,"phases":1573,"primaryCompletion":1516,"completion":457,"start":1517,"enrollment":1518,"conditions":1574,"interventions":1575},[92],[1509],[1479,1496],{"nctId":1522,"briefTitle":1523,"status":138,"phases":1577,"primaryCompletion":1525,"completion":1526,"start":1527,"enrollment":28,"conditions":1578,"interventions":1579},[92],[1509],[1530,1496,1479],{"trials":1581,"activeCount":117},[],{"trials":1583,"activeCount":117},[],{"trials":1585,"activeCount":117},[],{"intervention":1587,"totalTrials":129,"cells":1588},"Pembrolizumab",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1673,"PHASE4":1675,"NA":1677},{"trials":1590,"activeCount":117},[],{"trials":1592,"activeCount":117},[],{"trials":1594,"activeCount":99,"soonestReadout":1599},[1595,1608,1619,1634,1648,1660],{"nctId":1596,"briefTitle":1597,"status":186,"phases":1598,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1606},"NCT05379972","Study of SBRT\u002FOlaparib Followed by Pembrolizumab\u002FOlaparib in Gastric Cancers",[92],"2025-02-24","2028-12","2023-01-12",9,[1604,1605],"Gastric Cancer","GastroEsophageal Cancer",[1587,1607],"Olaparib",{"nctId":1609,"briefTitle":1610,"status":160,"phases":1611,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":649,"conditions":1615,"interventions":1617},"NCT03149822","Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma",[91,92],"2022-12-14","2024-02-16","2017-09-28",[1616],"Metastatic Renal Cell Carcinoma",[1618,1587],"Cabozantinib",{"nctId":1620,"briefTitle":1621,"status":1622,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1017,"enrollment":117,"conditions":1625,"interventions":1631},"NCT05233696","Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC","WITHDRAWN",[92],"2022-12-01",[1626,1627,1628,1629,1630],"Triple Negative Breast Cancer","Locally Advanced Breast Cancer","Unresectable Breast Carcinoma","Metastatic Breast Cancer","PD-L1 Gene Mutation",[1632,1633,1587],"Nab-paclitaxel","Paclitaxel",{"nctId":1635,"briefTitle":1636,"status":138,"phases":1637,"primaryCompletion":1638,"completion":1639,"start":1640,"enrollment":34,"conditions":1641,"interventions":1646},"NCT05969496","Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus",[92],"2026-11-01","2029-11","2023-12-04",[1642,1643,1644,1645],"Renal Cancer","Kidney Cancer","Renal Cell Carcinoma","Inferior Vena Cava Thrombosis",[1647,1587],"Axitinib",{"nctId":1649,"briefTitle":1650,"status":186,"phases":1651,"primaryCompletion":1652,"completion":937,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1657},"NCT05167409","A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer",[92],"2025-12-01","2022-07-28",48,[1656],"Microsatellite Stable Metastatic Colorectal Cancer",[1658,1659,1587],"Evorpacept","Cetuximab",{"nctId":1661,"briefTitle":1662,"status":160,"phases":1663,"primaryCompletion":1664,"completion":1665,"start":1536,"enrollment":1666,"conditions":1667,"interventions":1670},"NCT03475004","Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer",[92],"2022-04-14","2024-02-12",53,[1668,1669],"Colorectal Cancer","Metastatic Cancer",[1587,1671,1672],"Bevacizumab","Binimetinib",{"trials":1674,"activeCount":117},[],{"trials":1676,"activeCount":117},[],{"trials":1678,"activeCount":117},[],{"intervention":1607,"totalTrials":1548,"cells":1680},{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1707,"PHASE3":1725,"PHASE4":1727,"NA":1729},{"trials":1682,"activeCount":117},[],{"trials":1684,"activeCount":114,"soonestReadout":383},[1685,1697],{"nctId":1686,"briefTitle":1687,"status":138,"phases":1688,"primaryCompletion":383,"completion":1689,"start":1690,"enrollment":110,"conditions":1691,"interventions":1695},"NCT06856499","Cirtuvivint\u002FOlaparib in Breast Cancer Susceptibility Gene\u002FHomologous Recombination Deficiency Platinum Resistant Ovarian Cancer",[91],"2029-07","2025-12-08",[1692,1693,1694],"Endometrioid Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer",[1696,1607],"Cirtuvivint",{"nctId":1698,"briefTitle":1699,"status":160,"phases":1700,"primaryCompletion":1701,"completion":1702,"start":1703,"enrollment":34,"conditions":1704,"interventions":1706},"NCT01758731","Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History",[91],"2016-12-05","2018-10-31","2012-10-22",[1705],"Squamous Cell Carcinoma of the Head and Neck",[1607,1659],{"trials":1708,"activeCount":199,"soonestReadout":1599},[1709,1713],{"nctId":1596,"briefTitle":1597,"status":186,"phases":1710,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":1602,"conditions":1711,"interventions":1712},[92],[1604,1605],[1587,1607],{"nctId":1714,"briefTitle":1715,"status":138,"phases":1716,"primaryCompletion":1717,"completion":1718,"start":1719,"enrollment":1666,"conditions":1720,"interventions":1723},"NCT05887609","An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib",[92],"2029-01-31","2031-01-31","2023-10-03",[1721,1722,1694],"Ovary Cancer","Peritoneal Cancer",[1724,1607],"Mirvetuximab Soravtansine-gynx",{"trials":1726,"activeCount":117},[],{"trials":1728,"activeCount":117},[],{"trials":1730,"activeCount":117},[],{"intervention":1732,"totalTrials":99,"cells":1733},"Normal saline",{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1763,"PHASE4":1765,"NA":1778},{"trials":1735,"activeCount":117},[],{"trials":1737,"activeCount":117},[],{"trials":1739,"activeCount":199,"soonestReadout":1757},[1740,1753],{"nctId":1741,"briefTitle":1742,"status":138,"phases":1743,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":288,"conditions":1747,"interventions":1750},"NCT06670521","Corticosteroids for Post-Extubation Dysphagia",[92],"2026-11-30","2027-05-31","2024-12-02",[1748,1749],"Dysphagia","Laryngeal Edema",[1751,1752],"Methylprednisolone","Normal Saline",{"nctId":1754,"briefTitle":1755,"status":138,"phases":1756,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":190,"conditions":1759,"interventions":1761},"NCT06141447","Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation",[92],"2026-11-02","2024-05-02",[1760],"Hemorrhage",[1762,1732],"Oxytocin + normal saline",{"trials":1764,"activeCount":117},[],{"trials":1766,"activeCount":117},[1767],{"nctId":1768,"briefTitle":1769,"status":1622,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":117,"conditions":1773,"interventions":1775},"NCT02823977","Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal",[94],"2018-12","2018-02",[1774],"Alcohol Withdrawal",[1776,1777,1732],"Ketamine","Dexmedetomidine",{"trials":1779,"activeCount":117},[],{"intervention":1781,"totalTrials":99,"cells":1782},"Nivolumab",{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1784,"activeCount":117},[],{"trials":1786,"activeCount":117},[],{"trials":1788,"activeCount":199,"soonestReadout":1808},[1789,1804,1816],{"nctId":1790,"briefTitle":1791,"status":160,"phases":1792,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":31,"conditions":1796,"interventions":1798},"NCT03586999","Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas",[91,92],"2021-05-26","2022-09-20","2018-11-07",[1797],"Peripheral T Cell Lymphoma",[1781,1799,1800,1801,1802,1803],"Etoposide","Prednisolone","Oncovin","Cyclophosphamide","Hydroxydaunorubicin",{"nctId":1805,"briefTitle":1806,"status":186,"phases":1807,"primaryCompletion":1808,"completion":357,"start":1809,"enrollment":805,"conditions":1810,"interventions":1815},"NCT03347838","Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers",[92],"2025-06-18","2019-01-30",[1811,1812,1813,1814],"Bronchial Dysplasia","Tobacco Smoking","History of Non-Small Cell Lung Cancer","History of Head and Neck Cancer",[1781],{"nctId":1817,"briefTitle":1818,"status":186,"phases":1819,"primaryCompletion":1820,"completion":1821,"start":1822,"enrollment":1654,"conditions":1823,"interventions":1830},"NCT04963283","Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer",[92],"2026-02-24","2027-02-09","2021-06-23",[1824,1825,1826,1827,1828,1829,1668],"Colorectal Adenocarcinoma","Colon Cancer","Colon Adenocarcinoma","Rectum Cancer","Rectal Cancer","Rectal Adenocarcinoma",[1618,1781],{"trials":1832,"activeCount":117},[],{"trials":1834,"activeCount":117},[],{"trials":1836,"activeCount":117},[],{"intervention":1838,"totalTrials":199,"cells":1839},"Doxorubicin",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1841,"activeCount":117},[],{"trials":1843,"activeCount":117},[],{"trials":1845,"activeCount":199,"soonestReadout":1858},[1846,1854],{"nctId":1847,"briefTitle":1848,"status":138,"phases":1849,"primaryCompletion":1600,"completion":1850,"start":251,"enrollment":28,"conditions":1851,"interventions":1853},"NCT07125183","Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma",[92],"2029-12",[1852],"Sarcoma",[1838],{"nctId":1855,"briefTitle":1856,"status":186,"phases":1857,"primaryCompletion":1858,"completion":1163,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1864},"NCT04028063","Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas",[92],"2027-04-07","2020-01-28",65,[1862,1863],"Metastatic Soft Tissue Sarcoma","Advanced Soft Tissue Sarcoma",[1865,1866,1838,1867],"Balstilimab","Zalifrelimab","Botensilimab",{"trials":1869,"activeCount":117},[],{"trials":1871,"activeCount":117},[],{"trials":1873,"activeCount":117},[],{"intervention":1875,"totalTrials":199,"cells":1876},"Broad Spectrum Cannabidiol (bsCBD) 400 mg",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1899,"PHASE4":1901,"NA":1903},{"trials":1878,"activeCount":117},[],{"trials":1880,"activeCount":117},[],{"trials":1882,"activeCount":199,"soonestReadout":1427},[1883,1892],{"nctId":1884,"briefTitle":1885,"status":138,"phases":1886,"primaryCompletion":1427,"completion":1427,"start":1887,"enrollment":660,"conditions":1888,"interventions":1890},"NCT06575751","Cannabidiol and Cannabis Concentrate Users",[92],"2024-12-04",[1889],"Cannabis Use Disorder",[1875,1891],"Broad Spectrum Cannabidiol (bsCBD) 200 mg",{"nctId":1893,"briefTitle":1894,"status":138,"phases":1895,"primaryCompletion":1427,"completion":1427,"start":1896,"enrollment":938,"conditions":1897,"interventions":1898},"NCT06569394","A Study of Cannabidiol in Young Adult Cannabis Users",[92],"2024-12-09",[1889],[1875],{"trials":1900,"activeCount":117},[],{"trials":1902,"activeCount":117},[],{"trials":1904,"activeCount":117},[],{"intervention":1906,"totalTrials":902,"cells":1907},"Aminohippurate Sodium Inj 20%",{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1962,"PHASE4":1964,"NA":1966},{"trials":1909,"activeCount":117},[],{"trials":1911,"activeCount":117},[],{"trials":1913,"activeCount":114,"soonestReadout":1958},[1914,1933,1945,1954],{"nctId":1915,"briefTitle":1916,"status":160,"phases":1917,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":1920,"conditions":1921,"interventions":1931},"NCT03620773","Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes",[91,92],"2024-09-25","2018-10-01",24,[1922,15,1923,1924,131,1925,1926,1927,1928,1929,1405,1930],"Type 2 Diabetes Mellitus","Bariatric Surgery Candidate","Nephropathy","Diabetes Mellitus, Type 2","Diabetes Mellitus","Diabetes Complications","Weight Loss","Diabetic Nephropathies","Pediatric Obesity",[1906,1932],"Iohexol Inj 300 mg\u002FmL",{"nctId":1934,"briefTitle":1935,"status":160,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":1919,"enrollment":110,"conditions":1939,"interventions":1944},"NCT03618420","Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function",[91,92],"2019-10-19","2021-08-01",[1380,1924,1929,1940,1941,1942,1943],"Juvenile Diabetes","Diabetes Mellitus Complication","Autoimmune Diabetes","Type 1 Diabetes Mellitus",[1906,1932],{"nctId":1946,"briefTitle":1947,"status":715,"phases":1948,"primaryCompletion":1949,"completion":1950,"start":1919,"enrollment":315,"conditions":1951,"interventions":1952},"NCT03584217","Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study",[91,92],"2023-06-30","2023-10-30",[1922,15,1924,1405],[1906,1953],"Iohexol Inj 300 MG\u002FML",{"nctId":1955,"briefTitle":1956,"status":186,"phases":1957,"primaryCompletion":1958,"completion":1958,"start":912,"enrollment":649,"conditions":1959,"interventions":1960},"NCT05507892","Renal Mechanism of SGLT2 Inhibition",[92],"2026-12-15",[24,131],[1961,1906],"canagliflozin",{"trials":1963,"activeCount":117},[],{"trials":1965,"activeCount":117},[],{"trials":1967,"activeCount":114,"soonestReadout":1996},[1968,1979,1992],{"nctId":1969,"briefTitle":1970,"status":160,"phases":1971,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":1974,"conditions":1975,"interventions":1977},"NCT04407481","PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)",[],"2022-10-13","2020-11-01",22,[1976,166],"Polycystic Kidney Disease, Adult",[1906,1978],"Iohexol Inj 300 milligrams per milliliter",{"nctId":1980,"briefTitle":1981,"status":160,"phases":1982,"primaryCompletion":1983,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1990},"NCT04074668","Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance",[],"2022-05-15","2022-11-15","2020-01-01",58,[131,18,33,1926,1927,1929,1988,1989,1942,1940,1943],"Type1diabetes","Diabetes, Autoimmune",[1906,1991],"Iohexol Inj 300 milligrams\u002Fmilliliter",{"nctId":1993,"briefTitle":1994,"status":588,"phases":1995,"primaryCompletion":1996,"completion":1997,"start":1998,"enrollment":315,"conditions":1999,"interventions":2001},"NCT05530356","Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study",[],"2027-09","2029-05","2022-09-30",[24,2000,1929,1924,15,1405,131],"Diabetes Type 2",[1906,1953,2002],"Dextran 40",{"intervention":2004,"totalTrials":129,"cells":2005},"Dexamethasone",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2068,"PHASE4":2070,"NA":2083},{"trials":2007,"activeCount":117},[],{"trials":2009,"activeCount":117},[],{"trials":2011,"activeCount":114,"soonestReadout":77},[2012,2022,2036,2047,2056],{"nctId":75,"briefTitle":76,"status":186,"phases":2013,"primaryCompletion":77,"completion":2014,"start":2015,"enrollment":31,"conditions":2016,"interventions":2018},[92],"2026-11","2021-11-18",[2017],"Multiple Myeloma in Relapse",[78,2019,2020,2021,2004],"Pomalidomide","Daratumumab","Carfilzomib",{"nctId":2023,"briefTitle":2024,"status":125,"phases":2025,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":99,"conditions":2028,"interventions":2033},"NCT02353572","Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma",[91,92],"2011-09","2009-11",[2029,2030,2031,2032],"Plasma Cell Myeloma","Plasmacytosis","Recurrent Plasma Cell Myeloma","Smoldering Plasma Cell Myeloma",[2034,2035,2004],"Melphalan","Bortezomib",{"nctId":2037,"briefTitle":2038,"status":1622,"phases":2039,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":117,"conditions":2043,"interventions":2045},"NCT03255473","High Dose Oral Steroids in Sudden Sensorineural Hearing Loss",[92],"2022-08-01","2023-03-13","2017-08-30",[2044],"Sudden Sensorineural Hearing Loss (SSNHL)",[2004,2046],"Prednisone",{"nctId":2048,"briefTitle":2049,"status":125,"phases":2050,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":99,"conditions":2053,"interventions":2055},"NCT02353468","Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant",[92],"2011-10","2009-12",[2054],"Refractory Plasma Cell Myeloma",[2035,1511,2004],{"nctId":2057,"briefTitle":2058,"status":1622,"phases":2059,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":117,"conditions":2063,"interventions":2066},"NCT04360876","Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial",[92],"2020-12-31","2021-01-30","2020-09-01",[2064,2065],"COVID-19","ARDS",[2004,2067],"Placebos",{"trials":2069,"activeCount":117},[],{"trials":2071,"activeCount":117},[2072],{"nctId":2073,"briefTitle":2074,"status":160,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":2078,"conditions":2079,"interventions":2081},"NCT04563494","The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain",[94],"2023-05-24","2020-10-23",127,[2080],"Nausea and Vomiting, Postoperative",[2082],"dexamethasone",{"trials":2084,"activeCount":117},[],{"intervention":2086,"totalTrials":199,"cells":2087},"Lorazepam",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2105,"PHASE4":2107,"NA":2120},{"trials":2089,"activeCount":117},[],{"trials":2091,"activeCount":117},[],{"trials":2093,"activeCount":114,"soonestReadout":251},[2094],{"nctId":2095,"briefTitle":2096,"status":186,"phases":2097,"primaryCompletion":251,"completion":251,"start":2098,"enrollment":508,"conditions":2099,"interventions":2102},"NCT05662228","Therapies for Down Syndrome Regression Disorder",[92],"2023-06-29",[2100,2101],"Down Syndrome","Regression",[2086,2103,2104],"Intravenous immunoglobulin","Tofacitinib",{"trials":2106,"activeCount":117},[],{"trials":2108,"activeCount":117},[2109],{"nctId":2110,"briefTitle":2111,"status":160,"phases":2112,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":805,"conditions":2116,"interventions":2118},"NCT03090620","Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome",[94],"2020-07-31","2020-08-31","2017-03-30",[2117],"Anticholinergics Toxicity",[2119,2086],"Physostigmine",{"trials":2121,"activeCount":117},[],{"intervention":2123,"totalTrials":199,"cells":2124},"Ruxolitinib",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2144,"PHASE4":2155,"NA":2157},{"trials":2126,"activeCount":117},[],{"trials":2128,"activeCount":117},[],{"trials":2130,"activeCount":114,"soonestReadout":2135},[2131],{"nctId":2132,"briefTitle":2133,"status":138,"phases":2134,"primaryCompletion":2135,"completion":2136,"start":771,"enrollment":1920,"conditions":2137,"interventions":2143},"NCT07252050","Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease",[91,92],"2028-11-19","2029-11-19",[2138,2139,2140,2141,2142],"Sickle Cell Disease","Hematopoetic Stem Cell Transplant","Haploidentical Hematopoietic Stem Cell Transplant","Haploidentical Stem Cell Transplantation","Graft Failure",[2123],{"trials":2145,"activeCount":117},[2146],{"nctId":2147,"briefTitle":2148,"status":1622,"phases":2149,"primaryCompletion":2150,"completion":2151,"start":2152,"enrollment":117,"conditions":2153,"interventions":2154},"NCT04348071","Safety and Efficacy of Ruxolitinib for COVID-19",[92,93],"2021-08","2021-10","2021-07",[2064],[2123],{"trials":2156,"activeCount":117},[],{"trials":2158,"activeCount":117},[],{"intervention":2104,"totalTrials":199,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2162,"activeCount":117},[],{"trials":2164,"activeCount":117},[],{"trials":2166,"activeCount":114,"soonestReadout":251},[2167,2181],{"nctId":2168,"briefTitle":2169,"status":160,"phases":2170,"primaryCompletion":2171,"completion":2171,"start":2172,"enrollment":2173,"conditions":2174,"interventions":2180},"NCT04246372","Tofacitinib for Immune Skin Conditions in Down Syndrome",[92],"2024-10-30","2020-10-21",47,[2100,2175,2176,2177,2178,2179],"Alopecia Areata","Atopic Dermatitis \u002F Eczema","Hidradenitis Suppurativa","Vitiligo","Psoriasis",[2104],{"nctId":2095,"briefTitle":2096,"status":186,"phases":2182,"primaryCompletion":251,"completion":251,"start":2098,"enrollment":508,"conditions":2183,"interventions":2184},[92],[2100,2101],[2086,2103,2104],{"trials":2186,"activeCount":117},[],{"trials":2188,"activeCount":117},[],{"trials":2190,"activeCount":117},[],{"intervention":2192,"totalTrials":199,"cells":2193},"Atezolizumab",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2208,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2195,"activeCount":117},[],{"trials":2197,"activeCount":117},[2198],{"nctId":2199,"briefTitle":2200,"status":160,"phases":2201,"primaryCompletion":2202,"completion":2203,"start":2204,"enrollment":758,"conditions":2205,"interventions":2207},"NCT05053737","Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC",[91],"2023-11-24","2024-06-21","2021-11-02",[2206],"Squamous Cell Carcinoma of Head and Neck",[2192],{"trials":2209,"activeCount":114,"soonestReadout":2214},[2210],{"nctId":2211,"briefTitle":2212,"status":186,"phases":2213,"primaryCompletion":2214,"completion":2215,"start":2216,"enrollment":734,"conditions":2217,"interventions":2221},"NCT06784947","Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer",[92],"2025-09-18","2028-05","2025-03-25",[2218,2219,2220],"Microsatellite Stable (MSS) Colorectal Cancer (CRC)","Metastatic Colorectal Cancer (CRC)","Colorectal Cancer Stage IV",[2222,2192,1671],"Tiragolumab",{"trials":2224,"activeCount":117},[],{"trials":2226,"activeCount":117},[],{"trials":2228,"activeCount":117},[],{"intervention":48,"totalTrials":199,"cells":2230},{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2232,"activeCount":117},[],{"trials":2234,"activeCount":117},[],{"trials":2236,"activeCount":114,"soonestReadout":47},[2237,2241],{"nctId":799,"briefTitle":800,"status":160,"phases":2238,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":2239,"interventions":2240},[92],[807,808,809,810],[48,812,813,814,815,816],{"nctId":45,"briefTitle":46,"status":186,"phases":2242,"primaryCompletion":47,"completion":2243,"start":2244,"enrollment":2245,"conditions":2246,"interventions":2247},[92],"2027-02","2017-09-21",61,[21],[48,2248],"Fulvestrant",{"trials":2250,"activeCount":117},[],{"trials":2252,"activeCount":117},[],{"trials":2254,"activeCount":117},[],{"intervention":2256,"totalTrials":199,"cells":2257},"Liposomal bupivacaine",{"EARLY_PHASE1":2258,"PHASE1":2260,"PHASE2":2262,"PHASE3":2286,"PHASE4":2288,"NA":2290},{"trials":2259,"activeCount":117},[],{"trials":2261,"activeCount":117},[],{"trials":2263,"activeCount":114,"soonestReadout":2268},[2264,2274],{"nctId":2265,"briefTitle":2266,"status":138,"phases":2267,"primaryCompletion":2268,"completion":2269,"start":2270,"enrollment":315,"conditions":2271,"interventions":2273},"NCT04066296","Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine",[92],"2024-12-31","2025-01","2019-09-08",[2272],"Lumbar Spinal Stenosis",[2256],{"nctId":2275,"briefTitle":2276,"status":1622,"phases":2277,"primaryCompletion":2278,"completion":2279,"start":2280,"enrollment":117,"conditions":2281,"interventions":2284},"NCT05216055","Transverse Abdominus Plane Block Study",[92],"2022-12-16","2022-12-27","2022-04-19",[2282,2283],"Colorectal Disorders","Surgery",[2285,2256],"Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline",{"trials":2287,"activeCount":117},[],{"trials":2289,"activeCount":117},[],{"trials":2291,"activeCount":117},[],{"intervention":1618,"totalTrials":199,"cells":2293},{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2295,"activeCount":117},[],{"trials":2297,"activeCount":117},[],{"trials":2299,"activeCount":114,"soonestReadout":1820},[2300,2304],{"nctId":1609,"briefTitle":1610,"status":160,"phases":2301,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":649,"conditions":2302,"interventions":2303},[91,92],[1616],[1618,1587],{"nctId":1817,"briefTitle":1818,"status":186,"phases":2305,"primaryCompletion":1820,"completion":1821,"start":1822,"enrollment":1654,"conditions":2306,"interventions":2307},[92],[1824,1825,1826,1827,1828,1829,1668],[1618,1781],{"trials":2309,"activeCount":117},[],{"trials":2311,"activeCount":117},[],{"trials":2313,"activeCount":117},[],{"intervention":2315,"totalTrials":199,"cells":2316},"Nicotinamide Riboside",{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2348,"PHASE4":2350,"NA":2352},{"trials":2318,"activeCount":117},[],{"trials":2320,"activeCount":117},[],{"trials":2322,"activeCount":114,"soonestReadout":2327},[2323,2334],{"nctId":2324,"briefTitle":2325,"status":138,"phases":2326,"primaryCompletion":2327,"completion":2328,"start":771,"enrollment":228,"conditions":2329,"interventions":2332},"NCT07579429","Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)",[92],"2029-12-18","2030-12-18",[2330,2331],"Clonal Cytopenia of Undetermined Significance","Myelodysplastic Syndrome",[2315,2333],"Pterostilbene",{"nctId":2335,"briefTitle":2336,"status":715,"phases":2337,"primaryCompletion":2338,"completion":2339,"start":2340,"enrollment":2341,"conditions":2342,"interventions":2346},"NCT04040959","Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD",[92],"2024-05-15","2024-09-15","2019-11-19",118,[291,2343,2344,2345],"Kidney Disease","Blood Pressure","Oxidative Stress",[2347],"Nicotinamide riboside",{"trials":2349,"activeCount":117},[],{"trials":2351,"activeCount":117},[],{"trials":2353,"activeCount":117},[],{"intervention":2355,"totalTrials":199,"cells":2356},"sargramostim",{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2373,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2358,"activeCount":117},[],{"trials":2360,"activeCount":117},[2361],{"nctId":2362,"briefTitle":2363,"status":160,"phases":2364,"primaryCompletion":2365,"completion":2366,"start":2367,"enrollment":805,"conditions":2368,"interventions":2372},"NCT02250014","The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer",[91],"2017-12-01","2020-12-21","2015-10-05",[808,2369,2370,2371],"Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer",[2355],{"trials":2374,"activeCount":114,"soonestReadout":1744},[2375],{"nctId":2376,"briefTitle":2377,"status":138,"phases":2378,"primaryCompletion":1744,"completion":1744,"start":2379,"enrollment":2380,"conditions":2381,"interventions":2383},"NCT04902703","Phase II Trial to Evaluate Safety and Efficacy of GM-CSF\u002FSargramostim in Alzheimer's Disease",[92],"2022-06-01",42,[2382],"Alzheimer Disease",[2384],"Sargramostim",{"trials":2386,"activeCount":117},[],{"trials":2388,"activeCount":117},[],{"trials":2390,"activeCount":117},[],{"intervention":2392,"totalTrials":114,"cells":2393},"CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2395,"activeCount":117},[],{"trials":2397,"activeCount":117},[],{"trials":2399,"activeCount":114,"soonestReadout":2404},[2400],{"nctId":2401,"briefTitle":2402,"status":138,"phases":2403,"primaryCompletion":2404,"completion":109,"start":2405,"enrollment":649,"conditions":2406,"interventions":2409},"NCT04544592","UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",[91,92],"2026-06","2021-03-10",[2407,2408],"B-cell Acute Lymphoblastic Leukemia","B-cell Non Hodgkin Lymphoma",[2392],{"trials":2411,"activeCount":117},[],{"trials":2413,"activeCount":117},[],{"trials":2415,"activeCount":117},[],{"intervention":2222,"totalTrials":114,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2419,"activeCount":117},[],{"trials":2421,"activeCount":117},[],{"trials":2423,"activeCount":114,"soonestReadout":2214},[2424],{"nctId":2211,"briefTitle":2212,"status":186,"phases":2425,"primaryCompletion":2214,"completion":2215,"start":2216,"enrollment":734,"conditions":2426,"interventions":2427},[92],[2218,2219,2220],[2222,2192,1671],{"trials":2429,"activeCount":117},[],{"trials":2431,"activeCount":117},[],{"trials":2433,"activeCount":117},[],{"intervention":2435,"totalTrials":114,"cells":2436},"Sequential FLOT followed by chemoradiation",{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2455,"PHASE4":2457,"NA":2459},{"trials":2438,"activeCount":117},[],{"trials":2440,"activeCount":117},[],{"trials":2442,"activeCount":114,"soonestReadout":2447},[2443],{"nctId":2444,"briefTitle":2445,"status":186,"phases":2446,"primaryCompletion":2447,"completion":2448,"start":2449,"enrollment":2450,"conditions":2451,"interventions":2454},"NCT04028167","Induction FLOT With CROSS CRT for Esophageal Cancer",[92],"2026-01-02","2027-04-19","2020-04-08",40,[2452,2453],"Adenocarcinoma Esophagus","Adenocarcinoma of the Gastroesophageal Junction",[2435],{"trials":2456,"activeCount":117},[],{"trials":2458,"activeCount":117},[],{"trials":2460,"activeCount":117},[],{"intervention":2462,"totalTrials":114,"cells":2463},"Oral Decitabine\u002FCedazuridine (DEC-C) in Combination with Nivolumab",{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2465,"activeCount":117},[],{"trials":2467,"activeCount":117},[],{"trials":2469,"activeCount":114,"soonestReadout":658},[2470],{"nctId":2471,"briefTitle":2472,"status":186,"phases":2473,"primaryCompletion":658,"completion":1525,"start":2474,"enrollment":2475,"conditions":2476,"interventions":2478},"NCT05089370","Oral Decitabine\u002FCedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma",[91,92],"2022-06-20",8,[2477],"Malignant Melanoma",[2462],{"trials":2480,"activeCount":117},[],{"trials":2482,"activeCount":117},[],{"trials":2484,"activeCount":117},[],{"intervention":2486,"totalTrials":114,"cells":2487},"L-ctirulline",{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2492,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2489,"activeCount":117},[],{"trials":2491,"activeCount":117},[],{"trials":2493,"activeCount":114,"soonestReadout":2498},[2494],{"nctId":2495,"briefTitle":2496,"status":138,"phases":2497,"primaryCompletion":2498,"completion":2499,"start":409,"enrollment":1378,"conditions":2500,"interventions":2502},"NCT03885245","Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes",[92],"2025-12-30","2026-06-30",[2501,15],"Asthma",[2486],{"trials":2504,"activeCount":117},[],{"trials":2506,"activeCount":117},[],{"trials":2508,"activeCount":117},[],{"intervention":2510,"totalTrials":114,"cells":2511},"Estradiol Patches",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2513,"activeCount":117},[],{"trials":2515,"activeCount":117},[],{"trials":2517,"activeCount":114,"soonestReadout":1525},[2518],{"nctId":2519,"briefTitle":2520,"status":138,"phases":2521,"primaryCompletion":1525,"completion":251,"start":2522,"enrollment":28,"conditions":2523,"interventions":2525},"NCT06686537","Convergent Mechanisms Underlying Reprometabolic Syndrome in Women",[92],"2025-02-25",[2524,15],"Infertility, Female",[2510],{"trials":2527,"activeCount":117},[],{"trials":2529,"activeCount":117},[],{"trials":2531,"activeCount":117},[],{"intervention":2533,"totalTrials":114,"cells":2534},"BRC-002",{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2552,"PHASE4":2554,"NA":2556},{"trials":2536,"activeCount":117},[],{"trials":2538,"activeCount":117},[],{"trials":2540,"activeCount":114,"soonestReadout":2545},[2541],{"nctId":2542,"briefTitle":2543,"status":106,"phases":2544,"primaryCompletion":2545,"completion":2546,"start":2547,"enrollment":1378,"conditions":2548,"interventions":2550},"NCT07224932","Tolerability and Efficacy of CBD Extract for RLS Treatment",[92],"2026-01-01","2026-02-25","2025-12-19",[2549],"Restless Leg Syndrome",[2533,2551],"Placecbo",{"trials":2553,"activeCount":117},[],{"trials":2555,"activeCount":117},[],{"trials":2557,"activeCount":117},[],{"intervention":2551,"totalTrials":114,"cells":2559},{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2561,"activeCount":117},[],{"trials":2563,"activeCount":117},[],{"trials":2565,"activeCount":114,"soonestReadout":2545},[2566],{"nctId":2542,"briefTitle":2543,"status":106,"phases":2567,"primaryCompletion":2545,"completion":2546,"start":2547,"enrollment":1378,"conditions":2568,"interventions":2569},[92],[2549],[2533,2551],{"trials":2571,"activeCount":117},[],{"trials":2573,"activeCount":117},[],{"trials":2575,"activeCount":117},[],{"intervention":1891,"totalTrials":114,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2582,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2579,"activeCount":117},[],{"trials":2581,"activeCount":117},[],{"trials":2583,"activeCount":114,"soonestReadout":1427},[2584],{"nctId":1884,"briefTitle":1885,"status":138,"phases":2585,"primaryCompletion":1427,"completion":1427,"start":1887,"enrollment":660,"conditions":2586,"interventions":2587},[92],[1889],[1875,1891],{"trials":2589,"activeCount":117},[],{"trials":2591,"activeCount":117},[],{"trials":2593,"activeCount":117},[],{"intervention":2595,"totalTrials":114,"cells":2596},"Equol",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2598,"activeCount":117},[],{"trials":2600,"activeCount":117},[],{"trials":2602,"activeCount":114,"soonestReadout":2607},[2603],{"nctId":2604,"briefTitle":2605,"status":138,"phases":2606,"primaryCompletion":2607,"completion":2607,"start":2608,"enrollment":1019,"conditions":2609,"interventions":2614},"NCT07194590","Equol and Vascular Function in Women With Chronic Kidney Disease",[92],"2030-11-30","2026-02-19",[2610,2611,2612,2613,2344],"Chronic Kidney Disease (Stage 3-4)","Vascular Function","Cognitive Functions","Cerebrovascular Function",[2595],{"trials":2616,"activeCount":117},[],{"trials":2618,"activeCount":117},[],{"trials":2620,"activeCount":117},[],{"intervention":2622,"totalTrials":114,"cells":2623},"Dronabinol Pill",{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2625,"activeCount":117},[],{"trials":2627,"activeCount":117},[],{"trials":2629,"activeCount":114,"soonestReadout":2499},[2630],{"nctId":2631,"briefTitle":2632,"status":138,"phases":2633,"primaryCompletion":2499,"completion":2499,"start":2634,"enrollment":22,"conditions":2635,"interventions":2636},"NCT06446479","Effects of THC on Alcohol Consumption and Neural Correlates of Reward",[92],"2024-07-01",[1889],[2622],{"trials":2638,"activeCount":117},[],{"trials":2640,"activeCount":117},[],{"trials":2642,"activeCount":117},[],{"intervention":2644,"totalTrials":114,"cells":2645},"Advair HFA",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2661,"PHASE4":2663,"NA":2665},{"trials":2647,"activeCount":117},[],{"trials":2649,"activeCount":117},[],{"trials":2651,"activeCount":114,"soonestReadout":2656},[2652],{"nctId":2653,"briefTitle":2654,"status":138,"phases":2655,"primaryCompletion":2656,"completion":1958,"start":2657,"enrollment":1378,"conditions":2658,"interventions":2660},"NCT06040268","Advair HFA in Healthy and HAPE Predisposed Subjects",[91,92],"2026-12-01","2023-12-12",[2659],"Altitude Edema",[2644],{"trials":2662,"activeCount":117},[],{"trials":2664,"activeCount":117},[],{"trials":2666,"activeCount":117},[],{"intervention":2668,"totalTrials":114,"cells":2669},"Full-Spectrum Cannabidiol",{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2684,"PHASE4":2686,"NA":2688},{"trials":2671,"activeCount":117},[],{"trials":2673,"activeCount":117},[],{"trials":2675,"activeCount":114,"soonestReadout":2680},[2676],{"nctId":2677,"briefTitle":2678,"status":138,"phases":2679,"primaryCompletion":2680,"completion":2680,"start":482,"enrollment":190,"conditions":2681,"interventions":2682},"NCT07279558","Cannabidiol and Alcohol Use Disorder Phenotypes",[92],"2029-08-31",[1039],[2668,2683],"Broad-Spectrum Cannabidiol",{"trials":2685,"activeCount":117},[],{"trials":2687,"activeCount":117},[],{"trials":2689,"activeCount":117},[],{"intervention":2683,"totalTrials":114,"cells":2691},{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2702,"PHASE4":2704,"NA":2706},{"trials":2693,"activeCount":117},[],{"trials":2695,"activeCount":117},[],{"trials":2697,"activeCount":114,"soonestReadout":2680},[2698],{"nctId":2677,"briefTitle":2678,"status":138,"phases":2699,"primaryCompletion":2680,"completion":2680,"start":482,"enrollment":190,"conditions":2700,"interventions":2701},[92],[1039],[2668,2683],{"trials":2703,"activeCount":117},[],{"trials":2705,"activeCount":117},[],{"trials":2707,"activeCount":117},[],{"intervention":2709,"totalTrials":114,"cells":2710},"Clemastine Fumarate Combined With Engineered Sound",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2712,"activeCount":117},[],{"trials":2714,"activeCount":117},[],{"trials":2716,"activeCount":114,"soonestReadout":2721},[2717],{"nctId":2718,"briefTitle":2719,"status":138,"phases":2720,"primaryCompletion":2721,"completion":2721,"start":2722,"enrollment":2723,"conditions":2724,"interventions":2751},"NCT07304024","A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound",[91,92],"2028-07","2025-03-31",344,[2725,2726,2727,2728,2729,2730,2731,2732,2733,2734,2735,2736,2737,2738,2739,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750],"Central Auditory Processing Disorder","Hearing Impaired (Partially)","Hearing","Hearing Abnormality","Hearing Disability","Hearing Disorder","Hearing Disorders","Hearing Impairment, Sensorineural","Hearing Handicap","Hearing Impaired","Hearing Impairment","Hearing Loss","Central Auditory Disease","Noise Exposure","Noise Induced Hearing Loss","Noise-Induced Hearing Loss","Sound Perception","Myelin Degeneration","Myelinopathy","Myelin Integrity","Remyelination","Hidden Hearing Loss","Cocktail Party Skill","Cocktail Party Syndrome","CAPD","Age Problem",[2709,2752],"Clemastine Fumarate Combined With Pink Noise",{"trials":2754,"activeCount":117},[],{"trials":2756,"activeCount":117},[],{"trials":2758,"activeCount":117},[],{"intervention":2752,"totalTrials":114,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":117},[],{"trials":2764,"activeCount":117},[],{"trials":2766,"activeCount":114,"soonestReadout":2721},[2767],{"nctId":2718,"briefTitle":2719,"status":138,"phases":2768,"primaryCompletion":2721,"completion":2721,"start":2722,"enrollment":2723,"conditions":2769,"interventions":2770},[91,92],[2725,2726,2727,2728,2729,2730,2731,2732,2733,2734,2735,2736,2737,2738,2739,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750],[2709,2752],{"trials":2772,"activeCount":117},[],{"trials":2774,"activeCount":117},[],{"trials":2776,"activeCount":117},[],{"intervention":78,"totalTrials":114,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2780,"activeCount":117},[],{"trials":2782,"activeCount":117},[],{"trials":2784,"activeCount":114,"soonestReadout":77},[2785],{"nctId":75,"briefTitle":76,"status":186,"phases":2786,"primaryCompletion":77,"completion":2014,"start":2015,"enrollment":31,"conditions":2787,"interventions":2788},[92],[2017],[78,2019,2020,2021,2004],{"trials":2790,"activeCount":117},[],{"trials":2792,"activeCount":117},[],{"trials":2794,"activeCount":117},[],{"intervention":2019,"totalTrials":114,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2798,"activeCount":117},[],{"trials":2800,"activeCount":117},[],{"trials":2802,"activeCount":114,"soonestReadout":77},[2803],{"nctId":75,"briefTitle":76,"status":186,"phases":2804,"primaryCompletion":77,"completion":2014,"start":2015,"enrollment":31,"conditions":2805,"interventions":2806},[92],[2017],[78,2019,2020,2021,2004],{"trials":2808,"activeCount":117},[],{"trials":2810,"activeCount":117},[],{"trials":2812,"activeCount":117},[],{"intervention":2020,"totalTrials":114,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2825,"PHASE4":2827,"NA":2829},{"trials":2816,"activeCount":117},[],{"trials":2818,"activeCount":117},[],{"trials":2820,"activeCount":114,"soonestReadout":77},[2821],{"nctId":75,"briefTitle":76,"status":186,"phases":2822,"primaryCompletion":77,"completion":2014,"start":2015,"enrollment":31,"conditions":2823,"interventions":2824},[92],[2017],[78,2019,2020,2021,2004],{"trials":2826,"activeCount":117},[],{"trials":2828,"activeCount":117},[],{"trials":2830,"activeCount":117},[],{"intervention":2021,"totalTrials":114,"cells":2832},{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2837,"PHASE3":2843,"PHASE4":2845,"NA":2847},{"trials":2834,"activeCount":117},[],{"trials":2836,"activeCount":117},[],{"trials":2838,"activeCount":114,"soonestReadout":77},[2839],{"nctId":75,"briefTitle":76,"status":186,"phases":2840,"primaryCompletion":77,"completion":2014,"start":2015,"enrollment":31,"conditions":2841,"interventions":2842},[92],[2017],[78,2019,2020,2021,2004],{"trials":2844,"activeCount":117},[],{"trials":2846,"activeCount":117},[],{"trials":2848,"activeCount":117},[],{"intervention":2850,"totalTrials":114,"cells":2851},"Dupilumab",{"EARLY_PHASE1":2852,"PHASE1":2854,"PHASE2":2856,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2853,"activeCount":117},[],{"trials":2855,"activeCount":117},[],{"trials":2857,"activeCount":114,"soonestReadout":2862},[2858],{"nctId":2859,"briefTitle":2860,"status":138,"phases":2861,"primaryCompletion":2862,"completion":2863,"start":2864,"enrollment":1165,"conditions":2865,"interventions":2866},"NCT06705387","Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE",[92],"2026-09","2027-03","2024-12-23",[436],[2850,2867],"Fluticasone",{"trials":2869,"activeCount":117},[],{"trials":2871,"activeCount":117},[],{"trials":2873,"activeCount":117},[],{"intervention":2867,"totalTrials":114,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2877,"activeCount":117},[],{"trials":2879,"activeCount":117},[],{"trials":2881,"activeCount":114,"soonestReadout":2862},[2882],{"nctId":2859,"briefTitle":2860,"status":138,"phases":2883,"primaryCompletion":2862,"completion":2863,"start":2864,"enrollment":1165,"conditions":2884,"interventions":2885},[92],[436],[2850,2867],{"trials":2887,"activeCount":117},[],{"trials":2889,"activeCount":117},[],{"trials":2891,"activeCount":117},[],{"intervention":1762,"totalTrials":114,"cells":2893},{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2895,"activeCount":117},[],{"trials":2897,"activeCount":117},[],{"trials":2899,"activeCount":114,"soonestReadout":1757},[2900],{"nctId":1754,"briefTitle":1755,"status":138,"phases":2901,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":190,"conditions":2902,"interventions":2903},[92],[1760],[1762,1732],{"trials":2905,"activeCount":117},[],{"trials":2907,"activeCount":117},[],{"trials":2909,"activeCount":117},[],{"intervention":2911,"totalTrials":114,"cells":2912},"Empagliflozin",{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2928,"PHASE4":2930,"NA":2932},{"trials":2914,"activeCount":117},[],{"trials":2916,"activeCount":117},[],{"trials":2918,"activeCount":114,"soonestReadout":2923},[2919],{"nctId":2920,"briefTitle":2921,"status":186,"phases":2922,"primaryCompletion":2923,"completion":2924,"start":2925,"enrollment":110,"conditions":2926,"interventions":2927},"NCT05510115","Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease",[92],"2026-03-18","2026-08-01","2022-11-18",[166],[2911],{"trials":2929,"activeCount":117},[],{"trials":2931,"activeCount":117},[],{"trials":2933,"activeCount":117},[],{"intervention":1647,"totalTrials":114,"cells":2935},{"EARLY_PHASE1":2936,"PHASE1":2938,"PHASE2":2940,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2937,"activeCount":117},[],{"trials":2939,"activeCount":117},[],{"trials":2941,"activeCount":114,"soonestReadout":1638},[2942],{"nctId":1635,"briefTitle":1636,"status":138,"phases":2943,"primaryCompletion":1638,"completion":1639,"start":1640,"enrollment":34,"conditions":2944,"interventions":2945},[92],[1642,1643,1644,1645],[1647,1587],{"trials":2947,"activeCount":117},[],{"trials":2949,"activeCount":117},[],{"trials":2951,"activeCount":117},[],{"intervention":2333,"totalTrials":114,"cells":2953},{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2958,"PHASE3":2964,"PHASE4":2966,"NA":2968},{"trials":2955,"activeCount":117},[],{"trials":2957,"activeCount":117},[],{"trials":2959,"activeCount":114,"soonestReadout":2327},[2960],{"nctId":2324,"briefTitle":2325,"status":138,"phases":2961,"primaryCompletion":2327,"completion":2328,"start":771,"enrollment":228,"conditions":2962,"interventions":2963},[92],[2330,2331],[2315,2333],{"trials":2965,"activeCount":117},[],{"trials":2967,"activeCount":117},[],{"trials":2969,"activeCount":117},[],{"intervention":2971,"totalTrials":114,"cells":2972},"Zoster Vaccine Recombinant",{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2977,"PHASE3":2990,"PHASE4":2992,"NA":2994},{"trials":2974,"activeCount":117},[],{"trials":2976,"activeCount":117},[],{"trials":2978,"activeCount":114,"soonestReadout":2983},[2979],{"nctId":2980,"briefTitle":2981,"status":138,"phases":2982,"primaryCompletion":2983,"completion":2984,"start":2985,"enrollment":706,"conditions":2986,"interventions":2989},"NCT05775718","Shingrix In Recipients of Allogeneic Transplants",[92],"2028-01-20","2030-12-01","2023-10-24",[2987,2988],"Bone Marrow Transplant","Stem Cell Transplant",[2971],{"trials":2991,"activeCount":117},[],{"trials":2993,"activeCount":117},[],{"trials":2995,"activeCount":117},[],{"intervention":2997,"totalTrials":114,"cells":2998},"NT219",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3016,"PHASE4":3018,"NA":3020},{"trials":3000,"activeCount":117},[],{"trials":3002,"activeCount":117},[],{"trials":3004,"activeCount":114,"soonestReadout":108},[3005],{"nctId":3006,"briefTitle":3007,"status":186,"phases":3008,"primaryCompletion":108,"completion":3009,"start":3010,"enrollment":3011,"conditions":3012,"interventions":3015},"NCT06919666","NT219 Combined With Standard of Care Biologic Therapy in Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[91,92],"2031-02","2025-06-12",29,[3013,3014],"Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma",[2997],{"trials":3017,"activeCount":117},[],{"trials":3019,"activeCount":117},[],{"trials":3021,"activeCount":117},[],{"intervention":1658,"totalTrials":114,"cells":3023},{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3028,"PHASE3":3034,"PHASE4":3036,"NA":3038},{"trials":3025,"activeCount":117},[],{"trials":3027,"activeCount":117},[],{"trials":3029,"activeCount":114,"soonestReadout":1652},[3030],{"nctId":1649,"briefTitle":1650,"status":186,"phases":3031,"primaryCompletion":1652,"completion":937,"start":1653,"enrollment":1654,"conditions":3032,"interventions":3033},[92],[1656],[1658,1659,1587],{"trials":3035,"activeCount":117},[],{"trials":3037,"activeCount":117},[],{"trials":3039,"activeCount":117},[],{"intervention":3041,"totalTrials":114,"cells":3042},"Brexpiprazole",{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3044,"activeCount":117},[],{"trials":3046,"activeCount":117},[],{"trials":3048,"activeCount":114,"soonestReadout":658},[3049],{"nctId":3050,"briefTitle":3051,"status":138,"phases":3052,"primaryCompletion":658,"completion":658,"start":3053,"enrollment":3054,"conditions":3055,"interventions":3056},"NCT04066192","Brexpiprazole in Alcohol Use Disorder",[92],"2020-10-30",250,[1039],[3041],{"trials":3058,"activeCount":117},[],{"trials":3060,"activeCount":117},[],{"trials":3062,"activeCount":117},[],{"intervention":1961,"totalTrials":114,"cells":3064},{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3069,"PHASE3":3075,"PHASE4":3077,"NA":3079},{"trials":3066,"activeCount":117},[],{"trials":3068,"activeCount":117},[],{"trials":3070,"activeCount":114,"soonestReadout":1958},[3071],{"nctId":1955,"briefTitle":1956,"status":186,"phases":3072,"primaryCompletion":1958,"completion":1958,"start":912,"enrollment":649,"conditions":3073,"interventions":3074},[92],[24,131],[1961,1906],{"trials":3076,"activeCount":117},[],{"trials":3078,"activeCount":117},[],{"trials":3080,"activeCount":117},[],{"intervention":3082,"totalTrials":114,"cells":3083},"Tofacitinib Oral Solution",{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3098,"PHASE4":3100,"NA":3102},{"trials":3085,"activeCount":117},[],{"trials":3087,"activeCount":117},[],{"trials":3089,"activeCount":114,"soonestReadout":3094},[3090],{"nctId":3091,"briefTitle":3092,"status":138,"phases":3093,"primaryCompletion":3094,"completion":3094,"start":771,"enrollment":3095,"conditions":3096,"interventions":3097},"NCT07598643","Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1",[92],"2030-08",92,[2100],[3082],{"trials":3099,"activeCount":117},[],{"trials":3101,"activeCount":117},[],{"trials":3103,"activeCount":117},[],{"intervention":3105,"totalTrials":114,"cells":3106},"Amivantamab 1050mg",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3108,"activeCount":117},[],{"trials":3110,"activeCount":117},[],{"trials":3112,"activeCount":114,"soonestReadout":3117},[3113],{"nctId":3114,"briefTitle":3115,"status":186,"phases":3116,"primaryCompletion":3117,"completion":590,"start":3118,"enrollment":253,"conditions":3119,"interventions":3122},"NCT05845671","Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations",[91,92],"2027-01","2023-07-17",[3120,3121],"Lung Cancer","Non Small Cell Lung Cancer",[3105,3123,3124,3124],"Amivantamab 1400mg","Amivantamab",{"trials":3126,"activeCount":117},[],{"trials":3128,"activeCount":117},[],{"trials":3130,"activeCount":117},[],{"intervention":3123,"totalTrials":114,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3134,"activeCount":117},[],{"trials":3136,"activeCount":117},[],{"trials":3138,"activeCount":114,"soonestReadout":3117},[3139],{"nctId":3114,"briefTitle":3115,"status":186,"phases":3140,"primaryCompletion":3117,"completion":590,"start":3118,"enrollment":253,"conditions":3141,"interventions":3142},[91,92],[3120,3121],[3105,3123,3124,3124],{"trials":3144,"activeCount":117},[],{"trials":3146,"activeCount":117},[],{"trials":3148,"activeCount":117},[],{"intervention":3124,"totalTrials":114,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":117},[],{"trials":3154,"activeCount":117},[],{"trials":3156,"activeCount":114,"soonestReadout":3117},[3157],{"nctId":3114,"briefTitle":3115,"status":186,"phases":3158,"primaryCompletion":3117,"completion":590,"start":3118,"enrollment":253,"conditions":3159,"interventions":3160},[91,92],[3120,3121],[3105,3123,3124,3124],{"trials":3162,"activeCount":117},[],{"trials":3164,"activeCount":117},[],{"trials":3166,"activeCount":117},[],{"intervention":1530,"totalTrials":114,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3170,"activeCount":117},[],{"trials":3172,"activeCount":117},[],{"trials":3174,"activeCount":114,"soonestReadout":1525},[3175],{"nctId":1522,"briefTitle":1523,"status":138,"phases":3176,"primaryCompletion":1525,"completion":1526,"start":1527,"enrollment":28,"conditions":3177,"interventions":3178},[92],[1509],[1530,1496,1479],{"trials":3180,"activeCount":117},[],{"trials":3182,"activeCount":117},[],{"trials":3184,"activeCount":117},[],{"intervention":2248,"totalTrials":114,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3188,"activeCount":117},[],{"trials":3190,"activeCount":117},[],{"trials":3192,"activeCount":114,"soonestReadout":47},[3193],{"nctId":45,"briefTitle":46,"status":186,"phases":3194,"primaryCompletion":47,"completion":2243,"start":2244,"enrollment":2245,"conditions":3195,"interventions":3196},[92],[21],[48,2248],{"trials":3198,"activeCount":117},[],{"trials":3200,"activeCount":117},[],{"trials":3202,"activeCount":117},[],{"intervention":1865,"totalTrials":114,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3206,"activeCount":117},[],{"trials":3208,"activeCount":117},[],{"trials":3210,"activeCount":114,"soonestReadout":1858},[3211],{"nctId":1855,"briefTitle":1856,"status":186,"phases":3212,"primaryCompletion":1858,"completion":1163,"start":1859,"enrollment":1860,"conditions":3213,"interventions":3214},[92],[1862,1863],[1865,1866,1838,1867],{"trials":3216,"activeCount":117},[],{"trials":3218,"activeCount":117},[],{"trials":3220,"activeCount":117},[],{"intervention":1866,"totalTrials":114,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3224,"activeCount":117},[],{"trials":3226,"activeCount":117},[],{"trials":3228,"activeCount":114,"soonestReadout":1858},[3229],{"nctId":1855,"briefTitle":1856,"status":186,"phases":3230,"primaryCompletion":1858,"completion":1163,"start":1859,"enrollment":1860,"conditions":3231,"interventions":3232},[92],[1862,1863],[1865,1866,1838,1867],{"trials":3234,"activeCount":117},[],{"trials":3236,"activeCount":117},[],{"trials":3238,"activeCount":117},[],{"intervention":1867,"totalTrials":114,"cells":3240},{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3245,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3242,"activeCount":117},[],{"trials":3244,"activeCount":117},[],{"trials":3246,"activeCount":114,"soonestReadout":1858},[3247],{"nctId":1855,"briefTitle":1856,"status":186,"phases":3248,"primaryCompletion":1858,"completion":1163,"start":1859,"enrollment":1860,"conditions":3249,"interventions":3250},[92],[1862,1863],[1865,1866,1838,1867],{"trials":3252,"activeCount":117},[],{"trials":3254,"activeCount":117},[],{"trials":3256,"activeCount":117},[],{"intervention":3258,"totalTrials":114,"cells":3259},"CXA-10",{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3264,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3261,"activeCount":117},[],{"trials":3263,"activeCount":117},[],{"trials":3265,"activeCount":114,"soonestReadout":3270},[3266],{"nctId":3267,"briefTitle":3268,"status":138,"phases":3269,"primaryCompletion":3270,"completion":3271,"start":3272,"enrollment":1378,"conditions":3273,"interventions":3274},"NCT03762395","Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma",[92],"2029-11-30","2030-01-30","2023-02-08",[2501,15],[3258],{"trials":3276,"activeCount":117},[],{"trials":3278,"activeCount":117},[],{"trials":3280,"activeCount":117},[],{"intervention":1540,"totalTrials":114,"cells":3282},{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3287,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3284,"activeCount":117},[],{"trials":3286,"activeCount":117},[],{"trials":3288,"activeCount":114,"soonestReadout":1535},[3289],{"nctId":1532,"briefTitle":1533,"status":186,"phases":3290,"primaryCompletion":1535,"completion":457,"start":1536,"enrollment":22,"conditions":3291,"interventions":3292},[91,92],[1538],[1540,1479,1540,1479],{"trials":3294,"activeCount":117},[],{"trials":3296,"activeCount":117},[],{"trials":3298,"activeCount":117},[],{"intervention":1724,"totalTrials":114,"cells":3300},{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3311,"PHASE4":3313,"NA":3315},{"trials":3302,"activeCount":117},[],{"trials":3304,"activeCount":117},[],{"trials":3306,"activeCount":114,"soonestReadout":1717},[3307],{"nctId":1714,"briefTitle":1715,"status":138,"phases":3308,"primaryCompletion":1717,"completion":1718,"start":1719,"enrollment":1666,"conditions":3309,"interventions":3310},[92],[1721,1722,1694],[1724,1607],{"trials":3312,"activeCount":117},[],{"trials":3314,"activeCount":117},[],{"trials":3316,"activeCount":117},[],{"intervention":3318,"totalTrials":114,"cells":3319},"S-equol",{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3324,"PHASE3":3335,"PHASE4":3337,"NA":3339},{"trials":3321,"activeCount":117},[],{"trials":3323,"activeCount":117},[],{"trials":3325,"activeCount":114,"soonestReadout":357},[3326],{"nctId":3327,"briefTitle":3328,"status":138,"phases":3329,"primaryCompletion":357,"completion":357,"start":3330,"enrollment":3331,"conditions":3332,"interventions":3334},"NCT06128278","Acute Equol Supplementation and Vascular Function in Women With and Without CKD",[92],"2023-03-07",38,[3333,2611,710],"Chronic Kidney Diseases",[3318],{"trials":3336,"activeCount":117},[],{"trials":3338,"activeCount":117},[],{"trials":3340,"activeCount":117},[],{"intervention":3342,"totalTrials":114,"cells":3343},"Tirzepatide",{"EARLY_PHASE1":3344,"PHASE1":3346,"PHASE2":3348,"PHASE3":3357,"PHASE4":3359,"NA":3361},{"trials":3345,"activeCount":117},[],{"trials":3347,"activeCount":117},[],{"trials":3349,"activeCount":114,"soonestReadout":3354},[3350],{"nctId":3351,"briefTitle":3352,"status":138,"phases":3353,"primaryCompletion":3354,"completion":3354,"start":358,"enrollment":1009,"conditions":3355,"interventions":3356},"NCT06582875","Glucagon-Like Peptide-1 Receptor Agonist in ADPKD",[92],"2029-06-30",[193,15],[3342],{"trials":3358,"activeCount":117},[],{"trials":3360,"activeCount":117},[],{"trials":3362,"activeCount":117},[],{"intervention":2103,"totalTrials":114,"cells":3364},{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3366,"activeCount":117},[],{"trials":3368,"activeCount":117},[],{"trials":3370,"activeCount":114,"soonestReadout":251},[3371],{"nctId":2095,"briefTitle":2096,"status":186,"phases":3372,"primaryCompletion":251,"completion":251,"start":2098,"enrollment":508,"conditions":3373,"interventions":3374},[92],[2100,2101],[2086,2103,2104],{"trials":3376,"activeCount":117},[],{"trials":3378,"activeCount":117},[],{"trials":3380,"activeCount":117},[],{"intervention":3382,"totalTrials":114,"cells":3383},"L-citrulline",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3388,"PHASE3":3400,"PHASE4":3402,"NA":3404},{"trials":3385,"activeCount":117},[],{"trials":3387,"activeCount":117},[],{"trials":3389,"activeCount":114,"soonestReadout":3394},[3390],{"nctId":3391,"briefTitle":3392,"status":138,"phases":3393,"primaryCompletion":3394,"completion":3394,"start":3395,"enrollment":3396,"conditions":3397,"interventions":3399},"NCT05259904","Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation",[92],"2028-10","2023-03-08",75,[3398,2501],"Post Deployment Related Asthma",[3382],{"trials":3401,"activeCount":117},[],{"trials":3403,"activeCount":117},[],{"trials":3405,"activeCount":117},[],{"intervention":1671,"totalTrials":1548,"cells":3407},{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3412,"PHASE3":3433,"PHASE4":3435,"NA":3437},{"trials":3409,"activeCount":117},[],{"trials":3411,"activeCount":117},[],{"trials":3413,"activeCount":114,"soonestReadout":2214},[3414,3418,3429],{"nctId":2211,"briefTitle":2212,"status":186,"phases":3415,"primaryCompletion":2214,"completion":2215,"start":2216,"enrollment":734,"conditions":3416,"interventions":3417},[92],[2218,2219,2220],[2222,2192,1671],{"nctId":3419,"briefTitle":3420,"status":160,"phases":3421,"primaryCompletion":3422,"completion":3423,"start":3424,"enrollment":19,"conditions":3425,"interventions":3427},"NCT01209442","Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme",[92],"2014-09-07","2017-02-03","2010-09-16",[3426],"Glioblastoma Multiforme",[1671,3428],"Temozolomide",{"nctId":1661,"briefTitle":1662,"status":160,"phases":3430,"primaryCompletion":1664,"completion":1665,"start":1536,"enrollment":1666,"conditions":3431,"interventions":3432},[92],[1668,1669],[1587,1671,1672],{"trials":3434,"activeCount":117},[],{"trials":3436,"activeCount":117},[],{"trials":3438,"activeCount":117},[3439],{"nctId":3440,"briefTitle":3441,"status":125,"phases":3442,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":902,"conditions":3445,"interventions":3447},"NCT01201850","The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors",[95],"2016-08-04","2010-06-28",[3446],"Radiation Necrosis",[1671],{"intervention":1659,"totalTrials":1548,"cells":3449},{"EARLY_PHASE1":3450,"PHASE1":3452,"PHASE2":3468,"PHASE3":3474,"PHASE4":3476,"NA":3478},{"trials":3451,"activeCount":117},[],{"trials":3453,"activeCount":117},[3454,3464],{"nctId":3455,"briefTitle":3456,"status":160,"phases":3457,"primaryCompletion":3458,"completion":3459,"start":3460,"enrollment":99,"conditions":3461,"interventions":3462},"NCT04091867","sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC",[91],"2021-05-14","2022-10-25","2020-01-06",[2206],[3463,1659],"sEphB4-HSA with chemotherapy",{"nctId":1698,"briefTitle":1699,"status":160,"phases":3465,"primaryCompletion":1701,"completion":1702,"start":1703,"enrollment":34,"conditions":3466,"interventions":3467},[91],[1705],[1607,1659],{"trials":3469,"activeCount":114,"soonestReadout":1652},[3470],{"nctId":1649,"briefTitle":1650,"status":186,"phases":3471,"primaryCompletion":1652,"completion":937,"start":1653,"enrollment":1654,"conditions":3472,"interventions":3473},[92],[1656],[1658,1659,1587],{"trials":3475,"activeCount":117},[],{"trials":3477,"activeCount":117},[],{"trials":3479,"activeCount":117},[3480],{"nctId":3481,"briefTitle":3482,"status":125,"phases":3483,"primaryCompletion":3484,"completion":3484,"start":163,"enrollment":2475,"conditions":3485,"interventions":3487},"NCT00430027","Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma",[95],"2008-08",[3486],"Esophageal Adenocarcinoma",[3488,3489,1659],"Capecitabine","Oxaliplatin",{"intervention":1751,"totalTrials":199,"cells":3491},{"EARLY_PHASE1":3492,"PHASE1":3494,"PHASE2":3496,"PHASE3":3502,"PHASE4":3504,"NA":3506},{"trials":3493,"activeCount":117},[],{"trials":3495,"activeCount":117},[],{"trials":3497,"activeCount":114,"soonestReadout":1744},[3498],{"nctId":1741,"briefTitle":1742,"status":138,"phases":3499,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":288,"conditions":3500,"interventions":3501},[92],[1748,1749],[1751,1752],{"trials":3503,"activeCount":117},[],{"trials":3505,"activeCount":117},[],{"trials":3507,"activeCount":117},[3508],{"nctId":3509,"briefTitle":3510,"status":715,"phases":3511,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":3515,"conditions":3516,"interventions":3523},"NCT03680495","Steroid Resistance During COPD Exacerbations With Respiratory Failure",[],"2020-03","2021-01","2017-07-21",46,[3517,3518,3519,3520,3521,3522],"COPD","Emphysema or COPD","COPD Exacerbation","COPD Exacerbation Acute","Respiratory Failure","Ventilatory Failure",[1751],{"intervention":3525,"totalTrials":199,"cells":3526},"Psilocybin",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3549,"PHASE3":3551,"PHASE4":3553,"NA":3555},{"trials":3528,"activeCount":117},[],{"trials":3530,"activeCount":199,"soonestReadout":251},[3531,3541],{"nctId":3532,"briefTitle":3533,"status":138,"phases":3534,"primaryCompletion":3535,"completion":3535,"start":3536,"enrollment":2450,"conditions":3537,"interventions":3540},"NCT07516405","Safety and Tolerability Trial of Psilocybin in Healthy Older Adults",[91],"2028-03","2026-04-01",[3538,3539],"Healthy Volunteer","Older Adults (65-85 Years)",[3525],{"nctId":3542,"briefTitle":3543,"status":138,"phases":3544,"primaryCompletion":251,"completion":1600,"start":3545,"enrollment":28,"conditions":3546,"interventions":3548},"NCT06430541","Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence",[91],"2024-11-21",[21,3547],"Ovarian Cancer",[3525],{"trials":3550,"activeCount":117},[],{"trials":3552,"activeCount":117},[],{"trials":3554,"activeCount":117},[],{"trials":3556,"activeCount":117},[],{"intervention":1633,"totalTrials":199,"cells":3558},{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3574,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3560,"activeCount":117},[],{"trials":3562,"activeCount":114,"soonestReadout":3567},[3563],{"nctId":3564,"briefTitle":3565,"status":138,"phases":3566,"primaryCompletion":3567,"completion":3568,"start":3569,"enrollment":228,"conditions":3570,"interventions":3572},"NCT07030283","Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis",[91],"2028-07-01","2030-07-01","2025-12-31",[3571],"Pancreatic Ductal Adenocarcinoma (PDAC)",[1633,3573],"NALIRIFOX",{"trials":3575,"activeCount":117},[3576],{"nctId":1620,"briefTitle":1621,"status":1622,"phases":3577,"primaryCompletion":1624,"completion":1624,"start":1017,"enrollment":117,"conditions":3578,"interventions":3579},[92],[1626,1627,1628,1629,1630],[1632,1633,1587],{"trials":3581,"activeCount":117},[],{"trials":3583,"activeCount":117},[],{"trials":3585,"activeCount":117},[],{"intervention":3587,"totalTrials":99,"cells":3588},"Choline",{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3624,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3590,"activeCount":117},[],{"trials":3592,"activeCount":114,"soonestReadout":3608},[3593,3604,3614],{"nctId":3594,"briefTitle":3595,"status":160,"phases":3596,"primaryCompletion":3597,"completion":3597,"start":3598,"enrollment":3599,"conditions":3600,"interventions":3603},"NCT00332124","Safety and Effectiveness of Taking Choline Supplements During Pregnancy for Improving Infant Brain Development",[91],"2017-03","2006-06",351,[3601,3602],"Pregnancy","Child Development",[3587],{"nctId":3605,"briefTitle":3606,"status":138,"phases":3607,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":3610,"conditions":3611,"interventions":3613},"NCT06379971","Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development",[91],"2029-04-30","2024-11-25",140,[3602,3612],"Cannabis Use",[3587],{"nctId":3615,"briefTitle":3616,"status":160,"phases":3617,"primaryCompletion":3618,"completion":3618,"start":3619,"enrollment":3620,"conditions":3621,"interventions":3623},"NCT03028857","Choline Supplementation During Pregnancy: Impact on Attention and Social Withdrawal",[91],"2025-12-22","2017-06-12",216,[3602,3622],"Prenatal Stress",[3587],{"trials":3625,"activeCount":117},[],{"trials":3627,"activeCount":117},[],{"trials":3629,"activeCount":117},[],{"trials":3631,"activeCount":117},[],{"intervention":3633,"totalTrials":114,"cells":3634},"Follicle Stimulating Hormone",{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3648,"PHASE3":3650,"PHASE4":3652,"NA":3654},{"trials":3636,"activeCount":117},[],{"trials":3638,"activeCount":114,"soonestReadout":3643},[3639],{"nctId":3640,"briefTitle":3641,"status":138,"phases":3642,"primaryCompletion":3643,"completion":2014,"start":3644,"enrollment":263,"conditions":3645,"interventions":3647},"NCT06414096","Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome",[91],"2025-11","2024-10-01",[3646,15],"Infertility",[3633],{"trials":3649,"activeCount":117},[],{"trials":3651,"activeCount":117},[],{"trials":3653,"activeCount":117},[],{"trials":3655,"activeCount":117},[],{"intervention":3573,"totalTrials":114,"cells":3657},{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3666,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3659,"activeCount":117},[],{"trials":3661,"activeCount":114,"soonestReadout":3567},[3662],{"nctId":3564,"briefTitle":3565,"status":138,"phases":3663,"primaryCompletion":3567,"completion":3568,"start":3569,"enrollment":228,"conditions":3664,"interventions":3665},[91],[3571],[1633,3573],{"trials":3667,"activeCount":117},[],{"trials":3669,"activeCount":117},[],{"trials":3671,"activeCount":117},[],{"trials":3673,"activeCount":117},[],{"intervention":3675,"totalTrials":114,"cells":3676},"CD64 CAR T Cells",{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3691,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3678,"activeCount":117},[],{"trials":3680,"activeCount":114,"soonestReadout":1121},[3681],{"nctId":3682,"briefTitle":3683,"status":106,"phases":3684,"primaryCompletion":1121,"completion":3685,"start":2404,"enrollment":25,"conditions":3686,"interventions":3690},"NCT07347418","CD64 CAR T Cell Therapy in Adults With Relapsed and\u002For Refractory AML",[91],"2032-06",[3687,3688,2331,3689],"Refractory Acute Myeloid Leukemia (AML)","Relapsed Acute Myeloid Leukemia (AML)","AML (Acute Myeloid Leukemia)",[3675],{"trials":3692,"activeCount":117},[],{"trials":3694,"activeCount":117},[],{"trials":3696,"activeCount":117},[],{"trials":3698,"activeCount":117},[],{"intervention":3700,"totalTrials":114,"cells":3701},"Losartan",{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3716,"PHASE3":3718,"PHASE4":3720,"NA":3722},{"trials":3703,"activeCount":117},[],{"trials":3705,"activeCount":114,"soonestReadout":772},[3706],{"nctId":3707,"briefTitle":3708,"status":138,"phases":3709,"primaryCompletion":772,"completion":2243,"start":3710,"enrollment":3711,"conditions":3712,"interventions":3714},"NCT03900793","Losartan + Sunitinib in Treatment of Osteosarcoma",[91],"2019-08-26",41,[3713],"Osteosarcoma",[3700,3715],"Sunitinib",{"trials":3717,"activeCount":117},[],{"trials":3719,"activeCount":117},[],{"trials":3721,"activeCount":117},[],{"trials":3723,"activeCount":117},[],{"intervention":3715,"totalTrials":114,"cells":3725},{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3734,"PHASE3":3736,"PHASE4":3738,"NA":3740},{"trials":3727,"activeCount":117},[],{"trials":3729,"activeCount":114,"soonestReadout":772},[3730],{"nctId":3707,"briefTitle":3708,"status":138,"phases":3731,"primaryCompletion":772,"completion":2243,"start":3710,"enrollment":3711,"conditions":3732,"interventions":3733},[91],[3713],[3700,3715],{"trials":3735,"activeCount":117},[],{"trials":3737,"activeCount":117},[],{"trials":3739,"activeCount":117},[],{"trials":3741,"activeCount":117},[],{"intervention":3743,"totalTrials":114,"cells":3744},"CD19x22 CAR T",{"EARLY_PHASE1":3745,"PHASE1":3747,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3762},{"trials":3746,"activeCount":117},[],{"trials":3748,"activeCount":114,"soonestReadout":1600},[3749],{"nctId":3750,"briefTitle":3751,"status":138,"phases":3752,"primaryCompletion":1600,"completion":1850,"start":3753,"enrollment":1666,"conditions":3754,"interventions":3755},"NCT06559189","CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",[91],"2024-09-27",[2407],[3743],{"trials":3757,"activeCount":117},[],{"trials":3759,"activeCount":117},[],{"trials":3761,"activeCount":117},[],{"trials":3763,"activeCount":117},[],{"intervention":3765,"totalTrials":114,"cells":3766},"CD19 Directed CAR T Cell",{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3782,"PHASE3":3784,"PHASE4":3786,"NA":3788},{"trials":3768,"activeCount":117},[],{"trials":3770,"activeCount":114,"soonestReadout":3775},[3771],{"nctId":3772,"briefTitle":3773,"status":138,"phases":3774,"primaryCompletion":3775,"completion":3776,"start":3777,"enrollment":3011,"conditions":3778,"interventions":3781},"NCT05535855","UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1",[91],"2027-06-30","2030-06-30","2024-01-24",[3779,3780],"Acute Lymphoid Leukemia","Acute Lymphoblastic Leukemia",[3765],{"trials":3783,"activeCount":117},[],{"trials":3785,"activeCount":117},[],{"trials":3787,"activeCount":117},[],{"trials":3789,"activeCount":117},[],{"intervention":3791,"totalTrials":114,"cells":3792},"CD19x22 CAR T Cells",{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3810,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3794,"activeCount":117},[],{"trials":3796,"activeCount":114,"soonestReadout":251},[3797],{"nctId":3798,"briefTitle":3799,"status":138,"phases":3800,"primaryCompletion":251,"completion":3801,"start":3802,"enrollment":3803,"conditions":3804,"interventions":3809},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[91],"2027-12","2021-12-21",68,[3805,3806,3807,3808],"Non-Hodgkin Lymphoma","B-cell Non-Hodgkin Lymphoma (B-NHL)","Mantle Cell Lymphoma (MCL)","CNS Lymphoma",[3791],{"trials":3811,"activeCount":117},[],{"trials":3813,"activeCount":117},[],{"trials":3815,"activeCount":117},[],{"trials":3817,"activeCount":117},[],{"intervention":3819,"totalTrials":114,"cells":3820},"Injectable semaglutide",{"EARLY_PHASE1":3821,"PHASE1":3823,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3822,"activeCount":117},[],{"trials":3824,"activeCount":114,"soonestReadout":3829},[3825],{"nctId":3826,"briefTitle":3827,"status":138,"phases":3828,"primaryCompletion":3829,"completion":1375,"start":3830,"enrollment":2450,"conditions":3831,"interventions":3836},"NCT06575738","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents",[91],"2027-09-01","2024-10-11",[15,1405,3832,3833,3834,3835],"Body-Weight Trajectory","Weight Loss Trajectory","Bariatric Surgery","Anti-obesity Agents",[3819],{"trials":3838,"activeCount":117},[],{"trials":3840,"activeCount":117},[],{"trials":3842,"activeCount":117},[],{"trials":3844,"activeCount":117},[],{"intervention":1696,"totalTrials":114,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3855,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3848,"activeCount":117},[],{"trials":3850,"activeCount":114,"soonestReadout":383},[3851],{"nctId":1686,"briefTitle":1687,"status":138,"phases":3852,"primaryCompletion":383,"completion":1689,"start":1690,"enrollment":110,"conditions":3853,"interventions":3854},[91],[1692,1693,1694],[1696,1607],{"trials":3856,"activeCount":117},[],{"trials":3858,"activeCount":117},[],{"trials":3860,"activeCount":117},[],{"trials":3862,"activeCount":117},[],{"intervention":3864,"totalTrials":114,"cells":3865},"Trastuzumab after SubQ GM-CSF",{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3880,"PHASE3":3882,"PHASE4":3884,"NA":3886},{"trials":3867,"activeCount":117},[],{"trials":3869,"activeCount":114,"soonestReadout":3874},[3870],{"nctId":3871,"briefTitle":3872,"status":186,"phases":3873,"primaryCompletion":3874,"completion":2863,"start":3619,"enrollment":3875,"conditions":3876,"interventions":3878},"NCT02774421","Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma",[91],"2025-02-27",33,[3877],"Posterior Fossa Ependymoma (PFEPN)",[3864,3879],"Trastuzumab in combination with SubQ GM-CSF",{"trials":3881,"activeCount":117},[],{"trials":3883,"activeCount":117},[],{"trials":3885,"activeCount":117},[],{"trials":3887,"activeCount":117},[],{"intervention":3879,"totalTrials":114,"cells":3889},{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3898,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3891,"activeCount":117},[],{"trials":3893,"activeCount":114,"soonestReadout":3874},[3894],{"nctId":3871,"briefTitle":3872,"status":186,"phases":3895,"primaryCompletion":3874,"completion":2863,"start":3619,"enrollment":3875,"conditions":3896,"interventions":3897},[91],[3877],[3864,3879],{"trials":3899,"activeCount":117},[],{"trials":3901,"activeCount":117},[],{"trials":3903,"activeCount":117},[],{"trials":3905,"activeCount":117},[],{"intervention":1565,"totalTrials":114,"cells":3907},{"EARLY_PHASE1":3908,"PHASE1":3910,"PHASE2":3916,"PHASE3":3918,"PHASE4":3920,"NA":3922},{"trials":3909,"activeCount":117},[],{"trials":3911,"activeCount":114,"soonestReadout":1558},[3912],{"nctId":1555,"briefTitle":1556,"status":138,"phases":3913,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":1561,"conditions":3914,"interventions":3915},[91],[1563],[1496,1565],{"trials":3917,"activeCount":117},[],{"trials":3919,"activeCount":117},[],{"trials":3921,"activeCount":117},[],{"trials":3923,"activeCount":117},[],{"intervention":1497,"totalTrials":114,"cells":3925},{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3934,"PHASE3":3936,"PHASE4":3938,"NA":3940},{"trials":3927,"activeCount":117},[],{"trials":3929,"activeCount":114,"soonestReadout":251},[3930],{"nctId":1486,"briefTitle":1487,"status":138,"phases":3931,"primaryCompletion":251,"completion":1489,"start":1490,"enrollment":19,"conditions":3932,"interventions":3933},[91],[1492,1493,1494],[1496,1479,1497],{"trials":3935,"activeCount":117},[],{"trials":3937,"activeCount":117},[],{"trials":3939,"activeCount":117},[],{"trials":3941,"activeCount":117},[],{"intervention":3943,"totalTrials":114,"cells":3944},"Ferrous sulfate 325mg",{"EARLY_PHASE1":3945,"PHASE1":3956,"PHASE2":3958,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3946,"activeCount":114,"soonestReadout":1850},[3947],{"nctId":3948,"briefTitle":3949,"status":106,"phases":3950,"primaryCompletion":1850,"completion":3951,"start":3535,"enrollment":263,"conditions":3952,"interventions":3955},"NCT05349630","Impact of Iron Supplementation on Right Ventricular Function and Exercise Performance in Hypoxia",[90],"2030-05",[3953,3954],"Right Ventricular Dysfunction","Hypoxia",[3943],{"trials":3957,"activeCount":117},[],{"trials":3959,"activeCount":117},[],{"trials":3961,"activeCount":117},[],{"trials":3963,"activeCount":117},[],{"trials":3965,"activeCount":117},[],{"intervention":3967,"totalTrials":114,"cells":3968},"5-ALA",{"EARLY_PHASE1":3969,"PHASE1":3980,"PHASE2":3982,"PHASE3":3984,"PHASE4":3986,"NA":3988},{"trials":3970,"activeCount":114,"soonestReadout":3975},[3971],{"nctId":3972,"briefTitle":3973,"status":106,"phases":3974,"primaryCompletion":3975,"completion":3976,"start":3536,"enrollment":28,"conditions":3977,"interventions":3979},"NCT07038278","5-AminoLevulinic Acid Aided Resection Margins in Sarcoma",[90],"2027-11-01","2028-11-01",[3978],"Soft Tissue Sarcoma (STS)",[3967],{"trials":3981,"activeCount":117},[],{"trials":3983,"activeCount":117},[],{"trials":3985,"activeCount":117},[],{"trials":3987,"activeCount":117},[],{"trials":3989,"activeCount":117},[],{"intervention":113,"totalTrials":114,"cells":3991},{"EARLY_PHASE1":3992,"PHASE1":3998,"PHASE2":4000,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3993,"activeCount":114,"soonestReadout":108},[3994],{"nctId":104,"briefTitle":105,"status":106,"phases":3995,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":3996,"interventions":3997},[90],[24],[98,113],{"trials":3999,"activeCount":117},[],{"trials":4001,"activeCount":117},[],{"trials":4003,"activeCount":117},[],{"trials":4005,"activeCount":117},[],{"trials":4007,"activeCount":117},[],{"intervention":4009,"totalTrials":114,"cells":4010},"Ibuprofen 200 mg and acetaminphen 650 mg",{"EARLY_PHASE1":4011,"PHASE1":4024,"PHASE2":4026,"PHASE3":4028,"PHASE4":4030,"NA":4032},{"trials":4012,"activeCount":114,"soonestReadout":4017},[4013],{"nctId":4014,"briefTitle":4015,"status":138,"phases":4016,"primaryCompletion":4017,"completion":4017,"start":4018,"enrollment":4019,"conditions":4020,"interventions":4022},"NCT04059172","Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management",[90],"2028-06-01","2019-12-10",375,[4021],"Pain, Orofacial",[4009,4023],"Ibuprofen 200 mg",{"trials":4025,"activeCount":117},[],{"trials":4027,"activeCount":117},[],{"trials":4029,"activeCount":117},[],{"trials":4031,"activeCount":117},[],{"trials":4033,"activeCount":117},[],{"intervention":4023,"totalTrials":114,"cells":4035},{"EARLY_PHASE1":4036,"PHASE1":4042,"PHASE2":4044,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4037,"activeCount":114,"soonestReadout":4017},[4038],{"nctId":4014,"briefTitle":4015,"status":138,"phases":4039,"primaryCompletion":4017,"completion":4017,"start":4018,"enrollment":4019,"conditions":4040,"interventions":4041},[90],[4021],[4009,4023],{"trials":4043,"activeCount":117},[],{"trials":4045,"activeCount":117},[],{"trials":4047,"activeCount":117},[],{"trials":4049,"activeCount":117},[],{"trials":4051,"activeCount":117},[],{"intervention":83,"totalTrials":114,"cells":4053},{"EARLY_PHASE1":4054,"PHASE1":4062,"PHASE2":4064,"PHASE3":4066,"PHASE4":4068,"NA":4070},{"trials":4055,"activeCount":114,"soonestReadout":82},[4056],{"nctId":80,"briefTitle":81,"status":588,"phases":4057,"primaryCompletion":82,"completion":286,"start":4058,"enrollment":114,"conditions":4059,"interventions":4061},[90],"2023-08-23",[4060],"Posterior Column Ataxia With Retinitis Pigmentosa",[83],{"trials":4063,"activeCount":117},[],{"trials":4065,"activeCount":117},[],{"trials":4067,"activeCount":117},[],{"trials":4069,"activeCount":117},[],{"trials":4071,"activeCount":117},[],{"intervention":68,"totalTrials":114,"cells":4073},{"EARLY_PHASE1":4074,"PHASE1":4083,"PHASE2":4085,"PHASE3":4087,"PHASE4":4089,"NA":4091},{"trials":4075,"activeCount":114,"soonestReadout":67},[4076],{"nctId":65,"briefTitle":66,"status":186,"phases":4077,"primaryCompletion":67,"completion":4078,"start":4079,"enrollment":1602,"conditions":4080,"interventions":4082},[90],"2027-05","2019-09-16",[4081],"Adamantinomatous Craniopharyngioma",[68],{"trials":4084,"activeCount":117},[],{"trials":4086,"activeCount":117},[],{"trials":4088,"activeCount":117},[],{"trials":4090,"activeCount":117},[],{"trials":4092,"activeCount":117},[],{"intervention":4094,"totalTrials":114,"cells":4095},"Definity contrast during ultrasound",{"EARLY_PHASE1":4096,"PHASE1":4107,"PHASE2":4109,"PHASE3":4111,"PHASE4":4113,"NA":4115},{"trials":4097,"activeCount":114,"soonestReadout":357},[4098],{"nctId":4099,"briefTitle":4100,"status":138,"phases":4101,"primaryCompletion":357,"completion":457,"start":4102,"enrollment":315,"conditions":4103,"interventions":4106},"NCT07050836","Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation",[90],"2025-12-05",[4104,4105],"Glioma (Any Grade) in the Brain","Glioma",[4094],{"trials":4108,"activeCount":117},[],{"trials":4110,"activeCount":117},[],{"trials":4112,"activeCount":117},[],{"trials":4114,"activeCount":117},[],{"trials":4116,"activeCount":117},[],{"intervention":1932,"totalTrials":1548,"cells":4118},{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4137,"PHASE4":4139,"NA":4141},{"trials":4120,"activeCount":117},[],{"trials":4122,"activeCount":117},[],{"trials":4124,"activeCount":117},[4125,4129,4133],{"nctId":1915,"briefTitle":1916,"status":160,"phases":4126,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":1920,"conditions":4127,"interventions":4128},[91,92],[1922,15,1923,1924,131,1925,1926,1927,1928,1929,1405,1930],[1906,1932],{"nctId":1934,"briefTitle":1935,"status":160,"phases":4130,"primaryCompletion":1937,"completion":1938,"start":1919,"enrollment":110,"conditions":4131,"interventions":4132},[91,92],[1380,1924,1929,1940,1941,1942,1943],[1906,1932],{"nctId":1946,"briefTitle":1947,"status":715,"phases":4134,"primaryCompletion":1949,"completion":1950,"start":1919,"enrollment":315,"conditions":4135,"interventions":4136},[91,92],[1922,15,1924,1405],[1906,1953],{"trials":4138,"activeCount":117},[],{"trials":4140,"activeCount":117},[],{"trials":4142,"activeCount":114,"soonestReadout":1996},[4143],{"nctId":1993,"briefTitle":1994,"status":588,"phases":4144,"primaryCompletion":1996,"completion":1997,"start":1998,"enrollment":315,"conditions":4145,"interventions":4146},[],[24,2000,1929,1924,15,1405,131],[1906,1953,2002],{"intervention":4148,"totalTrials":1548,"cells":4149},"Heparin",{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4154,"PHASE3":4166,"PHASE4":4168,"NA":4170},{"trials":4151,"activeCount":117},[],{"trials":4153,"activeCount":117},[],{"trials":4155,"activeCount":117},[4156],{"nctId":4157,"briefTitle":4158,"status":1622,"phases":4159,"primaryCompletion":227,"completion":4160,"start":4161,"enrollment":117,"conditions":4162,"interventions":4164},"NCT01234285","Safety of Heparin in Patients With Septic Shock",[92],"2013-10","2010-12",[4163],"Sepsis",[4165,4165,4165,4165],"heparin",{"trials":4167,"activeCount":117},[],{"trials":4169,"activeCount":117},[],{"trials":4171,"activeCount":114,"soonestReadout":57},[4172,4183,4195],{"nctId":4173,"briefTitle":4174,"status":160,"phases":4175,"primaryCompletion":4176,"completion":4176,"start":4177,"enrollment":4178,"conditions":4179,"interventions":4181},"NCT01608906","Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery",[95],"2014-05","2007-05",152,[4180],"Venous Thrombosis",[4182,4148],"low dose intravenous heparin",{"nctId":55,"briefTitle":56,"status":186,"phases":4184,"primaryCompletion":57,"completion":4185,"start":4186,"enrollment":4187,"conditions":4188,"interventions":4191},[95],"2026-12-11","2016-06",84,[15,3646,4189,4190],"Hypogonadotropic Hypogonadotropism","Hyperinsulinemia",[58,4192,4193,4148,4194],"Intralipid","Dextrose","GnRH",{"nctId":4196,"briefTitle":4197,"status":160,"phases":4198,"primaryCompletion":4199,"completion":4199,"start":677,"enrollment":253,"conditions":4200,"interventions":4202},"NCT02656095","Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment",[],"2018-03-01",[4201],"Lipoprotein Lipase Deficiency",[4148],{"intervention":4194,"totalTrials":199,"cells":4204},{"EARLY_PHASE1":4205,"PHASE1":4207,"PHASE2":4209,"PHASE3":4211,"PHASE4":4213,"NA":4215},{"trials":4206,"activeCount":117},[],{"trials":4208,"activeCount":117},[],{"trials":4210,"activeCount":117},[],{"trials":4212,"activeCount":117},[],{"trials":4214,"activeCount":117},[],{"trials":4216,"activeCount":114,"soonestReadout":57},[4217,4221],{"nctId":55,"briefTitle":56,"status":186,"phases":4218,"primaryCompletion":57,"completion":4185,"start":4186,"enrollment":4187,"conditions":4219,"interventions":4220},[95],[15,3646,4189,4190],[58,4192,4193,4148,4194],{"nctId":4222,"briefTitle":4223,"status":160,"phases":4224,"primaryCompletion":4225,"completion":4225,"start":4226,"enrollment":4227,"conditions":4228,"interventions":4229},"NCT01894581","Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women",[95],"2014-12","2014-07",39,[15,843],[4194],{"intervention":4231,"totalTrials":199,"cells":4232},"alcohol",{"EARLY_PHASE1":4233,"PHASE1":4235,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4243},{"trials":4234,"activeCount":117},[],{"trials":4236,"activeCount":117},[],{"trials":4238,"activeCount":117},[],{"trials":4240,"activeCount":117},[],{"trials":4242,"activeCount":117},[],{"trials":4244,"activeCount":114,"soonestReadout":4260},[4245,4256],{"nctId":4246,"briefTitle":4247,"status":160,"phases":4248,"primaryCompletion":4249,"completion":4249,"start":4250,"enrollment":1920,"conditions":4251,"interventions":4254},"NCT02542150","Effects of Acetate and Alcohol on Brain Function",[95],"2017-03-31","2015-09",[4252,4253],"Cerebral Blood Flow","Brain Function",[4255,4231],"acetate",{"nctId":4257,"briefTitle":4258,"status":138,"phases":4259,"primaryCompletion":4260,"completion":4260,"start":4261,"enrollment":4262,"conditions":4263,"interventions":4267},"NCT06865872","Alcohol and Sexual Communication Among Couples in the Laboratory",[95],"2028-02","2025-04-18",480,[4264,4265,4266],"Alcohol Intoxication","Intimate Partner Violence (IPV)","Communication",[4268],"Alcohol",{"intervention":4270,"totalTrials":114,"cells":4271},"Definity Suspension for",{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4278,"PHASE4":4280,"NA":4282},{"trials":4273,"activeCount":117},[],{"trials":4275,"activeCount":117},[],{"trials":4277,"activeCount":117},[],{"trials":4279,"activeCount":117},[],{"trials":4281,"activeCount":117},[],{"trials":4283,"activeCount":114,"soonestReadout":2862},[4284],{"nctId":4285,"briefTitle":4286,"status":138,"phases":4287,"primaryCompletion":2862,"completion":2862,"start":4288,"enrollment":110,"conditions":4289,"interventions":4292},"NCT05482321","Pancreas Ultrasound Imaging in type1 Diabetes",[],"2023-02-27",[1988,4290,4291],"Insulitis","Pancreas Inflamed",[4270],{"intervention":4294,"totalTrials":114,"cells":4295},"Testosterone",{"EARLY_PHASE1":4296,"PHASE1":4298,"PHASE2":4300,"PHASE3":4302,"PHASE4":4304,"NA":4306},{"trials":4297,"activeCount":117},[],{"trials":4299,"activeCount":117},[],{"trials":4301,"activeCount":117},[],{"trials":4303,"activeCount":117},[],{"trials":4305,"activeCount":117},[],{"trials":4307,"activeCount":114,"soonestReadout":2404},[4308],{"nctId":4309,"briefTitle":4310,"status":138,"phases":4311,"primaryCompletion":2404,"completion":251,"start":2268,"enrollment":315,"conditions":4312,"interventions":4317},"NCT06670053","Puberty, Testosterone, and Brain Development",[],[4313,4314,4315,4316],"Gender Identity","Gender Dysphoria in Adolescents and Adults","Headache","Transgender",[4294],{"intervention":4319,"totalTrials":114,"cells":4320},"Aminohippurate Sodium Inj 20% Diagnostic aid\u002Fagent used to measure effective renal plasma flow",{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4322,"activeCount":117},[],{"trials":4324,"activeCount":117},[],{"trials":4326,"activeCount":117},[],{"trials":4328,"activeCount":117},[],{"trials":4330,"activeCount":117},[],{"trials":4332,"activeCount":114,"soonestReadout":3775},[4333],{"nctId":4334,"briefTitle":4335,"status":186,"phases":4336,"primaryCompletion":3775,"completion":1163,"start":4337,"enrollment":315,"conditions":4338,"interventions":4339},"NCT05319990","Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)",[],"2022-03-09",[18,131,1927,1929,1942],[4319,4340],"Iohexol Inj 300 MG\u002FML Diagnostic aid\u002Fagent used to measure glomerular filtration rate",{"intervention":4340,"totalTrials":114,"cells":4342},{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4349,"PHASE4":4351,"NA":4353},{"trials":4344,"activeCount":117},[],{"trials":4346,"activeCount":117},[],{"trials":4348,"activeCount":117},[],{"trials":4350,"activeCount":117},[],{"trials":4352,"activeCount":117},[],{"trials":4354,"activeCount":114,"soonestReadout":3775},[4355],{"nctId":4334,"briefTitle":4335,"status":186,"phases":4356,"primaryCompletion":3775,"completion":1163,"start":4337,"enrollment":315,"conditions":4357,"interventions":4358},[],[18,131,1927,1929,1942],[4319,4340],{"intervention":4360,"totalTrials":114,"cells":4361},"Research Testing Performed",{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4368,"PHASE4":4370,"NA":4372},{"trials":4363,"activeCount":117},[],{"trials":4365,"activeCount":117},[],{"trials":4367,"activeCount":117},[],{"trials":4369,"activeCount":117},[],{"trials":4371,"activeCount":117},[],{"trials":4373,"activeCount":114,"soonestReadout":4378},[4374],{"nctId":4375,"briefTitle":4376,"status":138,"phases":4377,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":4381,"conditions":4382,"interventions":4385},"NCT06397677","Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease",[],"2029-01","2034-01","2024-01-22",450,[4383,4384],"Rheumatoid Arthritis","Interstitial Lung Disease",[4360],{"intervention":4387,"totalTrials":114,"cells":4388},"Chemotherapy",{"EARLY_PHASE1":4389,"PHASE1":4391,"PHASE2":4393,"PHASE3":4395,"PHASE4":4397,"NA":4399},{"trials":4390,"activeCount":117},[],{"trials":4392,"activeCount":117},[],{"trials":4394,"activeCount":117},[],{"trials":4396,"activeCount":117},[],{"trials":4398,"activeCount":117},[],{"trials":4400,"activeCount":114,"soonestReadout":3117},[4401],{"nctId":4402,"briefTitle":4403,"status":138,"phases":4404,"primaryCompletion":3117,"completion":3117,"start":4405,"enrollment":4406,"conditions":4407,"interventions":4410},"NCT02634645","TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)",[],"2015-01",5000,[4408,4409],"Barrett's Esophagus","Esophageal Cancer",[4387],{"intervention":58,"totalTrials":114,"cells":4412},{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4419,"PHASE4":4421,"NA":4423},{"trials":4414,"activeCount":117},[],{"trials":4416,"activeCount":117},[],{"trials":4418,"activeCount":117},[],{"trials":4420,"activeCount":117},[],{"trials":4422,"activeCount":117},[],{"trials":4424,"activeCount":114,"soonestReadout":57},[4425],{"nctId":55,"briefTitle":56,"status":186,"phases":4426,"primaryCompletion":57,"completion":4185,"start":4186,"enrollment":4187,"conditions":4427,"interventions":4428},[95],[15,3646,4189,4190],[58,4192,4193,4148,4194],{"intervention":4192,"totalTrials":114,"cells":4430},{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4435,"PHASE3":4437,"PHASE4":4439,"NA":4441},{"trials":4432,"activeCount":117},[],{"trials":4434,"activeCount":117},[],{"trials":4436,"activeCount":117},[],{"trials":4438,"activeCount":117},[],{"trials":4440,"activeCount":117},[],{"trials":4442,"activeCount":114,"soonestReadout":57},[4443],{"nctId":55,"briefTitle":56,"status":186,"phases":4444,"primaryCompletion":57,"completion":4185,"start":4186,"enrollment":4187,"conditions":4445,"interventions":4446},[95],[15,3646,4189,4190],[58,4192,4193,4148,4194],{"intervention":4193,"totalTrials":114,"cells":4448},{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4455,"PHASE4":4457,"NA":4459},{"trials":4450,"activeCount":117},[],{"trials":4452,"activeCount":117},[],{"trials":4454,"activeCount":117},[],{"trials":4456,"activeCount":117},[],{"trials":4458,"activeCount":117},[],{"trials":4460,"activeCount":114,"soonestReadout":57},[4461],{"nctId":55,"briefTitle":56,"status":186,"phases":4462,"primaryCompletion":57,"completion":4185,"start":4186,"enrollment":4187,"conditions":4463,"interventions":4464},[95],[15,3646,4189,4190],[58,4192,4193,4148,4194],{"intervention":2002,"totalTrials":114,"cells":4466},{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4473,"PHASE4":4475,"NA":4477},{"trials":4468,"activeCount":117},[],{"trials":4470,"activeCount":117},[],{"trials":4472,"activeCount":117},[],{"trials":4474,"activeCount":117},[],{"trials":4476,"activeCount":117},[],{"trials":4478,"activeCount":114,"soonestReadout":1996},[4479],{"nctId":1993,"briefTitle":1994,"status":588,"phases":4480,"primaryCompletion":1996,"completion":1997,"start":1998,"enrollment":315,"conditions":4481,"interventions":4482},[],[24,2000,1929,1924,15,1405,131],[1906,1953,2002],{"intervention":4484,"totalTrials":114,"cells":4485},"Tyrosine Kinase Inhibitor",{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4492,"PHASE4":4494,"NA":4496},{"trials":4487,"activeCount":117},[],{"trials":4489,"activeCount":117},[],{"trials":4491,"activeCount":117},[],{"trials":4493,"activeCount":117},[],{"trials":4495,"activeCount":117},[],{"trials":4497,"activeCount":114,"soonestReadout":4502},[4498],{"nctId":4499,"briefTitle":4500,"status":138,"phases":4501,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":315,"conditions":4505,"interventions":4507},"NCT03958565","Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.",[],"2028-03-05","2028-04-28","2020-04-28",[4506],"Carcinoma, Non-Small-Cell Lung",[4484,4508,4509],"Zoledronic Acid 4 MG\u002F100 ML Intravenous Solution [ZOMETA]","Denosumab 120 MG\u002F1.7 ML Subcutaneous Solution [XGEVA]",{"intervention":4508,"totalTrials":114,"cells":4511},{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4518,"PHASE4":4520,"NA":4522},{"trials":4513,"activeCount":117},[],{"trials":4515,"activeCount":117},[],{"trials":4517,"activeCount":117},[],{"trials":4519,"activeCount":117},[],{"trials":4521,"activeCount":117},[],{"trials":4523,"activeCount":114,"soonestReadout":4502},[4524],{"nctId":4499,"briefTitle":4500,"status":138,"phases":4525,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":315,"conditions":4526,"interventions":4527},[],[4506],[4484,4508,4509],{"intervention":4509,"totalTrials":114,"cells":4529},{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4536,"PHASE4":4538,"NA":4540},{"trials":4531,"activeCount":117},[],{"trials":4533,"activeCount":117},[],{"trials":4535,"activeCount":117},[],{"trials":4537,"activeCount":117},[],{"trials":4539,"activeCount":117},[],{"trials":4541,"activeCount":114,"soonestReadout":4502},[4542],{"nctId":4499,"briefTitle":4500,"status":138,"phases":4543,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":315,"conditions":4544,"interventions":4545},[],[4506],[4484,4508,4509],{"intervention":1776,"totalTrials":99,"cells":4547},{"EARLY_PHASE1":4548,"PHASE1":4550,"PHASE2":4552,"PHASE3":4554,"PHASE4":4567,"NA":4582},{"trials":4549,"activeCount":117},[],{"trials":4551,"activeCount":117},[],{"trials":4553,"activeCount":117},[],{"trials":4555,"activeCount":117},[4556],{"nctId":4557,"briefTitle":4558,"status":160,"phases":4559,"primaryCompletion":678,"completion":4560,"start":4561,"enrollment":4562,"conditions":4563,"interventions":4565},"NCT01387139","Ketamine Versus Co-administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department",[93],"2017-11-03","2011-01",183,[4564],"Procedural Sedation and Analgesia",[1776,4566],"Ketamine Co-administered with Propofol",{"trials":4568,"activeCount":117},[4569,4573],{"nctId":1768,"briefTitle":1769,"status":1622,"phases":4570,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":117,"conditions":4571,"interventions":4572},[94],[1774],[1776,1777,1732],{"nctId":4574,"briefTitle":4575,"status":1622,"phases":4576,"primaryCompletion":4405,"completion":4405,"start":4405,"enrollment":117,"conditions":4577,"interventions":4581},"NCT02336308","A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients",[94],[4578,4579,4580],"Thermal Hyperalgesia","Anxiety","Pain",[1776],{"trials":4583,"activeCount":117},[],{"intervention":2067,"totalTrials":199,"cells":4585},{"EARLY_PHASE1":4586,"PHASE1":4588,"PHASE2":4590,"PHASE3":4596,"PHASE4":4598,"NA":4610},{"trials":4587,"activeCount":117},[],{"trials":4589,"activeCount":117},[],{"trials":4591,"activeCount":117},[4592],{"nctId":2057,"briefTitle":2058,"status":1622,"phases":4593,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":117,"conditions":4594,"interventions":4595},[92],[2064,2065],[2004,2067],{"trials":4597,"activeCount":117},[],{"trials":4599,"activeCount":117},[4600],{"nctId":4601,"briefTitle":4602,"status":1622,"phases":4603,"primaryCompletion":4604,"completion":4604,"start":4605,"enrollment":117,"conditions":4606,"interventions":4608},"NCT03997864","Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault",[94],"2021-08-20","2020-02-23",[4607],"Posttraumatic Stress Disorder",[4609,2067],"Prazosin",{"trials":4611,"activeCount":117},[],{"intervention":4613,"totalTrials":199,"cells":4614},"Ribavirin",{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4621,"PHASE4":4634,"NA":4645},{"trials":4616,"activeCount":117},[],{"trials":4618,"activeCount":117},[],{"trials":4620,"activeCount":117},[],{"trials":4622,"activeCount":117},[4623],{"nctId":4624,"briefTitle":4625,"status":125,"phases":4626,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":1602,"conditions":4629,"interventions":4631},"NCT02455167","Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis",[93],"2016-07-18","2015-05",[4630],"Hepatitis C",[4632,4633,4613],"Simeprivir","Sofosbuvir",{"trials":4635,"activeCount":117},[4636],{"nctId":4637,"briefTitle":4638,"status":160,"phases":4639,"primaryCompletion":983,"completion":983,"start":4640,"enrollment":1561,"conditions":4641,"interventions":4643},"NCT01097395","Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection",[94],"2010-02",[4642],"Hepatitis C Virus",[4644],"ribavirin",{"trials":4646,"activeCount":117},[],{"intervention":1144,"totalTrials":199,"cells":4648},{"EARLY_PHASE1":4649,"PHASE1":4651,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4673},{"trials":4650,"activeCount":117},[],{"trials":4652,"activeCount":117},[4653],{"nctId":4654,"briefTitle":4655,"status":160,"phases":4656,"primaryCompletion":677,"completion":4657,"start":4176,"enrollment":4658,"conditions":4659,"interventions":4661},"NCT02114333","Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds",[91],"2020-05",160,[4660,1142],"Shingles",[1144,4662],"HZ\u002Fsu vaccine",{"trials":4664,"activeCount":117},[],{"trials":4666,"activeCount":117},[],{"trials":4668,"activeCount":117},[4669],{"nctId":1134,"briefTitle":1135,"status":160,"phases":4670,"primaryCompletion":1137,"completion":1138,"start":1139,"enrollment":1140,"conditions":4671,"interventions":4672},[94],[1142],[1144,1107],{"trials":4674,"activeCount":117},[],{"intervention":4676,"totalTrials":199,"cells":4677},"Glargine",{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4690,"PHASE3":4692,"PHASE4":4694,"NA":4704},{"trials":4679,"activeCount":117},[],{"trials":4681,"activeCount":117},[4682],{"nctId":4683,"briefTitle":4684,"status":160,"phases":4685,"primaryCompletion":4686,"completion":4686,"start":4687,"enrollment":1378,"conditions":4688,"interventions":4689},"NCT01153100","Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy",[91],"2012-02","2010-04",[33],[4676],{"trials":4691,"activeCount":117},[],{"trials":4693,"activeCount":117},[],{"trials":4695,"activeCount":117},[4696],{"nctId":4697,"briefTitle":4698,"status":160,"phases":4699,"primaryCompletion":4700,"completion":4700,"start":3514,"enrollment":2245,"conditions":4701,"interventions":4703},"NCT03107208","Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes",[94],"2021-03-13",[4702,1943],"Diabetic Ketoacidosis",[4676],{"trials":4705,"activeCount":117},[],{"intervention":4707,"totalTrials":199,"cells":4708},"Sugar Pill",{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4713,"PHASE3":4715,"PHASE4":4726,"NA":4738},{"trials":4710,"activeCount":117},[],{"trials":4712,"activeCount":117},[],{"trials":4714,"activeCount":117},[],{"trials":4716,"activeCount":117},[4717],{"nctId":4718,"briefTitle":4719,"status":160,"phases":4720,"primaryCompletion":648,"completion":648,"start":4721,"enrollment":2245,"conditions":4722,"interventions":4723},"NCT01853553","Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[93],"2013-07",[192],[4724,4725],"Spironolactone","Sugar pill",{"trials":4727,"activeCount":117},[4728],{"nctId":4729,"briefTitle":4730,"status":160,"phases":4731,"primaryCompletion":4732,"completion":4733,"start":4734,"enrollment":28,"conditions":4735,"interventions":4736},"NCT00978796","Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes",[94],"2010-01","2010-03","2009-09",[18],[4737,4707],"Sitagliptin",{"trials":4739,"activeCount":117},[],{"intervention":4741,"totalTrials":199,"cells":4742},"Sirolimus",{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4747,"PHASE3":4759,"PHASE4":4761,"NA":4772},{"trials":4744,"activeCount":117},[],{"trials":4746,"activeCount":117},[],{"trials":4748,"activeCount":117},[4749],{"nctId":4750,"briefTitle":4751,"status":160,"phases":4752,"primaryCompletion":4753,"completion":4753,"start":4754,"enrollment":4755,"conditions":4756,"interventions":4757},"NCT00353301","Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma",[92],"2012-03","2006-07",25,[1644],[4758,4741],"Erlotinib hydrochloride",{"trials":4760,"activeCount":117},[],{"trials":4762,"activeCount":117},[4763],{"nctId":4764,"briefTitle":4765,"status":1622,"phases":4766,"primaryCompletion":4767,"completion":4767,"start":4768,"enrollment":117,"conditions":4769,"interventions":4770},"NCT02062892","Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients",[94],"2014-06","2013-12",[1128],[4771,4741],"Everolimus",{"trials":4773,"activeCount":117},[],{"intervention":4775,"totalTrials":114,"cells":4776},"Desogestrel and Ethinyl Estradiol",{"EARLY_PHASE1":4777,"PHASE1":4779,"PHASE2":4781,"PHASE3":4783,"PHASE4":4785,"NA":4795},{"trials":4778,"activeCount":117},[],{"trials":4780,"activeCount":117},[],{"trials":4782,"activeCount":117},[],{"trials":4784,"activeCount":117},[],{"trials":4786,"activeCount":117},[4787],{"nctId":4788,"briefTitle":4789,"status":160,"phases":4790,"primaryCompletion":4791,"completion":4791,"start":4792,"enrollment":1974,"conditions":4793,"interventions":4794},"NCT05002738","Desogestrel-containing COCP Pharmacokinetic Validation Study",[94],"2022-11-28","2021-09-10",[255],[4775],{"trials":4796,"activeCount":117},[],{"intervention":4609,"totalTrials":114,"cells":4798},{"EARLY_PHASE1":4799,"PHASE1":4801,"PHASE2":4803,"PHASE3":4805,"PHASE4":4807,"NA":4813},{"trials":4800,"activeCount":117},[],{"trials":4802,"activeCount":117},[],{"trials":4804,"activeCount":117},[],{"trials":4806,"activeCount":117},[],{"trials":4808,"activeCount":117},[4809],{"nctId":4601,"briefTitle":4602,"status":1622,"phases":4810,"primaryCompletion":4604,"completion":4604,"start":4605,"enrollment":117,"conditions":4811,"interventions":4812},[94],[4607],[4609,2067],{"trials":4814,"activeCount":117},[],{"intervention":4816,"totalTrials":114,"cells":4817},"Vancomycin",{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4843},{"trials":4819,"activeCount":117},[],{"trials":4821,"activeCount":117},[],{"trials":4823,"activeCount":117},[],{"trials":4825,"activeCount":117},[],{"trials":4827,"activeCount":117},[4828],{"nctId":4829,"briefTitle":4830,"status":160,"phases":4831,"primaryCompletion":4832,"completion":4832,"start":4833,"enrollment":28,"conditions":4834,"interventions":4841},"NCT04872400","Acute Application of Antibiotic Powder in Open Fracture Wounds",[94],"2023-09-30","2021-06-14",[4835,4836,4837,4838,4839,4840],"Fractures, Open","Wounds and Injuries--Infections","Anti-Bacterial Agents","Fractures, Bone","Extremity Fracture Lower","Extremity Fractures Upper",[4816,4842],"Tobramycin",{"trials":4844,"activeCount":117},[],{"intervention":4842,"totalTrials":114,"cells":4846},{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4851,"PHASE3":4853,"PHASE4":4855,"NA":4861},{"trials":4848,"activeCount":117},[],{"trials":4850,"activeCount":117},[],{"trials":4852,"activeCount":117},[],{"trials":4854,"activeCount":117},[],{"trials":4856,"activeCount":117},[4857],{"nctId":4829,"briefTitle":4830,"status":160,"phases":4858,"primaryCompletion":4832,"completion":4832,"start":4833,"enrollment":28,"conditions":4859,"interventions":4860},[94],[4835,4836,4837,4838,4839,4840],[4816,4842],{"trials":4862,"activeCount":117},[],{"intervention":4864,"totalTrials":114,"cells":4865},"Gadoxetate disodium",{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4872,"PHASE4":4874,"NA":4888},{"trials":4867,"activeCount":117},[],{"trials":4869,"activeCount":117},[],{"trials":4871,"activeCount":117},[],{"trials":4873,"activeCount":117},[],{"trials":4875,"activeCount":117},[4876],{"nctId":4877,"briefTitle":4878,"status":125,"phases":4879,"primaryCompletion":4880,"completion":4881,"start":4882,"enrollment":228,"conditions":4883,"interventions":4886},"NCT04973007","Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases",[94],"2025-05-06","2025-05-08","2021-06-22",[4884,4885,1668],"Oligometastatic Disease","Liver Metastases",[4864,4887],"Gadobenate dimeglumine",{"trials":4889,"activeCount":117},[],{"intervention":4887,"totalTrials":114,"cells":4891},{"EARLY_PHASE1":4892,"PHASE1":4894,"PHASE2":4896,"PHASE3":4898,"PHASE4":4900,"NA":4906},{"trials":4893,"activeCount":117},[],{"trials":4895,"activeCount":117},[],{"trials":4897,"activeCount":117},[],{"trials":4899,"activeCount":117},[],{"trials":4901,"activeCount":117},[4902],{"nctId":4877,"briefTitle":4878,"status":125,"phases":4903,"primaryCompletion":4880,"completion":4881,"start":4882,"enrollment":228,"conditions":4904,"interventions":4905},[94],[4884,4885,1668],[4864,4887],{"trials":4907,"activeCount":117},[],{"intervention":4909,"totalTrials":114,"cells":4910},"Carvedilol",{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4915,"PHASE3":4917,"PHASE4":4919,"NA":4932},{"trials":4912,"activeCount":117},[],{"trials":4914,"activeCount":117},[],{"trials":4916,"activeCount":117},[],{"trials":4918,"activeCount":117},[],{"trials":4920,"activeCount":117},[4921],{"nctId":4922,"briefTitle":4923,"status":160,"phases":4924,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":926,"conditions":4927,"interventions":4929},"NCT01798992","Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart",[94],"2009-03","2000-09",[4928],"Idiopathic Dilated Cardiomyopathy",[4909,4930,4931],"Metoprolol succinate","Metoprolol succinate + doxazosin",{"trials":4933,"activeCount":117},[],{"intervention":4931,"totalTrials":114,"cells":4935},{"EARLY_PHASE1":4936,"PHASE1":4938,"PHASE2":4940,"PHASE3":4942,"PHASE4":4944,"NA":4950},{"trials":4937,"activeCount":117},[],{"trials":4939,"activeCount":117},[],{"trials":4941,"activeCount":117},[],{"trials":4943,"activeCount":117},[],{"trials":4945,"activeCount":117},[4946],{"nctId":4922,"briefTitle":4923,"status":160,"phases":4947,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":926,"conditions":4948,"interventions":4949},[94],[4928],[4909,4930,4931],{"trials":4951,"activeCount":117},[],{"intervention":4953,"totalTrials":114,"cells":4954},"ACTHAR Gel",{"EARLY_PHASE1":4955,"PHASE1":4957,"PHASE2":4959,"PHASE3":4961,"PHASE4":4963,"NA":4974},{"trials":4956,"activeCount":117},[],{"trials":4958,"activeCount":117},[],{"trials":4960,"activeCount":117},[],{"trials":4962,"activeCount":117},[],{"trials":4964,"activeCount":117},[4965],{"nctId":4966,"briefTitle":4967,"status":125,"phases":4968,"primaryCompletion":4969,"completion":4969,"start":4970,"enrollment":1507,"conditions":4971,"interventions":4972},"NCT01838174","A Trial of Neuroprotection With ACTH in Acute Optic Neuritis",[94],"2022-01-13","2013-05",[36],[4953,4973],"IV methylprednisolone",{"trials":4975,"activeCount":117},[],{"intervention":4973,"totalTrials":114,"cells":4977},{"EARLY_PHASE1":4978,"PHASE1":4980,"PHASE2":4982,"PHASE3":4984,"PHASE4":4986,"NA":4992},{"trials":4979,"activeCount":117},[],{"trials":4981,"activeCount":117},[],{"trials":4983,"activeCount":117},[],{"trials":4985,"activeCount":117},[],{"trials":4987,"activeCount":117},[4988],{"nctId":4966,"briefTitle":4967,"status":125,"phases":4989,"primaryCompletion":4969,"completion":4969,"start":4970,"enrollment":1507,"conditions":4990,"interventions":4991},[94],[36],[4953,4973],{"trials":4993,"activeCount":117},[],{"intervention":4995,"totalTrials":114,"cells":4996},"Risperidone",{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5003,"PHASE4":5005,"NA":5015},{"trials":4998,"activeCount":117},[],{"trials":5000,"activeCount":117},[],{"trials":5002,"activeCount":117},[],{"trials":5004,"activeCount":117},[],{"trials":5006,"activeCount":117},[5007],{"nctId":5008,"briefTitle":5009,"status":160,"phases":5010,"primaryCompletion":2052,"completion":2052,"start":5011,"enrollment":3711,"conditions":5012,"interventions":5014},"NCT00140426","A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa",[94],"2004-08",[5013],"Anorexia Nervosa",[4995],{"trials":5016,"activeCount":117},[],{"intervention":5018,"totalTrials":114,"cells":5019},"Memantine",{"EARLY_PHASE1":5020,"PHASE1":5022,"PHASE2":5024,"PHASE3":5026,"PHASE4":5028,"NA":5039},{"trials":5021,"activeCount":117},[],{"trials":5023,"activeCount":117},[],{"trials":5025,"activeCount":117},[],{"trials":5027,"activeCount":117},[],{"trials":5029,"activeCount":117},[5030],{"nctId":5031,"briefTitle":5032,"status":160,"phases":5033,"primaryCompletion":5034,"completion":5035,"start":5036,"enrollment":2380,"conditions":5037,"interventions":5038},"NCT01112683","Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome",[94],"2011-07","2011-08","2008-07",[2100],[5018],{"trials":5040,"activeCount":117},[],{"intervention":5042,"totalTrials":114,"cells":5043},"Atazanavir",{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5048,"PHASE3":5050,"PHASE4":5052,"NA":5064},{"trials":5045,"activeCount":117},[],{"trials":5047,"activeCount":117},[],{"trials":5049,"activeCount":117},[],{"trials":5051,"activeCount":117},[],{"trials":5053,"activeCount":117},[5054],{"nctId":5055,"briefTitle":5056,"status":160,"phases":5057,"primaryCompletion":5058,"completion":5058,"start":5059,"enrollment":5060,"conditions":5061,"interventions":5063},"NCT01388543","Genetics and HIV-1 Protease Inhibitors",[94],"2008-06","2006-09",31,[5062],"HIV",[5042],{"trials":5065,"activeCount":117},[],{"intervention":5067,"totalTrials":114,"cells":5068},"Rilonacept",{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5073,"PHASE3":5075,"PHASE4":5077,"NA":5087},{"trials":5070,"activeCount":117},[],{"trials":5072,"activeCount":117},[],{"trials":5074,"activeCount":117},[],{"trials":5076,"activeCount":117},[],{"trials":5078,"activeCount":117},[5079],{"nctId":5080,"briefTitle":5081,"status":160,"phases":5082,"primaryCompletion":4225,"completion":4225,"start":5083,"enrollment":2380,"conditions":5084,"interventions":5086},"NCT01663103","Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)",[94],"2012-08",[5085],"Renal Insufficiency, Chronic",[5067],{"trials":5088,"activeCount":117},[],{"intervention":5090,"totalTrials":114,"cells":5091},"Intrathecal morphine",{"EARLY_PHASE1":5092,"PHASE1":5094,"PHASE2":5096,"PHASE3":5098,"PHASE4":5100,"NA":5115},{"trials":5093,"activeCount":117},[],{"trials":5095,"activeCount":117},[],{"trials":5097,"activeCount":117},[],{"trials":5099,"activeCount":117},[],{"trials":5101,"activeCount":117},[5102],{"nctId":5103,"briefTitle":5104,"status":160,"phases":5105,"primaryCompletion":5106,"completion":5107,"start":5108,"enrollment":4187,"conditions":5109,"interventions":5113},"NCT00880607","Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion",[94],"2011-04","2012-09","2008-12",[5110,5111,5112],"Pain Management","Spinal Fusion","Scoliosis",[5090,5114],"Extended Release Epidural Morphine",{"trials":5116,"activeCount":117},[],{"intervention":5114,"totalTrials":114,"cells":5118},{"EARLY_PHASE1":5119,"PHASE1":5121,"PHASE2":5123,"PHASE3":5125,"PHASE4":5127,"NA":5133},{"trials":5120,"activeCount":117},[],{"trials":5122,"activeCount":117},[],{"trials":5124,"activeCount":117},[],{"trials":5126,"activeCount":117},[],{"trials":5128,"activeCount":117},[5129],{"nctId":5103,"briefTitle":5104,"status":160,"phases":5130,"primaryCompletion":5106,"completion":5107,"start":5108,"enrollment":4187,"conditions":5131,"interventions":5132},[94],[5110,5111,5112],[5090,5114],{"trials":5134,"activeCount":117},[],{"intervention":5136,"totalTrials":114,"cells":5137},"testosterone cypionate 200mg\u002Fml",{"EARLY_PHASE1":5138,"PHASE1":5140,"PHASE2":5142,"PHASE3":5144,"PHASE4":5146,"NA":5157},{"trials":5139,"activeCount":117},[],{"trials":5141,"activeCount":117},[],{"trials":5143,"activeCount":117},[],{"trials":5145,"activeCount":117},[],{"trials":5147,"activeCount":117},[5148],{"nctId":5149,"briefTitle":5150,"status":160,"phases":5151,"primaryCompletion":5152,"completion":1985,"start":5153,"enrollment":28,"conditions":5154,"interventions":5156},"NCT02408445","Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment",[94],"2018-01-31","2015-05-08",[5155],"Klinefelter Syndrome",[5136],{"trials":5158,"activeCount":117},[],{"intervention":5160,"totalTrials":114,"cells":5161},"Caffeine Anhydrous with small sucrose pill",{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5168,"PHASE4":5170,"NA":5181},{"trials":5163,"activeCount":117},[],{"trials":5165,"activeCount":117},[],{"trials":5167,"activeCount":117},[],{"trials":5169,"activeCount":117},[],{"trials":5171,"activeCount":117},[5172],{"nctId":5173,"briefTitle":5174,"status":160,"phases":5175,"primaryCompletion":5176,"completion":5176,"start":1702,"enrollment":660,"conditions":5177,"interventions":5179},"NCT03694886","The Effect of Tablet Size on Cognitive Performance Caffeine",[94],"2019-03-01",[5178],"Placebo Effect",[5160,5180],"Caffeine Anhydrous with large sucrose pill",{"trials":5182,"activeCount":117},[],{"intervention":5180,"totalTrials":114,"cells":5184},{"EARLY_PHASE1":5185,"PHASE1":5187,"PHASE2":5189,"PHASE3":5191,"PHASE4":5193,"NA":5199},{"trials":5186,"activeCount":117},[],{"trials":5188,"activeCount":117},[],{"trials":5190,"activeCount":117},[],{"trials":5192,"activeCount":117},[],{"trials":5194,"activeCount":117},[5195],{"nctId":5173,"briefTitle":5174,"status":160,"phases":5196,"primaryCompletion":5176,"completion":5176,"start":1702,"enrollment":660,"conditions":5197,"interventions":5198},[94],[5178],[5160,5180],{"trials":5200,"activeCount":117},[],{"intervention":724,"totalTrials":114,"cells":5202},{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5207,"PHASE3":5209,"PHASE4":5211,"NA":5217},{"trials":5204,"activeCount":117},[],{"trials":5206,"activeCount":117},[],{"trials":5208,"activeCount":117},[],{"trials":5210,"activeCount":117},[],{"trials":5212,"activeCount":117},[5213],{"nctId":713,"briefTitle":714,"status":715,"phases":5214,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":5215,"interventions":5216},[94],[708,721,27,722],[88,724],{"trials":5218,"activeCount":117},[],{"intervention":5220,"totalTrials":114,"cells":5221},"Caudal block with ropivacaine",{"EARLY_PHASE1":5222,"PHASE1":5224,"PHASE2":5226,"PHASE3":5228,"PHASE4":5230,"NA":5244},{"trials":5223,"activeCount":117},[],{"trials":5225,"activeCount":117},[],{"trials":5227,"activeCount":117},[],{"trials":5229,"activeCount":117},[],{"trials":5231,"activeCount":117},[5232],{"nctId":5233,"briefTitle":5234,"status":160,"phases":5235,"primaryCompletion":5236,"completion":5236,"start":5237,"enrollment":5238,"conditions":5239,"interventions":5242},"NCT02861950","Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants?",[94],"2023-09-20","2017-05-24",165,[5240,5241],"Hypospadias","Urethrocutaneous Fistula",[5220,5243],"penile nerve block with bupivacaine",{"trials":5245,"activeCount":117},[],{"intervention":5243,"totalTrials":114,"cells":5247},{"EARLY_PHASE1":5248,"PHASE1":5250,"PHASE2":5252,"PHASE3":5254,"PHASE4":5256,"NA":5262},{"trials":5249,"activeCount":117},[],{"trials":5251,"activeCount":117},[],{"trials":5253,"activeCount":117},[],{"trials":5255,"activeCount":117},[],{"trials":5257,"activeCount":117},[5258],{"nctId":5233,"briefTitle":5234,"status":160,"phases":5259,"primaryCompletion":5236,"completion":5236,"start":5237,"enrollment":5238,"conditions":5260,"interventions":5261},[94],[5240,5241],[5220,5243],{"trials":5263,"activeCount":117},[],{"intervention":5265,"totalTrials":114,"cells":5266},"Administration of Vancomycin",{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5273,"PHASE4":5275,"NA":5287},{"trials":5268,"activeCount":117},[],{"trials":5270,"activeCount":117},[],{"trials":5272,"activeCount":117},[],{"trials":5274,"activeCount":117},[],{"trials":5276,"activeCount":117},[5277],{"nctId":5278,"briefTitle":5279,"status":160,"phases":5280,"primaryCompletion":5281,"completion":5282,"start":5283,"enrollment":1378,"conditions":5284,"interventions":5286},"NCT03453684","Pharmacokinetics of Preoperative Vancomycin",[94],"2013-06","2015-07-20","2012-12-01",[5285,4816],"Surgical Site Infection",[5265],{"trials":5288,"activeCount":117},[],{"intervention":2119,"totalTrials":114,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5299,"NA":5305},{"trials":5292,"activeCount":117},[],{"trials":5294,"activeCount":117},[],{"trials":5296,"activeCount":117},[],{"trials":5298,"activeCount":117},[],{"trials":5300,"activeCount":117},[5301],{"nctId":2110,"briefTitle":2111,"status":160,"phases":5302,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":805,"conditions":5303,"interventions":5304},[94],[2117],[2119,2086],{"trials":5306,"activeCount":117},[],{"intervention":5308,"totalTrials":114,"cells":5309},"Sucroferric Oxyhydroxide Chewable",{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5314,"PHASE3":5316,"PHASE4":5318,"NA":5331},{"trials":5311,"activeCount":117},[],{"trials":5313,"activeCount":117},[],{"trials":5315,"activeCount":117},[],{"trials":5317,"activeCount":117},[],{"trials":5319,"activeCount":117},[5320],{"nctId":5321,"briefTitle":5322,"status":160,"phases":5323,"primaryCompletion":5324,"completion":5324,"start":5325,"enrollment":34,"conditions":5326,"interventions":5330},"NCT04046263","Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients",[94],"2021-07-31","2020-02-01",[5327,5328,5329],"Peritoneal Dialysis Complication","Hyperphosphatemia","Hypoalbuminemia",[5308],{"trials":5332,"activeCount":117},[],{"intervention":5334,"totalTrials":114,"cells":5335},"injectable naltrexone",{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5340,"PHASE3":5342,"PHASE4":5344,"NA":5356},{"trials":5337,"activeCount":117},[],{"trials":5339,"activeCount":117},[],{"trials":5341,"activeCount":117},[],{"trials":5343,"activeCount":117},[],{"trials":5345,"activeCount":117},[5346],{"nctId":5347,"briefTitle":5348,"status":1622,"phases":5349,"primaryCompletion":5350,"completion":5351,"start":5352,"enrollment":117,"conditions":5353,"interventions":5354},"NCT05087771","In Hospital IM Naltrexone: A Pilot Study",[94],"2022-12","2023-06","2022-03",[1039],[5334,5355],"oral naltrexone",{"trials":5357,"activeCount":117},[],{"intervention":5355,"totalTrials":114,"cells":5359},{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5366,"PHASE4":5368,"NA":5374},{"trials":5361,"activeCount":117},[],{"trials":5363,"activeCount":117},[],{"trials":5365,"activeCount":117},[],{"trials":5367,"activeCount":117},[],{"trials":5369,"activeCount":117},[5370],{"nctId":5347,"briefTitle":5348,"status":1622,"phases":5371,"primaryCompletion":5350,"completion":5351,"start":5352,"enrollment":117,"conditions":5372,"interventions":5373},[94],[1039],[5334,5355],{"trials":5375,"activeCount":117},[],{"intervention":5377,"totalTrials":114,"cells":5378},"zidovudine 300mg and lamivudine 150mg as Combivir",{"EARLY_PHASE1":5379,"PHASE1":5381,"PHASE2":5383,"PHASE3":5385,"PHASE4":5387,"NA":5397},{"trials":5380,"activeCount":117},[],{"trials":5382,"activeCount":117},[],{"trials":5384,"activeCount":117},[],{"trials":5386,"activeCount":117},[],{"trials":5388,"activeCount":117},[5389],{"nctId":5390,"briefTitle":5391,"status":160,"phases":5392,"primaryCompletion":5036,"completion":5393,"start":5394,"enrollment":1028,"conditions":5395,"interventions":5396},"NCT01386970","Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics",[94],"2010-07","2005-05",[5062],[5377],{"trials":5398,"activeCount":117},[],{"intervention":5400,"totalTrials":114,"cells":5401},"Dalbavancin via Intravenous Administration",{"EARLY_PHASE1":5402,"PHASE1":5404,"PHASE2":5406,"PHASE3":5408,"PHASE4":5410,"NA":5422},{"trials":5403,"activeCount":117},[],{"trials":5405,"activeCount":117},[],{"trials":5407,"activeCount":117},[],{"trials":5409,"activeCount":117},[],{"trials":5411,"activeCount":117},[5412],{"nctId":5413,"briefTitle":5414,"status":160,"phases":5415,"primaryCompletion":5416,"completion":5416,"start":5417,"enrollment":228,"conditions":5418,"interventions":5420},"NCT02940730","Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients",[94],"2018-06-18","2017-05-01",[5419],"Infectious Peritonitis",[5400,5421],"Dalbavancin via Intraperitoneal Administration",{"trials":5423,"activeCount":117},[],{"intervention":5421,"totalTrials":114,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5430,"PHASE3":5432,"PHASE4":5434,"NA":5440},{"trials":5427,"activeCount":117},[],{"trials":5429,"activeCount":117},[],{"trials":5431,"activeCount":117},[],{"trials":5433,"activeCount":117},[],{"trials":5435,"activeCount":117},[5436],{"nctId":5413,"briefTitle":5414,"status":160,"phases":5437,"primaryCompletion":5416,"completion":5416,"start":5417,"enrollment":228,"conditions":5438,"interventions":5439},[94],[5419],[5400,5421],{"trials":5441,"activeCount":117},[],{"intervention":5443,"totalTrials":114,"cells":5444},"Bupropion",{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5451,"PHASE4":5453,"NA":5464},{"trials":5446,"activeCount":117},[],{"trials":5448,"activeCount":117},[],{"trials":5450,"activeCount":117},[],{"trials":5452,"activeCount":117},[],{"trials":5454,"activeCount":117},[5455],{"nctId":5456,"briefTitle":5457,"status":160,"phases":5458,"primaryCompletion":4970,"completion":4970,"start":5459,"enrollment":1140,"conditions":5460,"interventions":5463},"NCT00936299","Bupropion for ADHD in Adolescents With Substance Use Disorder",[94],"2009-01",[5461,5462,1889],"Attention Deficit Hyperactivity Disorder","Nicotine Dependence",[5443],{"trials":5465,"activeCount":117},[],{"intervention":5467,"totalTrials":114,"cells":5468},"dornase alfa",{"EARLY_PHASE1":5469,"PHASE1":5471,"PHASE2":5473,"PHASE3":5475,"PHASE4":5477,"NA":5488},{"trials":5470,"activeCount":117},[],{"trials":5472,"activeCount":117},[],{"trials":5474,"activeCount":117},[],{"trials":5476,"activeCount":117},[],{"trials":5478,"activeCount":117},[5479],{"nctId":5480,"briefTitle":5481,"status":160,"phases":5482,"primaryCompletion":5483,"completion":5483,"start":5484,"enrollment":2450,"conditions":5485,"interventions":5487},"NCT00419380","Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)",[94],"2011-05","2007-01",[5486],"Otitis Media",[5467],{"trials":5489,"activeCount":117},[],{"intervention":5491,"totalTrials":114,"cells":5492},"Rifampin 600 MG",{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5497,"PHASE3":5499,"PHASE4":5501,"NA":5512},{"trials":5494,"activeCount":117},[],{"trials":5496,"activeCount":117},[],{"trials":5498,"activeCount":117},[],{"trials":5500,"activeCount":117},[],{"trials":5502,"activeCount":117},[5503],{"nctId":5504,"briefTitle":5505,"status":160,"phases":5506,"primaryCompletion":5507,"completion":5507,"start":5508,"enrollment":1920,"conditions":5509,"interventions":5511},"NCT04463680","Rifampin and the Contraceptive Implant",[94],"2022-02-22","2020-09-23",[255,5510],"Tuberculosis",[5491],{"trials":5513,"activeCount":117},[],{"intervention":5515,"totalTrials":114,"cells":5516},"Minute Maid Heart Wise orange juice",{"EARLY_PHASE1":5517,"PHASE1":5519,"PHASE2":5521,"PHASE3":5523,"PHASE4":5525,"NA":5537},{"trials":5518,"activeCount":117},[],{"trials":5520,"activeCount":117},[],{"trials":5522,"activeCount":117},[],{"trials":5524,"activeCount":117},[],{"trials":5526,"activeCount":117},[5527],{"nctId":5528,"briefTitle":5529,"status":160,"phases":5530,"completion":5531,"start":5532,"enrollment":1378,"conditions":5533,"interventions":5535},"NCT00249938","Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.",[94],"2006-08","2005-03",[181,5534],"Dyslipidemia",[5515,5536],"Welchol",{"trials":5538,"activeCount":117},[],{"intervention":5536,"totalTrials":114,"cells":5540},{"EARLY_PHASE1":5541,"PHASE1":5543,"PHASE2":5545,"PHASE3":5547,"PHASE4":5549,"NA":5555},{"trials":5542,"activeCount":117},[],{"trials":5544,"activeCount":117},[],{"trials":5546,"activeCount":117},[],{"trials":5548,"activeCount":117},[],{"trials":5550,"activeCount":117},[5551],{"nctId":5528,"briefTitle":5529,"status":160,"phases":5552,"completion":5531,"start":5532,"enrollment":1378,"conditions":5553,"interventions":5554},[94],[181,5534],[5515,5536],{"trials":5556,"activeCount":117},[],{"intervention":5558,"totalTrials":114,"cells":5559},"EzPAP",{"EARLY_PHASE1":5560,"PHASE1":5562,"PHASE2":5564,"PHASE3":5566,"PHASE4":5568,"NA":5579},{"trials":5561,"activeCount":117},[],{"trials":5563,"activeCount":117},[],{"trials":5565,"activeCount":117},[],{"trials":5567,"activeCount":117},[],{"trials":5569,"activeCount":117},[5570],{"nctId":5571,"briefTitle":5572,"status":160,"phases":5573,"primaryCompletion":5574,"completion":5575,"start":5576,"enrollment":955,"conditions":5577,"interventions":5578},"NCT02494076","Positive Expiratory Pressure for the Treatment of Acute Asthma in Children",[94],"2016-05","2017-04-12","2014-10",[2501],[5558],{"trials":5580,"activeCount":117},[],{"intervention":5582,"totalTrials":114,"cells":5583},"atorvastatin",{"EARLY_PHASE1":5584,"PHASE1":5586,"PHASE2":5588,"PHASE3":5590,"PHASE4":5592,"NA":5600},{"trials":5585,"activeCount":117},[],{"trials":5587,"activeCount":117},[],{"trials":5589,"activeCount":117},[],{"trials":5591,"activeCount":117},[],{"trials":5593,"activeCount":117},[5594],{"nctId":5595,"briefTitle":5596,"status":160,"phases":5597,"primaryCompletion":5034,"completion":5034,"start":2027,"enrollment":3875,"conditions":5598,"interventions":5599},"NCT01112670","The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology",[94],[736],[4737,5582],{"trials":5601,"activeCount":117},[],{"intervention":5603,"totalTrials":114,"cells":5604},"Multiple daily ijnection using Insulin Degludec and Insulin Aspart",{"EARLY_PHASE1":5605,"PHASE1":5607,"PHASE2":5609,"PHASE3":5611,"PHASE4":5613,"NA":5623},{"trials":5606,"activeCount":117},[],{"trials":5608,"activeCount":117},[],{"trials":5610,"activeCount":117},[],{"trials":5612,"activeCount":117},[],{"trials":5614,"activeCount":117},[5615],{"nctId":5616,"briefTitle":5617,"status":160,"phases":5618,"primaryCompletion":5619,"completion":5619,"start":5620,"enrollment":3331,"conditions":5621,"interventions":5622},"NCT03987191","Insulin Pump to Multiple Daily Injection Transition Clinical Trial",[94],"2020-10-08","2020-01-10",[18],[5603],{"trials":5624,"activeCount":117},[],{"intervention":5626,"totalTrials":114,"cells":5627},"Standard Dose Group",{"EARLY_PHASE1":5628,"PHASE1":5630,"PHASE2":5632,"PHASE3":5634,"PHASE4":5636,"NA":5647},{"trials":5629,"activeCount":117},[],{"trials":5631,"activeCount":117},[],{"trials":5633,"activeCount":117},[],{"trials":5635,"activeCount":117},[],{"trials":5637,"activeCount":117},[5638],{"nctId":5639,"briefTitle":5640,"status":1622,"phases":5641,"primaryCompletion":5642,"completion":5642,"start":5643,"enrollment":117,"conditions":5644,"interventions":5645},"NCT01886742","Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients",[94],"2018-10","2017-09-01",[15],[5626,5646],"Weight Based Group",{"trials":5648,"activeCount":117},[],{"intervention":5646,"totalTrials":114,"cells":5650},{"EARLY_PHASE1":5651,"PHASE1":5653,"PHASE2":5655,"PHASE3":5657,"PHASE4":5659,"NA":5665},{"trials":5652,"activeCount":117},[],{"trials":5654,"activeCount":117},[],{"trials":5656,"activeCount":117},[],{"trials":5658,"activeCount":117},[],{"trials":5660,"activeCount":117},[5661],{"nctId":5639,"briefTitle":5640,"status":1622,"phases":5662,"primaryCompletion":5642,"completion":5642,"start":5643,"enrollment":117,"conditions":5663,"interventions":5664},[94],[15],[5626,5646],{"trials":5666,"activeCount":117},[],{"intervention":5668,"totalTrials":114,"cells":5669},"Betadine",{"EARLY_PHASE1":5670,"PHASE1":5672,"PHASE2":5674,"PHASE3":5676,"PHASE4":5678,"NA":5693},{"trials":5671,"activeCount":117},[],{"trials":5673,"activeCount":117},[],{"trials":5675,"activeCount":117},[],{"trials":5677,"activeCount":117},[],{"trials":5679,"activeCount":117},[5680],{"nctId":5681,"briefTitle":5682,"status":160,"phases":5683,"primaryCompletion":5684,"completion":5684,"start":5685,"enrollment":5686,"conditions":5687,"interventions":5690},"NCT02116608","Treatment of Tracheostomy Granulomas",[94],"2019-09-05","2014-09",26,[5688,5689],"Granuloma","Tracheostomy",[5668,5691,5692],"Silver Nitrate","Hydrocortisone Butyrate Cream, 1.0%",{"trials":5694,"activeCount":117},[],{"intervention":5691,"totalTrials":114,"cells":5696},{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5703,"PHASE4":5705,"NA":5711},{"trials":5698,"activeCount":117},[],{"trials":5700,"activeCount":117},[],{"trials":5702,"activeCount":117},[],{"trials":5704,"activeCount":117},[],{"trials":5706,"activeCount":117},[5707],{"nctId":5681,"briefTitle":5682,"status":160,"phases":5708,"primaryCompletion":5684,"completion":5684,"start":5685,"enrollment":5686,"conditions":5709,"interventions":5710},[94],[5688,5689],[5668,5691,5692],{"trials":5712,"activeCount":117},[],{"intervention":5692,"totalTrials":114,"cells":5714},{"EARLY_PHASE1":5715,"PHASE1":5717,"PHASE2":5719,"PHASE3":5721,"PHASE4":5723,"NA":5729},{"trials":5716,"activeCount":117},[],{"trials":5718,"activeCount":117},[],{"trials":5720,"activeCount":117},[],{"trials":5722,"activeCount":117},[],{"trials":5724,"activeCount":117},[5725],{"nctId":5681,"briefTitle":5682,"status":160,"phases":5726,"primaryCompletion":5684,"completion":5684,"start":5685,"enrollment":5686,"conditions":5727,"interventions":5728},[94],[5688,5689],[5668,5691,5692],{"trials":5730,"activeCount":117},[],{"intervention":5732,"totalTrials":114,"cells":5733},"TDF with a boosted protease inhibitor",{"EARLY_PHASE1":5734,"PHASE1":5736,"PHASE2":5738,"PHASE3":5740,"PHASE4":5742,"NA":5756},{"trials":5735,"activeCount":117},[],{"trials":5737,"activeCount":117},[],{"trials":5739,"activeCount":117},[],{"trials":5741,"activeCount":117},[],{"trials":5743,"activeCount":117},[5744],{"nctId":5745,"briefTitle":5746,"status":160,"phases":5747,"primaryCompletion":5748,"completion":5749,"start":5750,"enrollment":228,"conditions":5751,"interventions":5753},"NCT03126370","Effects of Ledipasvir\u002FSofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)",[94],"2019-07-12","2019-10-01","2018-01-08",[4630,5752],"HIV Coinfection",[5732,5754,5755],"TAF with a boosted protease inhibitor","TAF with a boosted protease inhibitor and LDV\u002FSOF",{"trials":5757,"activeCount":117},[],{"intervention":5754,"totalTrials":114,"cells":5759},{"EARLY_PHASE1":5760,"PHASE1":5762,"PHASE2":5764,"PHASE3":5766,"PHASE4":5768,"NA":5774},{"trials":5761,"activeCount":117},[],{"trials":5763,"activeCount":117},[],{"trials":5765,"activeCount":117},[],{"trials":5767,"activeCount":117},[],{"trials":5769,"activeCount":117},[5770],{"nctId":5745,"briefTitle":5746,"status":160,"phases":5771,"primaryCompletion":5748,"completion":5749,"start":5750,"enrollment":228,"conditions":5772,"interventions":5773},[94],[4630,5752],[5732,5754,5755],{"trials":5775,"activeCount":117},[],{"intervention":5755,"totalTrials":114,"cells":5777},{"EARLY_PHASE1":5778,"PHASE1":5780,"PHASE2":5782,"PHASE3":5784,"PHASE4":5786,"NA":5792},{"trials":5779,"activeCount":117},[],{"trials":5781,"activeCount":117},[],{"trials":5783,"activeCount":117},[],{"trials":5785,"activeCount":117},[],{"trials":5787,"activeCount":117},[5788],{"nctId":5745,"briefTitle":5746,"status":160,"phases":5789,"primaryCompletion":5748,"completion":5749,"start":5750,"enrollment":228,"conditions":5790,"interventions":5791},[94],[4630,5752],[5732,5754,5755],{"trials":5793,"activeCount":117},[],{"intervention":5795,"totalTrials":114,"cells":5796},"fidaxomicin",{"EARLY_PHASE1":5797,"PHASE1":5799,"PHASE2":5801,"PHASE3":5803,"PHASE4":5805,"NA":5817},{"trials":5798,"activeCount":117},[],{"trials":5800,"activeCount":117},[],{"trials":5802,"activeCount":117},[],{"trials":5804,"activeCount":117},[],{"trials":5806,"activeCount":117},[5807],{"nctId":5808,"briefTitle":5809,"status":1622,"phases":5810,"primaryCompletion":1771,"completion":5811,"start":5812,"enrollment":117,"conditions":5813,"interventions":5816},"NCT02464306","Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection",[94],"2019-06","2018-06",[5814,5815],"Clostridium Difficile Infection","Solid Organ Transplant",[5795],{"trials":5818,"activeCount":117},[],{"intervention":988,"totalTrials":114,"cells":5820},{"EARLY_PHASE1":5821,"PHASE1":5823,"PHASE2":5825,"PHASE3":5827,"PHASE4":5829,"NA":5835},{"trials":5822,"activeCount":117},[],{"trials":5824,"activeCount":117},[],{"trials":5826,"activeCount":117},[],{"trials":5828,"activeCount":117},[],{"trials":5830,"activeCount":117},[5831],{"nctId":979,"briefTitle":980,"status":160,"phases":5832,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":5833,"interventions":5834},[94],[986],[988,989,901,990],{"trials":5836,"activeCount":117},[],{"intervention":989,"totalTrials":114,"cells":5838},{"EARLY_PHASE1":5839,"PHASE1":5841,"PHASE2":5843,"PHASE3":5845,"PHASE4":5847,"NA":5853},{"trials":5840,"activeCount":117},[],{"trials":5842,"activeCount":117},[],{"trials":5844,"activeCount":117},[],{"trials":5846,"activeCount":117},[],{"trials":5848,"activeCount":117},[5849],{"nctId":979,"briefTitle":980,"status":160,"phases":5850,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":5851,"interventions":5852},[94],[986],[988,989,901,990],{"trials":5854,"activeCount":117},[],{"intervention":990,"totalTrials":114,"cells":5856},{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5861,"PHASE3":5863,"PHASE4":5865,"NA":5871},{"trials":5858,"activeCount":117},[],{"trials":5860,"activeCount":117},[],{"trials":5862,"activeCount":117},[],{"trials":5864,"activeCount":117},[],{"trials":5866,"activeCount":117},[5867],{"nctId":979,"briefTitle":980,"status":160,"phases":5868,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":5869,"interventions":5870},[94],[986],[988,989,901,990],{"trials":5872,"activeCount":117},[],{"intervention":183,"totalTrials":114,"cells":5874},{"EARLY_PHASE1":5875,"PHASE1":5877,"PHASE2":5879,"PHASE3":5881,"PHASE4":5883,"NA":5889},{"trials":5876,"activeCount":117},[],{"trials":5878,"activeCount":117},[],{"trials":5880,"activeCount":117},[],{"trials":5882,"activeCount":117},[],{"trials":5884,"activeCount":117},[5885],{"nctId":172,"briefTitle":173,"status":160,"phases":5886,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":5887,"interventions":5888},[94],[180,181],[63,183,184,63],{"trials":5890,"activeCount":117},[],{"intervention":184,"totalTrials":114,"cells":5892},{"EARLY_PHASE1":5893,"PHASE1":5895,"PHASE2":5897,"PHASE3":5899,"PHASE4":5901,"NA":5907},{"trials":5894,"activeCount":117},[],{"trials":5896,"activeCount":117},[],{"trials":5898,"activeCount":117},[],{"trials":5900,"activeCount":117},[],{"trials":5902,"activeCount":117},[5903],{"nctId":172,"briefTitle":173,"status":160,"phases":5904,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":5905,"interventions":5906},[94],[180,181],[63,183,184,63],{"trials":5908,"activeCount":117},[],{"intervention":5910,"totalTrials":114,"cells":5911},"Rosiglitazone",{"EARLY_PHASE1":5912,"PHASE1":5914,"PHASE2":5916,"PHASE3":5918,"PHASE4":5920,"NA":5931},{"trials":5913,"activeCount":117},[],{"trials":5915,"activeCount":117},[],{"trials":5917,"activeCount":117},[],{"trials":5919,"activeCount":117},[],{"trials":5921,"activeCount":117},[5922],{"nctId":5923,"briefTitle":5924,"status":160,"phases":5925,"primaryCompletion":4754,"completion":5926,"start":5927,"conditions":5928,"interventions":5930},"NCT00364221","Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome",[94],"2006-10","2004-11",[5929,968],"Metabolic Syndrome",[5910],{"trials":5932,"activeCount":117},[],{"intervention":5934,"totalTrials":114,"cells":5935},"bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide",{"EARLY_PHASE1":5936,"PHASE1":5938,"PHASE2":5940,"PHASE3":5942,"PHASE4":5944,"NA":5956},{"trials":5937,"activeCount":117},[],{"trials":5939,"activeCount":117},[],{"trials":5941,"activeCount":117},[],{"trials":5943,"activeCount":117},[],{"trials":5945,"activeCount":117},[5946],{"nctId":5947,"briefTitle":5948,"status":125,"phases":5949,"primaryCompletion":5950,"completion":5950,"start":5951,"enrollment":228,"conditions":5952,"interventions":5954},"NCT04249037","Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV",[94],"2023-07-01","2020-12-15",[5953],"HIV\u002FAIDS",[5934,5955],"Standard initiation of antiretroviral therapy",{"trials":5957,"activeCount":117},[],{"intervention":5955,"totalTrials":114,"cells":5959},{"EARLY_PHASE1":5960,"PHASE1":5962,"PHASE2":5964,"PHASE3":5966,"PHASE4":5968,"NA":5974},{"trials":5961,"activeCount":117},[],{"trials":5963,"activeCount":117},[],{"trials":5965,"activeCount":117},[],{"trials":5967,"activeCount":117},[],{"trials":5969,"activeCount":117},[5970],{"nctId":5947,"briefTitle":5948,"status":125,"phases":5971,"primaryCompletion":5950,"completion":5950,"start":5951,"enrollment":228,"conditions":5972,"interventions":5973},[94],[5953],[5934,5955],{"trials":5975,"activeCount":117},[],{"intervention":5977,"totalTrials":114,"cells":5978},"Inactivated Trivalent Influenza Vaccine",{"EARLY_PHASE1":5979,"PHASE1":5981,"PHASE2":5983,"PHASE3":5985,"PHASE4":5987,"NA":5999},{"trials":5980,"activeCount":117},[],{"trials":5982,"activeCount":117},[],{"trials":5984,"activeCount":117},[],{"trials":5986,"activeCount":117},[],{"trials":5988,"activeCount":117},[5989],{"nctId":5990,"briefTitle":5991,"status":160,"phases":5992,"primaryCompletion":4176,"completion":4176,"start":5993,"enrollment":5994,"conditions":5995,"interventions":5997},"NCT01680679","Influenza Immunization of Children in India",[94],"2012-05",18163,[5996],"Influenza",[5977,5998],"Inactivated poliovirus vaccine (IPV), trivalent",{"trials":6000,"activeCount":117},[],{"intervention":5998,"totalTrials":114,"cells":6002},{"EARLY_PHASE1":6003,"PHASE1":6005,"PHASE2":6007,"PHASE3":6009,"PHASE4":6011,"NA":6017},{"trials":6004,"activeCount":117},[],{"trials":6006,"activeCount":117},[],{"trials":6008,"activeCount":117},[],{"trials":6010,"activeCount":117},[],{"trials":6012,"activeCount":117},[6013],{"nctId":5990,"briefTitle":5991,"status":160,"phases":6014,"primaryCompletion":4176,"completion":4176,"start":5993,"enrollment":5994,"conditions":6015,"interventions":6016},[94],[5996],[5977,5998],{"trials":6018,"activeCount":117},[],{"intervention":6020,"totalTrials":114,"cells":6021},"Discontinuation of disease modifying therapy",{"EARLY_PHASE1":6022,"PHASE1":6024,"PHASE2":6026,"PHASE3":6028,"PHASE4":6030,"NA":6041},{"trials":6023,"activeCount":117},[],{"trials":6025,"activeCount":117},[],{"trials":6027,"activeCount":117},[],{"trials":6029,"activeCount":117},[],{"trials":6031,"activeCount":117},[6032],{"nctId":6033,"briefTitle":6034,"status":160,"phases":6035,"primaryCompletion":42,"completion":42,"start":6036,"enrollment":6037,"conditions":6038,"interventions":6039},"NCT03073603","Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)",[94],"2017-04-20",259,[36],[6020,6040],"Standard of Care",{"trials":6042,"activeCount":117},[],{"intervention":6040,"totalTrials":114,"cells":6044},{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6049,"PHASE3":6051,"PHASE4":6053,"NA":6059},{"trials":6046,"activeCount":117},[],{"trials":6048,"activeCount":117},[],{"trials":6050,"activeCount":117},[],{"trials":6052,"activeCount":117},[],{"trials":6054,"activeCount":117},[6055],{"nctId":6033,"briefTitle":6034,"status":160,"phases":6056,"primaryCompletion":42,"completion":42,"start":6036,"enrollment":6037,"conditions":6057,"interventions":6058},[94],[36],[6020,6040],{"trials":6060,"activeCount":117},[],{"intervention":6062,"totalTrials":114,"cells":6063},"Depo-subQ Provera Injectable Product",{"EARLY_PHASE1":6064,"PHASE1":6066,"PHASE2":6068,"PHASE3":6070,"PHASE4":6072,"NA":6083},{"trials":6065,"activeCount":117},[],{"trials":6067,"activeCount":117},[],{"trials":6069,"activeCount":117},[],{"trials":6071,"activeCount":117},[],{"trials":6073,"activeCount":117},[6074],{"nctId":6075,"briefTitle":6076,"status":160,"phases":6077,"primaryCompletion":6078,"completion":6078,"start":6079,"enrollment":1561,"conditions":6080,"interventions":6082},"NCT05726903","Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone",[94],"2023-11-17","2022-12-06",[6081],"Gender Dysphoria, Adolescent",[6062],{"trials":6084,"activeCount":117},[],{"intervention":6086,"totalTrials":114,"cells":6087},"Envarsus XR",{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6092,"PHASE3":6094,"PHASE4":6096,"NA":6107},{"trials":6089,"activeCount":117},[],{"trials":6091,"activeCount":117},[],{"trials":6093,"activeCount":117},[],{"trials":6095,"activeCount":117},[],{"trials":6097,"activeCount":117},[6098],{"nctId":6099,"briefTitle":6100,"status":160,"phases":6101,"primaryCompletion":6102,"completion":6103,"start":2365,"enrollment":28,"conditions":6104,"interventions":6106},"NCT03270462","CNS Study of Patients Switching From Tacrolimus to Envarsus",[94],"2020-05-02","2020-06-02",[6105],"Renal Transplant Patients",[6086],{"trials":6108,"activeCount":117},[],{"intervention":6110,"totalTrials":114,"cells":6111},"bupropion & Citalopram",{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6118,"PHASE4":6120,"NA":6130},{"trials":6113,"activeCount":117},[],{"trials":6115,"activeCount":117},[],{"trials":6117,"activeCount":117},[],{"trials":6119,"activeCount":117},[],{"trials":6121,"activeCount":117},[6122],{"nctId":6123,"briefTitle":6124,"status":160,"phases":6125,"primaryCompletion":954,"completion":954,"start":162,"enrollment":114,"conditions":6126,"interventions":6128},"NCT01716221","An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia",[94],[6127],"Friedreich Ataxia",[6110,6129],"Bupropion & Placebo",{"trials":6131,"activeCount":117},[],{"intervention":6129,"totalTrials":114,"cells":6133},{"EARLY_PHASE1":6134,"PHASE1":6136,"PHASE2":6138,"PHASE3":6140,"PHASE4":6142,"NA":6148},{"trials":6135,"activeCount":117},[],{"trials":6137,"activeCount":117},[],{"trials":6139,"activeCount":117},[],{"trials":6141,"activeCount":117},[],{"trials":6143,"activeCount":117},[6144],{"nctId":6123,"briefTitle":6124,"status":160,"phases":6145,"primaryCompletion":954,"completion":954,"start":162,"enrollment":114,"conditions":6146,"interventions":6147},[94],[6127],[6110,6129],{"trials":6149,"activeCount":117},[],{"intervention":6151,"totalTrials":114,"cells":6152},"Oxtellar XR 150Mg Extended Release",{"EARLY_PHASE1":6153,"PHASE1":6155,"PHASE2":6157,"PHASE3":6159,"PHASE4":6161,"NA":6171},{"trials":6154,"activeCount":117},[],{"trials":6156,"activeCount":117},[],{"trials":6158,"activeCount":117},[],{"trials":6160,"activeCount":117},[],{"trials":6162,"activeCount":117},[6163],{"nctId":6164,"briefTitle":6165,"status":1622,"phases":6166,"primaryCompletion":6167,"completion":6167,"start":6167,"enrollment":117,"conditions":6168,"interventions":6170},"NCT03374709","Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia",[94],"2018-12-14",[6169],"Trigeminal Neuralgia",[6151],{"trials":6172,"activeCount":117},[],{"intervention":6174,"totalTrials":114,"cells":6175},"Aliskiren",{"EARLY_PHASE1":6176,"PHASE1":6178,"PHASE2":6180,"PHASE3":6182,"PHASE4":6184,"NA":6195},{"trials":6177,"activeCount":117},[],{"trials":6179,"activeCount":117},[],{"trials":6181,"activeCount":117},[],{"trials":6183,"activeCount":117},[],{"trials":6185,"activeCount":117},[6186],{"nctId":6187,"briefTitle":6188,"status":125,"phases":6189,"primaryCompletion":6190,"completion":6190,"start":5483,"enrollment":114,"conditions":6191,"interventions":6194},"NCT01235910","Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation",[94],"2012-12",[6192,6193],"Hypertension","Cardiac Transplantation",[6174],{"trials":6196,"activeCount":117},[],{"intervention":6198,"totalTrials":114,"cells":6199},"Fresh Frozen Plasma",{"EARLY_PHASE1":6200,"PHASE1":6202,"PHASE2":6204,"PHASE3":6206,"PHASE4":6208,"NA":6220},{"trials":6201,"activeCount":117},[],{"trials":6203,"activeCount":117},[],{"trials":6205,"activeCount":117},[],{"trials":6207,"activeCount":117},[],{"trials":6209,"activeCount":117},[6210],{"nctId":6211,"briefTitle":6212,"status":160,"phases":6213,"primaryCompletion":6214,"completion":6215,"start":6216,"enrollment":110,"conditions":6217,"interventions":6219},"NCT02366845","Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease",[94],"2015-06-24","2019-03-27","2012-06-27",[6218],"Liver Disease",[6198],{"trials":6221,"activeCount":117},[],{"intervention":6223,"totalTrials":114,"cells":6224},"Nitrous Oxide",{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6229,"PHASE3":6231,"PHASE4":6233,"NA":6247},{"trials":6226,"activeCount":117},[],{"trials":6228,"activeCount":117},[],{"trials":6230,"activeCount":117},[],{"trials":6232,"activeCount":117},[],{"trials":6234,"activeCount":117},[6235],{"nctId":6236,"briefTitle":6237,"status":160,"phases":6238,"primaryCompletion":6239,"completion":6239,"start":5237,"enrollment":6240,"conditions":6241,"interventions":6245},"NCT03085563","A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department",[94],"2018-11-08",63,[1463,6242,6243,6244],"Simple Lacerations Less Than 4 cm","Lumbar Punctures","Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement",[6223,6246],"Midazolam",{"trials":6248,"activeCount":117},[],{"intervention":6250,"totalTrials":114,"cells":6251},"Ethinyl Estradiol \u002F Norgestimate Oral",{"EARLY_PHASE1":6252,"PHASE1":6254,"PHASE2":6256,"PHASE3":6258,"PHASE4":6260,"NA":6272},{"trials":6253,"activeCount":117},[],{"trials":6255,"activeCount":117},[],{"trials":6257,"activeCount":117},[],{"trials":6259,"activeCount":117},[],{"trials":6261,"activeCount":117},[6262],{"nctId":6263,"briefTitle":6264,"status":160,"phases":6265,"primaryCompletion":6266,"completion":6266,"start":6267,"enrollment":6268,"conditions":6269,"interventions":6271},"NCT04828824","Premature Discontinuation of Contraceptive Implants",[94],"2025-11-12","2021-06-18",600,[6270],"Contraception Behavior",[6250],{"trials":6273,"activeCount":117},[],{"intervention":6275,"totalTrials":114,"cells":6276},"Plasmalyte 3ml\u002Fkg\u002Fhr group",{"EARLY_PHASE1":6277,"PHASE1":6279,"PHASE2":6281,"PHASE3":6283,"PHASE4":6285,"NA":6296},{"trials":6278,"activeCount":117},[],{"trials":6280,"activeCount":117},[],{"trials":6282,"activeCount":117},[],{"trials":6284,"activeCount":117},[],{"trials":6286,"activeCount":117},[6287],{"nctId":6288,"briefTitle":6289,"status":160,"phases":6290,"primaryCompletion":982,"completion":982,"start":678,"enrollment":2450,"conditions":6291,"interventions":6294},"NCT02135146","Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach",[94],[6292,6293],"Hypotension","Kidney Injury",[6275,6295],"Plasmalyte 6ml\u002Fkg\u002Fhr group",{"trials":6297,"activeCount":117},[],{"intervention":6295,"totalTrials":114,"cells":6299},{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6304,"PHASE3":6306,"PHASE4":6308,"NA":6314},{"trials":6301,"activeCount":117},[],{"trials":6303,"activeCount":117},[],{"trials":6305,"activeCount":117},[],{"trials":6307,"activeCount":117},[],{"trials":6309,"activeCount":117},[6310],{"nctId":6288,"briefTitle":6289,"status":160,"phases":6311,"primaryCompletion":982,"completion":982,"start":678,"enrollment":2450,"conditions":6312,"interventions":6313},[94],[6292,6293],[6275,6295],{"trials":6315,"activeCount":117},[],{"intervention":6317,"totalTrials":114,"cells":6318},"Glargine insulin",{"EARLY_PHASE1":6319,"PHASE1":6321,"PHASE2":6323,"PHASE3":6325,"PHASE4":6327,"NA":6336},{"trials":6320,"activeCount":117},[],{"trials":6322,"activeCount":117},[],{"trials":6324,"activeCount":117},[],{"trials":6326,"activeCount":117},[],{"trials":6328,"activeCount":117},[6329],{"nctId":6330,"briefTitle":6331,"status":160,"phases":6332,"primaryCompletion":6333,"completion":6333,"start":176,"enrollment":1028,"conditions":6334,"interventions":6335},"NCT01203774","Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital",[94],"2013-08",[33],[6317],{"trials":6337,"activeCount":117},[],{"intervention":6339,"totalTrials":114,"cells":6340},"Gonadotropin Releasing Hormone Agonists",{"EARLY_PHASE1":6341,"PHASE1":6343,"PHASE2":6345,"PHASE3":6347,"PHASE4":6349,"NA":6362},{"trials":6342,"activeCount":117},[],{"trials":6344,"activeCount":117},[],{"trials":6346,"activeCount":117},[],{"trials":6348,"activeCount":117},[],{"trials":6350,"activeCount":117},[6351],{"nctId":6352,"briefTitle":6353,"status":160,"phases":6354,"primaryCompletion":6355,"completion":6355,"start":5236,"enrollment":228,"conditions":6356,"interventions":6360},"NCT05700903","Contributions to Hypertension With Androgen Deprivation Therapy",[94],"2025-07-16",[6357,914,6192,6358,6359],"Androgen Deprivation Therapy","Autonomic Dysfunction","Renal Disease",[6339,6361],"Androgen receptor (AR) inhibitor",{"trials":6363,"activeCount":117},[],{"intervention":6361,"totalTrials":114,"cells":6365},{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6372,"PHASE4":6374,"NA":6380},{"trials":6367,"activeCount":117},[],{"trials":6369,"activeCount":117},[],{"trials":6371,"activeCount":117},[],{"trials":6373,"activeCount":117},[],{"trials":6375,"activeCount":117},[6376],{"nctId":6352,"briefTitle":6353,"status":160,"phases":6377,"primaryCompletion":6355,"completion":6355,"start":5236,"enrollment":228,"conditions":6378,"interventions":6379},[94],[6357,914,6192,6358,6359],[6339,6361],{"trials":6381,"activeCount":117},[],{"intervention":4771,"totalTrials":114,"cells":6383},{"EARLY_PHASE1":6384,"PHASE1":6386,"PHASE2":6388,"PHASE3":6390,"PHASE4":6392,"NA":6398},{"trials":6385,"activeCount":117},[],{"trials":6387,"activeCount":117},[],{"trials":6389,"activeCount":117},[],{"trials":6391,"activeCount":117},[],{"trials":6393,"activeCount":117},[6394],{"nctId":4764,"briefTitle":4765,"status":1622,"phases":6395,"primaryCompletion":4767,"completion":4767,"start":4768,"enrollment":117,"conditions":6396,"interventions":6397},[94],[1128],[4771,4741],{"trials":6399,"activeCount":117},[],{"intervention":6401,"totalTrials":114,"cells":6402},"Fenofibrate 145 mg",{"EARLY_PHASE1":6403,"PHASE1":6405,"PHASE2":6407,"PHASE3":6409,"PHASE4":6411,"NA":6423},{"trials":6404,"activeCount":117},[],{"trials":6406,"activeCount":117},[],{"trials":6408,"activeCount":117},[],{"trials":6410,"activeCount":117},[],{"trials":6412,"activeCount":117},[6413],{"nctId":6414,"briefTitle":6415,"status":715,"phases":6416,"primaryCompletion":6417,"completion":6418,"start":6419,"enrollment":6420,"conditions":6421,"interventions":6422},"NCT05498090","Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males with Klinefelter Syndrome",[94],"2025-06-30","2025-08-30","2022-11-03",44,[5155],[6401],{"trials":6424,"activeCount":117},[],{"intervention":6426,"totalTrials":114,"cells":6427},"Curcumin",{"EARLY_PHASE1":6428,"PHASE1":6430,"PHASE2":6432,"PHASE3":6434,"PHASE4":6436,"NA":6445},{"trials":6429,"activeCount":117},[],{"trials":6431,"activeCount":117},[],{"trials":6433,"activeCount":117},[],{"trials":6435,"activeCount":117},[],{"trials":6437,"activeCount":117},[6438],{"nctId":6439,"briefTitle":6440,"status":160,"phases":6441,"primaryCompletion":627,"completion":627,"start":6442,"enrollment":3803,"conditions":6443,"interventions":6444},"NCT02494141","Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD",[94],"2015-11-12",[166],[6426],{"trials":6446,"activeCount":117},[],{"intervention":6448,"totalTrials":114,"cells":6449},"Sugammadex",{"EARLY_PHASE1":6450,"PHASE1":6452,"PHASE2":6454,"PHASE3":6456,"PHASE4":6458,"NA":6470},{"trials":6451,"activeCount":117},[],{"trials":6453,"activeCount":117},[],{"trials":6455,"activeCount":117},[],{"trials":6457,"activeCount":117},[],{"trials":6459,"activeCount":117},[6460],{"nctId":6461,"briefTitle":6462,"status":160,"phases":6463,"primaryCompletion":4832,"completion":1950,"start":6464,"enrollment":4187,"conditions":6465,"interventions":6468},"NCT03923556","Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery",[94],"2021-02-02",[290,6466,6467],"Postoperative Residual Curarization","Postoperative Residual Weakness",[6448,6469],"Neostigmine",{"trials":6471,"activeCount":117},[],{"intervention":6469,"totalTrials":114,"cells":6473},{"EARLY_PHASE1":6474,"PHASE1":6476,"PHASE2":6478,"PHASE3":6480,"PHASE4":6482,"NA":6488},{"trials":6475,"activeCount":117},[],{"trials":6477,"activeCount":117},[],{"trials":6479,"activeCount":117},[],{"trials":6481,"activeCount":117},[],{"trials":6483,"activeCount":117},[6484],{"nctId":6461,"briefTitle":6462,"status":160,"phases":6485,"primaryCompletion":4832,"completion":1950,"start":6464,"enrollment":4187,"conditions":6486,"interventions":6487},[94],[290,6466,6467],[6448,6469],{"trials":6489,"activeCount":117},[],{"intervention":6491,"totalTrials":114,"cells":6492},"Regadenoson myocardial perfusion imaging",{"EARLY_PHASE1":6493,"PHASE1":6495,"PHASE2":6497,"PHASE3":6499,"PHASE4":6501,"NA":6512},{"trials":6494,"activeCount":117},[],{"trials":6496,"activeCount":117},[],{"trials":6498,"activeCount":117},[],{"trials":6500,"activeCount":117},[],{"trials":6502,"activeCount":117},[6503],{"nctId":6504,"briefTitle":6505,"status":160,"phases":6506,"primaryCompletion":6507,"completion":6507,"start":2027,"enrollment":5686,"conditions":6508,"interventions":6510},"NCT01019486","Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)",[94],"2011-12",[6509,1943],"Coronary Artery Disease",[6491,6511],"Regadenoson MRI myocardial blood flow",{"trials":6513,"activeCount":117},[],{"intervention":6511,"totalTrials":114,"cells":6515},{"EARLY_PHASE1":6516,"PHASE1":6518,"PHASE2":6520,"PHASE3":6522,"PHASE4":6524,"NA":6530},{"trials":6517,"activeCount":117},[],{"trials":6519,"activeCount":117},[],{"trials":6521,"activeCount":117},[],{"trials":6523,"activeCount":117},[],{"trials":6525,"activeCount":117},[6526],{"nctId":6504,"briefTitle":6505,"status":160,"phases":6527,"primaryCompletion":6507,"completion":6507,"start":2027,"enrollment":5686,"conditions":6528,"interventions":6529},[94],[6509,1943],[6491,6511],{"trials":6531,"activeCount":117},[],{"intervention":6533,"totalTrials":114,"cells":6534},"Sphenopalatine ganglion Block",{"EARLY_PHASE1":6535,"PHASE1":6537,"PHASE2":6539,"PHASE3":6541,"PHASE4":6543,"NA":6551},{"trials":6536,"activeCount":117},[],{"trials":6538,"activeCount":117},[],{"trials":6540,"activeCount":117},[],{"trials":6542,"activeCount":117},[],{"trials":6544,"activeCount":117},[6545],{"nctId":6546,"briefTitle":6547,"status":125,"phases":6548,"primaryCompletion":1771,"completion":1771,"start":925,"enrollment":1548,"conditions":6549,"interventions":6550},"NCT02962427","Treatment of Post-dural Puncture Headache in Postpartum Patients: Sphenopalatine Ganglion Block to Epidural Blood Patch.",[94],[4315],[6533],{"trials":6552,"activeCount":117},[],{"intervention":6554,"totalTrials":114,"cells":6555},"Testosterone Cypionate 200 Milligram\u002FMilliliter Injectable Solution",{"EARLY_PHASE1":6556,"PHASE1":6558,"PHASE2":6560,"PHASE3":6562,"PHASE4":6564,"NA":6574},{"trials":6557,"activeCount":117},[],{"trials":6559,"activeCount":117},[],{"trials":6561,"activeCount":117},[],{"trials":6563,"activeCount":117},[],{"trials":6565,"activeCount":117},[6566],{"nctId":6567,"briefTitle":6568,"status":160,"phases":6569,"primaryCompletion":6570,"completion":6570,"start":6571,"enrollment":1165,"conditions":6572,"interventions":6573},"NCT03325647","TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY",[94],"2021-05-05","2017-11-06",[5155],[6554],{"trials":6575,"activeCount":117},[],{"intervention":6577,"totalTrials":114,"cells":6578},"Technosphere insulin",{"EARLY_PHASE1":6579,"PHASE1":6581,"PHASE2":6583,"PHASE3":6585,"PHASE4":6587,"NA":6597},{"trials":6580,"activeCount":117},[],{"trials":6582,"activeCount":117},[],{"trials":6584,"activeCount":117},[],{"trials":6586,"activeCount":117},[],{"trials":6588,"activeCount":117},[6589],{"nctId":6590,"briefTitle":6591,"status":160,"phases":6592,"primaryCompletion":6593,"completion":5152,"start":6594,"enrollment":1378,"conditions":6595,"interventions":6596},"NCT03143816","Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study",[94],"2017-12-15","2017-09-30",[1380],[6577],{"trials":6598,"activeCount":117},[],{"intervention":6600,"totalTrials":114,"cells":6601},"Ivabradine",{"EARLY_PHASE1":6602,"PHASE1":6604,"PHASE2":6606,"PHASE3":6608,"PHASE4":6610,"NA":6622},{"trials":6603,"activeCount":117},[],{"trials":6605,"activeCount":117},[],{"trials":6607,"activeCount":117},[],{"trials":6609,"activeCount":117},[],{"trials":6611,"activeCount":117},[6612],{"nctId":6613,"briefTitle":6614,"status":160,"phases":6615,"primaryCompletion":5350,"completion":1949,"start":925,"enrollment":22,"conditions":6616,"interventions":6621},"NCT02973594","Pulse Reduction On Beta-blocker and Ivabradine Therapy",[94],[6617,6618,6619,6620],"Dilated Cardiomyopathies, Idiopathic","Heart Failure, Systolic","Ventricular Remodeling","Electrical Remodeling",[6600],{"trials":6623,"activeCount":117},[],{"intervention":6625,"totalTrials":199,"cells":6626},"Rituximab",{"EARLY_PHASE1":6627,"PHASE1":6629,"PHASE2":6631,"PHASE3":6640,"PHASE4":6651,"NA":6653},{"trials":6628,"activeCount":117},[],{"trials":6630,"activeCount":117},[],{"trials":6632,"activeCount":117},[6633],{"nctId":6634,"briefTitle":6635,"status":160,"phases":6636,"primaryCompletion":4628,"completion":4628,"start":4686,"enrollment":1666,"conditions":6637,"interventions":6638},"NCT01569451","Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate",[92],[36],[6625,6639],"Glatiramer Acetate",{"trials":6641,"activeCount":117},[6642],{"nctId":6643,"briefTitle":6644,"status":160,"phases":6645,"primaryCompletion":6646,"completion":6646,"start":6647,"enrollment":938,"conditions":6648,"interventions":6649},"NCT02980042","Safety of Switching From Rituximab to Ocrelizumab in MS Patients",[93],"2019-03-06","2017-01-01",[36],[6650,6625],"Ocrelizumab",{"trials":6652,"activeCount":117},[],{"trials":6654,"activeCount":117},[],{"intervention":6656,"totalTrials":114,"cells":6657},"Budesonide",{"EARLY_PHASE1":6658,"PHASE1":6660,"PHASE2":6662,"PHASE3":6664,"PHASE4":6674,"NA":6676},{"trials":6659,"activeCount":117},[],{"trials":6661,"activeCount":117},[],{"trials":6663,"activeCount":117},[],{"trials":6665,"activeCount":117},[6666],{"nctId":6667,"briefTitle":6668,"status":1622,"phases":6669,"primaryCompletion":6670,"completion":6670,"start":6670,"enrollment":117,"conditions":6671,"interventions":6673},"NCT02941510","Inhaled Budesonide for Altitude Illness Prevention",[93],"2017-03-06",[6672],"Altitude Sickness",[6656],{"trials":6675,"activeCount":117},[],{"trials":6677,"activeCount":117},[],{"intervention":4632,"totalTrials":114,"cells":6679},{"EARLY_PHASE1":6680,"PHASE1":6682,"PHASE2":6684,"PHASE3":6686,"PHASE4":6692,"NA":6694},{"trials":6681,"activeCount":117},[],{"trials":6683,"activeCount":117},[],{"trials":6685,"activeCount":117},[],{"trials":6687,"activeCount":117},[6688],{"nctId":4624,"briefTitle":4625,"status":125,"phases":6689,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":1602,"conditions":6690,"interventions":6691},[93],[4630],[4632,4633,4613],{"trials":6693,"activeCount":117},[],{"trials":6695,"activeCount":117},[],{"intervention":4633,"totalTrials":114,"cells":6697},{"EARLY_PHASE1":6698,"PHASE1":6700,"PHASE2":6702,"PHASE3":6704,"PHASE4":6710,"NA":6712},{"trials":6699,"activeCount":117},[],{"trials":6701,"activeCount":117},[],{"trials":6703,"activeCount":117},[],{"trials":6705,"activeCount":117},[6706],{"nctId":4624,"briefTitle":4625,"status":125,"phases":6707,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":1602,"conditions":6708,"interventions":6709},[93],[4630],[4632,4633,4613],{"trials":6711,"activeCount":117},[],{"trials":6713,"activeCount":117},[],{"intervention":6715,"totalTrials":114,"cells":6716},"L-tryptophan supplementation",{"EARLY_PHASE1":6717,"PHASE1":6719,"PHASE2":6721,"PHASE3":6723,"PHASE4":6733,"NA":6735},{"trials":6718,"activeCount":117},[],{"trials":6720,"activeCount":117},[],{"trials":6722,"activeCount":117},[],{"trials":6724,"activeCount":117},[6725],{"nctId":6726,"briefTitle":6727,"status":160,"phases":6728,"primaryCompletion":6190,"completion":6190,"start":5108,"enrollment":6729,"conditions":6730,"interventions":6732},"NCT00865202","A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium",[93],301,[6731],"Post-operative Delirium",[6715],{"trials":6734,"activeCount":117},[],{"trials":6736,"activeCount":117},[],{"intervention":6738,"totalTrials":114,"cells":6739},"Recombinant tissue plasminogen activator",{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6744,"PHASE3":6746,"PHASE4":6759,"NA":6761},{"trials":6741,"activeCount":117},[],{"trials":6743,"activeCount":117},[],{"trials":6745,"activeCount":117},[],{"trials":6747,"activeCount":117},[6748],{"nctId":6749,"briefTitle":6750,"status":1622,"phases":6751,"primaryCompletion":6752,"completion":5351,"start":6753,"enrollment":117,"conditions":6754,"interventions":6757},"NCT02767232","Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial",[93],"2023-04","2018-07",[6755,6756,4180],"Deep Vein Thrombosis","Post-Thrombotic Syndrome",[6738,6758],"Standard Anticoagulation Therapy",{"trials":6760,"activeCount":117},[],{"trials":6762,"activeCount":117},[],{"intervention":6758,"totalTrials":114,"cells":6764},{"EARLY_PHASE1":6765,"PHASE1":6767,"PHASE2":6769,"PHASE3":6771,"PHASE4":6777,"NA":6779},{"trials":6766,"activeCount":117},[],{"trials":6768,"activeCount":117},[],{"trials":6770,"activeCount":117},[],{"trials":6772,"activeCount":117},[6773],{"nctId":6749,"briefTitle":6750,"status":1622,"phases":6774,"primaryCompletion":6752,"completion":5351,"start":6753,"enrollment":117,"conditions":6775,"interventions":6776},[93],[6755,6756,4180],[6738,6758],{"trials":6778,"activeCount":117},[],{"trials":6780,"activeCount":117},[],{"intervention":6782,"totalTrials":114,"cells":6783},"Acthar",{"EARLY_PHASE1":6784,"PHASE1":6786,"PHASE2":6788,"PHASE3":6790,"PHASE4":6802,"NA":6804},{"trials":6785,"activeCount":117},[],{"trials":6787,"activeCount":117},[],{"trials":6789,"activeCount":117},[],{"trials":6791,"activeCount":117},[6792],{"nctId":6793,"briefTitle":6794,"status":160,"phases":6795,"primaryCompletion":6796,"completion":6797,"start":6798,"enrollment":217,"conditions":6799,"interventions":6801},"NCT02683889","Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation",[93],"2024-06-06","2024-06-10","2019-02-01",[6800],"FSGS",[6782],{"trials":6803,"activeCount":117},[],{"trials":6805,"activeCount":117},[],{"intervention":6650,"totalTrials":114,"cells":6807},{"EARLY_PHASE1":6808,"PHASE1":6810,"PHASE2":6812,"PHASE3":6814,"PHASE4":6820,"NA":6822},{"trials":6809,"activeCount":117},[],{"trials":6811,"activeCount":117},[],{"trials":6813,"activeCount":117},[],{"trials":6815,"activeCount":117},[6816],{"nctId":6643,"briefTitle":6644,"status":160,"phases":6817,"primaryCompletion":6646,"completion":6646,"start":6647,"enrollment":938,"conditions":6818,"interventions":6819},[93],[36],[6650,6625],{"trials":6821,"activeCount":117},[],{"trials":6823,"activeCount":117},[],{"intervention":6825,"totalTrials":114,"cells":6826},"Cosyntropin Injectable Suspension, 1 mg\u002FmL",{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6833,"PHASE4":6848,"NA":6850},{"trials":6828,"activeCount":117},[],{"trials":6830,"activeCount":117},[],{"trials":6832,"activeCount":117},[],{"trials":6834,"activeCount":117},[6835],{"nctId":6836,"briefTitle":6837,"status":6838,"phases":6839,"primaryCompletion":6840,"completion":2150,"start":6841,"enrollment":6842,"conditions":6843,"interventions":6845},"NCT03347526","A Novel Approach to Infantile Spasms","SUSPENDED",[93],"2021-06","2018-04-19",394,[6844],"Infantile Spasm",[6825,6846,6847],"Cosyntropin Injectable Suspension 1 MG\u002FML + vigabatrin","Vigabatrin",{"trials":6849,"activeCount":117},[],{"trials":6851,"activeCount":117},[],{"intervention":6846,"totalTrials":114,"cells":6853},{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6858,"PHASE3":6860,"PHASE4":6866,"NA":6868},{"trials":6855,"activeCount":117},[],{"trials":6857,"activeCount":117},[],{"trials":6859,"activeCount":117},[],{"trials":6861,"activeCount":117},[6862],{"nctId":6836,"briefTitle":6837,"status":6838,"phases":6863,"primaryCompletion":6840,"completion":2150,"start":6841,"enrollment":6842,"conditions":6864,"interventions":6865},[93],[6844],[6825,6846,6847],{"trials":6867,"activeCount":117},[],{"trials":6869,"activeCount":117},[],{"intervention":6847,"totalTrials":114,"cells":6871},{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6878,"PHASE4":6884,"NA":6886},{"trials":6873,"activeCount":117},[],{"trials":6875,"activeCount":117},[],{"trials":6877,"activeCount":117},[],{"trials":6879,"activeCount":117},[6880],{"nctId":6836,"briefTitle":6837,"status":6838,"phases":6881,"primaryCompletion":6840,"completion":2150,"start":6841,"enrollment":6842,"conditions":6882,"interventions":6883},[93],[6844],[6825,6846,6847],{"trials":6885,"activeCount":117},[],{"trials":6887,"activeCount":117},[],{"intervention":6889,"totalTrials":114,"cells":6890},"Ga-PSMA-11",{"EARLY_PHASE1":6891,"PHASE1":6893,"PHASE2":6895,"PHASE3":6897,"PHASE4":6907,"NA":6909},{"trials":6892,"activeCount":117},[],{"trials":6894,"activeCount":117},[],{"trials":6896,"activeCount":117},[],{"trials":6898,"activeCount":117},[6899],{"nctId":6900,"briefTitle":6901,"status":160,"phases":6902,"primaryCompletion":1664,"completion":1664,"start":6903,"enrollment":4227,"conditions":6904,"interventions":6906},"NCT05197257","68Ga-PSMA-11 PET in Patients With Prostate Cancer",[93],"2021-09-29",[914,6905],"Prostate Adenocarcinoma",[6889],{"trials":6908,"activeCount":117},[],{"trials":6910,"activeCount":117},[],{"intervention":6912,"totalTrials":114,"cells":6913},"Cholecalciferol",{"EARLY_PHASE1":6914,"PHASE1":6916,"PHASE2":6918,"PHASE3":6920,"PHASE4":6931,"NA":6933},{"trials":6915,"activeCount":117},[],{"trials":6917,"activeCount":117},[],{"trials":6919,"activeCount":117},[],{"trials":6921,"activeCount":117},[6922],{"nctId":6923,"briefTitle":6924,"status":160,"phases":6925,"primaryCompletion":4250,"completion":4250,"start":5034,"enrollment":6926,"conditions":6927,"interventions":6929},"NCT01384539","Vitamin D and Arterial Function in Patients With Chronic Kidney Disease",[93],128,[6928,460],"Arterial Dysfunction",[6912,6930],"Calcitriol",{"trials":6932,"activeCount":117},[],{"trials":6934,"activeCount":117},[],{"intervention":6930,"totalTrials":114,"cells":6936},{"EARLY_PHASE1":6937,"PHASE1":6939,"PHASE2":6941,"PHASE3":6943,"PHASE4":6949,"NA":6951},{"trials":6938,"activeCount":117},[],{"trials":6940,"activeCount":117},[],{"trials":6942,"activeCount":117},[],{"trials":6944,"activeCount":117},[6945],{"nctId":6923,"briefTitle":6924,"status":160,"phases":6946,"primaryCompletion":4250,"completion":4250,"start":5034,"enrollment":6926,"conditions":6947,"interventions":6948},[93],[6928,460],[6912,6930],{"trials":6950,"activeCount":117},[],{"trials":6952,"activeCount":117},[],{"intervention":6954,"totalTrials":114,"cells":6955},"Baricitinib",{"EARLY_PHASE1":6956,"PHASE1":6958,"PHASE2":6960,"PHASE3":6962,"PHASE4":6971,"NA":6973},{"trials":6957,"activeCount":117},[],{"trials":6959,"activeCount":117},[],{"trials":6961,"activeCount":117},[],{"trials":6963,"activeCount":117},[6964],{"nctId":6965,"briefTitle":6966,"status":1622,"phases":6967,"primaryCompletion":2150,"completion":2151,"start":6968,"enrollment":117,"conditions":6969,"interventions":6970},"NCT04340232","Safety and Efficacy of Baricitinib for COVID-19",[92,93],"2021-03",[2064],[6954],{"trials":6972,"activeCount":117},[],{"trials":6974,"activeCount":117},[],{"intervention":6976,"totalTrials":114,"cells":6977},"Low Risk: Oupatient Management",{"EARLY_PHASE1":6978,"PHASE1":6980,"PHASE2":6982,"PHASE3":6984,"PHASE4":6998,"NA":7000},{"trials":6979,"activeCount":117},[],{"trials":6981,"activeCount":117},[],{"trials":6983,"activeCount":117},[],{"trials":6985,"activeCount":117},[6986],{"nctId":6987,"briefTitle":6988,"status":1622,"phases":6989,"primaryCompletion":6990,"completion":6990,"start":6991,"enrollment":117,"conditions":6992,"interventions":6995},"NCT03768869","Fever and Neutropenia in Pediatric Oncology Patients",[93],"2009-04-03","2006-02",[6993,6994],"Fever","Neutropenia",[6976,6996,6997],"Low Risk: Inpatient Management","High Risk: Inpatient Management",{"trials":6999,"activeCount":117},[],{"trials":7001,"activeCount":117},[],{"intervention":6996,"totalTrials":114,"cells":7003},{"EARLY_PHASE1":7004,"PHASE1":7006,"PHASE2":7008,"PHASE3":7010,"PHASE4":7016,"NA":7018},{"trials":7005,"activeCount":117},[],{"trials":7007,"activeCount":117},[],{"trials":7009,"activeCount":117},[],{"trials":7011,"activeCount":117},[7012],{"nctId":6987,"briefTitle":6988,"status":1622,"phases":7013,"primaryCompletion":6990,"completion":6990,"start":6991,"enrollment":117,"conditions":7014,"interventions":7015},[93],[6993,6994],[6976,6996,6997],{"trials":7017,"activeCount":117},[],{"trials":7019,"activeCount":117},[],{"intervention":6997,"totalTrials":114,"cells":7021},{"EARLY_PHASE1":7022,"PHASE1":7024,"PHASE2":7026,"PHASE3":7028,"PHASE4":7034,"NA":7036},{"trials":7023,"activeCount":117},[],{"trials":7025,"activeCount":117},[],{"trials":7027,"activeCount":117},[],{"trials":7029,"activeCount":117},[7030],{"nctId":6987,"briefTitle":6988,"status":1622,"phases":7031,"primaryCompletion":6990,"completion":6990,"start":6991,"enrollment":117,"conditions":7032,"interventions":7033},[93],[6993,6994],[6976,6996,6997],{"trials":7035,"activeCount":117},[],{"trials":7037,"activeCount":117},[],{"intervention":7039,"totalTrials":114,"cells":7040},"Estradiol Transdermal",{"EARLY_PHASE1":7041,"PHASE1":7043,"PHASE2":7045,"PHASE3":7047,"PHASE4":7057,"NA":7059},{"trials":7042,"activeCount":117},[],{"trials":7044,"activeCount":117},[],{"trials":7046,"activeCount":117},[],{"trials":7048,"activeCount":117},[7049],{"nctId":7050,"briefTitle":7051,"status":160,"phases":7052,"primaryCompletion":4767,"completion":4767,"start":7053,"enrollment":7054,"conditions":7055,"interventions":7056},"NCT00687739","Prevention of Obesity in Women Via Estradiol Regulation",[93],"2008-05",79,[15],[812,7039],{"trials":7058,"activeCount":117},[],{"trials":7060,"activeCount":117},[],{"intervention":7062,"totalTrials":114,"cells":7063},"Byetta 5Mcg Pen",{"EARLY_PHASE1":7064,"PHASE1":7066,"PHASE2":7068,"PHASE3":7070,"PHASE4":7080,"NA":7082},{"trials":7065,"activeCount":117},[],{"trials":7067,"activeCount":117},[],{"trials":7069,"activeCount":117},[],{"trials":7071,"activeCount":117},[7072],{"nctId":7073,"briefTitle":7074,"status":160,"phases":7075,"primaryCompletion":5350,"completion":5350,"start":7076,"enrollment":3095,"conditions":7077,"interventions":7079},"NCT02157974","Liver and Fat Regulation in Overweight Adolescent Girls",[92,93],"2014-08",[1403,7078,15],"Polycystic Ovarian Syndrome",[7062],{"trials":7081,"activeCount":117},[],{"trials":7083,"activeCount":117},[],{"intervention":7085,"totalTrials":114,"cells":7086},"Ondansetron followed by placebo",{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7091,"PHASE3":7093,"PHASE4":7104,"NA":7106},{"trials":7088,"activeCount":117},[],{"trials":7090,"activeCount":117},[],{"trials":7092,"activeCount":117},[],{"trials":7094,"activeCount":117},[7095],{"nctId":7096,"briefTitle":7097,"status":160,"phases":7098,"primaryCompletion":7099,"completion":7099,"start":7100,"enrollment":2475,"conditions":7101,"interventions":7103},"NCT00149734","Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia",[93],"2010-05","2005-01",[7102],"Schizophrenia",[7085],{"trials":7105,"activeCount":117},[],{"trials":7107,"activeCount":117},[],{"intervention":7109,"totalTrials":114,"cells":7110},"HepQuant-SHUNT",{"EARLY_PHASE1":7111,"PHASE1":7113,"PHASE2":7115,"PHASE3":7117,"PHASE4":7126,"NA":7128},{"trials":7112,"activeCount":117},[],{"trials":7114,"activeCount":117},[],{"trials":7116,"activeCount":117},[],{"trials":7118,"activeCount":117},[7119],{"nctId":7120,"briefTitle":7121,"status":160,"phases":7122,"primaryCompletion":7123,"completion":7123,"start":677,"enrollment":28,"conditions":7124,"interventions":7125},"NCT02523196","Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)",[93],"2017-02-23",[6218],[7109],{"trials":7127,"activeCount":117},[],{"trials":7129,"activeCount":117},[],{"intervention":4724,"totalTrials":114,"cells":7131},{"EARLY_PHASE1":7132,"PHASE1":7134,"PHASE2":7136,"PHASE3":7138,"PHASE4":7144,"NA":7146},{"trials":7133,"activeCount":117},[],{"trials":7135,"activeCount":117},[],{"trials":7137,"activeCount":117},[],{"trials":7139,"activeCount":117},[7140],{"nctId":4718,"briefTitle":4719,"status":160,"phases":7141,"primaryCompletion":648,"completion":648,"start":4721,"enrollment":2245,"conditions":7142,"interventions":7143},[93],[192],[4724,4725],{"trials":7145,"activeCount":117},[],{"trials":7147,"activeCount":117},[],{"intervention":7149,"totalTrials":114,"cells":7150},"Semaglutide 3mg and 7mg [Rybelsus]",{"EARLY_PHASE1":7151,"PHASE1":7153,"PHASE2":7155,"PHASE3":7157,"PHASE4":7167,"NA":7169},{"trials":7152,"activeCount":117},[],{"trials":7154,"activeCount":117},[],{"trials":7156,"activeCount":117},[],{"trials":7158,"activeCount":117},[7159],{"nctId":7160,"briefTitle":7161,"status":160,"phases":7162,"primaryCompletion":1719,"completion":1719,"start":7163,"enrollment":1378,"conditions":7164,"interventions":7166},"NCT03919929","Treating PCOS With Semaglutide vs Active Lifestyle Intervention",[92,93],"2019-05-03",[7165,1405,1404],"PCOS",[7149],{"trials":7168,"activeCount":117},[],{"trials":7170,"activeCount":117},[],{"intervention":4566,"totalTrials":114,"cells":7172},{"EARLY_PHASE1":7173,"PHASE1":7175,"PHASE2":7177,"PHASE3":7179,"PHASE4":7185,"NA":7187},{"trials":7174,"activeCount":117},[],{"trials":7176,"activeCount":117},[],{"trials":7178,"activeCount":117},[],{"trials":7180,"activeCount":117},[7181],{"nctId":4557,"briefTitle":4558,"status":160,"phases":7182,"primaryCompletion":678,"completion":4560,"start":4561,"enrollment":4562,"conditions":7183,"interventions":7184},[93],[4564],[1776,4566],{"trials":7186,"activeCount":117},[],{"trials":7188,"activeCount":117},[],{"intervention":7190,"totalTrials":114,"cells":7191},"Cannabis",{"EARLY_PHASE1":7192,"PHASE1":7194,"PHASE2":7196,"PHASE3":7198,"PHASE4":7208,"NA":7210},{"trials":7193,"activeCount":117},[],{"trials":7195,"activeCount":117},[],{"trials":7197,"activeCount":117},[],{"trials":7199,"activeCount":117},[7200],{"nctId":7201,"briefTitle":7202,"status":160,"phases":7203,"primaryCompletion":7204,"completion":7204,"start":7205,"enrollment":3875,"conditions":7206,"interventions":7207},"NCT02892591","Cannabis Versus Oxycodone for Pain Relief",[93],"2023-06-07","2017-06-01",[1283,1284],[7190,1476],{"trials":7209,"activeCount":117},[],{"trials":7211,"activeCount":117},[],{"intervention":7213,"totalTrials":114,"cells":7214},"iNO",{"EARLY_PHASE1":7215,"PHASE1":7217,"PHASE2":7219,"PHASE3":7221,"PHASE4":7234,"NA":7236},{"trials":7216,"activeCount":117},[],{"trials":7218,"activeCount":117},[],{"trials":7220,"activeCount":117},[],{"trials":7222,"activeCount":117},[7223],{"nctId":7224,"briefTitle":7225,"status":160,"phases":7226,"primaryCompletion":7227,"completion":7228,"start":4926,"enrollment":7229,"conditions":7230,"interventions":7233},"NCT00006401","Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants",[93],"2005-09","2007-10",793,[7231,7232],"Lung Diseases","Bronchopulmonary Dysplasia",[7213],{"trials":7235,"activeCount":117},[],{"trials":7237,"activeCount":117},[],{"intervention":7239,"totalTrials":99,"cells":7240},"Durvalumab",{"EARLY_PHASE1":7241,"PHASE1":7243,"PHASE2":7266,"PHASE3":7276,"PHASE4":7278,"NA":7280},{"trials":7242,"activeCount":117},[],{"trials":7244,"activeCount":117},[7245,7256],{"nctId":7246,"briefTitle":7247,"status":1622,"phases":7248,"primaryCompletion":7249,"completion":547,"start":7250,"enrollment":117,"conditions":7251,"interventions":7252},"NCT03802747","Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases",[91],"2023-12","2019-08",[1668],[7239,7253,7254,7255],"Durvalumab and Tremelimumab","Y-90 Selective Internal Radiation Therapy","Stereotactic Body Radiation Therapy",{"nctId":7257,"briefTitle":7258,"status":160,"phases":7259,"primaryCompletion":7260,"completion":7261,"start":7262,"enrollment":7263,"conditions":7264,"interventions":7265},"NCT03635164","Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma",[91],"2021-11-09","2023-05-02","2018-11-12",21,[1705],[7239],{"trials":7267,"activeCount":117},[7268],{"nctId":7269,"briefTitle":7270,"status":1622,"phases":7271,"primaryCompletion":7272,"completion":7272,"start":3619,"enrollment":117,"conditions":7273,"interventions":7275},"NCT03038477","A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection",[92],"2019-04-01",[7274],"Pancreatic Cancer",[7239],{"trials":7277,"activeCount":117},[],{"trials":7279,"activeCount":117},[],{"trials":7281,"activeCount":117},[],{"intervention":7283,"totalTrials":99,"cells":7284},"Opioid-Related Disorders",{"EARLY_PHASE1":7285,"PHASE1":7287,"PHASE2":7289,"PHASE3":7316,"PHASE4":7318,"NA":7320},{"trials":7286,"activeCount":117},[],{"trials":7288,"activeCount":117},[],{"trials":7290,"activeCount":117},[7291,7300,7308],{"nctId":7292,"briefTitle":7293,"status":1622,"phases":7294,"primaryCompletion":7295,"completion":7295,"start":7296,"enrollment":117,"conditions":7297,"interventions":7299},"NCT00000329","Buprenorphine\u002FNaloxone Treatment for Opioid Dependence-Experiment II-1 - 4",[92],"1999-08","1999-04",[7298,7283],"Heroin Dependence",[7283],{"nctId":7301,"briefTitle":7302,"status":1622,"phases":7303,"primaryCompletion":7304,"completion":7304,"start":7305,"enrollment":117,"conditions":7306,"interventions":7307},"NCT00000328","Buprenorphine\u002FNaloxone Treatment for Opioid Dependence-Experiment III) - 3",[92],"1997-08","1997-07",[7298,7283],[7283],{"nctId":7309,"briefTitle":7310,"status":1622,"phases":7311,"primaryCompletion":7312,"completion":7312,"start":7313,"enrollment":117,"conditions":7314,"interventions":7315},"NCT00000330","Buprenorphine\u002FNaloxone Treatment for Opioid Dependence-Experiment II-2 - 5",[92],"1999-11","1999-10",[7298,7283],[7283],{"trials":7317,"activeCount":117},[],{"trials":7319,"activeCount":117},[],{"trials":7321,"activeCount":117},[],{"intervention":3428,"totalTrials":199,"cells":7323},{"EARLY_PHASE1":7324,"PHASE1":7326,"PHASE2":7336,"PHASE3":7342,"PHASE4":7344,"NA":7346},{"trials":7325,"activeCount":117},[],{"trials":7327,"activeCount":117},[7328],{"nctId":7329,"briefTitle":7330,"status":160,"phases":7331,"primaryCompletion":7332,"completion":7332,"start":7333,"enrollment":1507,"conditions":7334,"interventions":7335},"NCT00792012","A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma",[91],"2016-07","2005-11",[3426],[3428],{"trials":7337,"activeCount":117},[7338],{"nctId":3419,"briefTitle":3420,"status":160,"phases":7339,"primaryCompletion":3422,"completion":3423,"start":3424,"enrollment":19,"conditions":7340,"interventions":7341},[92],[3426],[1671,3428],{"trials":7343,"activeCount":117},[],{"trials":7345,"activeCount":117},[],{"trials":7347,"activeCount":117},[],{"intervention":7298,"totalTrials":199,"cells":7349},{"EARLY_PHASE1":7350,"PHASE1":7352,"PHASE2":7354,"PHASE3":7370,"PHASE4":7372,"NA":7374},{"trials":7351,"activeCount":117},[],{"trials":7353,"activeCount":117},[],{"trials":7355,"activeCount":117},[7356,7363],{"nctId":7357,"briefTitle":7358,"status":1622,"phases":7359,"primaryCompletion":7304,"completion":7304,"start":7360,"enrollment":117,"conditions":7361,"interventions":7362},"NCT00000326","Buprenorphine\u002FNaloxone Treatment for Opioid Dependence-Experiment 1 - 1",[92],"1997-04",[7298,7283],[7298],{"nctId":7364,"briefTitle":7365,"status":1622,"phases":7366,"primaryCompletion":7304,"completion":7304,"start":7367,"enrollment":117,"conditions":7368,"interventions":7369},"NCT00000327","Buprenorphine\u002FNaloxone Treatment for Opioid Dependence-Experiment I(2) - 2",[92],"1997-06",[7298,7283],[7298],{"trials":7371,"activeCount":117},[],{"trials":7373,"activeCount":117},[],{"trials":7375,"activeCount":117},[],{"intervention":7377,"totalTrials":199,"cells":7378},"Pioglitazone",{"EARLY_PHASE1":7379,"PHASE1":7388,"PHASE2":7390,"PHASE3":7400,"PHASE4":7402,"NA":7404},{"trials":7380,"activeCount":117},[7381],{"nctId":7382,"briefTitle":7383,"status":160,"phases":7384,"primaryCompletion":4225,"completion":4225,"start":954,"enrollment":228,"conditions":7385,"interventions":7386},"NCT01817400","Mediators of Abnormal Reproductive Function in Obesity (MARO)",[90],[2524,15],[7387,7377],"Aspirin",{"trials":7389,"activeCount":117},[],{"trials":7391,"activeCount":117},[7392],{"nctId":7393,"briefTitle":7394,"status":160,"phases":7395,"primaryCompletion":4768,"completion":4768,"start":7396,"enrollment":7397,"conditions":7398,"interventions":7399},"NCT00736996","Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)",[92],"2008-11",78,[1050],[7377],{"trials":7401,"activeCount":117},[],{"trials":7403,"activeCount":117},[],{"trials":7405,"activeCount":117},[],{"intervention":7407,"totalTrials":199,"cells":7408},"Ranibizumab",{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7423,"PHASE3":7435,"PHASE4":7437,"NA":7439},{"trials":7410,"activeCount":117},[],{"trials":7412,"activeCount":117},[7413],{"nctId":7414,"briefTitle":7415,"status":160,"phases":7416,"primaryCompletion":7417,"completion":7417,"start":7418,"enrollment":199,"conditions":7419,"interventions":7421},"NCT00561834","Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy",[91],"2009-04","2007-11",[7420],"Nonarteritic Anterior Ischemic Optic Neuropathy",[7422],"ranibizumab",{"trials":7424,"activeCount":117},[7425],{"nctId":7426,"briefTitle":7427,"status":160,"phases":7428,"primaryCompletion":5685,"completion":5685,"start":7429,"enrollment":19,"conditions":7430,"interventions":7432},"NCT00661583","Use of Ranibizumab With Mitomycin C During Trabeculectomy",[91,92],"2008-04",[7431],"Glaucoma",[7407,7433,7434],"Ranibizumab and MMC","MMC",{"trials":7436,"activeCount":117},[],{"trials":7438,"activeCount":117},[],{"trials":7440,"activeCount":117},[],{"intervention":1511,"totalTrials":199,"cells":7442},{"EARLY_PHASE1":7443,"PHASE1":7445,"PHASE2":7447,"PHASE3":7457,"PHASE4":7459,"NA":7461},{"trials":7444,"activeCount":117},[],{"trials":7446,"activeCount":117},[],{"trials":7448,"activeCount":117},[7449,7453],{"nctId":1501,"briefTitle":1502,"status":160,"phases":7450,"primaryCompletion":1504,"completion":1505,"start":1506,"enrollment":1507,"conditions":7451,"interventions":7452},[92],[1509],[1479,1511],{"nctId":2048,"briefTitle":2049,"status":125,"phases":7454,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":99,"conditions":7455,"interventions":7456},[92],[2054],[2035,1511,2004],{"trials":7458,"activeCount":117},[],{"trials":7460,"activeCount":117},[],{"trials":7462,"activeCount":117},[],{"intervention":1802,"totalTrials":199,"cells":7464},{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7487,"PHASE4":7489,"NA":7491},{"trials":7466,"activeCount":117},[],{"trials":7468,"activeCount":117},[],{"trials":7470,"activeCount":117},[7471,7475],{"nctId":1790,"briefTitle":1791,"status":160,"phases":7472,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":31,"conditions":7473,"interventions":7474},[91,92],[1797],[1781,1799,1800,1801,1802,1803],{"nctId":7476,"briefTitle":7477,"status":160,"phases":7478,"primaryCompletion":7479,"completion":7480,"start":7481,"enrollment":1165,"conditions":7482,"interventions":7484},"NCT01869192","Phase II Trial for Large ER-Negative Breast Cancers",[92],"2009-12-18","2010-08-21","2003-03-05",[7483],"Malignant Neoplasm of Female Breast",[7485,1802,7486,3488],"Epirubicin","Docetaxel",{"trials":7488,"activeCount":117},[],{"trials":7490,"activeCount":117},[],{"trials":7492,"activeCount":117},[],{"intervention":2035,"totalTrials":199,"cells":7494},{"EARLY_PHASE1":7495,"PHASE1":7497,"PHASE2":7499,"PHASE3":7509,"PHASE4":7511,"NA":7513},{"trials":7496,"activeCount":117},[],{"trials":7498,"activeCount":117},[],{"trials":7500,"activeCount":117},[7501,7505],{"nctId":2023,"briefTitle":2024,"status":125,"phases":7502,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":99,"conditions":7503,"interventions":7504},[91,92],[2029,2030,2031,2032],[2034,2035,2004],{"nctId":2048,"briefTitle":2049,"status":125,"phases":7506,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":99,"conditions":7507,"interventions":7508},[92],[2054],[2035,1511,2004],{"trials":7510,"activeCount":117},[],{"trials":7512,"activeCount":117},[],{"trials":7514,"activeCount":117},[],{"intervention":7486,"totalTrials":199,"cells":7516},{"EARLY_PHASE1":7517,"PHASE1":7519,"PHASE2":7521,"PHASE3":7537,"PHASE4":7539,"NA":7541},{"trials":7518,"activeCount":117},[],{"trials":7520,"activeCount":117},[],{"trials":7522,"activeCount":117},[7523,7527],{"nctId":7476,"briefTitle":7477,"status":160,"phases":7524,"primaryCompletion":7479,"completion":7480,"start":7481,"enrollment":1165,"conditions":7525,"interventions":7526},[92],[7483],[7485,1802,7486,3488],{"nctId":7528,"briefTitle":7529,"status":1622,"phases":7530,"primaryCompletion":7531,"completion":7531,"start":7532,"enrollment":117,"conditions":7533,"interventions":7535},"NCT01907308","Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma",[92],"2014-04","2014-02",[7534],"Urothelial Carcinoma",[7536,7486],"AMG 386",{"trials":7538,"activeCount":117},[],{"trials":7540,"activeCount":117},[],{"trials":7542,"activeCount":117},[],{"intervention":7544,"totalTrials":114,"cells":7545},"Oral cannabidiol 100mg\u002FmL",{"EARLY_PHASE1":7546,"PHASE1":7548,"PHASE2":7550,"PHASE3":7561,"PHASE4":7563,"NA":7565},{"trials":7547,"activeCount":117},[],{"trials":7549,"activeCount":117},[],{"trials":7551,"activeCount":117},[7552],{"nctId":7553,"briefTitle":7554,"status":715,"phases":7555,"primaryCompletion":783,"completion":2268,"start":7556,"enrollment":7557,"conditions":7558,"interventions":7560},"NCT04520685","CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr",[92],"2021-12-15",86,[7559],"Autism Spectrum Disorder",[7544],{"trials":7562,"activeCount":117},[],{"trials":7564,"activeCount":117},[],{"trials":7566,"activeCount":117},[],{"intervention":7568,"totalTrials":114,"cells":7569},"Dronabinol",{"EARLY_PHASE1":7570,"PHASE1":7572,"PHASE2":7574,"PHASE3":7583,"PHASE4":7585,"NA":7587},{"trials":7571,"activeCount":117},[],{"trials":7573,"activeCount":117},[],{"trials":7575,"activeCount":117},[7576],{"nctId":7577,"briefTitle":7578,"status":125,"phases":7579,"primaryCompletion":7099,"completion":5483,"start":7580,"enrollment":734,"conditions":7581,"interventions":7582},"NCT01832766","The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes",[91,92],"2005-06",[7102],[7568],{"trials":7584,"activeCount":117},[],{"trials":7586,"activeCount":117},[],{"trials":7588,"activeCount":117},[],{"intervention":7590,"totalTrials":114,"cells":7591},"Dutasteride",{"EARLY_PHASE1":7592,"PHASE1":7594,"PHASE2":7596,"PHASE3":7604,"PHASE4":7606,"NA":7608},{"trials":7593,"activeCount":117},[],{"trials":7595,"activeCount":117},[],{"trials":7597,"activeCount":117},[7598],{"nctId":7599,"briefTitle":7600,"status":125,"phases":7601,"primaryCompletion":1469,"completion":1469,"start":4734,"enrollment":37,"conditions":7602,"interventions":7603},"NCT00985738","Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer",[92],[914],[7590],{"trials":7605,"activeCount":117},[],{"trials":7607,"activeCount":117},[],{"trials":7609,"activeCount":117},[],{"intervention":7611,"totalTrials":114,"cells":7612},"Acai Juice Product",{"EARLY_PHASE1":7613,"PHASE1":7615,"PHASE2":7617,"PHASE3":7628,"PHASE4":7630,"NA":7632},{"trials":7614,"activeCount":117},[],{"trials":7616,"activeCount":117},[],{"trials":7618,"activeCount":117},[7619],{"nctId":7620,"briefTitle":7621,"status":160,"phases":7622,"primaryCompletion":7623,"completion":7624,"start":7625,"enrollment":7263,"conditions":7626,"interventions":7627},"NCT01521949","Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA",[92],"2013-12-25","2018-02-01","2011-11-04",[914],[7611],{"trials":7629,"activeCount":117},[],{"trials":7631,"activeCount":117},[],{"trials":7633,"activeCount":117},[],{"intervention":7635,"totalTrials":114,"cells":7636},"Anakinra",{"EARLY_PHASE1":7637,"PHASE1":7639,"PHASE2":7641,"PHASE3":7651,"PHASE4":7653,"NA":7655},{"trials":7638,"activeCount":117},[],{"trials":7640,"activeCount":117},[],{"trials":7642,"activeCount":117},[7643],{"nctId":7644,"briefTitle":7645,"status":1622,"phases":7646,"primaryCompletion":677,"completion":7647,"start":4753,"enrollment":117,"conditions":7648,"interventions":7650},"NCT01477476","Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes",[92],"2016-04-22",[7649],"Type I Diabetes",[7635],{"trials":7652,"activeCount":117},[],{"trials":7654,"activeCount":117},[],{"trials":7656,"activeCount":117},[],{"intervention":7658,"totalTrials":114,"cells":7659},"Simvastatin",{"EARLY_PHASE1":7660,"PHASE1":7662,"PHASE2":7664,"PHASE3":7674,"PHASE4":7676,"NA":7678},{"trials":7661,"activeCount":117},[],{"trials":7663,"activeCount":117},[],{"trials":7665,"activeCount":117},[7666],{"nctId":7667,"briefTitle":7668,"status":160,"phases":7669,"primaryCompletion":7670,"completion":7670,"start":4177,"enrollment":1602,"conditions":7671,"interventions":7672},"NCT00477204","Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe\u002FSimvastatin) in Adolescents With Type 1 Diabetes",[92],"2010-08",[1943,5534],[7658,7673],"Ezetimibe\u002FSimvastatin",{"trials":7675,"activeCount":117},[],{"trials":7677,"activeCount":117},[],{"trials":7679,"activeCount":117},[],{"intervention":7673,"totalTrials":114,"cells":7681},{"EARLY_PHASE1":7682,"PHASE1":7684,"PHASE2":7686,"PHASE3":7692,"PHASE4":7694,"NA":7696},{"trials":7683,"activeCount":117},[],{"trials":7685,"activeCount":117},[],{"trials":7687,"activeCount":117},[7688],{"nctId":7667,"briefTitle":7668,"status":160,"phases":7689,"primaryCompletion":7670,"completion":7670,"start":4177,"enrollment":1602,"conditions":7690,"interventions":7691},[92],[1943,5534],[7658,7673],{"trials":7693,"activeCount":117},[],{"trials":7695,"activeCount":117},[],{"trials":7697,"activeCount":117},[],{"intervention":7433,"totalTrials":114,"cells":7699},{"EARLY_PHASE1":7700,"PHASE1":7702,"PHASE2":7704,"PHASE3":7710,"PHASE4":7712,"NA":7714},{"trials":7701,"activeCount":117},[],{"trials":7703,"activeCount":117},[],{"trials":7705,"activeCount":117},[7706],{"nctId":7426,"briefTitle":7427,"status":160,"phases":7707,"primaryCompletion":5685,"completion":5685,"start":7429,"enrollment":19,"conditions":7708,"interventions":7709},[91,92],[7431],[7407,7433,7434],{"trials":7711,"activeCount":117},[],{"trials":7713,"activeCount":117},[],{"trials":7715,"activeCount":117},[],{"intervention":7434,"totalTrials":114,"cells":7717},{"EARLY_PHASE1":7718,"PHASE1":7720,"PHASE2":7722,"PHASE3":7728,"PHASE4":7730,"NA":7732},{"trials":7719,"activeCount":117},[],{"trials":7721,"activeCount":117},[],{"trials":7723,"activeCount":117},[7724],{"nctId":7426,"briefTitle":7427,"status":160,"phases":7725,"primaryCompletion":5685,"completion":5685,"start":7429,"enrollment":19,"conditions":7726,"interventions":7727},[91,92],[7431],[7407,7433,7434],{"trials":7729,"activeCount":117},[],{"trials":7731,"activeCount":117},[],{"trials":7733,"activeCount":117},[],{"intervention":7735,"totalTrials":114,"cells":7736},"Sagramostim",{"EARLY_PHASE1":7737,"PHASE1":7739,"PHASE2":7741,"PHASE3":7752,"PHASE4":7754,"NA":7756},{"trials":7738,"activeCount":117},[],{"trials":7740,"activeCount":117},[],{"trials":7742,"activeCount":117},[7743],{"nctId":7744,"briefTitle":7745,"status":160,"phases":7746,"primaryCompletion":7747,"completion":7747,"start":7748,"enrollment":6420,"conditions":7749,"interventions":7751},"NCT01409915","Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease",[92],"2019-12-09","2011-03",[7750],"Alzheimer's Disease",[7735],{"trials":7753,"activeCount":117},[],{"trials":7755,"activeCount":117},[],{"trials":7757,"activeCount":117},[],{"intervention":7759,"totalTrials":114,"cells":7760},"LowT",{"EARLY_PHASE1":7761,"PHASE1":7763,"PHASE2":7765,"PHASE3":7776,"PHASE4":7778,"NA":7780},{"trials":7762,"activeCount":117},[],{"trials":7764,"activeCount":117},[],{"trials":7766,"activeCount":117},[7767],{"nctId":7768,"briefTitle":7769,"status":160,"phases":7770,"primaryCompletion":7771,"completion":7771,"start":7100,"enrollment":7772,"conditions":7773,"interventions":7774},"NCT00112151","TEAM: Testosterone Supplementation and Exercise in Elderly Men",[92],"2010-11",167,[736],[7759,7775],"HighT",{"trials":7777,"activeCount":117},[],{"trials":7779,"activeCount":117},[],{"trials":7781,"activeCount":117},[],{"intervention":7775,"totalTrials":114,"cells":7783},{"EARLY_PHASE1":7784,"PHASE1":7786,"PHASE2":7788,"PHASE3":7794,"PHASE4":7796,"NA":7798},{"trials":7785,"activeCount":117},[],{"trials":7787,"activeCount":117},[],{"trials":7789,"activeCount":117},[7790],{"nctId":7768,"briefTitle":7769,"status":160,"phases":7791,"primaryCompletion":7771,"completion":7771,"start":7100,"enrollment":7772,"conditions":7792,"interventions":7793},[92],[736],[7759,7775],{"trials":7795,"activeCount":117},[],{"trials":7797,"activeCount":117},[],{"trials":7799,"activeCount":117},[],{"intervention":7801,"totalTrials":114,"cells":7802},"Oral apixaban",{"EARLY_PHASE1":7803,"PHASE1":7805,"PHASE2":7807,"PHASE3":7819,"PHASE4":7821,"NA":7823},{"trials":7804,"activeCount":117},[],{"trials":7806,"activeCount":117},[],{"trials":7808,"activeCount":117},[7809],{"nctId":7810,"briefTitle":7811,"status":160,"phases":7812,"primaryCompletion":5811,"completion":5811,"start":7813,"enrollment":1326,"conditions":7814,"interventions":7817},"NCT02366871","Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy",[92],"2015-04-28",[7815,7816],"Gynecologic Cancer","Venous Thromboembolism",[7801,7818],"Subcutaneous enoxaparin",{"trials":7820,"activeCount":117},[],{"trials":7822,"activeCount":117},[],{"trials":7824,"activeCount":117},[],{"intervention":7818,"totalTrials":114,"cells":7826},{"EARLY_PHASE1":7827,"PHASE1":7829,"PHASE2":7831,"PHASE3":7837,"PHASE4":7839,"NA":7841},{"trials":7828,"activeCount":117},[],{"trials":7830,"activeCount":117},[],{"trials":7832,"activeCount":117},[7833],{"nctId":7810,"briefTitle":7811,"status":160,"phases":7834,"primaryCompletion":5811,"completion":5811,"start":7813,"enrollment":1326,"conditions":7835,"interventions":7836},[92],[7815,7816],[7801,7818],{"trials":7838,"activeCount":117},[],{"trials":7840,"activeCount":117},[],{"trials":7842,"activeCount":117},[],{"intervention":7844,"totalTrials":114,"cells":7845},"therapeutic allogeneic lymphocytes",{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7859,"PHASE4":7861,"NA":7863},{"trials":7847,"activeCount":117},[],{"trials":7849,"activeCount":117},[],{"trials":7851,"activeCount":117},[7852],{"nctId":7853,"briefTitle":7854,"status":160,"phases":7855,"primaryCompletion":7856,"completion":7856,"start":7312,"conditions":7857,"interventions":7858},"NCT00005801","Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia",[92],"2001-09",[1492],[7844],{"trials":7860,"activeCount":117},[],{"trials":7862,"activeCount":117},[],{"trials":7864,"activeCount":117},[],{"intervention":7866,"totalTrials":114,"cells":7867},"DMXB-A-SR",{"EARLY_PHASE1":7868,"PHASE1":7870,"PHASE2":7872,"PHASE3":7883,"PHASE4":7885,"NA":7887},{"trials":7869,"activeCount":117},[],{"trials":7871,"activeCount":117},[],{"trials":7873,"activeCount":117},[7874],{"nctId":7875,"briefTitle":7876,"status":160,"phases":7877,"primaryCompletion":7878,"completion":7878,"start":5034,"enrollment":7879,"conditions":7880,"interventions":7882},"NCT01400477","Nicotinic Receptors and Schizophrenia",[92],"2015-06",97,[7102,7881],"Schizoaffective Disorder",[7866],{"trials":7884,"activeCount":117},[],{"trials":7886,"activeCount":117},[],{"trials":7888,"activeCount":117},[],{"intervention":6639,"totalTrials":114,"cells":7890},{"EARLY_PHASE1":7891,"PHASE1":7893,"PHASE2":7895,"PHASE3":7901,"PHASE4":7903,"NA":7905},{"trials":7892,"activeCount":117},[],{"trials":7894,"activeCount":117},[],{"trials":7896,"activeCount":117},[7897],{"nctId":6634,"briefTitle":6635,"status":160,"phases":7898,"primaryCompletion":4628,"completion":4628,"start":4686,"enrollment":1666,"conditions":7899,"interventions":7900},[92],[36],[6625,6639],{"trials":7902,"activeCount":117},[],{"trials":7904,"activeCount":117},[],{"trials":7906,"activeCount":117},[],{"intervention":7908,"totalTrials":114,"cells":7909},"Calcium Acetate Oral Solution",{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7928,"PHASE4":7930,"NA":7932},{"trials":7911,"activeCount":117},[],{"trials":7913,"activeCount":117},[],{"trials":7915,"activeCount":117},[7916],{"nctId":7917,"briefTitle":7918,"status":715,"phases":7919,"primaryCompletion":7920,"completion":7921,"start":7922,"enrollment":508,"conditions":7923,"interventions":7926},"NCT05424263","Acetate and Age-associated Arterial Dysfunction",[92],"2025-07-01","2025-09-01","2022-09-29",[27,7924,7925],"Vascular Stiffness","Vascular Dilation",[7908,7927],"Calcium Carbonate Oral Suspension",{"trials":7929,"activeCount":117},[],{"trials":7931,"activeCount":117},[],{"trials":7933,"activeCount":117},[],{"intervention":7927,"totalTrials":114,"cells":7935},{"EARLY_PHASE1":7936,"PHASE1":7938,"PHASE2":7940,"PHASE3":7946,"PHASE4":7948,"NA":7950},{"trials":7937,"activeCount":117},[],{"trials":7939,"activeCount":117},[],{"trials":7941,"activeCount":117},[7942],{"nctId":7917,"briefTitle":7918,"status":715,"phases":7943,"primaryCompletion":7920,"completion":7921,"start":7922,"enrollment":508,"conditions":7944,"interventions":7945},[92],[27,7924,7925],[7908,7927],{"trials":7947,"activeCount":117},[],{"trials":7949,"activeCount":117},[],{"trials":7951,"activeCount":117},[],{"intervention":7953,"totalTrials":114,"cells":7954},"phosphatidylcholine supplementation",{"EARLY_PHASE1":7955,"PHASE1":7957,"PHASE2":7959,"PHASE3":7969,"PHASE4":7971,"NA":7973},{"trials":7956,"activeCount":117},[],{"trials":7958,"activeCount":117},[],{"trials":7960,"activeCount":117},[7961],{"nctId":7962,"briefTitle":7963,"status":1622,"phases":7964,"primaryCompletion":648,"completion":648,"start":7965,"enrollment":117,"conditions":7966,"interventions":7968},"NCT01905605","Phosphatidylcholine Supplementation in Infants",[91,92],"2013-09",[7102,7967],"Diminished P50 Sensory Gating",[7953],{"trials":7970,"activeCount":117},[],{"trials":7972,"activeCount":117},[],{"trials":7974,"activeCount":117},[],{"intervention":7976,"totalTrials":114,"cells":7977},"Brigatinib",{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7992,"PHASE4":7994,"NA":7996},{"trials":7979,"activeCount":117},[],{"trials":7981,"activeCount":117},[],{"trials":7983,"activeCount":117},[7984],{"nctId":7985,"briefTitle":7986,"status":125,"phases":7987,"primaryCompletion":1664,"completion":1664,"start":7988,"enrollment":114,"conditions":7989,"interventions":7991},"NCT04634110","Brigatinib Before Brain Irradiation Trial (B3i Trial)",[92],"2020-11-17",[7990,3120],"Brain Metastases",[7976],{"trials":7993,"activeCount":117},[],{"trials":7995,"activeCount":117},[],{"trials":7997,"activeCount":117},[],{"intervention":7999,"totalTrials":114,"cells":8000},"N-acetylcysteine",{"EARLY_PHASE1":8001,"PHASE1":8003,"PHASE2":8005,"PHASE3":8016,"PHASE4":8018,"NA":8020},{"trials":8002,"activeCount":117},[],{"trials":8004,"activeCount":117},[],{"trials":8006,"activeCount":117},[8007],{"nctId":8008,"briefTitle":8009,"status":160,"phases":8010,"primaryCompletion":7965,"completion":7965,"start":5281,"enrollment":8011,"conditions":8012,"interventions":8014},"NCT01187108","Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru",[91,92],85,[8013,986],"Erythrocytosis",[7999,8015],"Acetazolamide",{"trials":8017,"activeCount":117},[],{"trials":8019,"activeCount":117},[],{"trials":8021,"activeCount":117},[],{"intervention":8015,"totalTrials":114,"cells":8023},{"EARLY_PHASE1":8024,"PHASE1":8026,"PHASE2":8028,"PHASE3":8034,"PHASE4":8036,"NA":8038},{"trials":8025,"activeCount":117},[],{"trials":8027,"activeCount":117},[],{"trials":8029,"activeCount":117},[8030],{"nctId":8008,"briefTitle":8009,"status":160,"phases":8031,"primaryCompletion":7965,"completion":7965,"start":5281,"enrollment":8011,"conditions":8032,"interventions":8033},[91,92],[8013,986],[7999,8015],{"trials":8035,"activeCount":117},[],{"trials":8037,"activeCount":117},[],{"trials":8039,"activeCount":117},[],{"intervention":813,"totalTrials":114,"cells":8041},{"EARLY_PHASE1":8042,"PHASE1":8044,"PHASE2":8046,"PHASE3":8052,"PHASE4":8054,"NA":8056},{"trials":8043,"activeCount":117},[],{"trials":8045,"activeCount":117},[],{"trials":8047,"activeCount":117},[8048],{"nctId":799,"briefTitle":800,"status":160,"phases":8049,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":8050,"interventions":8051},[92],[807,808,809,810],[48,812,813,814,815,816],{"trials":8053,"activeCount":117},[],{"trials":8055,"activeCount":117},[],{"trials":8057,"activeCount":117},[],{"intervention":814,"totalTrials":114,"cells":8059},{"EARLY_PHASE1":8060,"PHASE1":8062,"PHASE2":8064,"PHASE3":8070,"PHASE4":8072,"NA":8074},{"trials":8061,"activeCount":117},[],{"trials":8063,"activeCount":117},[],{"trials":8065,"activeCount":117},[8066],{"nctId":799,"briefTitle":800,"status":160,"phases":8067,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":8068,"interventions":8069},[92],[807,808,809,810],[48,812,813,814,815,816],{"trials":8071,"activeCount":117},[],{"trials":8073,"activeCount":117},[],{"trials":8075,"activeCount":117},[],{"intervention":815,"totalTrials":114,"cells":8077},{"EARLY_PHASE1":8078,"PHASE1":8080,"PHASE2":8082,"PHASE3":8088,"PHASE4":8090,"NA":8092},{"trials":8079,"activeCount":117},[],{"trials":8081,"activeCount":117},[],{"trials":8083,"activeCount":117},[8084],{"nctId":799,"briefTitle":800,"status":160,"phases":8085,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":8086,"interventions":8087},[92],[807,808,809,810],[48,812,813,814,815,816],{"trials":8089,"activeCount":117},[],{"trials":8091,"activeCount":117},[],{"trials":8093,"activeCount":117},[],{"intervention":8095,"totalTrials":114,"cells":8096},"Fulvestrant with Enzalutamide",{"EARLY_PHASE1":8097,"PHASE1":8099,"PHASE2":8101,"PHASE3":8112,"PHASE4":8114,"NA":8116},{"trials":8098,"activeCount":117},[],{"trials":8100,"activeCount":117},[],{"trials":8102,"activeCount":117},[8103],{"nctId":8104,"briefTitle":8105,"status":160,"phases":8106,"primaryCompletion":8107,"completion":8108,"start":8109,"enrollment":178,"conditions":8110,"interventions":8111},"NCT02953860","Fulvestrant Plus Enzalutamide in ER+\u002FHer2- Advanced Breast Cancer",[92],"2019-11-21","2020-04-10","2017-07-06",[21],[8095],{"trials":8113,"activeCount":117},[],{"trials":8115,"activeCount":117},[],{"trials":8117,"activeCount":117},[],{"intervention":8119,"totalTrials":114,"cells":8120},"Antioxidants",{"EARLY_PHASE1":8121,"PHASE1":8123,"PHASE2":8125,"PHASE3":8137,"PHASE4":8139,"NA":8141},{"trials":8122,"activeCount":117},[],{"trials":8124,"activeCount":117},[],{"trials":8126,"activeCount":117},[8127],{"nctId":8128,"briefTitle":8129,"status":715,"phases":8130,"primaryCompletion":8131,"completion":8131,"start":5108,"enrollment":315,"conditions":8132,"interventions":8135},"NCT01773278","Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)",[92],"2025-12",[8133,8134,2736],"Smith-Lemli-Opitz Syndrome","Cone-Rod Dystrophy",[8119,8136],"Cholesterol",{"trials":8138,"activeCount":117},[],{"trials":8140,"activeCount":117},[],{"trials":8142,"activeCount":117},[],{"intervention":8136,"totalTrials":114,"cells":8144},{"EARLY_PHASE1":8145,"PHASE1":8147,"PHASE2":8149,"PHASE3":8155,"PHASE4":8157,"NA":8159},{"trials":8146,"activeCount":117},[],{"trials":8148,"activeCount":117},[],{"trials":8150,"activeCount":117},[8151],{"nctId":8128,"briefTitle":8129,"status":715,"phases":8152,"primaryCompletion":8131,"completion":8131,"start":5108,"enrollment":315,"conditions":8153,"interventions":8154},[92],[8133,8134,2736],[8119,8136],{"trials":8156,"activeCount":117},[],{"trials":8158,"activeCount":117},[],{"trials":8160,"activeCount":117},[],{"intervention":1799,"totalTrials":114,"cells":8162},{"EARLY_PHASE1":8163,"PHASE1":8165,"PHASE2":8167,"PHASE3":8173,"PHASE4":8175,"NA":8177},{"trials":8164,"activeCount":117},[],{"trials":8166,"activeCount":117},[],{"trials":8168,"activeCount":117},[8169],{"nctId":1790,"briefTitle":1791,"status":160,"phases":8170,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":31,"conditions":8171,"interventions":8172},[91,92],[1797],[1781,1799,1800,1801,1802,1803],{"trials":8174,"activeCount":117},[],{"trials":8176,"activeCount":117},[],{"trials":8178,"activeCount":117},[],{"intervention":1800,"totalTrials":114,"cells":8180},{"EARLY_PHASE1":8181,"PHASE1":8183,"PHASE2":8185,"PHASE3":8191,"PHASE4":8193,"NA":8195},{"trials":8182,"activeCount":117},[],{"trials":8184,"activeCount":117},[],{"trials":8186,"activeCount":117},[8187],{"nctId":1790,"briefTitle":1791,"status":160,"phases":8188,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":31,"conditions":8189,"interventions":8190},[91,92],[1797],[1781,1799,1800,1801,1802,1803],{"trials":8192,"activeCount":117},[],{"trials":8194,"activeCount":117},[],{"trials":8196,"activeCount":117},[],{"intervention":1801,"totalTrials":114,"cells":8198},{"EARLY_PHASE1":8199,"PHASE1":8201,"PHASE2":8203,"PHASE3":8209,"PHASE4":8211,"NA":8213},{"trials":8200,"activeCount":117},[],{"trials":8202,"activeCount":117},[],{"trials":8204,"activeCount":117},[8205],{"nctId":1790,"briefTitle":1791,"status":160,"phases":8206,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":31,"conditions":8207,"interventions":8208},[91,92],[1797],[1781,1799,1800,1801,1802,1803],{"trials":8210,"activeCount":117},[],{"trials":8212,"activeCount":117},[],{"trials":8214,"activeCount":117},[],{"intervention":1803,"totalTrials":114,"cells":8216},{"EARLY_PHASE1":8217,"PHASE1":8219,"PHASE2":8221,"PHASE3":8227,"PHASE4":8229,"NA":8231},{"trials":8218,"activeCount":117},[],{"trials":8220,"activeCount":117},[],{"trials":8222,"activeCount":117},[8223],{"nctId":1790,"briefTitle":1791,"status":160,"phases":8224,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":31,"conditions":8225,"interventions":8226},[91,92],[1797],[1781,1799,1800,1801,1802,1803],{"trials":8228,"activeCount":117},[],{"trials":8230,"activeCount":117},[],{"trials":8232,"activeCount":117},[],{"intervention":8234,"totalTrials":114,"cells":8235},"Cabazitaxel with Abiraterone Acetate",{"EARLY_PHASE1":8236,"PHASE1":8238,"PHASE2":8240,"PHASE3":8250,"PHASE4":8252,"NA":8254},{"trials":8237,"activeCount":117},[],{"trials":8239,"activeCount":117},[],{"trials":8241,"activeCount":117},[8242],{"nctId":8243,"briefTitle":8244,"status":125,"phases":8245,"primaryCompletion":8246,"completion":8246,"start":4721,"enrollment":902,"conditions":8247,"interventions":8248},"NCT01845792","Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer",[92],"2017-02",[914],[8234,8249],"Cabazitaxel",{"trials":8251,"activeCount":117},[],{"trials":8253,"activeCount":117},[],{"trials":8255,"activeCount":117},[],{"intervention":8249,"totalTrials":114,"cells":8257},{"EARLY_PHASE1":8258,"PHASE1":8260,"PHASE2":8262,"PHASE3":8268,"PHASE4":8270,"NA":8272},{"trials":8259,"activeCount":117},[],{"trials":8261,"activeCount":117},[],{"trials":8263,"activeCount":117},[8264],{"nctId":8243,"briefTitle":8244,"status":125,"phases":8265,"primaryCompletion":8246,"completion":8246,"start":4721,"enrollment":902,"conditions":8266,"interventions":8267},[92],[914],[8234,8249],{"trials":8269,"activeCount":117},[],{"trials":8271,"activeCount":117},[],{"trials":8273,"activeCount":117},[],{"intervention":8275,"totalTrials":114,"cells":8276},"Pegloticase 8 MG\u002FML [Krystexxa]",{"EARLY_PHASE1":8277,"PHASE1":8279,"PHASE2":8281,"PHASE3":8291,"PHASE4":8293,"NA":8295},{"trials":8278,"activeCount":117},[],{"trials":8280,"activeCount":117},[],{"trials":8282,"activeCount":117},[8283],{"nctId":8284,"briefTitle":8285,"status":715,"phases":8286,"primaryCompletion":1949,"completion":1949,"start":1985,"enrollment":228,"conditions":8287,"interventions":8290},"NCT03899883","Uric Acid Lowering Trial in Youth Onset T2D",[92],[131,8288,33,1925,8289,1922,1929,1927],"Hyperuricemia","Type2 Diabetes",[8275],{"trials":8292,"activeCount":117},[],{"trials":8294,"activeCount":117},[],{"trials":8296,"activeCount":117},[],{"intervention":8298,"totalTrials":114,"cells":8299},"Starbucks® Cold brew - 325ml bottle",{"EARLY_PHASE1":8300,"PHASE1":8302,"PHASE2":8304,"PHASE3":8316,"PHASE4":8318,"NA":8320},{"trials":8301,"activeCount":117},[],{"trials":8303,"activeCount":117},[],{"trials":8305,"activeCount":117},[8306],{"nctId":8307,"briefTitle":8308,"status":160,"phases":8309,"primaryCompletion":8310,"completion":8311,"start":8312,"enrollment":228,"conditions":8313,"interventions":8315},"NCT03878277","Evaluation of Coffee Therapy for Improvement of Renal Oxygenation",[92],"2020-01-21","2021-09-30","2019-07-01",[1988,8314,131,1940,1929,1927,1989],"Type1 Diabetes Mellitus",[8298],{"trials":8317,"activeCount":117},[],{"trials":8319,"activeCount":117},[],{"trials":8321,"activeCount":117},[],{"intervention":8323,"totalTrials":114,"cells":8324},"bryostatin 1",{"EARLY_PHASE1":8325,"PHASE1":8327,"PHASE2":8329,"PHASE3":8339,"PHASE4":8341,"NA":8343},{"trials":8326,"activeCount":117},[],{"trials":8328,"activeCount":117},[],{"trials":8330,"activeCount":117},[8331],{"nctId":8332,"briefTitle":8333,"status":160,"phases":8334,"primaryCompletion":8335,"completion":8335,"start":8336,"conditions":8337,"interventions":8338},"NCT00003205","Bryostatin 1 in Treating Patients With Stage IV Breast Cancer",[92],"2004-04","1998-04",[21],[8323],{"trials":8340,"activeCount":117},[],{"trials":8342,"activeCount":117},[],{"trials":8344,"activeCount":117},[],{"intervention":8346,"totalTrials":114,"cells":8347},"Iloperidone",{"EARLY_PHASE1":8348,"PHASE1":8350,"PHASE2":8352,"PHASE3":8361,"PHASE4":8363,"NA":8365},{"trials":8349,"activeCount":117},[],{"trials":8351,"activeCount":117},[],{"trials":8353,"activeCount":117},[8354],{"nctId":8355,"briefTitle":8356,"status":125,"phases":8357,"primaryCompletion":7532,"completion":7532,"start":4721,"enrollment":114,"conditions":8358,"interventions":8360},"NCT01917318","Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)",[92],[8359],"Post Traumatic Stress Disorder",[8346],{"trials":8362,"activeCount":117},[],{"trials":8364,"activeCount":117},[],{"trials":8366,"activeCount":117},[],{"intervention":8368,"totalTrials":114,"cells":8369},"AquADEKs-2",{"EARLY_PHASE1":8370,"PHASE1":8372,"PHASE2":8374,"PHASE3":8385,"PHASE4":8387,"NA":8389},{"trials":8371,"activeCount":117},[],{"trials":8373,"activeCount":117},[],{"trials":8375,"activeCount":117},[8376],{"nctId":8377,"briefTitle":8378,"status":160,"phases":8379,"primaryCompletion":8380,"completion":7332,"start":5281,"enrollment":8381,"conditions":8382,"interventions":8384},"NCT01859390","Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis",[92],"2015-04",73,[8383],"Cystic Fibrosis",[8368],{"trials":8386,"activeCount":117},[],{"trials":8388,"activeCount":117},[],{"trials":8390,"activeCount":117},[],{"intervention":8392,"totalTrials":114,"cells":8393},"Phentermine",{"EARLY_PHASE1":8394,"PHASE1":8396,"PHASE2":8398,"PHASE3":8413,"PHASE4":8415,"NA":8417},{"trials":8395,"activeCount":117},[],{"trials":8397,"activeCount":117},[],{"trials":8399,"activeCount":117},[8400],{"nctId":8401,"briefTitle":8402,"status":160,"phases":8403,"primaryCompletion":8404,"completion":8404,"start":8405,"enrollment":734,"conditions":8406,"interventions":8411},"NCT04095104","Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds",[92],"2022-01-25","2020-01-15",[8407,3834,8408,8409,8410],"Obesity, Morbid","Adolescent","Young Adult","Drug Therapy",[8392,8412],"Immediate Release Topiramate",{"trials":8414,"activeCount":117},[],{"trials":8416,"activeCount":117},[],{"trials":8418,"activeCount":117},[],{"intervention":8412,"totalTrials":114,"cells":8420},{"EARLY_PHASE1":8421,"PHASE1":8423,"PHASE2":8425,"PHASE3":8431,"PHASE4":8433,"NA":8435},{"trials":8422,"activeCount":117},[],{"trials":8424,"activeCount":117},[],{"trials":8426,"activeCount":117},[8427],{"nctId":8401,"briefTitle":8402,"status":160,"phases":8428,"primaryCompletion":8404,"completion":8404,"start":8405,"enrollment":734,"conditions":8429,"interventions":8430},[92],[8407,3834,8408,8409,8410],[8392,8412],{"trials":8432,"activeCount":117},[],{"trials":8434,"activeCount":117},[],{"trials":8436,"activeCount":117},[],{"intervention":8438,"totalTrials":114,"cells":8439},"Rucaparib",{"EARLY_PHASE1":8440,"PHASE1":8442,"PHASE2":8444,"PHASE3":8455,"PHASE4":8457,"NA":8459},{"trials":8441,"activeCount":117},[],{"trials":8443,"activeCount":117},[],{"trials":8445,"activeCount":117},[8446],{"nctId":8447,"briefTitle":8448,"status":160,"phases":8449,"primaryCompletion":8450,"completion":8451,"start":6646,"enrollment":7054,"conditions":8452,"interventions":8454},"NCT03617679","Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer",[92],"2023-10-31","2026-02-27",[8453],"Metastatic Endometrial Cancer",[8438],{"trials":8456,"activeCount":117},[],{"trials":8458,"activeCount":117},[],{"trials":8460,"activeCount":117},[],{"intervention":8462,"totalTrials":114,"cells":8463},"13-cis retinoic acid",{"EARLY_PHASE1":8464,"PHASE1":8466,"PHASE2":8468,"PHASE3":8480,"PHASE4":8482,"NA":8484},{"trials":8465,"activeCount":117},[],{"trials":8467,"activeCount":117},[],{"trials":8469,"activeCount":117},[8470],{"nctId":8471,"briefTitle":8472,"status":160,"phases":8473,"primaryCompletion":8474,"completion":8474,"start":8475,"enrollment":8476,"conditions":8477,"interventions":8479},"NCT00002586","13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer",[92],"2005-12","1993-01",96,[8478,3120],"Drug Toxicity",[8462],{"trials":8481,"activeCount":117},[],{"trials":8483,"activeCount":117},[],{"trials":8485,"activeCount":117},[],{"intervention":8487,"totalTrials":114,"cells":8488},"Semaglutide 3 MG [Rybelsus]",{"EARLY_PHASE1":8489,"PHASE1":8491,"PHASE2":8493,"PHASE3":8505,"PHASE4":8507,"NA":8509},{"trials":8490,"activeCount":117},[],{"trials":8492,"activeCount":117},[],{"trials":8494,"activeCount":117},[8495],{"nctId":8496,"briefTitle":8497,"status":160,"phases":8498,"primaryCompletion":8499,"completion":8500,"start":8501,"enrollment":110,"conditions":8502,"interventions":8503},"NCT05892432","Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)",[92],"2025-11-04","2025-11-15","2024-01-11",[1039],[8487,8504],"Semaglutide 7 MG [Rybelsus]",{"trials":8506,"activeCount":117},[],{"trials":8508,"activeCount":117},[],{"trials":8510,"activeCount":117},[],{"intervention":8504,"totalTrials":114,"cells":8512},{"EARLY_PHASE1":8513,"PHASE1":8515,"PHASE2":8517,"PHASE3":8523,"PHASE4":8525,"NA":8527},{"trials":8514,"activeCount":117},[],{"trials":8516,"activeCount":117},[],{"trials":8518,"activeCount":117},[8519],{"nctId":8496,"briefTitle":8497,"status":160,"phases":8520,"primaryCompletion":8499,"completion":8500,"start":8501,"enrollment":110,"conditions":8521,"interventions":8522},[92],[1039],[8487,8504],{"trials":8524,"activeCount":117},[],{"trials":8526,"activeCount":117},[],{"trials":8528,"activeCount":117},[],{"intervention":8530,"totalTrials":114,"cells":8531},"Naltrexone",{"EARLY_PHASE1":8532,"PHASE1":8534,"PHASE2":8536,"PHASE3":8548,"PHASE4":8550,"NA":8552},{"trials":8533,"activeCount":117},[],{"trials":8535,"activeCount":117},[],{"trials":8537,"activeCount":117},[8538],{"nctId":8539,"briefTitle":8540,"status":160,"phases":8541,"primaryCompletion":8542,"completion":8542,"start":8543,"enrollment":734,"conditions":8544,"interventions":8547},"NCT04854551","Opioid Modulation and Neural Reward Activation in Healthy Adults",[91,92],"2022-04-18","2021-05-01",[8545,8546],"Alcohol Drinking","Opioid Use, Unspecified",[8530],{"trials":8549,"activeCount":117},[],{"trials":8551,"activeCount":117},[],{"trials":8553,"activeCount":117},[],{"intervention":8555,"totalTrials":114,"cells":8556},"Ropivacaine HCL",{"EARLY_PHASE1":8557,"PHASE1":8559,"PHASE2":8561,"PHASE3":8575,"PHASE4":8577,"NA":8579},{"trials":8558,"activeCount":117},[],{"trials":8560,"activeCount":117},[],{"trials":8562,"activeCount":117},[8563],{"nctId":8564,"briefTitle":8565,"status":715,"phases":8566,"primaryCompletion":42,"completion":8567,"start":8568,"enrollment":288,"conditions":8569,"interventions":8573},"NCT03149783","Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores",[92],"2021-10-31","2018-02-13",[8570,8571,8572],"Pain, Postoperative","Delirium","Anesthesia, Local",[8555,8574],"sodium chloride",{"trials":8576,"activeCount":117},[],{"trials":8578,"activeCount":117},[],{"trials":8580,"activeCount":117},[],{"intervention":8574,"totalTrials":114,"cells":8582},{"EARLY_PHASE1":8583,"PHASE1":8585,"PHASE2":8587,"PHASE3":8593,"PHASE4":8595,"NA":8597},{"trials":8584,"activeCount":117},[],{"trials":8586,"activeCount":117},[],{"trials":8588,"activeCount":117},[8589],{"nctId":8564,"briefTitle":8565,"status":715,"phases":8590,"primaryCompletion":42,"completion":8567,"start":8568,"enrollment":288,"conditions":8591,"interventions":8592},[92],[8570,8571,8572],[8555,8574],{"trials":8594,"activeCount":117},[],{"trials":8596,"activeCount":117},[],{"trials":8598,"activeCount":117},[],{"intervention":2034,"totalTrials":114,"cells":8600},{"EARLY_PHASE1":8601,"PHASE1":8603,"PHASE2":8605,"PHASE3":8611,"PHASE4":8613,"NA":8615},{"trials":8602,"activeCount":117},[],{"trials":8604,"activeCount":117},[],{"trials":8606,"activeCount":117},[8607],{"nctId":2023,"briefTitle":2024,"status":125,"phases":8608,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":99,"conditions":8609,"interventions":8610},[91,92],[2029,2030,2031,2032],[2034,2035,2004],{"trials":8612,"activeCount":117},[],{"trials":8614,"activeCount":117},[],{"trials":8616,"activeCount":117},[],{"intervention":8618,"totalTrials":114,"cells":8619},"3-(2,4 dimethoxybenzylidene anabaseine) 150 mg",{"EARLY_PHASE1":8620,"PHASE1":8622,"PHASE2":8624,"PHASE3":8634,"PHASE4":8636,"NA":8638},{"trials":8621,"activeCount":117},[],{"trials":8623,"activeCount":117},[],{"trials":8625,"activeCount":117},[8626],{"nctId":8627,"briefTitle":8628,"status":160,"phases":8629,"primaryCompletion":8630,"completion":8630,"start":7100,"enrollment":3011,"conditions":8631,"interventions":8632},"NCT00100165","Phase 2 Trial of a Nicotinic Agonist in Schizophrenia",[92],"2007-07",[7102],[8618,8633],"3-(2,4 dimethoxybenzylidene anabaseine) 75 mg",{"trials":8635,"activeCount":117},[],{"trials":8637,"activeCount":117},[],{"trials":8639,"activeCount":117},[],{"intervention":8633,"totalTrials":114,"cells":8641},{"EARLY_PHASE1":8642,"PHASE1":8644,"PHASE2":8646,"PHASE3":8652,"PHASE4":8654,"NA":8656},{"trials":8643,"activeCount":117},[],{"trials":8645,"activeCount":117},[],{"trials":8647,"activeCount":117},[8648],{"nctId":8627,"briefTitle":8628,"status":160,"phases":8649,"primaryCompletion":8630,"completion":8630,"start":7100,"enrollment":3011,"conditions":8650,"interventions":8651},[92],[7102],[8618,8633],{"trials":8653,"activeCount":117},[],{"trials":8655,"activeCount":117},[],{"trials":8657,"activeCount":117},[],{"intervention":8659,"totalTrials":114,"cells":8660},"iloprost",{"EARLY_PHASE1":8661,"PHASE1":8663,"PHASE2":8665,"PHASE3":8675,"PHASE4":8677,"NA":8679},{"trials":8662,"activeCount":117},[],{"trials":8664,"activeCount":117},[],{"trials":8666,"activeCount":117},[8667],{"nctId":8668,"briefTitle":8669,"status":160,"phases":8670,"primaryCompletion":5459,"completion":5459,"start":8671,"enrollment":4178,"conditions":8672,"interventions":8674},"NCT00084409","Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease",[92],"2001-11",[3120,8673],"Precancerous Condition",[8659],{"trials":8676,"activeCount":117},[],{"trials":8678,"activeCount":117},[],{"trials":8680,"activeCount":117},[],{"intervention":8682,"totalTrials":114,"cells":8683},"PF-04449913",{"EARLY_PHASE1":8684,"PHASE1":8686,"PHASE2":8688,"PHASE3":8701,"PHASE4":8703,"NA":8705},{"trials":8685,"activeCount":117},[],{"trials":8687,"activeCount":117},[],{"trials":8689,"activeCount":117},[8690],{"nctId":8691,"briefTitle":8692,"status":160,"phases":8693,"primaryCompletion":8694,"completion":8695,"start":8696,"enrollment":5060,"conditions":8697,"interventions":8700},"NCT01841333","PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant",[92],"2019-05-08","2020-02-04","2013-04-29",[8698,8699],"Adult Acute Myeloid Leukemia in Remission","Recurrent Adult Acute Myeloid Leukemia",[8682],{"trials":8702,"activeCount":117},[],{"trials":8704,"activeCount":117},[],{"trials":8706,"activeCount":117},[],{"intervention":8708,"totalTrials":114,"cells":8709},"Ferrous sulfate",{"EARLY_PHASE1":8710,"PHASE1":8712,"PHASE2":8714,"PHASE3":8723,"PHASE4":8725,"NA":8727},{"trials":8711,"activeCount":117},[],{"trials":8713,"activeCount":117},[],{"trials":8715,"activeCount":117},[8716],{"nctId":8717,"briefTitle":8718,"status":160,"phases":8719,"primaryCompletion":983,"completion":983,"start":6190,"enrollment":1920,"conditions":8720,"interventions":8722},"NCT01745497","Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder",[92],[7559,8721],"Insomnia",[8708],{"trials":8724,"activeCount":117},[],{"trials":8726,"activeCount":117},[],{"trials":8728,"activeCount":117},[],{"intervention":8730,"totalTrials":114,"cells":8731},"irofulven",{"EARLY_PHASE1":8732,"PHASE1":8734,"PHASE2":8736,"PHASE3":8745,"PHASE4":8747,"NA":8749},{"trials":8733,"activeCount":117},[],{"trials":8735,"activeCount":117},[],{"trials":8737,"activeCount":117},[8738],{"nctId":8739,"briefTitle":8740,"status":160,"phases":8741,"primaryCompletion":1460,"completion":1460,"start":7312,"conditions":8742,"interventions":8744},"NCT00005968","Irofulven in Treating Patients With Stage IV Melanoma",[92],[8743],"Melanoma (Skin)",[8730],{"trials":8746,"activeCount":117},[],{"trials":8748,"activeCount":117},[],{"trials":8750,"activeCount":117},[],{"intervention":8752,"totalTrials":114,"cells":8753},"Ponatinib",{"EARLY_PHASE1":8754,"PHASE1":8756,"PHASE2":8758,"PHASE3":8776,"PHASE4":8778,"NA":8780},{"trials":8755,"activeCount":117},[],{"trials":8757,"activeCount":117},[],{"trials":8759,"activeCount":117},[8760],{"nctId":8761,"briefTitle":8762,"status":160,"phases":8763,"primaryCompletion":648,"completion":1056,"start":8764,"enrollment":8765,"conditions":8766,"interventions":8775},"NCT01935336","Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers",[92],"2013-09-24",171,[8767,8768,8769,8770,8771,8772,8773,8774],"Adenocarcinoma of the Lung","Extensive Stage Small Cell Lung Cancer","Limited Stage Small Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer","Recurrent Small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[8752],{"trials":8777,"activeCount":117},[],{"trials":8779,"activeCount":117},[],{"trials":8781,"activeCount":117},[],{"intervention":2046,"totalTrials":114,"cells":8783},{"EARLY_PHASE1":8784,"PHASE1":8786,"PHASE2":8788,"PHASE3":8794,"PHASE4":8796,"NA":8798},{"trials":8785,"activeCount":117},[],{"trials":8787,"activeCount":117},[],{"trials":8789,"activeCount":117},[8790],{"nctId":2037,"briefTitle":2038,"status":1622,"phases":8791,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":117,"conditions":8792,"interventions":8793},[92],[2044],[2004,2046],{"trials":8795,"activeCount":117},[],{"trials":8797,"activeCount":117},[],{"trials":8799,"activeCount":117},[],{"intervention":8801,"totalTrials":114,"cells":8802},"Adempas",{"EARLY_PHASE1":8803,"PHASE1":8805,"PHASE2":8807,"PHASE3":8819,"PHASE4":8821,"NA":8823},{"trials":8804,"activeCount":117},[],{"trials":8806,"activeCount":117},[],{"trials":8808,"activeCount":117},[8809],{"nctId":8810,"briefTitle":8811,"status":160,"phases":8812,"primaryCompletion":8813,"completion":8813,"start":8814,"enrollment":228,"conditions":8815,"interventions":8818},"NCT03409588","Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty",[92],"2026-01-26","2018-06-13",[8816,8817],"Chronic Thromboembolic Disease (CTED)","Exercise Intolerance Post PEA Surgery",[8801],{"trials":8820,"activeCount":117},[],{"trials":8822,"activeCount":117},[],{"trials":8824,"activeCount":117},[],{"intervention":8826,"totalTrials":114,"cells":8827},"Inhaled Nitric Oxide",{"EARLY_PHASE1":8828,"PHASE1":8830,"PHASE2":8832,"PHASE3":8842,"PHASE4":8844,"NA":8846},{"trials":8829,"activeCount":117},[],{"trials":8831,"activeCount":117},[],{"trials":8833,"activeCount":117},[8834],{"nctId":8835,"briefTitle":8836,"status":160,"phases":8837,"primaryCompletion":4226,"completion":4225,"start":5484,"enrollment":8838,"conditions":8839,"interventions":8840},"NCT00955487","Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns",[92],124,[7232],[8826,8841],"Nitrogen",{"trials":8843,"activeCount":117},[],{"trials":8845,"activeCount":117},[],{"trials":8847,"activeCount":117},[],{"intervention":8841,"totalTrials":114,"cells":8849},{"EARLY_PHASE1":8850,"PHASE1":8852,"PHASE2":8854,"PHASE3":8860,"PHASE4":8862,"NA":8864},{"trials":8851,"activeCount":117},[],{"trials":8853,"activeCount":117},[],{"trials":8855,"activeCount":117},[8856],{"nctId":8835,"briefTitle":8836,"status":160,"phases":8857,"primaryCompletion":4226,"completion":4225,"start":5484,"enrollment":8838,"conditions":8858,"interventions":8859},[92],[7232],[8826,8841],{"trials":8861,"activeCount":117},[],{"trials":8863,"activeCount":117},[],{"trials":8865,"activeCount":117},[],{"intervention":8867,"totalTrials":114,"cells":8868},"High Dose Vitamin D",{"EARLY_PHASE1":8869,"PHASE1":8871,"PHASE2":8873,"PHASE3":8884,"PHASE4":8886,"NA":8888},{"trials":8870,"activeCount":117},[],{"trials":8872,"activeCount":117},[],{"trials":8874,"activeCount":117},[8875],{"nctId":8876,"briefTitle":8877,"status":160,"phases":8878,"primaryCompletion":7076,"completion":7332,"start":7099,"enrollment":8879,"conditions":8880,"interventions":8882},"NCT01102374","Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents",[92],107,[8881],"Respiratory Infection",[8867,8883],"Standard Dose Vitamin D",{"trials":8885,"activeCount":117},[],{"trials":8887,"activeCount":117},[],{"trials":8889,"activeCount":117},[],{"intervention":8883,"totalTrials":114,"cells":8891},{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8896,"PHASE3":8902,"PHASE4":8904,"NA":8906},{"trials":8893,"activeCount":117},[],{"trials":8895,"activeCount":117},[],{"trials":8897,"activeCount":117},[8898],{"nctId":8876,"briefTitle":8877,"status":160,"phases":8899,"primaryCompletion":7076,"completion":7332,"start":7099,"enrollment":8879,"conditions":8900,"interventions":8901},[92],[8881],[8867,8883],{"trials":8903,"activeCount":117},[],{"trials":8905,"activeCount":117},[],{"trials":8907,"activeCount":117},[],{"intervention":8909,"totalTrials":114,"cells":8910},"Combined Oral Contraceptive Pill",{"EARLY_PHASE1":8911,"PHASE1":8913,"PHASE2":8915,"PHASE3":8925,"PHASE4":8927,"NA":8929},{"trials":8912,"activeCount":117},[],{"trials":8914,"activeCount":117},[],{"trials":8916,"activeCount":117},[8917],{"nctId":8918,"briefTitle":8919,"status":160,"phases":8920,"primaryCompletion":8921,"completion":8921,"start":4160,"enrollment":178,"conditions":8922,"interventions":8924},"NCT01968135","Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon\u002FNexplanon®)?: A Randomized Controlled Study",[92],"2014-11",[8923,255],"Uterine Hemorrhage",[8909],{"trials":8926,"activeCount":117},[],{"trials":8928,"activeCount":117},[],{"trials":8930,"activeCount":117},[],{"intervention":8932,"totalTrials":114,"cells":8933},"Silibin-Phytosome",{"EARLY_PHASE1":8934,"PHASE1":8936,"PHASE2":8938,"PHASE3":8947,"PHASE4":8949,"NA":8951},{"trials":8935,"activeCount":117},[],{"trials":8937,"activeCount":117},[],{"trials":8939,"activeCount":117},[8940],{"nctId":8941,"briefTitle":8942,"status":160,"phases":8943,"primaryCompletion":8944,"completion":7771,"start":5531,"enrollment":253,"conditions":8945,"interventions":8946},"NCT00487721","The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer",[92],"2007-09",[914],[8932],{"trials":8948,"activeCount":117},[],{"trials":8950,"activeCount":117},[],{"trials":8952,"activeCount":117},[],{"intervention":8954,"totalTrials":114,"cells":8955},"Bromocriptine",{"EARLY_PHASE1":8956,"PHASE1":8958,"PHASE2":8960,"PHASE3":8969,"PHASE4":8971,"NA":8973},{"trials":8957,"activeCount":117},[],{"trials":8959,"activeCount":117},[],{"trials":8961,"activeCount":117},[8962],{"nctId":8963,"briefTitle":8964,"status":160,"phases":8965,"primaryCompletion":5811,"completion":5811,"start":4250,"enrollment":8966,"conditions":8967,"interventions":8968},"NCT02544321","Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes",[92],108,[18],[8954],{"trials":8970,"activeCount":117},[],{"trials":8972,"activeCount":117},[],{"trials":8974,"activeCount":117},[],{"intervention":8976,"totalTrials":114,"cells":8977},"Human Insulin",{"EARLY_PHASE1":8978,"PHASE1":8980,"PHASE2":8982,"PHASE3":8990,"PHASE4":8992,"NA":8994},{"trials":8979,"activeCount":117},[],{"trials":8981,"activeCount":117},[],{"trials":8983,"activeCount":117},[8984],{"nctId":8985,"briefTitle":8986,"status":160,"phases":8987,"primaryCompletion":5281,"completion":678,"start":8944,"enrollment":4755,"conditions":8988,"interventions":8989},"NCT02620553","Primary Intervention With Mucosal Insulin",[91,92],[18],[8976],{"trials":8991,"activeCount":117},[],{"trials":8993,"activeCount":117},[],{"trials":8995,"activeCount":117},[],{"intervention":8997,"totalTrials":114,"cells":8998},"Crisaborole 2 % Topical Ointment",{"EARLY_PHASE1":8999,"PHASE1":9001,"PHASE2":9003,"PHASE3":9015,"PHASE4":9017,"NA":9019},{"trials":9000,"activeCount":117},[],{"trials":9002,"activeCount":117},[],{"trials":9004,"activeCount":117},[9005],{"nctId":9006,"briefTitle":9007,"status":160,"phases":9008,"primaryCompletion":9009,"completion":9009,"start":9010,"enrollment":178,"conditions":9011,"interventions":9012},"NCT05298033","Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo",[92],"2024-04-30","2022-09-07",[2178],[8997,9013,9014],"PF-07038124 0.01% topical ointment","Vehicle",{"trials":9016,"activeCount":117},[],{"trials":9018,"activeCount":117},[],{"trials":9020,"activeCount":117},[],{"intervention":9013,"totalTrials":114,"cells":9022},{"EARLY_PHASE1":9023,"PHASE1":9025,"PHASE2":9027,"PHASE3":9033,"PHASE4":9035,"NA":9037},{"trials":9024,"activeCount":117},[],{"trials":9026,"activeCount":117},[],{"trials":9028,"activeCount":117},[9029],{"nctId":9006,"briefTitle":9007,"status":160,"phases":9030,"primaryCompletion":9009,"completion":9009,"start":9010,"enrollment":178,"conditions":9031,"interventions":9032},[92],[2178],[8997,9013,9014],{"trials":9034,"activeCount":117},[],{"trials":9036,"activeCount":117},[],{"trials":9038,"activeCount":117},[],{"intervention":9014,"totalTrials":114,"cells":9040},{"EARLY_PHASE1":9041,"PHASE1":9043,"PHASE2":9045,"PHASE3":9051,"PHASE4":9053,"NA":9055},{"trials":9042,"activeCount":117},[],{"trials":9044,"activeCount":117},[],{"trials":9046,"activeCount":117},[9047],{"nctId":9006,"briefTitle":9007,"status":160,"phases":9048,"primaryCompletion":9009,"completion":9009,"start":9010,"enrollment":178,"conditions":9049,"interventions":9050},[92],[2178],[8997,9013,9014],{"trials":9052,"activeCount":117},[],{"trials":9054,"activeCount":117},[],{"trials":9056,"activeCount":117},[],{"intervention":1632,"totalTrials":114,"cells":9058},{"EARLY_PHASE1":9059,"PHASE1":9061,"PHASE2":9063,"PHASE3":9069,"PHASE4":9071,"NA":9073},{"trials":9060,"activeCount":117},[],{"trials":9062,"activeCount":117},[],{"trials":9064,"activeCount":117},[9065],{"nctId":1620,"briefTitle":1621,"status":1622,"phases":9066,"primaryCompletion":1624,"completion":1624,"start":1017,"enrollment":117,"conditions":9067,"interventions":9068},[92],[1626,1627,1628,1629,1630],[1632,1633,1587],{"trials":9070,"activeCount":117},[],{"trials":9072,"activeCount":117},[],{"trials":9074,"activeCount":117},[],{"intervention":9076,"totalTrials":114,"cells":9077},"Polatuzumab Vedotin",{"EARLY_PHASE1":9078,"PHASE1":9080,"PHASE2":9082,"PHASE3":9093,"PHASE4":9095,"NA":9097},{"trials":9079,"activeCount":117},[],{"trials":9081,"activeCount":117},[],{"trials":9083,"activeCount":117},[9084],{"nctId":9085,"briefTitle":9086,"status":1622,"phases":9087,"primaryCompletion":9088,"completion":9088,"start":9089,"enrollment":117,"conditions":9090,"interventions":9092},"NCT04535102","POLA+BR for Relapsed or Refractory DLBCL",[92],"2022-03-17","2021-01-29",[9091],"Diffuse Large B Cell Lymphoma",[9076],{"trials":9094,"activeCount":117},[],{"trials":9096,"activeCount":117},[],{"trials":9098,"activeCount":117},[],{"intervention":9100,"totalTrials":114,"cells":9101},"taurine",{"EARLY_PHASE1":9102,"PHASE1":9104,"PHASE2":9106,"PHASE3":9116,"PHASE4":9118,"NA":9120},{"trials":9103,"activeCount":117},[],{"trials":9105,"activeCount":117},[],{"trials":9107,"activeCount":117},[9108],{"nctId":9109,"briefTitle":9110,"status":160,"phases":9111,"primaryCompletion":9112,"completion":9112,"start":4732,"enrollment":217,"conditions":9113,"interventions":9115},"NCT01192828","Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine",[91,92],"2017-12",[9114],"Homocystinuria",[9100],{"trials":9117,"activeCount":117},[],{"trials":9119,"activeCount":117},[],{"trials":9121,"activeCount":117},[],{"intervention":9123,"totalTrials":114,"cells":9124},"Carboplatin",{"EARLY_PHASE1":9125,"PHASE1":9127,"PHASE2":9129,"PHASE3":9142,"PHASE4":9144,"NA":9146},{"trials":9126,"activeCount":117},[],{"trials":9128,"activeCount":117},[],{"trials":9130,"activeCount":117},[9131],{"nctId":9132,"briefTitle":9133,"status":160,"phases":9134,"primaryCompletion":9135,"completion":9135,"start":4177,"enrollment":2475,"conditions":9136,"interventions":9140},"NCT01542736","Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)",[92],"2020-09",[9137,9138,9139],"Metastatic Medulloblastoma","High Risk Supratentorial PNET","Metastatic PNET",[9123,9141],"Vincristine",{"trials":9143,"activeCount":117},[],{"trials":9145,"activeCount":117},[],{"trials":9147,"activeCount":117},[],{"intervention":9141,"totalTrials":114,"cells":9149},{"EARLY_PHASE1":9150,"PHASE1":9152,"PHASE2":9154,"PHASE3":9160,"PHASE4":9162,"NA":9164},{"trials":9151,"activeCount":117},[],{"trials":9153,"activeCount":117},[],{"trials":9155,"activeCount":117},[9156],{"nctId":9132,"briefTitle":9133,"status":160,"phases":9157,"primaryCompletion":9135,"completion":9135,"start":4177,"enrollment":2475,"conditions":9158,"interventions":9159},[92],[9137,9138,9139],[9123,9141],{"trials":9161,"activeCount":117},[],{"trials":9163,"activeCount":117},[],{"trials":9165,"activeCount":117},[],{"intervention":9167,"totalTrials":114,"cells":9168},"Intravenous Sildenafil",{"EARLY_PHASE1":9169,"PHASE1":9171,"PHASE2":9173,"PHASE3":9182,"PHASE4":9184,"NA":9186},{"trials":9170,"activeCount":117},[],{"trials":9172,"activeCount":117},[],{"trials":9174,"activeCount":117},[9175],{"nctId":9176,"briefTitle":9177,"status":125,"phases":9178,"primaryCompletion":4160,"completion":4160,"start":5034,"enrollment":99,"conditions":9179,"interventions":9181},"NCT01409031","Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension",[92],[9180,3521],"Persistent Pulmonary Hypertension",[9167],{"trials":9183,"activeCount":117},[],{"trials":9185,"activeCount":117},[],{"trials":9187,"activeCount":117},[],{"intervention":4758,"totalTrials":114,"cells":9189},{"EARLY_PHASE1":9190,"PHASE1":9192,"PHASE2":9194,"PHASE3":9200,"PHASE4":9202,"NA":9204},{"trials":9191,"activeCount":117},[],{"trials":9193,"activeCount":117},[],{"trials":9195,"activeCount":117},[9196],{"nctId":4750,"briefTitle":4751,"status":160,"phases":9197,"primaryCompletion":4753,"completion":4753,"start":4754,"enrollment":4755,"conditions":9198,"interventions":9199},[92],[1644],[4758,4741],{"trials":9201,"activeCount":117},[],{"trials":9203,"activeCount":117},[],{"trials":9205,"activeCount":117},[],{"intervention":7485,"totalTrials":114,"cells":9207},{"EARLY_PHASE1":9208,"PHASE1":9210,"PHASE2":9212,"PHASE3":9218,"PHASE4":9220,"NA":9222},{"trials":9209,"activeCount":117},[],{"trials":9211,"activeCount":117},[],{"trials":9213,"activeCount":117},[9214],{"nctId":7476,"briefTitle":7477,"status":160,"phases":9215,"primaryCompletion":7479,"completion":7480,"start":7481,"enrollment":1165,"conditions":9216,"interventions":9217},[92],[7483],[7485,1802,7486,3488],{"trials":9219,"activeCount":117},[],{"trials":9221,"activeCount":117},[],{"trials":9223,"activeCount":117},[],{"intervention":9225,"totalTrials":114,"cells":9226},"Adjuvant Hypofractionated Radiation",{"EARLY_PHASE1":9227,"PHASE1":9229,"PHASE2":9231,"PHASE3":9240,"PHASE4":9242,"NA":9244},{"trials":9228,"activeCount":117},[],{"trials":9230,"activeCount":117},[],{"trials":9232,"activeCount":117},[9233],{"nctId":9234,"briefTitle":9235,"status":160,"phases":9236,"primaryCompletion":1138,"completion":1138,"start":9237,"enrollment":8966,"conditions":9238,"interventions":9239},"NCT02700386","Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes",[92],"2016-08-11",[21],[9225],{"trials":9241,"activeCount":117},[],{"trials":9243,"activeCount":117},[],{"trials":9245,"activeCount":117},[],{"intervention":9247,"totalTrials":114,"cells":9248},"Catheter insertion with Povidone Iodine",{"EARLY_PHASE1":9249,"PHASE1":9251,"PHASE2":9253,"PHASE3":9266,"PHASE4":9268,"NA":9270},{"trials":9250,"activeCount":117},[],{"trials":9252,"activeCount":117},[],{"trials":9254,"activeCount":117},[9255],{"nctId":9256,"briefTitle":9257,"status":160,"phases":9258,"primaryCompletion":9259,"completion":9259,"start":9260,"enrollment":841,"conditions":9261,"interventions":9265},"NCT03101371","Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion",[92],"2019-02-15","2017-10-10",[9262,9263,9264],"Urinary Tract Infections","Catheter Infection","Catheter-Related Infections",[9247],{"trials":9267,"activeCount":117},[],{"trials":9269,"activeCount":117},[],{"trials":9271,"activeCount":117},[],{"intervention":9273,"totalTrials":114,"cells":9274},"RT and Anti-PD-1",{"EARLY_PHASE1":9275,"PHASE1":9277,"PHASE2":9279,"PHASE3":9292,"PHASE4":9294,"NA":9296},{"trials":9276,"activeCount":117},[],{"trials":9278,"activeCount":117},[],{"trials":9280,"activeCount":117},[9281],{"nctId":9282,"briefTitle":9283,"status":1622,"phases":9284,"primaryCompletion":9285,"completion":9285,"start":9286,"enrollment":117,"conditions":9287,"interventions":9290},"NCT04001101","Anti-PD-1 +\u002F- RT for MSI-H Solid Tumors",[92],"2021-11-17","2019-10-10",[9288,9289,1668],"Microsatellite Instability High","Mismatch Repair Deficiency",[9273,9291],"Anti-PD-1",{"trials":9293,"activeCount":117},[],{"trials":9295,"activeCount":117},[],{"trials":9297,"activeCount":117},[],{"intervention":9291,"totalTrials":114,"cells":9299},{"EARLY_PHASE1":9300,"PHASE1":9302,"PHASE2":9304,"PHASE3":9310,"PHASE4":9312,"NA":9314},{"trials":9301,"activeCount":117},[],{"trials":9303,"activeCount":117},[],{"trials":9305,"activeCount":117},[9306],{"nctId":9282,"briefTitle":9283,"status":1622,"phases":9307,"primaryCompletion":9285,"completion":9285,"start":9286,"enrollment":117,"conditions":9308,"interventions":9309},[92],[9288,9289,1668],[9273,9291],{"trials":9311,"activeCount":117},[],{"trials":9313,"activeCount":117},[],{"trials":9315,"activeCount":117},[],{"intervention":9317,"totalTrials":114,"cells":9318},"Drospirenone-only pill",{"EARLY_PHASE1":9319,"PHASE1":9321,"PHASE2":9323,"PHASE3":9332,"PHASE4":9334,"NA":9336},{"trials":9320,"activeCount":117},[],{"trials":9322,"activeCount":117},[],{"trials":9324,"activeCount":117},[9325],{"nctId":9326,"briefTitle":9327,"status":715,"phases":9328,"primaryCompletion":7249,"completion":7249,"start":9329,"enrollment":1561,"conditions":9330,"interventions":9331},"NCT05675644","Drospirenone-only Pill as Emergency Contraception",[92],"2023-02",[255],[9317],{"trials":9333,"activeCount":117},[],{"trials":9335,"activeCount":117},[],{"trials":9337,"activeCount":117},[],{"intervention":9339,"totalTrials":114,"cells":9340},"Truvada",{"EARLY_PHASE1":9341,"PHASE1":9343,"PHASE2":9345,"PHASE3":9354,"PHASE4":9356,"NA":9358},{"trials":9342,"activeCount":117},[],{"trials":9344,"activeCount":117},[],{"trials":9346,"activeCount":117},[9347],{"nctId":9348,"briefTitle":9349,"status":160,"phases":9350,"primaryCompletion":925,"completion":648,"start":7531,"enrollment":955,"conditions":9351,"interventions":9353},"NCT02022657","Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots",[91,92],[9352],"PrEP Adherence Monitoring",[9339],{"trials":9355,"activeCount":117},[],{"trials":9357,"activeCount":117},[],{"trials":9359,"activeCount":117},[],{"intervention":9361,"totalTrials":114,"cells":9362},"Tucatinib in Combination with Palbociclib and Letrozole",{"EARLY_PHASE1":9363,"PHASE1":9365,"PHASE2":9367,"PHASE3":9378,"PHASE4":9380,"NA":9382},{"trials":9364,"activeCount":117},[],{"trials":9366,"activeCount":117},[],{"trials":9368,"activeCount":117},[9369],{"nctId":9370,"briefTitle":9371,"status":160,"phases":9372,"primaryCompletion":9373,"completion":9374,"start":9375,"enrollment":2380,"conditions":9376,"interventions":9377},"NCT03054363","Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",[91,92],"2023-01-17","2023-02-07","2017-11-27",[21],[9361,9361],{"trials":9379,"activeCount":117},[],{"trials":9381,"activeCount":117},[],{"trials":9383,"activeCount":117},[],{"intervention":9385,"totalTrials":114,"cells":9386},"Test Drug",{"EARLY_PHASE1":9387,"PHASE1":9389,"PHASE2":9391,"PHASE3":9399,"PHASE4":9401,"NA":9403},{"trials":9388,"activeCount":117},[],{"trials":9390,"activeCount":117},[],{"trials":9392,"activeCount":117},[9393],{"nctId":9394,"briefTitle":9395,"status":1622,"phases":9396,"primaryCompletion":1460,"completion":1460,"start":1460,"enrollment":117,"conditions":9397,"interventions":9398},"NCT00000331","Buprenorphine\u002FNaloxone Treatment for Opioid Dependence-Experiment II-3 - 6",[92],[7298,7283],[9385],{"trials":9400,"activeCount":117},[],{"trials":9402,"activeCount":117},[],{"trials":9404,"activeCount":117},[],{"intervention":9406,"totalTrials":114,"cells":9407},"Azacitidine and Venetoclax",{"EARLY_PHASE1":9408,"PHASE1":9410,"PHASE2":9412,"PHASE3":9423,"PHASE4":9425,"NA":9427},{"trials":9409,"activeCount":117},[],{"trials":9411,"activeCount":117},[],{"trials":9413,"activeCount":117},[9414],{"nctId":9415,"briefTitle":9416,"status":160,"phases":9417,"primaryCompletion":9418,"completion":9419,"start":9420,"enrollment":2380,"conditions":9421,"interventions":9422},"NCT03466294","Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML",[92],"2025-01-29","2025-12-04","2018-05-15",[1509],[9406],{"trials":9424,"activeCount":117},[],{"trials":9426,"activeCount":117},[],{"trials":9428,"activeCount":117},[],{"intervention":9430,"totalTrials":114,"cells":9431},"Exemestane",{"EARLY_PHASE1":9432,"PHASE1":9434,"PHASE2":9436,"PHASE3":9449,"PHASE4":9451,"NA":9453},{"trials":9433,"activeCount":117},[],{"trials":9435,"activeCount":117},[],{"trials":9437,"activeCount":117},[9438],{"nctId":9439,"briefTitle":9440,"status":160,"phases":9441,"primaryCompletion":1470,"completion":9442,"start":9443,"enrollment":1518,"conditions":9444,"interventions":9447},"NCT01831076","Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors",[92],"2022-01-06","2002-04",[21,9445,9446],"Stage II Breast Cancer","Stage III Breast Cancer",[9430,9448],"Exemestane and tamoxifen",{"trials":9450,"activeCount":117},[],{"trials":9452,"activeCount":117},[],{"trials":9454,"activeCount":117},[],{"intervention":9448,"totalTrials":114,"cells":9456},{"EARLY_PHASE1":9457,"PHASE1":9459,"PHASE2":9461,"PHASE3":9467,"PHASE4":9469,"NA":9471},{"trials":9458,"activeCount":117},[],{"trials":9460,"activeCount":117},[],{"trials":9462,"activeCount":117},[9463],{"nctId":9439,"briefTitle":9440,"status":160,"phases":9464,"primaryCompletion":1470,"completion":9442,"start":9443,"enrollment":1518,"conditions":9465,"interventions":9466},[92],[21,9445,9446],[9430,9448],{"trials":9468,"activeCount":117},[],{"trials":9470,"activeCount":117},[],{"trials":9472,"activeCount":117},[],{"intervention":9474,"totalTrials":114,"cells":9475},"Crizotinib",{"EARLY_PHASE1":9476,"PHASE1":9478,"PHASE2":9480,"PHASE3":9491,"PHASE4":9493,"NA":9495},{"trials":9477,"activeCount":117},[],{"trials":9479,"activeCount":117},[],{"trials":9481,"activeCount":117},[9482],{"nctId":9483,"briefTitle":9484,"status":160,"phases":9485,"primaryCompletion":9486,"completion":9486,"start":9487,"enrollment":99,"conditions":9488,"interventions":9490},"NCT03088930","Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer",[92],"2021-01-13","2017-12-13",[9489],"Lung Cancer, Nonsmall Cell",[9474],{"trials":9492,"activeCount":117},[],{"trials":9494,"activeCount":117},[],{"trials":9496,"activeCount":117},[],{"intervention":9498,"totalTrials":114,"cells":9499},"Fluzone High Dose",{"EARLY_PHASE1":9500,"PHASE1":9502,"PHASE2":9504,"PHASE3":9519,"PHASE4":9521,"NA":9523},{"trials":9501,"activeCount":117},[],{"trials":9503,"activeCount":117},[],{"trials":9505,"activeCount":117},[9506],{"nctId":9507,"briefTitle":9508,"status":160,"phases":9509,"primaryCompletion":4250,"completion":9510,"start":5107,"enrollment":37,"conditions":9511,"interventions":9517},"NCT01685372","Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults",[92],"2017-09",[9512,9513,9514,9515,9516],"Solid Organ Transplant Recipient (Liver, Kidney, Heart)","Rheumatologic Disorder","Human Immunodeficiency Virus (HIV)","Bone Marrow Transplant (BMT)","Dialysis",[9498,9518],"Fluzone",{"trials":9520,"activeCount":117},[],{"trials":9522,"activeCount":117},[],{"trials":9524,"activeCount":117},[],{"intervention":9518,"totalTrials":114,"cells":9526},{"EARLY_PHASE1":9527,"PHASE1":9529,"PHASE2":9531,"PHASE3":9537,"PHASE4":9539,"NA":9541},{"trials":9528,"activeCount":117},[],{"trials":9530,"activeCount":117},[],{"trials":9532,"activeCount":117},[9533],{"nctId":9507,"briefTitle":9508,"status":160,"phases":9534,"primaryCompletion":4250,"completion":9510,"start":5107,"enrollment":37,"conditions":9535,"interventions":9536},[92],[9512,9513,9514,9515,9516],[9498,9518],{"trials":9538,"activeCount":117},[],{"trials":9540,"activeCount":117},[],{"trials":9542,"activeCount":117},[],{"intervention":7536,"totalTrials":114,"cells":9544},{"EARLY_PHASE1":9545,"PHASE1":9547,"PHASE2":9549,"PHASE3":9555,"PHASE4":9557,"NA":9559},{"trials":9546,"activeCount":117},[],{"trials":9548,"activeCount":117},[],{"trials":9550,"activeCount":117},[9551],{"nctId":7528,"briefTitle":7529,"status":1622,"phases":9552,"primaryCompletion":7531,"completion":7531,"start":7532,"enrollment":117,"conditions":9553,"interventions":9554},[92],[7534],[7536,7486],{"trials":9556,"activeCount":117},[],{"trials":9558,"activeCount":117},[],{"trials":9560,"activeCount":117},[],{"intervention":9562,"totalTrials":114,"cells":9563},"VESANOID",{"EARLY_PHASE1":9564,"PHASE1":9566,"PHASE2":9568,"PHASE3":9581,"PHASE4":9583,"NA":9585},{"trials":9565,"activeCount":117},[],{"trials":9567,"activeCount":117},[],{"trials":9569,"activeCount":117},[9570],{"nctId":9571,"briefTitle":9572,"status":160,"phases":9573,"primaryCompletion":9574,"completion":9575,"start":9576,"enrollment":228,"conditions":9577,"interventions":9579},"NCT02403778","Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma",[92],"2018-08","2023-01-18","2015-12-17",[9578],"Melanoma",[9562,9580],"Ipilimumab",{"trials":9582,"activeCount":117},[],{"trials":9584,"activeCount":117},[],{"trials":9586,"activeCount":117},[],{"intervention":9580,"totalTrials":114,"cells":9588},{"EARLY_PHASE1":9589,"PHASE1":9591,"PHASE2":9593,"PHASE3":9599,"PHASE4":9601,"NA":9603},{"trials":9590,"activeCount":117},[],{"trials":9592,"activeCount":117},[],{"trials":9594,"activeCount":117},[9595],{"nctId":9571,"briefTitle":9572,"status":160,"phases":9596,"primaryCompletion":9574,"completion":9575,"start":9576,"enrollment":228,"conditions":9597,"interventions":9598},[92],[9578],[9562,9580],{"trials":9600,"activeCount":117},[],{"trials":9602,"activeCount":117},[],{"trials":9604,"activeCount":117},[],{"intervention":9606,"totalTrials":114,"cells":9607},"Pembrolizumab with All-Trans Retinoic Acid",{"EARLY_PHASE1":9608,"PHASE1":9610,"PHASE2":9612,"PHASE3":9626,"PHASE4":9628,"NA":9630},{"trials":9609,"activeCount":117},[],{"trials":9611,"activeCount":117},[],{"trials":9613,"activeCount":117},[9614],{"nctId":9615,"briefTitle":9616,"status":160,"phases":9617,"primaryCompletion":9618,"completion":9619,"start":9620,"enrollment":5686,"conditions":9621,"interventions":9625},"NCT03200847","Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma",[91,92],"2022-07-20","2022-10-19","2017-10-31",[9622,9623,9624],"Stage IV Melanoma","Stage III Melanoma","Advanced Melanoma",[9606],{"trials":9627,"activeCount":117},[],{"trials":9629,"activeCount":117},[],{"trials":9631,"activeCount":117},[],{"intervention":9633,"totalTrials":114,"cells":9634},"Ublituximab",{"EARLY_PHASE1":9635,"PHASE1":9637,"PHASE2":9639,"PHASE3":9652,"PHASE4":9654,"NA":9656},{"trials":9636,"activeCount":117},[],{"trials":9638,"activeCount":117},[],{"trials":9640,"activeCount":117},[9641],{"nctId":9642,"briefTitle":9643,"status":160,"phases":9644,"primaryCompletion":9645,"completion":9645,"start":9646,"enrollment":1548,"conditions":9647,"interventions":9650},"NCT04508647","Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma",[92],"2022-07-14","2020-11-23",[9648,9649],"Marginal Zone Lymphoma","Follicular Lymphoma",[9633,9651],"Umbralisib",{"trials":9653,"activeCount":117},[],{"trials":9655,"activeCount":117},[],{"trials":9657,"activeCount":117},[],{"intervention":9651,"totalTrials":114,"cells":9659},{"EARLY_PHASE1":9660,"PHASE1":9662,"PHASE2":9664,"PHASE3":9670,"PHASE4":9672,"NA":9674},{"trials":9661,"activeCount":117},[],{"trials":9663,"activeCount":117},[],{"trials":9665,"activeCount":117},[9666],{"nctId":9642,"briefTitle":9643,"status":160,"phases":9667,"primaryCompletion":9645,"completion":9645,"start":9646,"enrollment":1548,"conditions":9668,"interventions":9669},[92],[9648,9649],[9633,9651],{"trials":9671,"activeCount":117},[],{"trials":9673,"activeCount":117},[],{"trials":9675,"activeCount":117},[],{"intervention":9677,"totalTrials":114,"cells":9678},"Haloperidol",{"EARLY_PHASE1":9679,"PHASE1":9681,"PHASE2":9683,"PHASE3":9692,"PHASE4":9694,"NA":9696},{"trials":9680,"activeCount":117},[],{"trials":9682,"activeCount":117},[],{"trials":9684,"activeCount":117},[9685],{"nctId":9686,"briefTitle":9687,"status":160,"phases":9688,"primaryCompletion":8944,"completion":8944,"start":8474,"enrollment":28,"conditions":9689,"interventions":9691},"NCT00429676","Pilot Study of Haloperidol to Treat Critical Illness Delirium",[92],[8571,9690],"Critical Illness",[9677],{"trials":9693,"activeCount":117},[],{"trials":9695,"activeCount":117},[],{"trials":9697,"activeCount":117},[],{"intervention":1672,"totalTrials":114,"cells":9699},{"EARLY_PHASE1":9700,"PHASE1":9702,"PHASE2":9704,"PHASE3":9710,"PHASE4":9712,"NA":9714},{"trials":9701,"activeCount":117},[],{"trials":9703,"activeCount":117},[],{"trials":9705,"activeCount":117},[9706],{"nctId":1661,"briefTitle":1662,"status":160,"phases":9707,"primaryCompletion":1664,"completion":1665,"start":1536,"enrollment":1666,"conditions":9708,"interventions":9709},[92],[1668,1669],[1587,1671,1672],{"trials":9711,"activeCount":117},[],{"trials":9713,"activeCount":117},[],{"trials":9715,"activeCount":117},[],{"intervention":9717,"totalTrials":114,"cells":9718},"Psilocybin 25mg",{"EARLY_PHASE1":9719,"PHASE1":9721,"PHASE2":9723,"PHASE3":9736,"PHASE4":9738,"NA":9740},{"trials":9720,"activeCount":117},[],{"trials":9722,"activeCount":117},[],{"trials":9724,"activeCount":117},[9725],{"nctId":9726,"briefTitle":9727,"status":160,"phases":9728,"primaryCompletion":9729,"completion":9729,"start":9730,"enrollment":28,"conditions":9731,"interventions":9735},"NCT06230757","Psilocybin for Treatment-Resistant Depression",[92],"2026-05-08","2024-07-08",[9732,9733,9734],"Major Depressive Disorder","Anhedonia","Treatment Resistant Depression",[9717],{"trials":9737,"activeCount":117},[],{"trials":9739,"activeCount":117},[],{"trials":9741,"activeCount":117},[],{"intervention":9743,"totalTrials":114,"cells":9744},"Sargramostim for",{"EARLY_PHASE1":9745,"PHASE1":9747,"PHASE2":9749,"PHASE3":9759,"PHASE4":9761,"NA":9763},{"trials":9746,"activeCount":117},[],{"trials":9748,"activeCount":117},[],{"trials":9750,"activeCount":117},[9751],{"nctId":9752,"briefTitle":9753,"status":1622,"phases":9754,"primaryCompletion":2862,"completion":2862,"start":9755,"enrollment":117,"conditions":9756,"interventions":9757},"NCT05482334","Trial to Evaluate Safety and Efficacy of GM-CSF \u002FSargramostim in Down Syndrome",[92],"2023-10-23",[2100],[9743,9758],"Saline Placebo",{"trials":9760,"activeCount":117},[],{"trials":9762,"activeCount":117},[],{"trials":9764,"activeCount":117},[],{"intervention":9758,"totalTrials":114,"cells":9766},{"EARLY_PHASE1":9767,"PHASE1":9769,"PHASE2":9771,"PHASE3":9777,"PHASE4":9779,"NA":9781},{"trials":9768,"activeCount":117},[],{"trials":9770,"activeCount":117},[],{"trials":9772,"activeCount":117},[9773],{"nctId":9752,"briefTitle":9753,"status":1622,"phases":9774,"primaryCompletion":2862,"completion":2862,"start":9755,"enrollment":117,"conditions":9775,"interventions":9776},[92],[2100],[9743,9758],{"trials":9778,"activeCount":117},[],{"trials":9780,"activeCount":117},[],{"trials":9782,"activeCount":117},[],{"intervention":9784,"totalTrials":114,"cells":9785},"Tolcapone",{"EARLY_PHASE1":9786,"PHASE1":9788,"PHASE2":9790,"PHASE3":9800,"PHASE4":9802,"NA":9804},{"trials":9787,"activeCount":117},[],{"trials":9789,"activeCount":117},[],{"trials":9791,"activeCount":117},[9792],{"nctId":9793,"briefTitle":9794,"status":160,"phases":9795,"primaryCompletion":9796,"completion":9796,"start":9797,"enrollment":25,"conditions":9798,"interventions":9799},"NCT03904498","COMT Inhibition Among Individuals With Comorbid AUD\u002FADHD",[92],"2026-03-09","2021-08-16",[1039,5461],[9784],{"trials":9801,"activeCount":117},[],{"trials":9803,"activeCount":117},[],{"trials":9805,"activeCount":117},[],{"intervention":9807,"totalTrials":114,"cells":9808},"Quadrivalent Live Attenuated Influenza Vaccine",{"EARLY_PHASE1":9809,"PHASE1":9811,"PHASE2":9813,"PHASE3":9823,"PHASE4":9825,"NA":9827},{"trials":9810,"activeCount":117},[],{"trials":9812,"activeCount":117},[],{"trials":9814,"activeCount":117},[9815],{"nctId":9816,"briefTitle":9817,"status":160,"phases":9818,"primaryCompletion":677,"completion":9819,"start":4721,"enrollment":9820,"conditions":9821,"interventions":9822},"NCT02474901","Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults",[92],"2016-12",101,[9514],[9807],{"trials":9824,"activeCount":117},[],{"trials":9826,"activeCount":117},[],{"trials":9828,"activeCount":117},[],{"intervention":2285,"totalTrials":114,"cells":9830},{"EARLY_PHASE1":9831,"PHASE1":9833,"PHASE2":9835,"PHASE3":9841,"PHASE4":9843,"NA":9845},{"trials":9832,"activeCount":117},[],{"trials":9834,"activeCount":117},[],{"trials":9836,"activeCount":117},[9837],{"nctId":2275,"briefTitle":2276,"status":1622,"phases":9838,"primaryCompletion":2278,"completion":2279,"start":2280,"enrollment":117,"conditions":9839,"interventions":9840},[92],[2282,2283],[2285,2256],{"trials":9842,"activeCount":117},[],{"trials":9844,"activeCount":117},[],{"trials":9846,"activeCount":117},[],{"intervention":9848,"totalTrials":114,"cells":9849},"N-acetyl cysteine then Placebo",{"EARLY_PHASE1":9850,"PHASE1":9852,"PHASE2":9854,"PHASE3":9864,"PHASE4":9866,"NA":9868},{"trials":9851,"activeCount":117},[],{"trials":9853,"activeCount":117},[],{"trials":9855,"activeCount":117},[9856],{"nctId":9857,"briefTitle":9858,"status":1622,"phases":9859,"primaryCompletion":7249,"completion":7249,"start":9860,"enrollment":117,"conditions":9861,"interventions":9863},"NCT03720483","Inhaled NAC in Treatment of IPF",[91,92],"2022-01",[9862],"Idiopathic Pulmonary Fibrosis (IPF)",[9848],{"trials":9865,"activeCount":117},[],{"trials":9867,"activeCount":117},[],{"trials":9869,"activeCount":117},[],{"intervention":9871,"totalTrials":114,"cells":9872},"Prochlorperazine Maleate",{"EARLY_PHASE1":9873,"PHASE1":9875,"PHASE2":9877,"PHASE3":9888,"PHASE4":9890,"NA":9892},{"trials":9874,"activeCount":117},[],{"trials":9876,"activeCount":117},[],{"trials":9878,"activeCount":117},[9879],{"nctId":9880,"briefTitle":9881,"status":160,"phases":9882,"primaryCompletion":9883,"completion":9883,"start":9884,"enrollment":719,"conditions":9885,"interventions":9887},"NCT06450899","Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness",[92],"2024-08-28","2024-08-05",[9886],"Acute Mountain Sickness",[9871],{"trials":9889,"activeCount":117},[],{"trials":9891,"activeCount":117},[],{"trials":9893,"activeCount":117},[],{"intervention":9895,"totalTrials":199,"cells":9896},"Cephalexin",{"EARLY_PHASE1":9897,"PHASE1":9899,"PHASE2":9922,"PHASE3":9924,"PHASE4":9926,"NA":9928},{"trials":9898,"activeCount":117},[],{"trials":9900,"activeCount":117},[9901,9912],{"nctId":9902,"briefTitle":9903,"status":160,"phases":9904,"primaryCompletion":757,"completion":757,"start":9905,"enrollment":34,"conditions":9906,"interventions":9910},"NCT03802552","Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections",[91],"2019-05-01",[9907,9908,9909],"Osteomyelitis","Septic Arthritis","Pyomyositis",[9911,9895],"Cefadroxil",{"nctId":9913,"briefTitle":9914,"status":160,"phases":9915,"primaryCompletion":9916,"completion":9916,"start":9917,"enrollment":1165,"conditions":9918,"interventions":9920},"NCT04916951","Oral Amoxicillin and Cephalexin PK\u002FPD in Neonates",[91],"2025-11-30","2021-07-14",[9919],"Neonatal Infection",[9921,9895],"Amoxicillin",{"trials":9923,"activeCount":117},[],{"trials":9925,"activeCount":117},[],{"trials":9927,"activeCount":117},[],{"trials":9929,"activeCount":117},[],{"intervention":9931,"totalTrials":199,"cells":9932},"Gemcitabine",{"EARLY_PHASE1":9933,"PHASE1":9945,"PHASE2":9956,"PHASE3":9958,"PHASE4":9960,"NA":9962},{"trials":9934,"activeCount":117},[9935],{"nctId":9936,"briefTitle":9937,"status":160,"phases":9938,"primaryCompletion":9939,"completion":9940,"start":9941,"enrollment":199,"conditions":9942,"interventions":9944},"NCT02992015","Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma",[90],"2018-02-28","2024-03-06","2016-09-23",[9943],"Diffuse Intrinsic Pontine Glioma",[9931],{"trials":9946,"activeCount":117},[9947],{"nctId":9948,"briefTitle":9949,"status":160,"phases":9950,"primaryCompletion":4970,"completion":4970,"start":7228,"enrollment":25,"conditions":9951,"interventions":9954},"NCT00551096","Gemcitabine\u002FCapecitabine\u002FZD6474 in Advanced Solid Tumors",[91],[9952,9953,7274],"Malignant Solid Tumour","Biliary Cancer",[9931,3488,9955],"ZD6474",{"trials":9957,"activeCount":117},[],{"trials":9959,"activeCount":117},[],{"trials":9961,"activeCount":117},[],{"trials":9963,"activeCount":117},[],{"intervention":9965,"totalTrials":199,"cells":9966},"irinotecan",{"EARLY_PHASE1":9967,"PHASE1":9969,"PHASE2":9991,"PHASE3":9993,"PHASE4":9995,"NA":9997},{"trials":9968,"activeCount":117},[],{"trials":9970,"activeCount":117},[9971,9978],{"nctId":9972,"briefTitle":9973,"status":125,"phases":9974,"primaryCompletion":227,"completion":227,"start":2052,"enrollment":37,"conditions":9975,"interventions":9976},"NCT01016860","OSI-906 and Irinotecan in Patients With Advanced Cancer",[91],[1668],[9977,9965],"OSI-906",{"nctId":9979,"briefTitle":9980,"status":160,"phases":9981,"primaryCompletion":9982,"completion":9983,"start":9984,"enrollment":199,"conditions":9985,"interventions":9988},"NCT02596503","A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors",[91],"2019-04","2020-01-24","2015-10-21",[9986,9987],"Relapsed Solid Tumors","Refractory Solid Tumors",[9989,9990],"Eribulin","Irinotecan",{"trials":9992,"activeCount":117},[],{"trials":9994,"activeCount":117},[],{"trials":9996,"activeCount":117},[],{"trials":9998,"activeCount":117},[],{"intervention":10000,"totalTrials":199,"cells":10001},"aldesleukin",{"EARLY_PHASE1":10002,"PHASE1":10004,"PHASE2":10025,"PHASE3":10027,"PHASE4":10029,"NA":10031},{"trials":10003,"activeCount":117},[],{"trials":10005,"activeCount":117},[10006,10017],{"nctId":10007,"briefTitle":10008,"status":160,"phases":10009,"primaryCompletion":10010,"completion":10010,"start":10011,"enrollment":228,"conditions":10012,"interventions":10014},"NCT00002572","Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors",[91],"1999-12","1994-11",[10013],"Brain and Central Nervous System Tumors",[10000,10015,10016],"muromonab-CD3","therapeutic tumor infiltrating lymphocytes",{"nctId":10018,"briefTitle":10019,"status":160,"phases":10020,"primaryCompletion":7856,"completion":7856,"start":10021,"conditions":10022,"interventions":10023},"NCT00005943","Gene Therapy in Treating Patients With Metastatic Melanoma",[91],"2000-02",[8743],[10000,10024],"staphylococcal enterotoxin B",{"trials":10026,"activeCount":117},[],{"trials":10028,"activeCount":117},[],{"trials":10030,"activeCount":117},[],{"trials":10032,"activeCount":117},[],{"intervention":9911,"totalTrials":114,"cells":10034},{"EARLY_PHASE1":10035,"PHASE1":10037,"PHASE2":10043,"PHASE3":10045,"PHASE4":10047,"NA":10049},{"trials":10036,"activeCount":117},[],{"trials":10038,"activeCount":117},[10039],{"nctId":9902,"briefTitle":9903,"status":160,"phases":10040,"primaryCompletion":757,"completion":757,"start":9905,"enrollment":34,"conditions":10041,"interventions":10042},[91],[9907,9908,9909],[9911,9895],{"trials":10044,"activeCount":117},[],{"trials":10046,"activeCount":117},[],{"trials":10048,"activeCount":117},[],{"trials":10050,"activeCount":117},[],{"intervention":9955,"totalTrials":114,"cells":10052},{"EARLY_PHASE1":10053,"PHASE1":10055,"PHASE2":10061,"PHASE3":10063,"PHASE4":10065,"NA":10067},{"trials":10054,"activeCount":117},[],{"trials":10056,"activeCount":117},[10057],{"nctId":9948,"briefTitle":9949,"status":160,"phases":10058,"primaryCompletion":4970,"completion":4970,"start":7228,"enrollment":25,"conditions":10059,"interventions":10060},[91],[9952,9953,7274],[9931,3488,9955],{"trials":10062,"activeCount":117},[],{"trials":10064,"activeCount":117},[],{"trials":10066,"activeCount":117},[],{"trials":10068,"activeCount":117},[],{"intervention":10070,"totalTrials":114,"cells":10071},"MAS-1 adjuvanted Insulin B-chain",{"EARLY_PHASE1":10072,"PHASE1":10074,"PHASE2":10082,"PHASE3":10084,"PHASE4":10086,"NA":10088},{"trials":10073,"activeCount":117},[],{"trials":10075,"activeCount":117},[10076],{"nctId":10077,"briefTitle":10078,"status":160,"phases":10079,"primaryCompletion":6417,"completion":6417,"start":2114,"enrollment":7263,"conditions":10080,"interventions":10081},"NCT03624062","MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes",[91],[1943],[10070],{"trials":10083,"activeCount":117},[],{"trials":10085,"activeCount":117},[],{"trials":10087,"activeCount":117},[],{"trials":10089,"activeCount":117},[],{"intervention":10091,"totalTrials":114,"cells":10092},"Vandetanib",{"EARLY_PHASE1":10093,"PHASE1":10095,"PHASE2":10104,"PHASE3":10106,"PHASE4":10108,"NA":10110},{"trials":10094,"activeCount":117},[],{"trials":10096,"activeCount":117},[10097],{"nctId":10098,"briefTitle":10099,"status":160,"phases":10100,"primaryCompletion":7099,"completion":4561,"start":870,"enrollment":734,"conditions":10101,"interventions":10103},"NCT00822887","Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas",[91],[10102],"Malignant Gliomas",[10091],{"trials":10105,"activeCount":117},[],{"trials":10107,"activeCount":117},[],{"trials":10109,"activeCount":117},[],{"trials":10111,"activeCount":117},[],{"intervention":10113,"totalTrials":114,"cells":10114},"UCD19 CAR T Cells",{"EARLY_PHASE1":10115,"PHASE1":10117,"PHASE2":10128,"PHASE3":10130,"PHASE4":10132,"NA":10134},{"trials":10116,"activeCount":117},[],{"trials":10118,"activeCount":117},[10119],{"nctId":10120,"briefTitle":10121,"status":160,"phases":10122,"primaryCompletion":10123,"completion":9755,"start":10124,"enrollment":228,"conditions":10125,"interventions":10127},"NCT04240808","Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed\u002FRefractory (R\u002FR) B-Cell Non-Hodgkin's Lymphoma (B-NHL)",[91],"2023-03-24","2020-07-17",[10126],"Non Hodgkin Lymphoma",[10113],{"trials":10129,"activeCount":117},[],{"trials":10131,"activeCount":117},[],{"trials":10133,"activeCount":117},[],{"trials":10135,"activeCount":117},[],{"intervention":10137,"totalTrials":114,"cells":10138},"COR-001",{"EARLY_PHASE1":10139,"PHASE1":10141,"PHASE2":10152,"PHASE3":10154,"PHASE4":10156,"NA":10158},{"trials":10140,"activeCount":117},[],{"trials":10142,"activeCount":117},[10143],{"nctId":10144,"briefTitle":10145,"status":160,"phases":10146,"primaryCompletion":10147,"completion":10148,"start":10149,"enrollment":178,"conditions":10150,"interventions":10151},"NCT03126318","A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001",[91],"2019-03-14","2019-12-19","2017-05-19",[3333],[10137],{"trials":10153,"activeCount":117},[],{"trials":10155,"activeCount":117},[],{"trials":10157,"activeCount":117},[],{"trials":10159,"activeCount":117},[],{"intervention":10161,"totalTrials":114,"cells":10162},"IPI-926 and Cetuximab",{"EARLY_PHASE1":10163,"PHASE1":10165,"PHASE2":10174,"PHASE3":10176,"PHASE4":10178,"NA":10180},{"trials":10164,"activeCount":117},[],{"trials":10166,"activeCount":117},[10167],{"nctId":10168,"briefTitle":10169,"status":160,"phases":10170,"primaryCompletion":4768,"completion":4768,"start":5106,"enrollment":1602,"conditions":10171,"interventions":10173},"NCT01255800","Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer",[91],[10172],"Recurrent Head and Neck Cancer",[10161],{"trials":10175,"activeCount":117},[],{"trials":10177,"activeCount":117},[],{"trials":10179,"activeCount":117},[],{"trials":10181,"activeCount":117},[],{"intervention":10183,"totalTrials":114,"cells":10184},"DMXB-A 150 mg",{"EARLY_PHASE1":10185,"PHASE1":10187,"PHASE2":10197,"PHASE3":10199,"PHASE4":10201,"NA":10203},{"trials":10186,"activeCount":117},[],{"trials":10188,"activeCount":117},[10189],{"nctId":10190,"briefTitle":10191,"status":125,"phases":10192,"primaryCompletion":5574,"completion":5574,"start":7878,"enrollment":199,"conditions":10193,"interventions":10195},"NCT02111551","Phase I Nicotinic Agonist Treatment Trial for Autism",[91],[10194],"Autism",[10183,10196],"DMXB-A 75 mg",{"trials":10198,"activeCount":117},[],{"trials":10200,"activeCount":117},[],{"trials":10202,"activeCount":117},[],{"trials":10204,"activeCount":117},[],{"intervention":10196,"totalTrials":114,"cells":10206},{"EARLY_PHASE1":10207,"PHASE1":10209,"PHASE2":10215,"PHASE3":10217,"PHASE4":10219,"NA":10221},{"trials":10208,"activeCount":117},[],{"trials":10210,"activeCount":117},[10211],{"nctId":10190,"briefTitle":10191,"status":125,"phases":10212,"primaryCompletion":5574,"completion":5574,"start":7878,"enrollment":199,"conditions":10213,"interventions":10214},[91],[10194],[10183,10196],{"trials":10216,"activeCount":117},[],{"trials":10218,"activeCount":117},[],{"trials":10220,"activeCount":117},[],{"trials":10222,"activeCount":117},[],{"intervention":10224,"totalTrials":114,"cells":10225},"raltegravir",{"EARLY_PHASE1":10226,"PHASE1":10228,"PHASE2":10238,"PHASE3":10240,"PHASE4":10242,"NA":10244},{"trials":10227,"activeCount":117},[],{"trials":10229,"activeCount":117},[10230],{"nctId":10231,"briefTitle":10232,"status":160,"phases":10233,"primaryCompletion":2052,"completion":2052,"start":10234,"enrollment":34,"conditions":10235,"interventions":10236},"NCT00944307","Effect of Antacids on the Pharmacokinetics of Raltegravir",[91],"2009-07",[180],[10224,10237],"antacid",{"trials":10239,"activeCount":117},[],{"trials":10241,"activeCount":117},[],{"trials":10243,"activeCount":117},[],{"trials":10245,"activeCount":117},[],{"intervention":10237,"totalTrials":114,"cells":10247},{"EARLY_PHASE1":10248,"PHASE1":10250,"PHASE2":10256,"PHASE3":10258,"PHASE4":10260,"NA":10262},{"trials":10249,"activeCount":117},[],{"trials":10251,"activeCount":117},[10252],{"nctId":10231,"briefTitle":10232,"status":160,"phases":10253,"primaryCompletion":2052,"completion":2052,"start":10234,"enrollment":34,"conditions":10254,"interventions":10255},[91],[180],[10224,10237],{"trials":10257,"activeCount":117},[],{"trials":10259,"activeCount":117},[],{"trials":10261,"activeCount":117},[],{"trials":10263,"activeCount":117},[],{"intervention":10265,"totalTrials":114,"cells":10266},"KPT-9274",{"EARLY_PHASE1":10267,"PHASE1":10269,"PHASE2":10282,"PHASE3":10284,"PHASE4":10286,"NA":10288},{"trials":10268,"activeCount":117},[],{"trials":10270,"activeCount":117},[10271],{"nctId":10272,"briefTitle":10273,"status":160,"phases":10274,"primaryCompletion":10275,"completion":10276,"start":10277,"enrollment":37,"conditions":10278,"interventions":10281},"NCT04914845","KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia",[91],"2025-07-08","2025-10-22","2021-08-27",[1509,10279,10280],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory",[10265],{"trials":10283,"activeCount":117},[],{"trials":10285,"activeCount":117},[],{"trials":10287,"activeCount":117},[],{"trials":10289,"activeCount":117},[],{"intervention":7253,"totalTrials":114,"cells":10291},{"EARLY_PHASE1":10292,"PHASE1":10294,"PHASE2":10300,"PHASE3":10302,"PHASE4":10304,"NA":10306},{"trials":10293,"activeCount":117},[],{"trials":10295,"activeCount":117},[10296],{"nctId":7246,"briefTitle":7247,"status":1622,"phases":10297,"primaryCompletion":7249,"completion":547,"start":7250,"enrollment":117,"conditions":10298,"interventions":10299},[91],[1668],[7239,7253,7254,7255],{"trials":10301,"activeCount":117},[],{"trials":10303,"activeCount":117},[],{"trials":10305,"activeCount":117},[],{"trials":10307,"activeCount":117},[],{"intervention":7254,"totalTrials":114,"cells":10309},{"EARLY_PHASE1":10310,"PHASE1":10312,"PHASE2":10318,"PHASE3":10320,"PHASE4":10322,"NA":10324},{"trials":10311,"activeCount":117},[],{"trials":10313,"activeCount":117},[10314],{"nctId":7246,"briefTitle":7247,"status":1622,"phases":10315,"primaryCompletion":7249,"completion":547,"start":7250,"enrollment":117,"conditions":10316,"interventions":10317},[91],[1668],[7239,7253,7254,7255],{"trials":10319,"activeCount":117},[],{"trials":10321,"activeCount":117},[],{"trials":10323,"activeCount":117},[],{"trials":10325,"activeCount":117},[],{"intervention":7255,"totalTrials":114,"cells":10327},{"EARLY_PHASE1":10328,"PHASE1":10330,"PHASE2":10336,"PHASE3":10338,"PHASE4":10340,"NA":10342},{"trials":10329,"activeCount":117},[],{"trials":10331,"activeCount":117},[10332],{"nctId":7246,"briefTitle":7247,"status":1622,"phases":10333,"primaryCompletion":7249,"completion":547,"start":7250,"enrollment":117,"conditions":10334,"interventions":10335},[91],[1668],[7239,7253,7254,7255],{"trials":10337,"activeCount":117},[],{"trials":10339,"activeCount":117},[],{"trials":10341,"activeCount":117},[],{"trials":10343,"activeCount":117},[],{"intervention":10345,"totalTrials":114,"cells":10346},"Alpha Lipoic Acid",{"EARLY_PHASE1":10347,"PHASE1":10349,"PHASE2":10361,"PHASE3":10363,"PHASE4":10365,"NA":10367},{"trials":10348,"activeCount":117},[],{"trials":10350,"activeCount":117},[10351],{"nctId":10352,"briefTitle":10353,"status":160,"phases":10354,"primaryCompletion":10355,"completion":10356,"start":10357,"enrollment":263,"conditions":10358,"interventions":10360},"NCT04042935","Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC",[91],"2021-02-19","2021-09-24","2020-02-27",[10359],"HNSCC",[10345],{"trials":10362,"activeCount":117},[],{"trials":10364,"activeCount":117},[],{"trials":10366,"activeCount":117},[],{"trials":10368,"activeCount":117},[],{"intervention":10370,"totalTrials":114,"cells":10371},"Etonogestrel 68Mg Implant",{"EARLY_PHASE1":10372,"PHASE1":10374,"PHASE2":10384,"PHASE3":10386,"PHASE4":10388,"NA":10390},{"trials":10373,"activeCount":117},[],{"trials":10375,"activeCount":117},[10376],{"nctId":10377,"briefTitle":10378,"status":1622,"phases":10379,"primaryCompletion":10380,"completion":10380,"start":10381,"enrollment":117,"conditions":10382,"interventions":10383},"NCT03656289","Antepartum Etonogestrel Contraceptive Implant Insertion at Term",[91],"2019-04-15","2019-01-01",[255],[10370],{"trials":10385,"activeCount":117},[],{"trials":10387,"activeCount":117},[],{"trials":10389,"activeCount":117},[],{"trials":10391,"activeCount":117},[],{"intervention":10393,"totalTrials":114,"cells":10394},"Plerixafor mobilization of autologous CD117 stem cells",{"EARLY_PHASE1":10395,"PHASE1":10397,"PHASE2":10406,"PHASE3":10408,"PHASE4":10410,"NA":10412},{"trials":10396,"activeCount":117},[],{"trials":10398,"activeCount":117},[10399],{"nctId":10400,"briefTitle":10401,"status":160,"phases":10402,"primaryCompletion":226,"completion":9112,"start":6333,"enrollment":217,"conditions":10403,"interventions":10405},"NCT01916577","Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation",[91],[3517,8383,10404],"Pulmonary Fibrosis",[10393],{"trials":10407,"activeCount":117},[],{"trials":10409,"activeCount":117},[],{"trials":10411,"activeCount":117},[],{"trials":10413,"activeCount":117},[],{"intervention":10415,"totalTrials":114,"cells":10416},"Glycerol Phenylbutyrate",{"EARLY_PHASE1":10417,"PHASE1":10419,"PHASE2":10428,"PHASE3":10430,"PHASE4":10432,"NA":10434},{"trials":10418,"activeCount":117},[],{"trials":10420,"activeCount":117},[10421],{"nctId":10422,"briefTitle":10423,"status":160,"phases":10424,"primaryCompletion":10425,"completion":10425,"start":678,"enrollment":3331,"conditions":10426,"interventions":10427},"NCT02046434","Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain",[91],"2019-09",[1059],[10415],{"trials":10429,"activeCount":117},[],{"trials":10431,"activeCount":117},[],{"trials":10433,"activeCount":117},[],{"trials":10435,"activeCount":117},[],{"intervention":9977,"totalTrials":114,"cells":10437},{"EARLY_PHASE1":10438,"PHASE1":10440,"PHASE2":10446,"PHASE3":10448,"PHASE4":10450,"NA":10452},{"trials":10439,"activeCount":117},[],{"trials":10441,"activeCount":117},[10442],{"nctId":9972,"briefTitle":9973,"status":125,"phases":10443,"primaryCompletion":227,"completion":227,"start":2052,"enrollment":37,"conditions":10444,"interventions":10445},[91],[1668],[9977,9965],{"trials":10447,"activeCount":117},[],{"trials":10449,"activeCount":117},[],{"trials":10451,"activeCount":117},[],{"trials":10453,"activeCount":117},[],{"intervention":9921,"totalTrials":114,"cells":10455},{"EARLY_PHASE1":10456,"PHASE1":10458,"PHASE2":10464,"PHASE3":10466,"PHASE4":10468,"NA":10470},{"trials":10457,"activeCount":117},[],{"trials":10459,"activeCount":117},[10460],{"nctId":9913,"briefTitle":9914,"status":160,"phases":10461,"primaryCompletion":9916,"completion":9916,"start":9917,"enrollment":1165,"conditions":10462,"interventions":10463},[91],[9919],[9921,9895],{"trials":10465,"activeCount":117},[],{"trials":10467,"activeCount":117},[],{"trials":10469,"activeCount":117},[],{"trials":10471,"activeCount":117},[],{"intervention":9989,"totalTrials":114,"cells":10473},{"EARLY_PHASE1":10474,"PHASE1":10476,"PHASE2":10482,"PHASE3":10484,"PHASE4":10486,"NA":10488},{"trials":10475,"activeCount":117},[],{"trials":10477,"activeCount":117},[10478],{"nctId":9979,"briefTitle":9980,"status":160,"phases":10479,"primaryCompletion":9982,"completion":9983,"start":9984,"enrollment":199,"conditions":10480,"interventions":10481},[91],[9986,9987],[9989,9990],{"trials":10483,"activeCount":117},[],{"trials":10485,"activeCount":117},[],{"trials":10487,"activeCount":117},[],{"trials":10489,"activeCount":117},[],{"intervention":10491,"totalTrials":114,"cells":10492},"Dose Escalation of Durvalumab and Trabectedin",{"EARLY_PHASE1":10493,"PHASE1":10495,"PHASE2":10505,"PHASE3":10507,"PHASE4":10509,"NA":10511},{"trials":10494,"activeCount":117},[],{"trials":10496,"activeCount":117},[10497],{"nctId":10498,"briefTitle":10499,"status":1622,"phases":10500,"primaryCompletion":8567,"completion":8567,"start":1919,"enrollment":117,"conditions":10501,"interventions":10503},"NCT03496519","Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors",[91],[10502],"Solid Tumor, Adult",[10491,10504],"Dose Expansion of Durvalumab and Trabectedin",{"trials":10506,"activeCount":117},[],{"trials":10508,"activeCount":117},[],{"trials":10510,"activeCount":117},[],{"trials":10512,"activeCount":117},[],{"intervention":10504,"totalTrials":114,"cells":10514},{"EARLY_PHASE1":10515,"PHASE1":10517,"PHASE2":10523,"PHASE3":10525,"PHASE4":10527,"NA":10529},{"trials":10516,"activeCount":117},[],{"trials":10518,"activeCount":117},[10519],{"nctId":10498,"briefTitle":10499,"status":1622,"phases":10520,"primaryCompletion":8567,"completion":8567,"start":1919,"enrollment":117,"conditions":10521,"interventions":10522},[91],[10502],[10491,10504],{"trials":10524,"activeCount":117},[],{"trials":10526,"activeCount":117},[],{"trials":10528,"activeCount":117},[],{"trials":10530,"activeCount":117},[],{"intervention":10532,"totalTrials":114,"cells":10533},"Administration of drug (Interferon-gamma 1-b) subcutaneously",{"EARLY_PHASE1":10534,"PHASE1":10536,"PHASE2":10546,"PHASE3":10548,"PHASE4":10550,"NA":10552},{"trials":10535,"activeCount":117},[],{"trials":10537,"activeCount":117},[10538],{"nctId":10539,"briefTitle":10540,"status":160,"phases":10541,"primaryCompletion":9574,"completion":10542,"start":7332,"enrollment":28,"conditions":10543,"interventions":10545},"NCT02609932","Effect of IFN-γ on Innate Immune Cells",[91],"2019-02",[10544],"Chronic Granulomatous Disease",[10532],{"trials":10547,"activeCount":117},[],{"trials":10549,"activeCount":117},[],{"trials":10551,"activeCount":117},[],{"trials":10553,"activeCount":117},[],{"intervention":4662,"totalTrials":114,"cells":10555},{"EARLY_PHASE1":10556,"PHASE1":10558,"PHASE2":10564,"PHASE3":10566,"PHASE4":10568,"NA":10570},{"trials":10557,"activeCount":117},[],{"trials":10559,"activeCount":117},[10560],{"nctId":4654,"briefTitle":4655,"status":160,"phases":10561,"primaryCompletion":677,"completion":4657,"start":4176,"enrollment":4658,"conditions":10562,"interventions":10563},[91],[4660,1142],[1144,4662],{"trials":10565,"activeCount":117},[],{"trials":10567,"activeCount":117},[],{"trials":10569,"activeCount":117},[],{"trials":10571,"activeCount":117},[],{"intervention":10573,"totalTrials":114,"cells":10574},"Alpha 1-Antitrypsin",{"EARLY_PHASE1":10575,"PHASE1":10577,"PHASE2":10587,"PHASE3":10589,"PHASE4":10591,"NA":10593},{"trials":10576,"activeCount":117},[],{"trials":10578,"activeCount":117},[10579],{"nctId":10580,"briefTitle":10581,"status":160,"phases":10582,"primaryCompletion":10583,"completion":5574,"start":10584,"enrollment":253,"conditions":10585,"interventions":10586},"NCT01319331","The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes",[91],"2015-10","2010-10",[33,18],[10573],{"trials":10588,"activeCount":117},[],{"trials":10590,"activeCount":117},[],{"trials":10592,"activeCount":117},[],{"trials":10594,"activeCount":117},[],{"intervention":10596,"totalTrials":114,"cells":10597},"Alisertib",{"EARLY_PHASE1":10598,"PHASE1":10600,"PHASE2":10612,"PHASE3":10614,"PHASE4":10616,"NA":10618},{"trials":10599,"activeCount":117},[],{"trials":10601,"activeCount":117},[10602],{"nctId":10603,"briefTitle":10604,"status":160,"phases":10605,"primaryCompletion":10606,"completion":10606,"start":10607,"enrollment":2173,"conditions":10608,"interventions":10610},"NCT02719691","Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer",[91],"2020-03-18","2016-05-13",[1629,10609],"Solid Tumors",[10596,10611],"MLN0128",{"trials":10613,"activeCount":117},[],{"trials":10615,"activeCount":117},[],{"trials":10617,"activeCount":117},[],{"trials":10619,"activeCount":117},[],{"intervention":10611,"totalTrials":114,"cells":10621},{"EARLY_PHASE1":10622,"PHASE1":10624,"PHASE2":10630,"PHASE3":10632,"PHASE4":10634,"NA":10636},{"trials":10623,"activeCount":117},[],{"trials":10625,"activeCount":117},[10626],{"nctId":10603,"briefTitle":10604,"status":160,"phases":10627,"primaryCompletion":10606,"completion":10606,"start":10607,"enrollment":2173,"conditions":10628,"interventions":10629},[91],[1629,10609],[10596,10611],{"trials":10631,"activeCount":117},[],{"trials":10633,"activeCount":117},[],{"trials":10635,"activeCount":117},[],{"trials":10637,"activeCount":117},[],{"intervention":10639,"totalTrials":114,"cells":10640},"Dimethoxybenzylidene anabaseine",{"EARLY_PHASE1":10641,"PHASE1":10643,"PHASE2":10654,"PHASE3":10656,"PHASE4":10658,"NA":10660},{"trials":10642,"activeCount":117},[],{"trials":10644,"activeCount":117},[10645],{"nctId":10646,"briefTitle":10647,"status":160,"phases":10648,"primaryCompletion":10649,"completion":10649,"start":10650,"enrollment":253,"conditions":10651,"interventions":10653},"NCT00255918","Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients",[91],"2005-10","2004-03",[7102,10652],"Psychotic Disorders",[10639,10639],{"trials":10655,"activeCount":117},[],{"trials":10657,"activeCount":117},[],{"trials":10659,"activeCount":117},[],{"trials":10661,"activeCount":117},[],{"intervention":10663,"totalTrials":114,"cells":10664},"DMXB-A",{"EARLY_PHASE1":10665,"PHASE1":10667,"PHASE2":10677,"PHASE3":10679,"PHASE4":10681,"NA":10683},{"trials":10666,"activeCount":117},[],{"trials":10668,"activeCount":117},[10669],{"nctId":10670,"briefTitle":10671,"status":160,"phases":10672,"primaryCompletion":10673,"completion":10673,"start":10674,"enrollment":2245,"conditions":10675,"interventions":10676},"NCT02458313","Nicotinic Agonist Effects on BMI and Neuronal Response",[91],"2021-12-13","2016-04-14",[15],[10663],{"trials":10678,"activeCount":117},[],{"trials":10680,"activeCount":117},[],{"trials":10682,"activeCount":117},[],{"trials":10684,"activeCount":117},[],{"intervention":10686,"totalTrials":114,"cells":10687},"Pasireotide",{"EARLY_PHASE1":10688,"PHASE1":10690,"PHASE2":10702,"PHASE3":10704,"PHASE4":10706,"NA":10708},{"trials":10689,"activeCount":117},[],{"trials":10691,"activeCount":117},[10692],{"nctId":10693,"briefTitle":10694,"status":160,"phases":10695,"primaryCompletion":10696,"completion":10696,"start":10697,"enrollment":114,"conditions":10698,"interventions":10701},"NCT03103009","Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia",[91],"2017-12-22","2017-03-22",[10699,10700],"Hyperinsulinemic Hypoglycemia","Post Gastrointestinal Tract Surgery Hypoglycaemia",[10686],{"trials":10703,"activeCount":117},[],{"trials":10705,"activeCount":117},[],{"trials":10707,"activeCount":117},[],{"trials":10709,"activeCount":117},[],{"intervention":10711,"totalTrials":114,"cells":10712},"Varicella Zoster Virus Vaccine",{"EARLY_PHASE1":10713,"PHASE1":10715,"PHASE2":10725,"PHASE3":10727,"PHASE4":10729,"NA":10731},{"trials":10714,"activeCount":117},[],{"trials":10716,"activeCount":117},[10717],{"nctId":10718,"briefTitle":10719,"status":160,"phases":10720,"primaryCompletion":10721,"completion":10721,"start":7771,"enrollment":3875,"conditions":10722,"interventions":10724},"NCT01262300","Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents",[91],"2014-01-23",[10723,4660],"Immunosenescence",[10711],{"trials":10726,"activeCount":117},[],{"trials":10728,"activeCount":117},[],{"trials":10730,"activeCount":117},[],{"trials":10732,"activeCount":117},[],{"intervention":3463,"totalTrials":114,"cells":10734},{"EARLY_PHASE1":10735,"PHASE1":10737,"PHASE2":10743,"PHASE3":10745,"PHASE4":10747,"NA":10749},{"trials":10736,"activeCount":117},[],{"trials":10738,"activeCount":117},[10739],{"nctId":3455,"briefTitle":3456,"status":160,"phases":10740,"primaryCompletion":3458,"completion":3459,"start":3460,"enrollment":99,"conditions":10741,"interventions":10742},[91],[2206],[3463,1659],{"trials":10744,"activeCount":117},[],{"trials":10746,"activeCount":117},[],{"trials":10748,"activeCount":117},[],{"trials":10750,"activeCount":117},[],{"intervention":10015,"totalTrials":114,"cells":10752},{"EARLY_PHASE1":10753,"PHASE1":10755,"PHASE2":10761,"PHASE3":10763,"PHASE4":10765,"NA":10767},{"trials":10754,"activeCount":117},[],{"trials":10756,"activeCount":117},[10757],{"nctId":10007,"briefTitle":10008,"status":160,"phases":10758,"primaryCompletion":10010,"completion":10010,"start":10011,"enrollment":228,"conditions":10759,"interventions":10760},[91],[10013],[10000,10015,10016],{"trials":10762,"activeCount":117},[],{"trials":10764,"activeCount":117},[],{"trials":10766,"activeCount":117},[],{"trials":10768,"activeCount":117},[],{"intervention":10016,"totalTrials":114,"cells":10770},{"EARLY_PHASE1":10771,"PHASE1":10773,"PHASE2":10779,"PHASE3":10781,"PHASE4":10783,"NA":10785},{"trials":10772,"activeCount":117},[],{"trials":10774,"activeCount":117},[10775],{"nctId":10007,"briefTitle":10008,"status":160,"phases":10776,"primaryCompletion":10010,"completion":10010,"start":10011,"enrollment":228,"conditions":10777,"interventions":10778},[91],[10013],[10000,10015,10016],{"trials":10780,"activeCount":117},[],{"trials":10782,"activeCount":117},[],{"trials":10784,"activeCount":117},[],{"trials":10786,"activeCount":117},[],{"intervention":10788,"totalTrials":114,"cells":10789},"Corlicyte",{"EARLY_PHASE1":10790,"PHASE1":10792,"PHASE2":10803,"PHASE3":10805,"PHASE4":10807,"NA":10809},{"trials":10791,"activeCount":117},[],{"trials":10793,"activeCount":117},[10794],{"nctId":10795,"briefTitle":10796,"status":160,"phases":10797,"primaryCompletion":10798,"completion":10798,"start":10799,"enrollment":37,"conditions":10800,"interventions":10802},"NCT04104451","PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS",[91],"2023-08-01","2019-11-12",[10801],"Diabetic Foot Ulcer",[10788],{"trials":10804,"activeCount":117},[],{"trials":10806,"activeCount":117},[],{"trials":10808,"activeCount":117},[],{"trials":10810,"activeCount":117},[],{"intervention":10812,"totalTrials":114,"cells":10813},"rhTSH",{"EARLY_PHASE1":10814,"PHASE1":10816,"PHASE2":10827,"PHASE3":10829,"PHASE4":10831,"NA":10833},{"trials":10815,"activeCount":117},[],{"trials":10817,"activeCount":117},[10818],{"nctId":10819,"briefTitle":10820,"status":160,"phases":10821,"primaryCompletion":10822,"completion":10822,"start":10823,"enrollment":263,"conditions":10824,"interventions":10826},"NCT02278198","Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123",[91],"2019-09-20","2012-11-30",[10825],"Differentiated Thyroid Cancer",[10812],{"trials":10828,"activeCount":117},[],{"trials":10830,"activeCount":117},[],{"trials":10832,"activeCount":117},[],{"trials":10834,"activeCount":117},[],{"intervention":10836,"totalTrials":114,"cells":10837},"FMT Lower Delivery",{"EARLY_PHASE1":10838,"PHASE1":10840,"PHASE2":10850,"PHASE3":10852,"PHASE4":10854,"NA":10856},{"trials":10839,"activeCount":117},[],{"trials":10841,"activeCount":117},[10842],{"nctId":10843,"briefTitle":10844,"status":1622,"phases":10845,"primaryCompletion":10846,"completion":10846,"start":2152,"enrollment":117,"conditions":10847,"interventions":10849},"NCT04373252","FMT as a Treatment for Severe Motility Disorder",[91],"2021-07-01",[10848],"Severe Motility Disorder",[10836],{"trials":10851,"activeCount":117},[],{"trials":10853,"activeCount":117},[],{"trials":10855,"activeCount":117},[],{"trials":10857,"activeCount":117},[],{"intervention":10859,"totalTrials":114,"cells":10860},"Temozolomide plus Osimertinib",{"EARLY_PHASE1":10861,"PHASE1":10863,"PHASE2":10876,"PHASE3":10878,"PHASE4":10880,"NA":10882},{"trials":10862,"activeCount":117},[],{"trials":10864,"activeCount":117},[10865],{"nctId":10866,"briefTitle":10867,"status":160,"phases":10868,"primaryCompletion":10869,"completion":10870,"start":10871,"enrollment":114,"conditions":10872,"interventions":10874},"NCT04541407","Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease",[91],"2022-04-25","2022-06-07","2020-10-29",[3121,10873],"CNS Progression",[10859,10875],"Temozolomide plus Lorlatinib",{"trials":10877,"activeCount":117},[],{"trials":10879,"activeCount":117},[],{"trials":10881,"activeCount":117},[],{"trials":10883,"activeCount":117},[],{"intervention":10875,"totalTrials":114,"cells":10885},{"EARLY_PHASE1":10886,"PHASE1":10888,"PHASE2":10894,"PHASE3":10896,"PHASE4":10898,"NA":10900},{"trials":10887,"activeCount":117},[],{"trials":10889,"activeCount":117},[10890],{"nctId":10866,"briefTitle":10867,"status":160,"phases":10891,"primaryCompletion":10869,"completion":10870,"start":10871,"enrollment":114,"conditions":10892,"interventions":10893},[91],[3121,10873],[10859,10875],{"trials":10895,"activeCount":117},[],{"trials":10897,"activeCount":117},[],{"trials":10899,"activeCount":117},[],{"trials":10901,"activeCount":117},[],{"intervention":10903,"totalTrials":114,"cells":10904},"Cyclophosphamide 500 MG",{"EARLY_PHASE1":10905,"PHASE1":10907,"PHASE2":10921,"PHASE3":10923,"PHASE4":10925,"NA":10927},{"trials":10906,"activeCount":117},[],{"trials":10908,"activeCount":117},[10909],{"nctId":10910,"briefTitle":10911,"status":125,"phases":10912,"primaryCompletion":8405,"completion":10913,"start":6593,"enrollment":263,"conditions":10914,"interventions":10916},"NCT03318016","Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[91],"2021-01-20",[1509,10915],"Relapsed\u002FRefractory Acute Myeloid Leukemia",[10903,10917,10918,10919,10920],"Cyclophosphamide 1000 MG","Cyclophosphamide 2000 MG","Cyclophosphamide 3000 MG","Cyclophosphamide 4000 MG",{"trials":10922,"activeCount":117},[],{"trials":10924,"activeCount":117},[],{"trials":10926,"activeCount":117},[],{"trials":10928,"activeCount":117},[],{"intervention":10917,"totalTrials":114,"cells":10930},{"EARLY_PHASE1":10931,"PHASE1":10933,"PHASE2":10939,"PHASE3":10941,"PHASE4":10943,"NA":10945},{"trials":10932,"activeCount":117},[],{"trials":10934,"activeCount":117},[10935],{"nctId":10910,"briefTitle":10911,"status":125,"phases":10936,"primaryCompletion":8405,"completion":10913,"start":6593,"enrollment":263,"conditions":10937,"interventions":10938},[91],[1509,10915],[10903,10917,10918,10919,10920],{"trials":10940,"activeCount":117},[],{"trials":10942,"activeCount":117},[],{"trials":10944,"activeCount":117},[],{"trials":10946,"activeCount":117},[],{"intervention":10918,"totalTrials":114,"cells":10948},{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10957,"PHASE3":10959,"PHASE4":10961,"NA":10963},{"trials":10950,"activeCount":117},[],{"trials":10952,"activeCount":117},[10953],{"nctId":10910,"briefTitle":10911,"status":125,"phases":10954,"primaryCompletion":8405,"completion":10913,"start":6593,"enrollment":263,"conditions":10955,"interventions":10956},[91],[1509,10915],[10903,10917,10918,10919,10920],{"trials":10958,"activeCount":117},[],{"trials":10960,"activeCount":117},[],{"trials":10962,"activeCount":117},[],{"trials":10964,"activeCount":117},[],{"intervention":10919,"totalTrials":114,"cells":10966},{"EARLY_PHASE1":10967,"PHASE1":10969,"PHASE2":10975,"PHASE3":10977,"PHASE4":10979,"NA":10981},{"trials":10968,"activeCount":117},[],{"trials":10970,"activeCount":117},[10971],{"nctId":10910,"briefTitle":10911,"status":125,"phases":10972,"primaryCompletion":8405,"completion":10913,"start":6593,"enrollment":263,"conditions":10973,"interventions":10974},[91],[1509,10915],[10903,10917,10918,10919,10920],{"trials":10976,"activeCount":117},[],{"trials":10978,"activeCount":117},[],{"trials":10980,"activeCount":117},[],{"trials":10982,"activeCount":117},[],{"intervention":10920,"totalTrials":114,"cells":10984},{"EARLY_PHASE1":10985,"PHASE1":10987,"PHASE2":10993,"PHASE3":10995,"PHASE4":10997,"NA":10999},{"trials":10986,"activeCount":117},[],{"trials":10988,"activeCount":117},[10989],{"nctId":10910,"briefTitle":10911,"status":125,"phases":10990,"primaryCompletion":8405,"completion":10913,"start":6593,"enrollment":263,"conditions":10991,"interventions":10992},[91],[1509,10915],[10903,10917,10918,10919,10920],{"trials":10994,"activeCount":117},[],{"trials":10996,"activeCount":117},[],{"trials":10998,"activeCount":117},[],{"trials":11000,"activeCount":117},[],{"intervention":11002,"totalTrials":114,"cells":11003},"levonorgestrel, efavirenz",{"EARLY_PHASE1":11004,"PHASE1":11006,"PHASE2":11015,"PHASE3":11017,"PHASE4":11019,"NA":11021},{"trials":11005,"activeCount":117},[],{"trials":11007,"activeCount":117},[11008],{"nctId":11009,"briefTitle":11010,"status":160,"phases":11011,"primaryCompletion":5108,"completion":5108,"start":4177,"enrollment":1920,"conditions":11012,"interventions":11014},"NCT00482963","A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication",[91],[180,255,11013],"Pharmacokinetics",[11002],{"trials":11016,"activeCount":117},[],{"trials":11018,"activeCount":117},[],{"trials":11020,"activeCount":117},[],{"trials":11022,"activeCount":117},[],{"intervention":11024,"totalTrials":114,"cells":11025},"FOLFIRINOX or gemcitabine\u002Fabraxane",{"EARLY_PHASE1":11026,"PHASE1":11028,"PHASE2":11039,"PHASE3":11041,"PHASE4":11043,"NA":11045},{"trials":11027,"activeCount":117},[],{"trials":11029,"activeCount":117},[11030],{"nctId":11031,"briefTitle":11032,"status":160,"phases":11033,"primaryCompletion":11034,"completion":4791,"start":11035,"enrollment":11036,"conditions":11037,"interventions":11038},"NCT02873598","A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer",[91],"2019-06-07","2016-11-17",14,[7274],[11024],{"trials":11040,"activeCount":117},[],{"trials":11042,"activeCount":117},[],{"trials":11044,"activeCount":117},[],{"trials":11046,"activeCount":117},[],{"intervention":11048,"totalTrials":114,"cells":11049},"Topiramate",{"EARLY_PHASE1":11050,"PHASE1":11052,"PHASE2":11064,"PHASE3":11066,"PHASE4":11068,"NA":11070},{"trials":11051,"activeCount":117},[],{"trials":11053,"activeCount":117},[11054],{"nctId":11055,"briefTitle":11056,"status":160,"phases":11057,"primaryCompletion":11058,"completion":11058,"start":11059,"enrollment":1654,"conditions":11060,"interventions":11063},"NCT03335163","The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users",[91],"2021-04-22","2018-03-15",[11061,11062,255],"Migraine","Migraine;Menstrual",[11048],{"trials":11065,"activeCount":117},[],{"trials":11067,"activeCount":117},[],{"trials":11069,"activeCount":117},[],{"trials":11071,"activeCount":117},[],{"intervention":11073,"totalTrials":114,"cells":11074},"Vitamin E",{"EARLY_PHASE1":11075,"PHASE1":11077,"PHASE2":11087,"PHASE3":11089,"PHASE4":11091,"NA":11093},{"trials":11076,"activeCount":117},[],{"trials":11078,"activeCount":117},[11079],{"nctId":11080,"briefTitle":11081,"status":160,"phases":11082,"primaryCompletion":7965,"completion":7965,"start":965,"enrollment":6420,"conditions":11083,"interventions":11086},"NCT01700426","Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E",[91],[11084,11085],"Iron Deficiency","Iron Deficiency Anemia",[11073],{"trials":11088,"activeCount":117},[],{"trials":11090,"activeCount":117},[],{"trials":11092,"activeCount":117},[],{"trials":11094,"activeCount":117},[],{"intervention":11096,"totalTrials":114,"cells":11097},"Inhaled Treprostinil Therapy",{"EARLY_PHASE1":11098,"PHASE1":11100,"PHASE2":11109,"PHASE3":11111,"PHASE4":11113,"NA":11115},{"trials":11099,"activeCount":117},[],{"trials":11101,"activeCount":117},[11102],{"nctId":11103,"briefTitle":11104,"status":160,"phases":11105,"primaryCompletion":7332,"completion":7332,"start":6190,"enrollment":228,"conditions":11106,"interventions":11108},"NCT01758744","Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1",[91],[11107,3517],"Pulmonary Hypertension",[11096],{"trials":11110,"activeCount":117},[],{"trials":11112,"activeCount":117},[],{"trials":11114,"activeCount":117},[],{"trials":11116,"activeCount":117},[],{"intervention":11118,"totalTrials":114,"cells":11119},"Sorafenib",{"EARLY_PHASE1":11120,"PHASE1":11122,"PHASE2":11133,"PHASE3":11135,"PHASE4":11137,"NA":11139},{"trials":11121,"activeCount":117},[],{"trials":11123,"activeCount":117},[11124],{"nctId":11125,"briefTitle":11126,"status":160,"phases":11127,"primaryCompletion":2051,"completion":4753,"start":11128,"enrollment":1518,"conditions":11129,"interventions":11131},"NCT00635791","Phase I Study of Vorinostat and Sorafenib in Advanced Cancer",[91],"2008-03",[9952,1644,11130],"Non Small Cell Lung Carcinoma",[11118,11132],"Vorinostat",{"trials":11134,"activeCount":117},[],{"trials":11136,"activeCount":117},[],{"trials":11138,"activeCount":117},[],{"trials":11140,"activeCount":117},[],{"intervention":11132,"totalTrials":114,"cells":11142},{"EARLY_PHASE1":11143,"PHASE1":11145,"PHASE2":11151,"PHASE3":11153,"PHASE4":11155,"NA":11157},{"trials":11144,"activeCount":117},[],{"trials":11146,"activeCount":117},[11147],{"nctId":11125,"briefTitle":11126,"status":160,"phases":11148,"primaryCompletion":2051,"completion":4753,"start":11128,"enrollment":1518,"conditions":11149,"interventions":11150},[91],[9952,1644,11130],[11118,11132],{"trials":11152,"activeCount":117},[],{"trials":11154,"activeCount":117},[],{"trials":11156,"activeCount":117},[],{"trials":11158,"activeCount":117},[],{"intervention":10024,"totalTrials":114,"cells":11160},{"EARLY_PHASE1":11161,"PHASE1":11163,"PHASE2":11169,"PHASE3":11171,"PHASE4":11173,"NA":11175},{"trials":11162,"activeCount":117},[],{"trials":11164,"activeCount":117},[11165],{"nctId":10018,"briefTitle":10019,"status":160,"phases":11166,"primaryCompletion":7856,"completion":7856,"start":10021,"conditions":11167,"interventions":11168},[91],[8743],[10000,10024],{"trials":11170,"activeCount":117},[],{"trials":11172,"activeCount":117},[],{"trials":11174,"activeCount":117},[],{"trials":11176,"activeCount":117},[],{"intervention":11178,"totalTrials":114,"cells":11179},"emtricitabine 200 mg\u002Ftenofovir alafenamide 25mg",{"EARLY_PHASE1":11180,"PHASE1":11182,"PHASE2":11192,"PHASE3":11194,"PHASE4":11196,"NA":11198},{"trials":11181,"activeCount":117},[],{"trials":11183,"activeCount":117},[11184],{"nctId":11185,"briefTitle":11186,"status":160,"phases":11187,"primaryCompletion":11188,"completion":11188,"start":677,"enrollment":3331,"conditions":11189,"interventions":11191},"NCT02962739","The Cellular Pharmacology of F-TAF in Dried Blood Spots",[91],"2019-05-22",[11190],"Healthy Volunteers",[11178],{"trials":11193,"activeCount":117},[],{"trials":11195,"activeCount":117},[],{"trials":11197,"activeCount":117},[],{"trials":11199,"activeCount":117},[],{"intervention":7387,"totalTrials":114,"cells":11201},{"EARLY_PHASE1":11202,"PHASE1":11208,"PHASE2":11210,"PHASE3":11212,"PHASE4":11214,"NA":11216},{"trials":11203,"activeCount":117},[11204],{"nctId":7382,"briefTitle":7383,"status":160,"phases":11205,"primaryCompletion":4225,"completion":4225,"start":954,"enrollment":228,"conditions":11206,"interventions":11207},[90],[2524,15],[7387,7377],{"trials":11209,"activeCount":117},[],{"trials":11211,"activeCount":117},[],{"trials":11213,"activeCount":117},[],{"trials":11215,"activeCount":117},[],{"trials":11217,"activeCount":117},[],{"intervention":11219,"totalTrials":114,"cells":11220},"Transdermal Testosterone",{"EARLY_PHASE1":11221,"PHASE1":11233,"PHASE2":11235,"PHASE3":11237,"PHASE4":11239,"NA":11241},{"trials":11222,"activeCount":117},[11223],{"nctId":11224,"briefTitle":11225,"status":160,"phases":11226,"primaryCompletion":11227,"completion":188,"start":11228,"enrollment":19,"conditions":11229,"interventions":11231},"NCT03734653","Testosterone Therapy in Castration Resistant Prostate Cancer",[90],"2024-08-14","2019-01-18",[914,11230],"Castration-Resistant Prostate Cancer",[11219,11232],"Standard of Care, Enzalutamide",{"trials":11234,"activeCount":117},[],{"trials":11236,"activeCount":117},[],{"trials":11238,"activeCount":117},[],{"trials":11240,"activeCount":117},[],{"trials":11242,"activeCount":117},[],{"intervention":11232,"totalTrials":114,"cells":11244},{"EARLY_PHASE1":11245,"PHASE1":11251,"PHASE2":11253,"PHASE3":11255,"PHASE4":11257,"NA":11259},{"trials":11246,"activeCount":117},[11247],{"nctId":11224,"briefTitle":11225,"status":160,"phases":11248,"primaryCompletion":11227,"completion":188,"start":11228,"enrollment":19,"conditions":11249,"interventions":11250},[90],[914,11230],[11219,11232],{"trials":11252,"activeCount":117},[],{"trials":11254,"activeCount":117},[],{"trials":11256,"activeCount":117},[],{"trials":11258,"activeCount":117},[],{"trials":11260,"activeCount":117},[],{"intervention":11262,"totalTrials":114,"cells":11263},"Tacrolimus Extended Release Oral Tablet [Envarsus]",{"EARLY_PHASE1":11264,"PHASE1":11275,"PHASE2":11277,"PHASE3":11279,"PHASE4":11281,"NA":11283},{"trials":11265,"activeCount":117},[11266],{"nctId":11267,"briefTitle":11268,"status":125,"phases":11269,"primaryCompletion":11270,"completion":11270,"start":11271,"enrollment":1548,"conditions":11272,"interventions":11274},"NCT03380936","Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients",[90],"2019-10-16","2018-01-17",[11273],"Kidney Transplant Rejection",[11262],{"trials":11276,"activeCount":117},[],{"trials":11278,"activeCount":117},[],{"trials":11280,"activeCount":117},[],{"trials":11282,"activeCount":117},[],{"trials":11284,"activeCount":117},[],{"intervention":11286,"totalTrials":114,"cells":11287},"Bexarotene",{"EARLY_PHASE1":11288,"PHASE1":11297,"PHASE2":11299,"PHASE3":11301,"PHASE4":11303,"NA":11305},{"trials":11289,"activeCount":117},[11290],{"nctId":11291,"briefTitle":11292,"status":160,"phases":11293,"primaryCompletion":1469,"completion":1470,"start":7396,"enrollment":228,"conditions":11294,"interventions":11296},"NCT00718770","A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression",[90],[11295],"Thyroid Cancer",[11286],{"trials":11298,"activeCount":117},[],{"trials":11300,"activeCount":117},[],{"trials":11302,"activeCount":117},[],{"trials":11304,"activeCount":117},[],{"trials":11306,"activeCount":117},[],{"intervention":11308,"totalTrials":114,"cells":11309},"Autologous platelet rich plasma",{"EARLY_PHASE1":11310,"PHASE1":11320,"PHASE2":11322,"PHASE3":11324,"PHASE4":11326,"NA":11328},{"trials":11311,"activeCount":117},[11312],{"nctId":11313,"briefTitle":11314,"status":160,"phases":11315,"primaryCompletion":11316,"completion":11316,"start":10355,"enrollment":263,"conditions":11317,"interventions":11319},"NCT04522674","Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine",[90],"2022-04-28",[11318],"Platelet-Rich Plasma",[11308],{"trials":11321,"activeCount":117},[],{"trials":11323,"activeCount":117},[],{"trials":11325,"activeCount":117},[],{"trials":11327,"activeCount":117},[],{"trials":11329,"activeCount":117},[],{"intervention":11331,"totalTrials":114,"cells":11332},"KUVAN",{"EARLY_PHASE1":11333,"PHASE1":11343,"PHASE2":11345,"PHASE3":11347,"PHASE4":11349,"NA":11351},{"trials":11334,"activeCount":117},[11335],{"nctId":11336,"briefTitle":867,"status":160,"phases":11337,"primaryCompletion":11338,"completion":11338,"start":4768,"enrollment":315,"conditions":11339,"interventions":11340},"NCT02042196",[90],"2016-05-02",[708,27],[11331,11341,11342],"Cetrotide","Climara",{"trials":11344,"activeCount":117},[],{"trials":11346,"activeCount":117},[],{"trials":11348,"activeCount":117},[],{"trials":11350,"activeCount":117},[],{"trials":11352,"activeCount":117},[],{"intervention":11341,"totalTrials":114,"cells":11354},{"EARLY_PHASE1":11355,"PHASE1":11361,"PHASE2":11363,"PHASE3":11365,"PHASE4":11367,"NA":11369},{"trials":11356,"activeCount":117},[11357],{"nctId":11336,"briefTitle":867,"status":160,"phases":11358,"primaryCompletion":11338,"completion":11338,"start":4768,"enrollment":315,"conditions":11359,"interventions":11360},[90],[708,27],[11331,11341,11342],{"trials":11362,"activeCount":117},[],{"trials":11364,"activeCount":117},[],{"trials":11366,"activeCount":117},[],{"trials":11368,"activeCount":117},[],{"trials":11370,"activeCount":117},[],{"intervention":11372,"totalTrials":114,"cells":11373},"Granulocyte Macrophage Colony Stimulation Factor",{"EARLY_PHASE1":11374,"PHASE1":11387,"PHASE2":11389,"PHASE3":11391,"PHASE4":11393,"NA":11395},{"trials":11375,"activeCount":117},[11376],{"nctId":11377,"briefTitle":11378,"status":160,"phases":11379,"primaryCompletion":11380,"completion":11381,"start":11382,"enrollment":129,"conditions":11383,"interventions":11386},"NCT04408092","Study of the Effect of GM-CSF on Macrophages in Ependymoma",[90],"2021-09-21","2023-07-21","2013-06-25",[11384,11385],"Ependymoma, Recurrent Childhood","Ependymoma",[11372],{"trials":11388,"activeCount":117},[],{"trials":11390,"activeCount":117},[],{"trials":11392,"activeCount":117},[],{"trials":11394,"activeCount":117},[],{"trials":11396,"activeCount":117},[],{"intervention":11398,"totalTrials":114,"cells":11399},"Creatine monohydrate",{"EARLY_PHASE1":11400,"PHASE1":11411,"PHASE2":11413,"PHASE3":11415,"PHASE4":11417,"NA":11419},{"trials":11401,"activeCount":117},[11402],{"nctId":11403,"briefTitle":11404,"status":1622,"phases":11405,"primaryCompletion":11406,"completion":11406,"start":11407,"enrollment":117,"conditions":11408,"interventions":11410},"NCT02463305","Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)",[90],"2023-03-01","2022-08",[11409],"Colitis, Ulcerative",[11398],{"trials":11412,"activeCount":117},[],{"trials":11414,"activeCount":117},[],{"trials":11416,"activeCount":117},[],{"trials":11418,"activeCount":117},[],{"trials":11420,"activeCount":117},[],{"intervention":11422,"totalTrials":114,"cells":11423},"Once-Daily Tacrolimus extended release",{"EARLY_PHASE1":11424,"PHASE1":11435,"PHASE2":11437,"PHASE3":11439,"PHASE4":11441,"NA":11443},{"trials":11425,"activeCount":117},[11426],{"nctId":11427,"briefTitle":11428,"status":125,"phases":11429,"primaryCompletion":11430,"completion":11430,"start":11431,"enrollment":114,"conditions":11432,"interventions":11434},"NCT04156204","Immunosuppressant Medication Dosed Daily After Kidney Transplant",[90],"2020-11-27","2019-11-20",[11273,11433],"Medication Adherence",[11422],{"trials":11436,"activeCount":117},[],{"trials":11438,"activeCount":117},[],{"trials":11440,"activeCount":117},[],{"trials":11442,"activeCount":117},[],{"trials":11444,"activeCount":117},[],{"intervention":11446,"totalTrials":114,"cells":11447},"Celecoxib",{"EARLY_PHASE1":11448,"PHASE1":11465,"PHASE2":11467,"PHASE3":11469,"PHASE4":11471,"NA":11473},{"trials":11449,"activeCount":117},[11450],{"nctId":11451,"briefTitle":11452,"status":160,"phases":11453,"primaryCompletion":11454,"completion":11455,"start":11456,"enrollment":2380,"conditions":11457,"interventions":11464},"NCT01881048","Window of Opportunity Study Targeting the Inflammatory Milieu",[90],"2014-01-14","2015-12-14","2009-12-08",[11458,11459,9445,11460,11461,11462,11463],"Stage IA Breast Cancer","Stage IB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer",[11446],{"trials":11466,"activeCount":117},[],{"trials":11468,"activeCount":117},[],{"trials":11470,"activeCount":117},[],{"trials":11472,"activeCount":117},[],{"trials":11474,"activeCount":117},[],{"intervention":11476,"totalTrials":114,"cells":11477},"Oxytocin",{"EARLY_PHASE1":11478,"PHASE1":11489,"PHASE2":11491,"PHASE3":11493,"PHASE4":11495,"NA":11497},{"trials":11479,"activeCount":117},[11480],{"nctId":11481,"briefTitle":11482,"status":160,"phases":11483,"primaryCompletion":11484,"completion":11484,"start":11485,"enrollment":508,"conditions":11486,"interventions":11488},"NCT02221830","Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)",[90],"2019-07-17","2015-02",[11487],"Preeclampsia",[11476],{"trials":11490,"activeCount":117},[],{"trials":11492,"activeCount":117},[],{"trials":11494,"activeCount":117},[],{"trials":11496,"activeCount":117},[],{"trials":11498,"activeCount":117},[],{"intervention":11500,"totalTrials":1548,"cells":11501},"Estradiol",{"EARLY_PHASE1":11502,"PHASE1":11504,"PHASE2":11506,"PHASE3":11508,"PHASE4":11510,"NA":11512},{"trials":11503,"activeCount":117},[],{"trials":11505,"activeCount":117},[],{"trials":11507,"activeCount":117},[],{"trials":11509,"activeCount":117},[],{"trials":11511,"activeCount":117},[],{"trials":11513,"activeCount":117},[11514,11523,11530,11538],{"nctId":11515,"briefTitle":11516,"status":160,"phases":11517,"primaryCompletion":4767,"completion":4767,"start":11518,"enrollment":4227,"conditions":11519,"interventions":11521},"NCT01613131","Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression",[95],"2012-04",[11520],"Menopausal and Other Perimenopausal Disorders",[11522,11500],"Mirena",{"nctId":11524,"briefTitle":11525,"status":160,"phases":11526,"primaryCompletion":11527,"completion":648,"start":2026,"enrollment":1666,"conditions":11528,"interventions":11529},"NCT01605071","Timing Estrogen After MenoPaUSe",[95],"2015-11",[968],[11500],{"nctId":11531,"briefTitle":11532,"status":160,"phases":11533,"primaryCompletion":1469,"completion":1469,"start":965,"enrollment":19,"conditions":11534,"interventions":11535},"NCT01381016","Estrogen Sensitivity and Ovulatory Dysfunction in Obesity",[95],[15,3646],[11500,11536,11537],"Gonadotropin-releasing hormone","Progesterone",{"nctId":11539,"briefTitle":11540,"status":160,"phases":11541,"primaryCompletion":11542,"completion":11543,"start":11544,"enrollment":34,"conditions":11545,"interventions":11550},"NCT02122198","Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women",[95],"2017-05-30","2017-09-15","2014-09-08",[11546,11547,11548,11549],"Cognitive Impairment","Executive Dysfunction","Endothelial Dysfunction","Cardiovascular Disease",[11551,11500,11552],"Leuprolide acetate","Medroxyprogesterone",{"intervention":812,"totalTrials":1548,"cells":11554},{"EARLY_PHASE1":11555,"PHASE1":11557,"PHASE2":11559,"PHASE3":11565,"PHASE4":11571,"NA":11573},{"trials":11556,"activeCount":117},[],{"trials":11558,"activeCount":117},[],{"trials":11560,"activeCount":117},[11561],{"nctId":799,"briefTitle":800,"status":160,"phases":11562,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":11563,"interventions":11564},[92],[807,808,809,810],[48,812,813,814,815,816],{"trials":11566,"activeCount":117},[11567],{"nctId":7050,"briefTitle":7051,"status":160,"phases":11568,"primaryCompletion":4767,"completion":4767,"start":7053,"enrollment":7054,"conditions":11569,"interventions":11570},[93],[15],[812,7039],{"trials":11572,"activeCount":117},[],{"trials":11574,"activeCount":117},[11575,11582],{"nctId":11576,"briefTitle":11577,"status":160,"phases":11578,"primaryCompletion":7261,"completion":7261,"start":11579,"enrollment":1098,"conditions":11580,"interventions":11581},"NCT02927392","Brown Adipose Tissue Activity in Pre- and Postmenopausal Women",[95],"2017-03-16",[708,15],[11551],{"nctId":11539,"briefTitle":11540,"status":160,"phases":11583,"primaryCompletion":11542,"completion":11543,"start":11544,"enrollment":34,"conditions":11584,"interventions":11585},[95],[11546,11547,11548,11549],[11551,11500,11552],{"intervention":3488,"totalTrials":99,"cells":11587},{"EARLY_PHASE1":11588,"PHASE1":11590,"PHASE2":11596,"PHASE3":11602,"PHASE4":11604,"NA":11606},{"trials":11589,"activeCount":117},[],{"trials":11591,"activeCount":117},[11592],{"nctId":9948,"briefTitle":9949,"status":160,"phases":11593,"primaryCompletion":4970,"completion":4970,"start":7228,"enrollment":25,"conditions":11594,"interventions":11595},[91],[9952,9953,7274],[9931,3488,9955],{"trials":11597,"activeCount":117},[11598],{"nctId":7476,"briefTitle":7477,"status":160,"phases":11599,"primaryCompletion":7479,"completion":7480,"start":7481,"enrollment":1165,"conditions":11600,"interventions":11601},[92],[7483],[7485,1802,7486,3488],{"trials":11603,"activeCount":117},[],{"trials":11605,"activeCount":117},[],{"trials":11607,"activeCount":117},[11608],{"nctId":3481,"briefTitle":3482,"status":125,"phases":11609,"primaryCompletion":3484,"completion":3484,"start":163,"enrollment":2475,"conditions":11610,"interventions":11611},[95],[3486],[3488,3489,1659],{"intervention":1777,"totalTrials":99,"cells":11613},{"EARLY_PHASE1":11614,"PHASE1":11616,"PHASE2":11618,"PHASE3":11620,"PHASE4":11622,"NA":11628},{"trials":11615,"activeCount":117},[],{"trials":11617,"activeCount":117},[],{"trials":11619,"activeCount":117},[],{"trials":11621,"activeCount":117},[],{"trials":11623,"activeCount":117},[11624],{"nctId":1768,"briefTitle":1769,"status":1622,"phases":11625,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":117,"conditions":11626,"interventions":11627},[94],[1774],[1776,1777,1732],{"trials":11629,"activeCount":117},[11630,11637],{"nctId":11631,"briefTitle":11632,"status":160,"phases":11633,"primaryCompletion":162,"completion":162,"start":4734,"enrollment":1920,"conditions":11634,"interventions":11636},"NCT00936377","Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal",[95],[11635],"Acute Alcohol Withdrawal",[1777],{"nctId":11638,"briefTitle":11639,"status":160,"phases":11640,"primaryCompletion":162,"completion":162,"start":3484,"enrollment":25,"conditions":11641,"interventions":11642},"NCT00744380","Dexmedetomidine Versus Midazolam for Facilitating Extubation",[95],[9690],[6246,1777],{"intervention":4737,"totalTrials":99,"cells":11644},{"EARLY_PHASE1":11645,"PHASE1":11647,"PHASE2":11649,"PHASE3":11651,"PHASE4":11653,"NA":11663},{"trials":11646,"activeCount":117},[],{"trials":11648,"activeCount":117},[],{"trials":11650,"activeCount":117},[],{"trials":11652,"activeCount":117},[],{"trials":11654,"activeCount":117},[11655,11659],{"nctId":5595,"briefTitle":5596,"status":160,"phases":11656,"primaryCompletion":5034,"completion":5034,"start":2027,"enrollment":3875,"conditions":11657,"interventions":11658},[94],[736],[4737,5582],{"nctId":4729,"briefTitle":4730,"status":160,"phases":11660,"primaryCompletion":4732,"completion":4733,"start":4734,"enrollment":28,"conditions":11661,"interventions":11662},[94],[18],[4737,4707],{"trials":11664,"activeCount":117},[11665],{"nctId":11666,"briefTitle":11667,"status":160,"phases":11668,"primaryCompletion":5812,"completion":5812,"start":4160,"enrollment":1518,"conditions":11669,"interventions":11670},"NCT01951339","Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes",[95],[24,11549],[4737,11671],"Glimepiride",{"intervention":4930,"totalTrials":199,"cells":11673},{"EARLY_PHASE1":11674,"PHASE1":11676,"PHASE2":11678,"PHASE3":11680,"PHASE4":11682,"NA":11688},{"trials":11675,"activeCount":117},[],{"trials":11677,"activeCount":117},[],{"trials":11679,"activeCount":117},[],{"trials":11681,"activeCount":117},[],{"trials":11683,"activeCount":117},[11684],{"nctId":4922,"briefTitle":4923,"status":160,"phases":11685,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":926,"conditions":11686,"interventions":11687},[94],[4928],[4909,4930,4931],{"trials":11689,"activeCount":117},[11690],{"nctId":11691,"briefTitle":11692,"status":125,"phases":11693,"primaryCompletion":11694,"completion":11694,"start":5685,"enrollment":11695,"conditions":11696,"interventions":11697},"NCT02293096","Pharmacogenetic Prediction of Metoprolol Effectiveness",[95],"2017-08-23",462,[6192],[11698,11699],"metoprolol succinate","Genotyping",{"intervention":11701,"totalTrials":199,"cells":11702},"Ibuprofen",{"EARLY_PHASE1":11703,"PHASE1":11705,"PHASE2":11707,"PHASE3":11709,"PHASE4":11711,"NA":11713},{"trials":11704,"activeCount":117},[],{"trials":11706,"activeCount":117},[],{"trials":11708,"activeCount":117},[],{"trials":11710,"activeCount":117},[],{"trials":11712,"activeCount":117},[],{"trials":11714,"activeCount":117},[11715,11723],{"nctId":11716,"briefTitle":11717,"status":160,"phases":11718,"primaryCompletion":6507,"completion":6507,"start":8630,"enrollment":11719,"conditions":11720,"interventions":11722},"NCT00462722","Myogenic and Osteogenic Responses to eXercise and Ibuprofen",[95],159,[27,11721],"Physical Fitness",[11701],{"nctId":11724,"briefTitle":11725,"status":160,"phases":11726,"primaryCompletion":11727,"completion":11727,"start":4176,"enrollment":11728,"conditions":11729,"interventions":11734},"NCT02140970","Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal",[95],"2020-01-11",51,[11730,11731,11732,11733],"Disorder of Urinary Stent","Ureteral Spasm","Ureteropelvic Junction Obstruction","Urolithiasis",[11701],{"intervention":11522,"totalTrials":199,"cells":11736},{"EARLY_PHASE1":11737,"PHASE1":11739,"PHASE2":11741,"PHASE3":11743,"PHASE4":11745,"NA":11747},{"trials":11738,"activeCount":117},[],{"trials":11740,"activeCount":117},[],{"trials":11742,"activeCount":117},[],{"trials":11744,"activeCount":117},[],{"trials":11746,"activeCount":117},[],{"trials":11748,"activeCount":117},[11749,11753],{"nctId":11515,"briefTitle":11516,"status":160,"phases":11750,"primaryCompletion":4767,"completion":4767,"start":11518,"enrollment":4227,"conditions":11751,"interventions":11752},[95],[11520],[11522,11500],{"nctId":11754,"briefTitle":11755,"status":160,"phases":11756,"primaryCompletion":4250,"completion":4250,"start":7531,"enrollment":11757,"conditions":11758,"interventions":11759},"NCT02067663","Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study",[],123,[255],[11522],{"intervention":11761,"totalTrials":199,"cells":11762},"Varicella vaccine",{"EARLY_PHASE1":11763,"PHASE1":11765,"PHASE2":11767,"PHASE3":11769,"PHASE4":11771,"NA":11782},{"trials":11764,"activeCount":117},[],{"trials":11766,"activeCount":117},[],{"trials":11768,"activeCount":117},[],{"trials":11770,"activeCount":117},[],{"trials":11772,"activeCount":117},[11773],{"nctId":11774,"briefTitle":11775,"status":1622,"phases":11776,"primaryCompletion":11777,"completion":11777,"start":11778,"enrollment":117,"conditions":11779,"interventions":11781},"NCT02026089","Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine",[94],"2022-06","2021-12",[11780],"Persistence of Varicella Immunity",[11761],{"trials":11783,"activeCount":117},[11784],{"nctId":11785,"briefTitle":11786,"status":1622,"phases":11787,"primaryCompletion":225,"completion":225,"start":225,"enrollment":117,"conditions":11788,"interventions":11791},"NCT02692066","Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.",[],[11789,11790],"Varicella","Transplants",[11792],"varicella vaccine",{"intervention":11794,"totalTrials":199,"cells":11795},"Testosterone Gel",{"EARLY_PHASE1":11796,"PHASE1":11798,"PHASE2":11800,"PHASE3":11802,"PHASE4":11804,"NA":11806},{"trials":11797,"activeCount":117},[],{"trials":11799,"activeCount":117},[],{"trials":11801,"activeCount":117},[],{"trials":11803,"activeCount":117},[],{"trials":11805,"activeCount":117},[],{"trials":11807,"activeCount":117},[11808,11820],{"nctId":11809,"briefTitle":11810,"status":160,"phases":11811,"primaryCompletion":11812,"completion":11812,"start":11813,"enrollment":11814,"conditions":11815,"interventions":11817},"NCT02758431","Cardiovascular Outcomes of Low Testosterone",[95],"2023-01-04","2016-07-01",232,[11816],"Hypogonadism",[11818,11794,11819],"Acyline","Arimidex",{"nctId":728,"briefTitle":729,"status":160,"phases":11821,"primaryCompletion":731,"completion":732,"start":733,"enrollment":734,"conditions":11822,"interventions":11823},[95],[736,737],[88,739,740],{"intervention":846,"totalTrials":199,"cells":11825},{"EARLY_PHASE1":11826,"PHASE1":11828,"PHASE2":11830,"PHASE3":11832,"PHASE4":11834,"NA":11836},{"trials":11827,"activeCount":117},[],{"trials":11829,"activeCount":117},[],{"trials":11831,"activeCount":117},[],{"trials":11833,"activeCount":117},[],{"trials":11835,"activeCount":117},[],{"trials":11837,"activeCount":117},[11838,11849],{"nctId":11839,"briefTitle":11840,"status":160,"phases":11841,"primaryCompletion":4721,"completion":4721,"start":11842,"enrollment":11843,"conditions":11844,"interventions":11845},"NCT01457703","Reproductive Hormonal Alterations in Obesity",[95],"2010-06",62,[15],[846,11846,11847,11848],"Gonadorelin-GnRH","Recombinant LH","Letrozole",{"nctId":836,"briefTitle":837,"status":160,"phases":11850,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":11851,"interventions":11852},[95],[15,843],[790,845,846],{"intervention":1476,"totalTrials":199,"cells":11854},{"EARLY_PHASE1":11855,"PHASE1":11857,"PHASE2":11859,"PHASE3":11861,"PHASE4":11867,"NA":11869},{"trials":11856,"activeCount":117},[],{"trials":11858,"activeCount":117},[],{"trials":11860,"activeCount":117},[],{"trials":11862,"activeCount":117},[11863],{"nctId":7201,"briefTitle":7202,"status":160,"phases":11864,"primaryCompletion":7204,"completion":7204,"start":7205,"enrollment":3875,"conditions":11865,"interventions":11866},[93],[1283,1284],[7190,1476],{"trials":11868,"activeCount":117},[],{"trials":11870,"activeCount":117},[11871],{"nctId":1466,"briefTitle":1467,"status":160,"phases":11872,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":11873,"interventions":11874},[95],[1474],[1476,1477,1169],{"intervention":11342,"totalTrials":199,"cells":11876},{"EARLY_PHASE1":11877,"PHASE1":11883,"PHASE2":11885,"PHASE3":11887,"PHASE4":11889,"NA":11891},{"trials":11878,"activeCount":117},[11879],{"nctId":11336,"briefTitle":867,"status":160,"phases":11880,"primaryCompletion":11338,"completion":11338,"start":4768,"enrollment":315,"conditions":11881,"interventions":11882},[90],[708,27],[11331,11341,11342],{"trials":11884,"activeCount":117},[],{"trials":11886,"activeCount":117},[],{"trials":11888,"activeCount":117},[],{"trials":11890,"activeCount":117},[],{"trials":11892,"activeCount":117},[11893],{"nctId":11894,"briefTitle":11895,"status":160,"phases":11896,"primaryCompletion":11897,"completion":11897,"start":7076,"enrollment":4755,"conditions":11898,"interventions":11899},"NCT02256540","The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women",[95],"2016-03-25",[11548],[11342],{"intervention":11901,"totalTrials":199,"cells":11902},"Acipimox",{"EARLY_PHASE1":11903,"PHASE1":11905,"PHASE2":11907,"PHASE3":11909,"PHASE4":11917,"NA":11919},{"trials":11904,"activeCount":117},[],{"trials":11906,"activeCount":117},[],{"trials":11908,"activeCount":117},[],{"trials":11910,"activeCount":117},[11911],{"nctId":11912,"briefTitle":11913,"status":160,"phases":11914,"primaryCompletion":6214,"completion":6214,"start":965,"enrollment":22,"conditions":11915,"interventions":11916},"NCT01816165","Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes",[93],[18],[11901],{"trials":11918,"activeCount":117},[],{"trials":11920,"activeCount":117},[11921],{"nctId":11922,"briefTitle":11923,"status":160,"phases":11924,"primaryCompletion":11925,"completion":11925,"start":965,"enrollment":734,"conditions":11926,"interventions":11927},"NCT01580813","Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes",[95],"2015-06-05",[24],[11901],{"intervention":6246,"totalTrials":199,"cells":11929},{"EARLY_PHASE1":11930,"PHASE1":11932,"PHASE2":11934,"PHASE3":11936,"PHASE4":11938,"NA":11944},{"trials":11931,"activeCount":117},[],{"trials":11933,"activeCount":117},[],{"trials":11935,"activeCount":117},[],{"trials":11937,"activeCount":117},[],{"trials":11939,"activeCount":117},[11940],{"nctId":6236,"briefTitle":6237,"status":160,"phases":11941,"primaryCompletion":6239,"completion":6239,"start":5237,"enrollment":6240,"conditions":11942,"interventions":11943},[94],[1463,6242,6243,6244],[6223,6246],{"trials":11945,"activeCount":117},[11946],{"nctId":11638,"briefTitle":11639,"status":160,"phases":11947,"primaryCompletion":162,"completion":162,"start":3484,"enrollment":25,"conditions":11948,"interventions":11949},[95],[9690],[6246,1777],{"intervention":11951,"totalTrials":199,"cells":11952},"pramlintide",{"EARLY_PHASE1":11953,"PHASE1":11955,"PHASE2":11957,"PHASE3":11967,"PHASE4":11969,"NA":11971},{"trials":11954,"activeCount":117},[],{"trials":11956,"activeCount":117},[],{"trials":11958,"activeCount":117},[11959],{"nctId":11960,"briefTitle":11961,"status":1622,"phases":11962,"primaryCompletion":5035,"completion":5035,"start":11963,"enrollment":117,"conditions":11964,"interventions":11965},"NCT01165944","Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus",[91,92],"2009-08",[1926],[11966],"Pramlintide",{"trials":11968,"activeCount":117},[],{"trials":11970,"activeCount":117},[],{"trials":11972,"activeCount":117},[11973],{"nctId":11974,"briefTitle":11975,"status":160,"phases":11976,"primaryCompletion":2052,"completion":2052,"start":1459,"enrollment":228,"conditions":11977,"interventions":11978},"NCT00842075","Pramlintide in Adolescents With Type 1 Diabetes",[95],[18],[11951],{"intervention":11980,"totalTrials":114,"cells":11981},"PPI treatment",{"EARLY_PHASE1":11982,"PHASE1":11984,"PHASE2":11986,"PHASE3":11988,"PHASE4":11990,"NA":11992},{"trials":11983,"activeCount":117},[],{"trials":11985,"activeCount":117},[],{"trials":11987,"activeCount":117},[],{"trials":11989,"activeCount":117},[],{"trials":11991,"activeCount":117},[],{"trials":11993,"activeCount":117},[11994],{"nctId":11995,"briefTitle":11996,"status":125,"phases":11997,"primaryCompletion":11998,"completion":11998,"start":11999,"enrollment":199,"conditions":12000,"interventions":12001},"NCT02769637","Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)",[],"2018-01-18","2017-09-07",[8383],[11980],{"intervention":12003,"totalTrials":114,"cells":12004},"oral placebo",{"EARLY_PHASE1":12005,"PHASE1":12007,"PHASE2":12009,"PHASE3":12011,"PHASE4":12013,"NA":12015},{"trials":12006,"activeCount":117},[],{"trials":12008,"activeCount":117},[],{"trials":12010,"activeCount":117},[],{"trials":12012,"activeCount":117},[],{"trials":12014,"activeCount":117},[],{"trials":12016,"activeCount":117},[12017],{"nctId":12018,"briefTitle":12019,"status":125,"phases":12020,"primaryCompletion":12021,"completion":12021,"start":4160,"enrollment":12022,"conditions":12023,"interventions":12024},"NCT01971853","Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry",[95],"2016-12-31",88,[4580],[12003,12025],"Oral Analgesics",{"intervention":12025,"totalTrials":114,"cells":12027},{"EARLY_PHASE1":12028,"PHASE1":12030,"PHASE2":12032,"PHASE3":12034,"PHASE4":12036,"NA":12038},{"trials":12029,"activeCount":117},[],{"trials":12031,"activeCount":117},[],{"trials":12033,"activeCount":117},[],{"trials":12035,"activeCount":117},[],{"trials":12037,"activeCount":117},[],{"trials":12039,"activeCount":117},[12040],{"nctId":12018,"briefTitle":12019,"status":125,"phases":12041,"primaryCompletion":12021,"completion":12021,"start":4160,"enrollment":12022,"conditions":12042,"interventions":12043},[95],[4580],[12003,12025],{"intervention":12045,"totalTrials":114,"cells":12046},"Butterfly handheld ultrasound machine",{"EARLY_PHASE1":12047,"PHASE1":12049,"PHASE2":12051,"PHASE3":12053,"PHASE4":12055,"NA":12057},{"trials":12048,"activeCount":117},[],{"trials":12050,"activeCount":117},[],{"trials":12052,"activeCount":117},[],{"trials":12054,"activeCount":117},[],{"trials":12056,"activeCount":117},[],{"trials":12058,"activeCount":117},[12059],{"nctId":12060,"briefTitle":12061,"status":160,"phases":12062,"primaryCompletion":12063,"completion":12063,"start":8311,"enrollment":9,"conditions":12064,"interventions":12068},"NCT05013476","Tele-Ultrasound: VIrtual Hands-on Education for Novice Users",[95],"2023-10-04",[12065,12066,12067],"Ultrasound","Education","Virtual",[12045],{"intervention":12070,"totalTrials":114,"cells":12071},"Ranolazine",{"EARLY_PHASE1":12072,"PHASE1":12074,"PHASE2":12076,"PHASE3":12078,"PHASE4":12080,"NA":12082},{"trials":12073,"activeCount":117},[],{"trials":12075,"activeCount":117},[],{"trials":12077,"activeCount":117},[],{"trials":12079,"activeCount":117},[],{"trials":12081,"activeCount":117},[],{"trials":12083,"activeCount":117},[12084],{"nctId":12085,"briefTitle":12086,"status":160,"phases":12087,"primaryCompletion":12088,"completion":12089,"start":12090,"enrollment":758,"conditions":12091,"interventions":12094},"NCT01992016","A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine",[95],"2016-10-08","2018-04-11","2014-04-07",[807,12092,12093,2370,2371,809,810],"Bone Metastases","Soft Tissue Metastases",[12070],{"intervention":12096,"totalTrials":114,"cells":12097},"estrogen patch",{"EARLY_PHASE1":12098,"PHASE1":12100,"PHASE2":12102,"PHASE3":12104,"PHASE4":12106,"NA":12108},{"trials":12099,"activeCount":117},[],{"trials":12101,"activeCount":117},[],{"trials":12103,"activeCount":117},[],{"trials":12105,"activeCount":117},[],{"trials":12107,"activeCount":117},[],{"trials":12109,"activeCount":117},[12110],{"nctId":12111,"briefTitle":12112,"status":160,"phases":12113,"primaryCompletion":12114,"completion":12114,"start":12115,"enrollment":2173,"conditions":12116,"interventions":12117},"NCT01208324","Estrogen and Serotonin on Changing Brain Chemistry",[95],"2018-11","2010-03-04",[708],[12096,12118],"Amino acids",{"intervention":12118,"totalTrials":114,"cells":12120},{"EARLY_PHASE1":12121,"PHASE1":12123,"PHASE2":12125,"PHASE3":12127,"PHASE4":12129,"NA":12131},{"trials":12122,"activeCount":117},[],{"trials":12124,"activeCount":117},[],{"trials":12126,"activeCount":117},[],{"trials":12128,"activeCount":117},[],{"trials":12130,"activeCount":117},[],{"trials":12132,"activeCount":117},[12133],{"nctId":12111,"briefTitle":12112,"status":160,"phases":12134,"primaryCompletion":12114,"completion":12114,"start":12115,"enrollment":2173,"conditions":12135,"interventions":12136},[95],[708],[12096,12118],{"intervention":12138,"totalTrials":114,"cells":12139},"Spironolactone and conivaptan",{"EARLY_PHASE1":12140,"PHASE1":12142,"PHASE2":12144,"PHASE3":12146,"PHASE4":12148,"NA":12150},{"trials":12141,"activeCount":117},[],{"trials":12143,"activeCount":117},[],{"trials":12145,"activeCount":117},[],{"trials":12147,"activeCount":117},[],{"trials":12149,"activeCount":117},[],{"trials":12151,"activeCount":117},[12152],{"nctId":12153,"briefTitle":12154,"status":1622,"phases":12155,"primaryCompletion":5393,"completion":4161,"start":5459,"enrollment":117,"conditions":12156,"interventions":12158},"NCT00811486","Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure",[95],[12157,11107],"Right Heart Failure",[12138],{"intervention":3489,"totalTrials":114,"cells":12160},{"EARLY_PHASE1":12161,"PHASE1":12163,"PHASE2":12165,"PHASE3":12167,"PHASE4":12169,"NA":12171},{"trials":12162,"activeCount":117},[],{"trials":12164,"activeCount":117},[],{"trials":12166,"activeCount":117},[],{"trials":12168,"activeCount":117},[],{"trials":12170,"activeCount":117},[],{"trials":12172,"activeCount":117},[12173],{"nctId":3481,"briefTitle":3482,"status":125,"phases":12174,"primaryCompletion":3484,"completion":3484,"start":163,"enrollment":2475,"conditions":12175,"interventions":12176},[95],[3486],[3488,3489,1659],{"intervention":12178,"totalTrials":114,"cells":12179},"levothyroxine in thyroidectomy patients",{"EARLY_PHASE1":12180,"PHASE1":12182,"PHASE2":12184,"PHASE3":12186,"PHASE4":12188,"NA":12190},{"trials":12181,"activeCount":117},[],{"trials":12183,"activeCount":117},[],{"trials":12185,"activeCount":117},[],{"trials":12187,"activeCount":117},[],{"trials":12189,"activeCount":117},[],{"trials":12191,"activeCount":117},[12192],{"nctId":12193,"briefTitle":12194,"status":125,"phases":12195,"primaryCompletion":12196,"completion":12196,"start":925,"enrollment":253,"conditions":12197,"interventions":12200},"NCT02567877","Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?",[],"2020-06",[12198,12199],"Postsurgical Hypothyroidism","Hypothyroidism",[12178],{"intervention":1978,"totalTrials":114,"cells":12202},{"EARLY_PHASE1":12203,"PHASE1":12205,"PHASE2":12207,"PHASE3":12209,"PHASE4":12211,"NA":12213},{"trials":12204,"activeCount":117},[],{"trials":12206,"activeCount":117},[],{"trials":12208,"activeCount":117},[],{"trials":12210,"activeCount":117},[],{"trials":12212,"activeCount":117},[],{"trials":12214,"activeCount":117},[12215],{"nctId":1969,"briefTitle":1970,"status":160,"phases":12216,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":1974,"conditions":12217,"interventions":12218},[],[1976,166],[1906,1978],{"intervention":12220,"totalTrials":114,"cells":12221},"Serology",{"EARLY_PHASE1":12222,"PHASE1":12224,"PHASE2":12226,"PHASE3":12228,"PHASE4":12230,"NA":12232},{"trials":12223,"activeCount":117},[],{"trials":12225,"activeCount":117},[],{"trials":12227,"activeCount":117},[],{"trials":12229,"activeCount":117},[],{"trials":12231,"activeCount":117},[],{"trials":12233,"activeCount":117},[12234],{"nctId":12235,"briefTitle":12236,"status":160,"phases":12237,"primaryCompletion":9112,"completion":2060,"start":983,"enrollment":5060,"conditions":12238,"interventions":12242},"NCT02545790","Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions",[],[12239,12240,12241],"Coarctation of Aorta","Aortic Stenosis","Cardiac Hypertrophy",[12220],{"intervention":12244,"totalTrials":114,"cells":12245},"3, 4-Diaminopyridine",{"EARLY_PHASE1":12246,"PHASE1":12248,"PHASE2":12250,"PHASE3":12252,"PHASE4":12254,"NA":12256},{"trials":12247,"activeCount":117},[],{"trials":12249,"activeCount":117},[],{"trials":12251,"activeCount":117},[],{"trials":12253,"activeCount":117},[],{"trials":12255,"activeCount":117},[],{"trials":12257,"activeCount":117},[12258],{"nctId":12259,"briefTitle":12260,"status":12261,"phases":12262,"conditions":12263,"interventions":12265},"NCT01825395","Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome","APPROVED_FOR_MARKETING",[],[12264],"Lambert Eaton Myasthenic Syndrome",[12244],{"intervention":12267,"totalTrials":114,"cells":12268},"Medical Cannabis",{"EARLY_PHASE1":12269,"PHASE1":12271,"PHASE2":12273,"PHASE3":12275,"PHASE4":12277,"NA":12279},{"trials":12270,"activeCount":117},[],{"trials":12272,"activeCount":117},[],{"trials":12274,"activeCount":117},[],{"trials":12276,"activeCount":117},[],{"trials":12278,"activeCount":117},[],{"trials":12280,"activeCount":117},[12281],{"nctId":12282,"briefTitle":12283,"status":715,"phases":12284,"primaryCompletion":12285,"completion":12286,"start":840,"enrollment":190,"conditions":12287,"interventions":12289},"NCT02523183","The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy",[],"2020-10","2020-11",[12288],"Epilepsy, Unspecified, Refractory (Medically)",[12267],{"intervention":12291,"totalTrials":114,"cells":12292},"Terbutaline",{"EARLY_PHASE1":12293,"PHASE1":12295,"PHASE2":12297,"PHASE3":12299,"PHASE4":12301,"NA":12303},{"trials":12294,"activeCount":117},[],{"trials":12296,"activeCount":117},[],{"trials":12298,"activeCount":117},[],{"trials":12300,"activeCount":117},[],{"trials":12302,"activeCount":117},[],{"trials":12304,"activeCount":117},[12305],{"nctId":12306,"briefTitle":12307,"status":160,"phases":12308,"primaryCompletion":5108,"completion":5108,"start":11128,"enrollment":37,"conditions":12309,"interventions":12310},"NCT00974051","Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia",[95],[18],[12291],{"intervention":12312,"totalTrials":114,"cells":12313},"Mannose",{"EARLY_PHASE1":12314,"PHASE1":12316,"PHASE2":12318,"PHASE3":12320,"PHASE4":12322,"NA":12324},{"trials":12315,"activeCount":117},[],{"trials":12317,"activeCount":117},[],{"trials":12319,"activeCount":117},[],{"trials":12321,"activeCount":117},[],{"trials":12323,"activeCount":117},[],{"trials":12325,"activeCount":117},[12326],{"nctId":12327,"briefTitle":12328,"status":125,"phases":12329,"primaryCompletion":9819,"completion":9819,"start":12330,"enrollment":1920,"conditions":12331,"interventions":12333},"NCT02397291","Transplacental Gradients and Transport in Intrauterine Growth Restricted (IUGR) Pregnancies Compared to Normal Pregnancies.",[95],"2001-01",[12332,3601],"IUGR",[12312,12334],"Myoinositol",{"intervention":12334,"totalTrials":114,"cells":12336},{"EARLY_PHASE1":12337,"PHASE1":12339,"PHASE2":12341,"PHASE3":12343,"PHASE4":12345,"NA":12347},{"trials":12338,"activeCount":117},[],{"trials":12340,"activeCount":117},[],{"trials":12342,"activeCount":117},[],{"trials":12344,"activeCount":117},[],{"trials":12346,"activeCount":117},[],{"trials":12348,"activeCount":117},[12349],{"nctId":12327,"briefTitle":12328,"status":125,"phases":12350,"primaryCompletion":9819,"completion":9819,"start":12330,"enrollment":1920,"conditions":12351,"interventions":12352},[95],[12332,3601],[12312,12334],{"intervention":12354,"totalTrials":114,"cells":12355},"COVID-19 Convalescent Plasma",{"EARLY_PHASE1":12356,"PHASE1":12358,"PHASE2":12360,"PHASE3":12362,"PHASE4":12364,"NA":12366},{"trials":12357,"activeCount":117},[],{"trials":12359,"activeCount":117},[],{"trials":12361,"activeCount":117},[],{"trials":12363,"activeCount":117},[],{"trials":12365,"activeCount":117},[],{"trials":12367,"activeCount":117},[12368],{"nctId":12369,"briefTitle":12370,"status":12371,"phases":12372,"conditions":12373,"interventions":12375},"NCT04372368","Convalescent Plasma for the Treatment of Patients With COVID-19","NO_LONGER_AVAILABLE",[],[2064,12374],"SARS-CoV 2",[12354],{"intervention":12377,"totalTrials":114,"cells":12378},"Nitric Oxide",{"EARLY_PHASE1":12379,"PHASE1":12381,"PHASE2":12383,"PHASE3":12385,"PHASE4":12387,"NA":12389},{"trials":12380,"activeCount":117},[],{"trials":12382,"activeCount":117},[],{"trials":12384,"activeCount":117},[],{"trials":12386,"activeCount":117},[],{"trials":12388,"activeCount":117},[],{"trials":12390,"activeCount":117},[12391],{"nctId":12392,"briefTitle":12393,"status":125,"phases":12394,"primaryCompletion":12395,"completion":12395,"start":175,"enrollment":734,"conditions":12396,"interventions":12400},"NCT00948194","Effect of Nitric Oxide (NO) on Ischemic\u002FReperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation",[95],"2015-12",[12397,12398,12399],"Liver Transplantation","Ischemia\u002FReperfusion Injury","Oxidative Injury",[12377],{"intervention":12402,"totalTrials":114,"cells":12403},"Acular LS",{"EARLY_PHASE1":12404,"PHASE1":12406,"PHASE2":12408,"PHASE3":12410,"PHASE4":12412,"NA":12414},{"trials":12405,"activeCount":117},[],{"trials":12407,"activeCount":117},[],{"trials":12409,"activeCount":117},[],{"trials":12411,"activeCount":117},[],{"trials":12413,"activeCount":117},[],{"trials":12415,"activeCount":117},[12416],{"nctId":12417,"briefTitle":12418,"status":125,"phases":12419,"primaryCompletion":678,"completion":678,"start":4177,"enrollment":5060,"conditions":12420,"interventions":12422},"NCT00478036","Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells",[95],[12421],"Open Angle Glaucoma",[12402,12423],"Pred Forte",{"intervention":12423,"totalTrials":114,"cells":12425},{"EARLY_PHASE1":12426,"PHASE1":12428,"PHASE2":12430,"PHASE3":12432,"PHASE4":12434,"NA":12436},{"trials":12427,"activeCount":117},[],{"trials":12429,"activeCount":117},[],{"trials":12431,"activeCount":117},[],{"trials":12433,"activeCount":117},[],{"trials":12435,"activeCount":117},[],{"trials":12437,"activeCount":117},[12438],{"nctId":12417,"briefTitle":12418,"status":125,"phases":12439,"primaryCompletion":678,"completion":678,"start":4177,"enrollment":5060,"conditions":12440,"interventions":12441},[95],[12421],[12402,12423],{"intervention":12443,"totalTrials":114,"cells":12444},"Doravirine",{"EARLY_PHASE1":12445,"PHASE1":12447,"PHASE2":12449,"PHASE3":12451,"PHASE4":12453,"NA":12455},{"trials":12446,"activeCount":117},[],{"trials":12448,"activeCount":117},[],{"trials":12450,"activeCount":117},[],{"trials":12452,"activeCount":117},[],{"trials":12454,"activeCount":117},[],{"trials":12456,"activeCount":117},[12457],{"nctId":12458,"briefTitle":12459,"status":160,"phases":12460,"primaryCompletion":12461,"completion":12462,"start":12463,"enrollment":31,"conditions":12464,"interventions":12466},"NCT04495348","Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance",[],"2023-01-25","2023-06-05","2020-10-22",[12465,722],"HIV-1-infection",[12443],{"intervention":12468,"totalTrials":114,"cells":12469},"Sitagliptin Phosphate",{"EARLY_PHASE1":12470,"PHASE1":12472,"PHASE2":12474,"PHASE3":12476,"PHASE4":12478,"NA":12480},{"trials":12471,"activeCount":117},[],{"trials":12473,"activeCount":117},[],{"trials":12475,"activeCount":117},[],{"trials":12477,"activeCount":117},[],{"trials":12479,"activeCount":117},[],{"trials":12481,"activeCount":117},[12482],{"nctId":12483,"briefTitle":12484,"status":160,"phases":12485,"primaryCompletion":7396,"completion":7396,"start":12486,"enrollment":5686,"conditions":12487,"interventions":12488},"NCT00795275","Incretin Effect in People With Impaired Fasting Glucose",[95],"2008-01",[15],[12468],{"intervention":12490,"totalTrials":114,"cells":12491},"Exenatide",{"EARLY_PHASE1":12492,"PHASE1":12494,"PHASE2":12496,"PHASE3":12498,"PHASE4":12500,"NA":12502},{"trials":12493,"activeCount":117},[],{"trials":12495,"activeCount":117},[],{"trials":12497,"activeCount":117},[],{"trials":12499,"activeCount":117},[],{"trials":12501,"activeCount":117},[],{"trials":12503,"activeCount":117},[12504],{"nctId":12505,"briefTitle":12506,"status":160,"phases":12507,"primaryCompletion":4225,"completion":4225,"start":10584,"enrollment":25,"conditions":12508,"interventions":12509},"NCT01364584","Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes",[95],[24],[12490],{"intervention":12511,"totalTrials":114,"cells":12512},"11C-PiB",{"EARLY_PHASE1":12513,"PHASE1":12515,"PHASE2":12517,"PHASE3":12519,"PHASE4":12521,"NA":12523},{"trials":12514,"activeCount":117},[],{"trials":12516,"activeCount":117},[],{"trials":12518,"activeCount":117},[],{"trials":12520,"activeCount":117},[],{"trials":12522,"activeCount":117},[],{"trials":12524,"activeCount":117},[12525],{"nctId":12526,"briefTitle":12527,"status":125,"phases":12528,"primaryCompletion":12529,"completion":12529,"start":12530,"enrollment":4755,"conditions":12531,"interventions":12533},"NCT04505735","Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment",[],"2022-09-23","2016-11-22",[2382,12532],"Healthy Aging",[12511],{"intervention":12535,"totalTrials":114,"cells":12536},"Estrogen suppression",{"EARLY_PHASE1":12537,"PHASE1":12539,"PHASE2":12541,"PHASE3":12543,"PHASE4":12545,"NA":12547},{"trials":12538,"activeCount":117},[],{"trials":12540,"activeCount":117},[],{"trials":12542,"activeCount":117},[],{"trials":12544,"activeCount":117},[],{"trials":12546,"activeCount":117},[],{"trials":12548,"activeCount":117},[12549],{"nctId":12550,"briefTitle":12551,"status":160,"phases":12552,"primaryCompletion":10583,"completion":1057,"start":227,"enrollment":129,"conditions":12553,"interventions":12554},"NCT01846728","Effects of Estrogen Deficiency on Energy Expenditure",[95],[15],[12535],{"intervention":12556,"totalTrials":114,"cells":12557},"Filgrastim",{"EARLY_PHASE1":12558,"PHASE1":12560,"PHASE2":12562,"PHASE3":12564,"PHASE4":12566,"NA":12568},{"trials":12559,"activeCount":117},[],{"trials":12561,"activeCount":117},[],{"trials":12563,"activeCount":117},[],{"trials":12565,"activeCount":117},[],{"trials":12567,"activeCount":117},[],{"trials":12569,"activeCount":117},[12570],{"nctId":12571,"briefTitle":12572,"status":160,"phases":12573,"primaryCompletion":12574,"completion":358,"start":12575,"enrollment":1602,"conditions":12576,"interventions":12577},"NCT02331134","Tissue and Hematopoietic\u002FMesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer",[95],"2018-07-06","2015-05-13",[2477,3013],[12556],{"intervention":11818,"totalTrials":114,"cells":12579},{"EARLY_PHASE1":12580,"PHASE1":12582,"PHASE2":12584,"PHASE3":12586,"PHASE4":12588,"NA":12590},{"trials":12581,"activeCount":117},[],{"trials":12583,"activeCount":117},[],{"trials":12585,"activeCount":117},[],{"trials":12587,"activeCount":117},[],{"trials":12589,"activeCount":117},[],{"trials":12591,"activeCount":117},[12592],{"nctId":11809,"briefTitle":11810,"status":160,"phases":12593,"primaryCompletion":11812,"completion":11812,"start":11813,"enrollment":11814,"conditions":12594,"interventions":12595},[95],[11816],[11818,11794,11819],{"intervention":11819,"totalTrials":114,"cells":12597},{"EARLY_PHASE1":12598,"PHASE1":12600,"PHASE2":12602,"PHASE3":12604,"PHASE4":12606,"NA":12608},{"trials":12599,"activeCount":117},[],{"trials":12601,"activeCount":117},[],{"trials":12603,"activeCount":117},[],{"trials":12605,"activeCount":117},[],{"trials":12607,"activeCount":117},[],{"trials":12609,"activeCount":117},[12610],{"nctId":11809,"briefTitle":11810,"status":160,"phases":12611,"primaryCompletion":11812,"completion":11812,"start":11813,"enrollment":11814,"conditions":12612,"interventions":12613},[95],[11816],[11818,11794,11819],{"intervention":12615,"totalTrials":114,"cells":12616},"Voriconazole",{"EARLY_PHASE1":12617,"PHASE1":12619,"PHASE2":12621,"PHASE3":12623,"PHASE4":12625,"NA":12627},{"trials":12618,"activeCount":117},[],{"trials":12620,"activeCount":117},[],{"trials":12622,"activeCount":117},[],{"trials":12624,"activeCount":117},[],{"trials":12626,"activeCount":117},[],{"trials":12628,"activeCount":117},[12629],{"nctId":12630,"briefTitle":12631,"status":160,"phases":12632,"primaryCompletion":12633,"completion":12633,"start":7099,"enrollment":228,"conditions":12634,"interventions":12636},"NCT01101386","Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis",[],"2012-11",[12635],"Fungal Infection",[12615],{"intervention":12638,"totalTrials":114,"cells":12639},"boceprevir; etravirine",{"EARLY_PHASE1":12640,"PHASE1":12642,"PHASE2":12644,"PHASE3":12646,"PHASE4":12648,"NA":12650},{"trials":12641,"activeCount":117},[],{"trials":12643,"activeCount":117},[],{"trials":12645,"activeCount":117},[],{"trials":12647,"activeCount":117},[],{"trials":12649,"activeCount":117},[],{"trials":12651,"activeCount":117},[12652],{"nctId":12653,"briefTitle":12654,"status":160,"phases":12655,"primaryCompletion":6507,"completion":4753,"start":5035,"enrollment":5686,"conditions":12656,"interventions":12657},"NCT01427504","Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV\u002FHepatitis C Virus Negative Volunteers",[95],[4630,5062],[12638],{"intervention":12659,"totalTrials":114,"cells":12660},"divalproex sodium",{"EARLY_PHASE1":12661,"PHASE1":12663,"PHASE2":12665,"PHASE3":12667,"PHASE4":12669,"NA":12671},{"trials":12662,"activeCount":117},[],{"trials":12664,"activeCount":117},[],{"trials":12666,"activeCount":117},[],{"trials":12668,"activeCount":117},[],{"trials":12670,"activeCount":117},[],{"trials":12672,"activeCount":117},[12673],{"nctId":12674,"briefTitle":12675,"status":160,"phases":12676,"primaryCompletion":7076,"completion":4186,"start":12677,"enrollment":110,"conditions":12678,"interventions":12681},"NCT01760785","Valproate for Mood Swings and Alcohol Use Following Head Injury",[95],"2008-09",[12679,12680],"Traumatic Brain Injury (TBI)","Alcoholism",[12659],{"intervention":11846,"totalTrials":114,"cells":12683},{"EARLY_PHASE1":12684,"PHASE1":12686,"PHASE2":12688,"PHASE3":12690,"PHASE4":12692,"NA":12694},{"trials":12685,"activeCount":117},[],{"trials":12687,"activeCount":117},[],{"trials":12689,"activeCount":117},[],{"trials":12691,"activeCount":117},[],{"trials":12693,"activeCount":117},[],{"trials":12695,"activeCount":117},[12696],{"nctId":11839,"briefTitle":11840,"status":160,"phases":12697,"primaryCompletion":4721,"completion":4721,"start":11842,"enrollment":11843,"conditions":12698,"interventions":12699},[95],[15],[846,11846,11847,11848],{"intervention":11847,"totalTrials":114,"cells":12701},{"EARLY_PHASE1":12702,"PHASE1":12704,"PHASE2":12706,"PHASE3":12708,"PHASE4":12710,"NA":12712},{"trials":12703,"activeCount":117},[],{"trials":12705,"activeCount":117},[],{"trials":12707,"activeCount":117},[],{"trials":12709,"activeCount":117},[],{"trials":12711,"activeCount":117},[],{"trials":12713,"activeCount":117},[12714],{"nctId":11839,"briefTitle":11840,"status":160,"phases":12715,"primaryCompletion":4721,"completion":4721,"start":11842,"enrollment":11843,"conditions":12716,"interventions":12717},[95],[15],[846,11846,11847,11848],{"intervention":11848,"totalTrials":114,"cells":12719},{"EARLY_PHASE1":12720,"PHASE1":12722,"PHASE2":12724,"PHASE3":12726,"PHASE4":12728,"NA":12730},{"trials":12721,"activeCount":117},[],{"trials":12723,"activeCount":117},[],{"trials":12725,"activeCount":117},[],{"trials":12727,"activeCount":117},[],{"trials":12729,"activeCount":117},[],{"trials":12731,"activeCount":117},[12732],{"nctId":11839,"briefTitle":11840,"status":160,"phases":12733,"primaryCompletion":4721,"completion":4721,"start":11842,"enrollment":11843,"conditions":12734,"interventions":12735},[95],[15],[846,11846,11847,11848],{"intervention":12737,"totalTrials":114,"cells":12738},"acetaminophen",{"EARLY_PHASE1":12739,"PHASE1":12741,"PHASE2":12743,"PHASE3":12745,"PHASE4":12747,"NA":12749},{"trials":12740,"activeCount":117},[],{"trials":12742,"activeCount":117},[],{"trials":12744,"activeCount":117},[],{"trials":12746,"activeCount":117},[],{"trials":12748,"activeCount":117},[],{"trials":12750,"activeCount":117},[12751],{"nctId":12752,"briefTitle":12753,"status":160,"phases":12754,"primaryCompletion":5484,"completion":5484,"start":12755,"enrollment":16,"conditions":12756,"interventions":12757},"NCT00429624","Randomized Controlled Trial of Chiropractic Manipulation Versus Medical Therapy for Chronic Neck Pain",[95],"1994-09",[1284],[12737],{"intervention":12759,"totalTrials":114,"cells":12760},"Multi-Cancer Cancer Panel",{"EARLY_PHASE1":12761,"PHASE1":12763,"PHASE2":12765,"PHASE3":12767,"PHASE4":12769,"NA":12771},{"trials":12762,"activeCount":117},[],{"trials":12764,"activeCount":117},[],{"trials":12766,"activeCount":117},[],{"trials":12768,"activeCount":117},[],{"trials":12770,"activeCount":117},[],{"trials":12772,"activeCount":117},[12773],{"nctId":12774,"briefTitle":12775,"status":160,"phases":12776,"primaryCompletion":12777,"completion":12777,"start":12778,"enrollment":938,"conditions":12779,"interventions":12781},"NCT04160832","Prevalence and Spectrum of Cancer Susceptibility Among Patients with Advanced Colorectal Polyps",[],"2024-08-30","2019-10-24",[12780],"Colorectal Neoplasm",[12759],{"intervention":875,"totalTrials":114,"cells":12783},{"EARLY_PHASE1":12784,"PHASE1":12786,"PHASE2":12788,"PHASE3":12790,"PHASE4":12792,"NA":12794},{"trials":12785,"activeCount":117},[],{"trials":12787,"activeCount":117},[],{"trials":12789,"activeCount":117},[],{"trials":12791,"activeCount":117},[],{"trials":12793,"activeCount":117},[],{"trials":12795,"activeCount":117},[12796],{"nctId":866,"briefTitle":867,"status":160,"phases":12797,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":12798,"interventions":12799},[95],[873,27,708],[875,876,877],{"intervention":12801,"totalTrials":114,"cells":12802},"PRP",{"EARLY_PHASE1":12803,"PHASE1":12805,"PHASE2":12807,"PHASE3":12809,"PHASE4":12811,"NA":12813},{"trials":12804,"activeCount":117},[],{"trials":12806,"activeCount":117},[],{"trials":12808,"activeCount":117},[],{"trials":12810,"activeCount":117},[],{"trials":12812,"activeCount":117},[],{"trials":12814,"activeCount":117},[12815],{"nctId":12816,"briefTitle":12817,"status":160,"phases":12818,"primaryCompletion":12819,"completion":12819,"start":6333,"enrollment":3331,"conditions":12820,"interventions":12822},"NCT01920152","Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)",[95],"2019-12-05",[12821],"Hip Osteoarthritis",[12801],{"intervention":1991,"totalTrials":114,"cells":12824},{"EARLY_PHASE1":12825,"PHASE1":12827,"PHASE2":12829,"PHASE3":12831,"PHASE4":12833,"NA":12835},{"trials":12826,"activeCount":117},[],{"trials":12828,"activeCount":117},[],{"trials":12830,"activeCount":117},[],{"trials":12832,"activeCount":117},[],{"trials":12834,"activeCount":117},[],{"trials":12836,"activeCount":117},[12837],{"nctId":1980,"briefTitle":1981,"status":160,"phases":12838,"primaryCompletion":1983,"completion":1984,"start":1985,"enrollment":1986,"conditions":12839,"interventions":12840},[],[131,18,33,1926,1927,1929,1988,1989,1942,1940,1943],[1906,1991],{"intervention":12842,"totalTrials":114,"cells":12843},"Interferon Gamma-1B",{"EARLY_PHASE1":12844,"PHASE1":12846,"PHASE2":12848,"PHASE3":12850,"PHASE4":12852,"NA":12854},{"trials":12845,"activeCount":117},[],{"trials":12847,"activeCount":117},[],{"trials":12849,"activeCount":117},[],{"trials":12851,"activeCount":117},[],{"trials":12853,"activeCount":117},[],{"trials":12855,"activeCount":117},[12856],{"nctId":12857,"briefTitle":12858,"status":160,"phases":12859,"primaryCompletion":12860,"completion":12860,"start":12861,"enrollment":1602,"conditions":12862,"interventions":12863},"NCT03548818","Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease",[],"2020-07-15","2018-05-16",[10544],[12842],{"intervention":1477,"totalTrials":114,"cells":12865},{"EARLY_PHASE1":12866,"PHASE1":12868,"PHASE2":12870,"PHASE3":12872,"PHASE4":12874,"NA":12876},{"trials":12867,"activeCount":117},[],{"trials":12869,"activeCount":117},[],{"trials":12871,"activeCount":117},[],{"trials":12873,"activeCount":117},[],{"trials":12875,"activeCount":117},[],{"trials":12877,"activeCount":117},[12878],{"nctId":1466,"briefTitle":1467,"status":160,"phases":12879,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":12880,"interventions":12881},[95],[1474],[1476,1477,1169],{"intervention":12883,"totalTrials":114,"cells":12884},"Aflibercept",{"EARLY_PHASE1":12885,"PHASE1":12887,"PHASE2":12889,"PHASE3":12891,"PHASE4":12893,"NA":12895},{"trials":12886,"activeCount":117},[],{"trials":12888,"activeCount":117},[],{"trials":12890,"activeCount":117},[],{"trials":12892,"activeCount":117},[],{"trials":12894,"activeCount":117},[],{"trials":12896,"activeCount":117},[12897],{"nctId":12898,"briefTitle":12899,"status":160,"phases":12900,"primaryCompletion":10583,"completion":10583,"start":1469,"enrollment":902,"conditions":12901,"interventions":12903},"NCT01711879","Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma",[95],[12902],"Neovascular Glaucoma",[12883],{"intervention":4182,"totalTrials":114,"cells":12905},{"EARLY_PHASE1":12906,"PHASE1":12908,"PHASE2":12910,"PHASE3":12912,"PHASE4":12914,"NA":12916},{"trials":12907,"activeCount":117},[],{"trials":12909,"activeCount":117},[],{"trials":12911,"activeCount":117},[],{"trials":12913,"activeCount":117},[],{"trials":12915,"activeCount":117},[],{"trials":12917,"activeCount":117},[12918],{"nctId":4173,"briefTitle":4174,"status":160,"phases":12919,"primaryCompletion":4176,"completion":4176,"start":4177,"enrollment":4178,"conditions":12920,"interventions":12921},[95],[4180],[4182,4148],{"intervention":12923,"totalTrials":114,"cells":12924},"Tenofovir disoproxil fumarate\u002FEmtricitabine",{"EARLY_PHASE1":12925,"PHASE1":12927,"PHASE2":12929,"PHASE3":12931,"PHASE4":12933,"NA":12935},{"trials":12926,"activeCount":117},[],{"trials":12928,"activeCount":117},[],{"trials":12930,"activeCount":117},[],{"trials":12932,"activeCount":117},[],{"trials":12934,"activeCount":117},[],{"trials":12936,"activeCount":117},[12937],{"nctId":12938,"briefTitle":12939,"status":160,"phases":12940,"primaryCompletion":4640,"completion":4640,"start":5484,"enrollment":37,"conditions":12941,"interventions":12942},"NCT00414518","Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection",[95],[180],[12923,12943],"Lopinavir\u002FRitonavir",{"intervention":12943,"totalTrials":114,"cells":12945},{"EARLY_PHASE1":12946,"PHASE1":12948,"PHASE2":12950,"PHASE3":12952,"PHASE4":12954,"NA":12956},{"trials":12947,"activeCount":117},[],{"trials":12949,"activeCount":117},[],{"trials":12951,"activeCount":117},[],{"trials":12953,"activeCount":117},[],{"trials":12955,"activeCount":117},[],{"trials":12957,"activeCount":117},[12958],{"nctId":12938,"briefTitle":12939,"status":160,"phases":12959,"primaryCompletion":4640,"completion":4640,"start":5484,"enrollment":37,"conditions":12960,"interventions":12961},[95],[180],[12923,12943],{"intervention":12963,"totalTrials":114,"cells":12964},"oral analgesic",{"EARLY_PHASE1":12965,"PHASE1":12967,"PHASE2":12969,"PHASE3":12971,"PHASE4":12973,"NA":12975},{"trials":12966,"activeCount":117},[],{"trials":12968,"activeCount":117},[],{"trials":12970,"activeCount":117},[],{"trials":12972,"activeCount":117},[],{"trials":12974,"activeCount":117},[],{"trials":12976,"activeCount":117},[12977],{"nctId":12978,"briefTitle":12979,"status":160,"phases":12980,"primaryCompletion":7429,"completion":7429,"start":7580,"enrollment":12981,"conditions":12982,"interventions":12984},"NCT00884650","Managing Post-operative Pain in Children With Cerebral Palsy Using a Pain Pump",[95],54,[12983],"Cerebral Palsy",[12963,12985],"intravenous analgesic per pump",{"intervention":12985,"totalTrials":114,"cells":12987},{"EARLY_PHASE1":12988,"PHASE1":12990,"PHASE2":12992,"PHASE3":12994,"PHASE4":12996,"NA":12998},{"trials":12989,"activeCount":117},[],{"trials":12991,"activeCount":117},[],{"trials":12993,"activeCount":117},[],{"trials":12995,"activeCount":117},[],{"trials":12997,"activeCount":117},[],{"trials":12999,"activeCount":117},[13000],{"nctId":12978,"briefTitle":12979,"status":160,"phases":13001,"primaryCompletion":7429,"completion":7429,"start":7580,"enrollment":12981,"conditions":13002,"interventions":13003},[95],[12983],[12963,12985],{"intervention":13005,"totalTrials":114,"cells":13006},"Methyldopa",{"EARLY_PHASE1":13007,"PHASE1":13009,"PHASE2":13011,"PHASE3":13013,"PHASE4":13015,"NA":13017},{"trials":13008,"activeCount":117},[],{"trials":13010,"activeCount":117},[],{"trials":13012,"activeCount":117},[],{"trials":13014,"activeCount":117},[],{"trials":13016,"activeCount":117},[],{"trials":13018,"activeCount":117},[13019],{"nctId":13020,"briefTitle":13021,"status":160,"phases":13022,"primaryCompletion":13023,"completion":13023,"start":5281,"enrollment":19,"conditions":13024,"interventions":13025},"NCT01883804","Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes",[95],"2016-02",[1380],[13005],{"intervention":13027,"totalTrials":114,"cells":13028},"Detemir",{"EARLY_PHASE1":13029,"PHASE1":13031,"PHASE2":13033,"PHASE3":13035,"PHASE4":13037,"NA":13039},{"trials":13030,"activeCount":117},[],{"trials":13032,"activeCount":117},[],{"trials":13034,"activeCount":117},[],{"trials":13036,"activeCount":117},[],{"trials":13038,"activeCount":117},[],{"trials":13040,"activeCount":117},[13041],{"nctId":13042,"briefTitle":13043,"status":160,"phases":13044,"primaryCompletion":4176,"completion":4176,"start":7670,"enrollment":19,"conditions":13045,"interventions":13046},"NCT01186003","Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy",[95],[33],[13027],{"intervention":13048,"totalTrials":114,"cells":13049},"PF-03084014",{"EARLY_PHASE1":13050,"PHASE1":13052,"PHASE2":13054,"PHASE3":13056,"PHASE4":13058,"NA":13060},{"trials":13051,"activeCount":117},[],{"trials":13053,"activeCount":117},[],{"trials":13055,"activeCount":117},[],{"trials":13057,"activeCount":117},[],{"trials":13059,"activeCount":117},[],{"trials":13061,"activeCount":117},[13062],{"nctId":13063,"briefTitle":13064,"status":12371,"phases":13065,"conditions":13066,"interventions":13069},"NCT02955446","Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies",[],[13067,13068],"Neoplasm","Desmoid Tumor",[13048],{"intervention":13071,"totalTrials":114,"cells":13072},"Nicotine Patch",{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13077,"PHASE3":13079,"PHASE4":13081,"NA":13083},{"trials":13074,"activeCount":117},[],{"trials":13076,"activeCount":117},[],{"trials":13078,"activeCount":117},[],{"trials":13080,"activeCount":117},[],{"trials":13082,"activeCount":117},[],{"trials":13084,"activeCount":117},[13085],{"nctId":13086,"briefTitle":13087,"status":160,"phases":13088,"primaryCompletion":4753,"completion":4753,"start":4733,"enrollment":13089,"conditions":13090,"interventions":13091},"NCT01889771","A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline",[95],1495,[1329],[13071],{"intervention":13093,"totalTrials":114,"cells":13094},"PCV-13",{"EARLY_PHASE1":13095,"PHASE1":13097,"PHASE2":13099,"PHASE3":13101,"PHASE4":13103,"NA":13105},{"trials":13096,"activeCount":117},[],{"trials":13098,"activeCount":117},[],{"trials":13100,"activeCount":117},[],{"trials":13102,"activeCount":117},[],{"trials":13104,"activeCount":117},[],{"trials":13106,"activeCount":117},[13107],{"nctId":13108,"briefTitle":13109,"status":715,"phases":13110,"primaryCompletion":6840,"completion":6840,"start":7076,"enrollment":1378,"conditions":13111,"interventions":13114},"NCT02012309","Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses",[95],[5062,13112,13113],"Pneumococcal Infections","Pneumococcal Vaccines",[13093,13115],"PPSV-23",{"intervention":13115,"totalTrials":114,"cells":13117},{"EARLY_PHASE1":13118,"PHASE1":13120,"PHASE2":13122,"PHASE3":13124,"PHASE4":13126,"NA":13128},{"trials":13119,"activeCount":117},[],{"trials":13121,"activeCount":117},[],{"trials":13123,"activeCount":117},[],{"trials":13125,"activeCount":117},[],{"trials":13127,"activeCount":117},[],{"trials":13129,"activeCount":117},[13130],{"nctId":13108,"briefTitle":13109,"status":715,"phases":13131,"primaryCompletion":6840,"completion":6840,"start":7076,"enrollment":1378,"conditions":13132,"interventions":13133},[95],[5062,13112,13113],[13093,13115],{"intervention":13135,"totalTrials":114,"cells":13136},"Bupivicaine",{"EARLY_PHASE1":13137,"PHASE1":13139,"PHASE2":13141,"PHASE3":13143,"PHASE4":13145,"NA":13147},{"trials":13138,"activeCount":117},[],{"trials":13140,"activeCount":117},[],{"trials":13142,"activeCount":117},[],{"trials":13144,"activeCount":117},[],{"trials":13146,"activeCount":117},[],{"trials":13148,"activeCount":117},[13149],{"nctId":13150,"briefTitle":13151,"status":125,"phases":13152,"primaryCompletion":4176,"completion":4176,"start":5034,"enrollment":902,"conditions":13153,"interventions":13155},"NCT01916590","Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control",[95],[13154],"Post-operative Pain",[13135],{"intervention":13157,"totalTrials":114,"cells":13158},"sildenafil",{"EARLY_PHASE1":13159,"PHASE1":13161,"PHASE2":13163,"PHASE3":13165,"PHASE4":13167,"NA":13169},{"trials":13160,"activeCount":117},[],{"trials":13162,"activeCount":117},[],{"trials":13164,"activeCount":117},[],{"trials":13166,"activeCount":117},[],{"trials":13168,"activeCount":117},[],{"trials":13170,"activeCount":117},[13171],{"nctId":13172,"briefTitle":13173,"status":160,"phases":13174,"primaryCompletion":162,"completion":162,"start":4177,"enrollment":1548,"conditions":13175,"interventions":13177},"NCT00478335","Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus",[95],[13176],"Nephrogenic Diabetes Insipidus",[13157,13178,13179,13180],"calcitonin","hydrochlorothiazide\u002Familoride","indomethacin",{"intervention":13178,"totalTrials":114,"cells":13182},{"EARLY_PHASE1":13183,"PHASE1":13185,"PHASE2":13187,"PHASE3":13189,"PHASE4":13191,"NA":13193},{"trials":13184,"activeCount":117},[],{"trials":13186,"activeCount":117},[],{"trials":13188,"activeCount":117},[],{"trials":13190,"activeCount":117},[],{"trials":13192,"activeCount":117},[],{"trials":13194,"activeCount":117},[13195],{"nctId":13172,"briefTitle":13173,"status":160,"phases":13196,"primaryCompletion":162,"completion":162,"start":4177,"enrollment":1548,"conditions":13197,"interventions":13198},[95],[13176],[13157,13178,13179,13180],{"intervention":13179,"totalTrials":114,"cells":13200},{"EARLY_PHASE1":13201,"PHASE1":13203,"PHASE2":13205,"PHASE3":13207,"PHASE4":13209,"NA":13211},{"trials":13202,"activeCount":117},[],{"trials":13204,"activeCount":117},[],{"trials":13206,"activeCount":117},[],{"trials":13208,"activeCount":117},[],{"trials":13210,"activeCount":117},[],{"trials":13212,"activeCount":117},[13213],{"nctId":13172,"briefTitle":13173,"status":160,"phases":13214,"primaryCompletion":162,"completion":162,"start":4177,"enrollment":1548,"conditions":13215,"interventions":13216},[95],[13176],[13157,13178,13179,13180],{"intervention":13180,"totalTrials":114,"cells":13218},{"EARLY_PHASE1":13219,"PHASE1":13221,"PHASE2":13223,"PHASE3":13225,"PHASE4":13227,"NA":13229},{"trials":13220,"activeCount":117},[],{"trials":13222,"activeCount":117},[],{"trials":13224,"activeCount":117},[],{"trials":13226,"activeCount":117},[],{"trials":13228,"activeCount":117},[],{"trials":13230,"activeCount":117},[13231],{"nctId":13172,"briefTitle":13173,"status":160,"phases":13232,"primaryCompletion":162,"completion":162,"start":4177,"enrollment":1548,"conditions":13233,"interventions":13234},[95],[13176],[13157,13178,13179,13180],{"intervention":13236,"totalTrials":114,"cells":13237},"Gabapentin",{"EARLY_PHASE1":13238,"PHASE1":13240,"PHASE2":13242,"PHASE3":13244,"PHASE4":13246,"NA":13248},{"trials":13239,"activeCount":117},[],{"trials":13241,"activeCount":117},[],{"trials":13243,"activeCount":117},[],{"trials":13245,"activeCount":117},[],{"trials":13247,"activeCount":117},[],{"trials":13249,"activeCount":117},[13250],{"nctId":13251,"briefTitle":13252,"status":160,"phases":13253,"primaryCompletion":12395,"completion":12395,"start":5083,"enrollment":1518,"conditions":13254,"interventions":13256},"NCT01707420","Preoperative Gabapentin for Post-tonsillectomy Pain in Children",[95],[13255],"Post Operative Pain Management in Children With Tonsillectomy\u002FAdenoidectomy",[13236,13257],"liquid placebo",{"intervention":13257,"totalTrials":114,"cells":13259},{"EARLY_PHASE1":13260,"PHASE1":13262,"PHASE2":13264,"PHASE3":13266,"PHASE4":13268,"NA":13270},{"trials":13261,"activeCount":117},[],{"trials":13263,"activeCount":117},[],{"trials":13265,"activeCount":117},[],{"trials":13267,"activeCount":117},[],{"trials":13269,"activeCount":117},[],{"trials":13271,"activeCount":117},[13272],{"nctId":13251,"briefTitle":13252,"status":160,"phases":13273,"primaryCompletion":12395,"completion":12395,"start":5083,"enrollment":1518,"conditions":13274,"interventions":13275},[95],[13255],[13236,13257],{"intervention":13277,"totalTrials":114,"cells":13278},"Misoprostol",{"EARLY_PHASE1":13279,"PHASE1":13281,"PHASE2":13283,"PHASE3":13285,"PHASE4":13287,"NA":13289},{"trials":13280,"activeCount":117},[],{"trials":13282,"activeCount":117},[],{"trials":13284,"activeCount":117},[],{"trials":13286,"activeCount":117},[],{"trials":13288,"activeCount":117},[],{"trials":13290,"activeCount":117},[13291],{"nctId":13292,"briefTitle":13293,"status":125,"phases":13294,"primaryCompletion":4686,"completion":5083,"start":5034,"enrollment":99,"conditions":13295,"interventions":13296},"NCT01422226","Intra Uterine Device Insertion in Nulliparous Women",[95],[255],[13277],{"intervention":11699,"totalTrials":114,"cells":13298},{"EARLY_PHASE1":13299,"PHASE1":13301,"PHASE2":13303,"PHASE3":13305,"PHASE4":13307,"NA":13309},{"trials":13300,"activeCount":117},[],{"trials":13302,"activeCount":117},[],{"trials":13304,"activeCount":117},[],{"trials":13306,"activeCount":117},[],{"trials":13308,"activeCount":117},[],{"trials":13310,"activeCount":117},[13311],{"nctId":11691,"briefTitle":11692,"status":125,"phases":13312,"primaryCompletion":11694,"completion":11694,"start":5685,"enrollment":11695,"conditions":13313,"interventions":13314},[95],[6192],[11698,11699],{"intervention":13316,"totalTrials":114,"cells":13317},"Abacavir\u002Flamivudine",{"EARLY_PHASE1":13318,"PHASE1":13320,"PHASE2":13322,"PHASE3":13324,"PHASE4":13326,"NA":13328},{"trials":13319,"activeCount":117},[],{"trials":13321,"activeCount":117},[],{"trials":13323,"activeCount":117},[],{"trials":13325,"activeCount":117},[],{"trials":13327,"activeCount":117},[],{"trials":13329,"activeCount":117},[13330],{"nctId":13331,"briefTitle":13332,"status":160,"phases":13333,"primaryCompletion":13334,"completion":13334,"start":13335,"enrollment":4755,"conditions":13336,"interventions":13337},"NCT04301661","Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites",[],"2021-12-17","2020-03-06",[12465],[13316,13338,13339],"Tenofovir alafenamide\u002Femtricitabine","Switch",{"intervention":13338,"totalTrials":114,"cells":13341},{"EARLY_PHASE1":13342,"PHASE1":13344,"PHASE2":13346,"PHASE3":13348,"PHASE4":13350,"NA":13352},{"trials":13343,"activeCount":117},[],{"trials":13345,"activeCount":117},[],{"trials":13347,"activeCount":117},[],{"trials":13349,"activeCount":117},[],{"trials":13351,"activeCount":117},[],{"trials":13353,"activeCount":117},[13354],{"nctId":13331,"briefTitle":13332,"status":160,"phases":13355,"primaryCompletion":13334,"completion":13334,"start":13335,"enrollment":4755,"conditions":13356,"interventions":13357},[],[12465],[13316,13338,13339],{"intervention":13339,"totalTrials":114,"cells":13359},{"EARLY_PHASE1":13360,"PHASE1":13362,"PHASE2":13364,"PHASE3":13366,"PHASE4":13368,"NA":13370},{"trials":13361,"activeCount":117},[],{"trials":13363,"activeCount":117},[],{"trials":13365,"activeCount":117},[],{"trials":13367,"activeCount":117},[],{"trials":13369,"activeCount":117},[],{"trials":13371,"activeCount":117},[13372],{"nctId":13331,"briefTitle":13332,"status":160,"phases":13373,"primaryCompletion":13334,"completion":13334,"start":13335,"enrollment":4755,"conditions":13374,"interventions":13375},[],[12465],[13316,13338,13339],{"intervention":13377,"totalTrials":114,"cells":13378},"Ascorbic Acid",{"EARLY_PHASE1":13379,"PHASE1":13381,"PHASE2":13383,"PHASE3":13385,"PHASE4":13387,"NA":13389},{"trials":13380,"activeCount":117},[],{"trials":13382,"activeCount":117},[],{"trials":13384,"activeCount":117},[],{"trials":13386,"activeCount":117},[],{"trials":13388,"activeCount":117},[],{"trials":13390,"activeCount":117},[13391],{"nctId":13392,"briefTitle":13393,"status":160,"phases":13394,"primaryCompletion":2051,"completion":2051,"start":7053,"enrollment":2173,"conditions":13395,"interventions":13396},"NCT00786019","Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes",[95],[24],[13377],{"intervention":13398,"totalTrials":114,"cells":13399},"Levetiracetam",{"EARLY_PHASE1":13400,"PHASE1":13402,"PHASE2":13404,"PHASE3":13406,"PHASE4":13408,"NA":13410},{"trials":13401,"activeCount":117},[],{"trials":13403,"activeCount":117},[],{"trials":13405,"activeCount":117},[],{"trials":13407,"activeCount":117},[],{"trials":13409,"activeCount":117},[],{"trials":13411,"activeCount":117},[13412],{"nctId":13413,"briefTitle":13414,"status":160,"phases":13415,"primaryCompletion":13416,"completion":13416,"start":5281,"enrollment":31,"conditions":13417,"interventions":13418},"NCT02647437","Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia",[95],"2024-09",[7102],[13398],{"intervention":13420,"totalTrials":114,"cells":13421},"iohexol",{"EARLY_PHASE1":13422,"PHASE1":13424,"PHASE2":13426,"PHASE3":13428,"PHASE4":13430,"NA":13432},{"trials":13423,"activeCount":117},[],{"trials":13425,"activeCount":117},[],{"trials":13427,"activeCount":117},[],{"trials":13429,"activeCount":117},[],{"trials":13431,"activeCount":117},[],{"trials":13433,"activeCount":117},[13434],{"nctId":13435,"briefTitle":13436,"status":160,"phases":13437,"primaryCompletion":982,"completion":982,"start":11485,"enrollment":649,"conditions":13438,"interventions":13439},"NCT02304263","Tenofovir Pharmacology in Older HIV Infected Individuals",[],[5062,27],[13420],{"intervention":13441,"totalTrials":114,"cells":13442},"Allopurinol",{"EARLY_PHASE1":13443,"PHASE1":13445,"PHASE2":13447,"PHASE3":13449,"PHASE4":13451,"NA":13453},{"trials":13444,"activeCount":117},[],{"trials":13446,"activeCount":117},[],{"trials":13448,"activeCount":117},[],{"trials":13450,"activeCount":117},[],{"trials":13452,"activeCount":117},[],{"trials":13454,"activeCount":117},[13455],{"nctId":13456,"briefTitle":13457,"status":160,"phases":13458,"primaryCompletion":982,"completion":982,"start":10584,"enrollment":288,"conditions":13459,"interventions":13460},"NCT01228903","Uric Acid and the Endothelium in CKD",[95],[2343],[13441],{"intervention":13462,"totalTrials":114,"cells":13463},"Triclabendazole",{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13468,"PHASE3":13470,"PHASE4":13472,"NA":13474},{"trials":13465,"activeCount":117},[],{"trials":13467,"activeCount":117},[],{"trials":13469,"activeCount":117},[],{"trials":13471,"activeCount":117},[],{"trials":13473,"activeCount":117},[],{"trials":13475,"activeCount":117},[13476],{"nctId":13477,"briefTitle":13478,"status":12371,"phases":13479,"conditions":13480,"interventions":13482},"NCT01931085","Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)",[],[13481],"Parasitic Disease",[13462],{"intervention":13484,"totalTrials":114,"cells":13485},"Cetrorelix acetate, 0.25 mg\u002Fday",{"EARLY_PHASE1":13486,"PHASE1":13488,"PHASE2":13490,"PHASE3":13492,"PHASE4":13494,"NA":13496},{"trials":13487,"activeCount":117},[],{"trials":13489,"activeCount":117},[],{"trials":13491,"activeCount":117},[],{"trials":13493,"activeCount":117},[],{"trials":13495,"activeCount":117},[],{"trials":13497,"activeCount":117},[13498],{"nctId":13499,"briefTitle":13500,"status":160,"phases":13501,"primaryCompletion":13502,"completion":13502,"start":13503,"enrollment":2450,"conditions":13504,"interventions":13505},"NCT04418908","Estrogen, Diabetes, and Endothelial Function",[95],"2018-10-22","2010-11-24",[18],[13484,13506],"Estradiol Patch, 0.025 Mg\u002F24 Hours Weekly Transdermal Film, Extended Release",{"intervention":13506,"totalTrials":114,"cells":13508},{"EARLY_PHASE1":13509,"PHASE1":13511,"PHASE2":13513,"PHASE3":13515,"PHASE4":13517,"NA":13519},{"trials":13510,"activeCount":117},[],{"trials":13512,"activeCount":117},[],{"trials":13514,"activeCount":117},[],{"trials":13516,"activeCount":117},[],{"trials":13518,"activeCount":117},[],{"trials":13520,"activeCount":117},[13521],{"nctId":13499,"briefTitle":13500,"status":160,"phases":13522,"primaryCompletion":13502,"completion":13502,"start":13503,"enrollment":2450,"conditions":13523,"interventions":13524},[95],[18],[13484,13506],{"intervention":11671,"totalTrials":114,"cells":13526},{"EARLY_PHASE1":13527,"PHASE1":13529,"PHASE2":13531,"PHASE3":13533,"PHASE4":13535,"NA":13537},{"trials":13528,"activeCount":117},[],{"trials":13530,"activeCount":117},[],{"trials":13532,"activeCount":117},[],{"trials":13534,"activeCount":117},[],{"trials":13536,"activeCount":117},[],{"trials":13538,"activeCount":117},[13539],{"nctId":11666,"briefTitle":11667,"status":160,"phases":13540,"primaryCompletion":5812,"completion":5812,"start":4160,"enrollment":1518,"conditions":13541,"interventions":13542},[95],[24,11549],[4737,11671],{"intervention":13544,"totalTrials":114,"cells":13545},"EMLA",{"EARLY_PHASE1":13546,"PHASE1":13548,"PHASE2":13550,"PHASE3":13552,"PHASE4":13554,"NA":13556},{"trials":13547,"activeCount":117},[],{"trials":13549,"activeCount":117},[],{"trials":13551,"activeCount":117},[],{"trials":13553,"activeCount":117},[],{"trials":13555,"activeCount":117},[],{"trials":13557,"activeCount":117},[13558],{"nctId":13559,"briefTitle":13560,"status":125,"phases":13561,"primaryCompletion":13562,"completion":13562,"start":5107,"enrollment":508,"conditions":13563,"interventions":13566},"NCT01628874","Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children",[95],"2016-08",[13564,13565],"Lumbar Puncture","Topical Analgesia",[13544,13567],"Lidocaine",{"intervention":13567,"totalTrials":114,"cells":13569},{"EARLY_PHASE1":13570,"PHASE1":13572,"PHASE2":13574,"PHASE3":13576,"PHASE4":13578,"NA":13580},{"trials":13571,"activeCount":117},[],{"trials":13573,"activeCount":117},[],{"trials":13575,"activeCount":117},[],{"trials":13577,"activeCount":117},[],{"trials":13579,"activeCount":117},[],{"trials":13581,"activeCount":117},[13582],{"nctId":13559,"briefTitle":13560,"status":125,"phases":13583,"primaryCompletion":13562,"completion":13562,"start":5107,"enrollment":508,"conditions":13584,"interventions":13585},[95],[13564,13565],[13544,13567],{"intervention":13587,"totalTrials":114,"cells":13588},"colistimethate sodium",{"EARLY_PHASE1":13589,"PHASE1":13591,"PHASE2":13593,"PHASE3":13595,"PHASE4":13597,"NA":13599},{"trials":13590,"activeCount":117},[],{"trials":13592,"activeCount":117},[],{"trials":13594,"activeCount":117},[],{"trials":13596,"activeCount":117},[],{"trials":13598,"activeCount":117},[],{"trials":13600,"activeCount":117},[13601],{"nctId":13602,"briefTitle":13603,"status":160,"phases":13604,"primaryCompletion":5811,"completion":5811,"start":7965,"enrollment":37,"conditions":13605,"interventions":13607},"NCT02288429","Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium",[],[13606],"Colistin",[13587],{"intervention":11536,"totalTrials":114,"cells":13609},{"EARLY_PHASE1":13610,"PHASE1":13612,"PHASE2":13614,"PHASE3":13616,"PHASE4":13618,"NA":13620},{"trials":13611,"activeCount":117},[],{"trials":13613,"activeCount":117},[],{"trials":13615,"activeCount":117},[],{"trials":13617,"activeCount":117},[],{"trials":13619,"activeCount":117},[],{"trials":13621,"activeCount":117},[13622],{"nctId":11531,"briefTitle":11532,"status":160,"phases":13623,"primaryCompletion":1469,"completion":1469,"start":965,"enrollment":19,"conditions":13624,"interventions":13625},[95],[15,3646],[11500,11536,11537],{"intervention":11537,"totalTrials":114,"cells":13627},{"EARLY_PHASE1":13628,"PHASE1":13630,"PHASE2":13632,"PHASE3":13634,"PHASE4":13636,"NA":13638},{"trials":13629,"activeCount":117},[],{"trials":13631,"activeCount":117},[],{"trials":13633,"activeCount":117},[],{"trials":13635,"activeCount":117},[],{"trials":13637,"activeCount":117},[],{"trials":13639,"activeCount":117},[13640],{"nctId":11531,"briefTitle":11532,"status":160,"phases":13641,"primaryCompletion":1469,"completion":1469,"start":965,"enrollment":19,"conditions":13642,"interventions":13643},[95],[15,3646],[11500,11536,11537],{"intervention":13645,"totalTrials":114,"cells":13646},"Ethambutol",{"EARLY_PHASE1":13647,"PHASE1":13649,"PHASE2":13651,"PHASE3":13653,"PHASE4":13655,"NA":13657},{"trials":13648,"activeCount":117},[],{"trials":13650,"activeCount":117},[],{"trials":13652,"activeCount":117},[],{"trials":13654,"activeCount":117},[],{"trials":13656,"activeCount":117},[],{"trials":13658,"activeCount":117},[13659],{"nctId":13660,"briefTitle":13661,"status":160,"phases":13662,"primaryCompletion":4186,"completion":4186,"start":5576,"enrollment":5060,"conditions":13663,"interventions":13664},"NCT02372383","Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis",[95],[8383],[13645,13665,13666,13667],"Rifampin","Azithromycin","Pancrelipase",{"intervention":13665,"totalTrials":114,"cells":13669},{"EARLY_PHASE1":13670,"PHASE1":13672,"PHASE2":13674,"PHASE3":13676,"PHASE4":13678,"NA":13680},{"trials":13671,"activeCount":117},[],{"trials":13673,"activeCount":117},[],{"trials":13675,"activeCount":117},[],{"trials":13677,"activeCount":117},[],{"trials":13679,"activeCount":117},[],{"trials":13681,"activeCount":117},[13682],{"nctId":13660,"briefTitle":13661,"status":160,"phases":13683,"primaryCompletion":4186,"completion":4186,"start":5576,"enrollment":5060,"conditions":13684,"interventions":13685},[95],[8383],[13645,13665,13666,13667],{"intervention":13666,"totalTrials":114,"cells":13687},{"EARLY_PHASE1":13688,"PHASE1":13690,"PHASE2":13692,"PHASE3":13694,"PHASE4":13696,"NA":13698},{"trials":13689,"activeCount":117},[],{"trials":13691,"activeCount":117},[],{"trials":13693,"activeCount":117},[],{"trials":13695,"activeCount":117},[],{"trials":13697,"activeCount":117},[],{"trials":13699,"activeCount":117},[13700],{"nctId":13660,"briefTitle":13661,"status":160,"phases":13701,"primaryCompletion":4186,"completion":4186,"start":5576,"enrollment":5060,"conditions":13702,"interventions":13703},[95],[8383],[13645,13665,13666,13667],{"intervention":13667,"totalTrials":114,"cells":13705},{"EARLY_PHASE1":13706,"PHASE1":13708,"PHASE2":13710,"PHASE3":13712,"PHASE4":13714,"NA":13716},{"trials":13707,"activeCount":117},[],{"trials":13709,"activeCount":117},[],{"trials":13711,"activeCount":117},[],{"trials":13713,"activeCount":117},[],{"trials":13715,"activeCount":117},[],{"trials":13717,"activeCount":117},[13718],{"nctId":13660,"briefTitle":13661,"status":160,"phases":13719,"primaryCompletion":4186,"completion":4186,"start":5576,"enrollment":5060,"conditions":13720,"interventions":13721},[95],[8383],[13645,13665,13666,13667],{"intervention":13723,"totalTrials":114,"cells":13724},"Calcium Chloride\u002FCalcium Gluconate",{"EARLY_PHASE1":13725,"PHASE1":13727,"PHASE2":13729,"PHASE3":13731,"PHASE4":13733,"NA":13735},{"trials":13726,"activeCount":117},[],{"trials":13728,"activeCount":117},[],{"trials":13730,"activeCount":117},[],{"trials":13732,"activeCount":117},[],{"trials":13734,"activeCount":117},[],{"trials":13736,"activeCount":117},[13737],{"nctId":13738,"briefTitle":13739,"status":160,"phases":13740,"primaryCompletion":13741,"completion":13742,"start":11527,"enrollment":253,"conditions":13743,"interventions":13745},"NCT02580604","PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)",[95],"2024-07-31","2025-07-31",[13744],"Osteoporosis",[13723,13746],"Half-Normal Saline",{"intervention":13746,"totalTrials":114,"cells":13748},{"EARLY_PHASE1":13749,"PHASE1":13751,"PHASE2":13753,"PHASE3":13755,"PHASE4":13757,"NA":13759},{"trials":13750,"activeCount":117},[],{"trials":13752,"activeCount":117},[],{"trials":13754,"activeCount":117},[],{"trials":13756,"activeCount":117},[],{"trials":13758,"activeCount":117},[],{"trials":13760,"activeCount":117},[13761],{"nctId":13738,"briefTitle":13739,"status":160,"phases":13762,"primaryCompletion":13741,"completion":13742,"start":11527,"enrollment":253,"conditions":13763,"interventions":13764},[95],[13744],[13723,13746],{"intervention":13766,"totalTrials":114,"cells":13767},"Oxybutynin 3% gel",{"EARLY_PHASE1":13768,"PHASE1":13770,"PHASE2":13772,"PHASE3":13774,"PHASE4":13776,"NA":13778},{"trials":13769,"activeCount":117},[],{"trials":13771,"activeCount":117},[],{"trials":13773,"activeCount":117},[],{"trials":13775,"activeCount":117},[],{"trials":13777,"activeCount":117},[],{"trials":13779,"activeCount":117},[13780],{"nctId":13781,"briefTitle":13782,"status":160,"phases":13783,"primaryCompletion":4186,"completion":13784,"start":13023,"enrollment":228,"conditions":13785,"interventions":13787},"NCT02633371","A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults",[95],"2017-05",[13786],"Hyperhidrosis",[13766],{"intervention":13789,"totalTrials":114,"cells":13790},"Testosterone gel 1%",{"EARLY_PHASE1":13791,"PHASE1":13793,"PHASE2":13795,"PHASE3":13797,"PHASE4":13799,"NA":13801},{"trials":13792,"activeCount":117},[],{"trials":13794,"activeCount":117},[],{"trials":13796,"activeCount":117},[],{"trials":13798,"activeCount":117},[],{"trials":13800,"activeCount":117},[],{"trials":13802,"activeCount":117},[13803],{"nctId":13804,"briefTitle":13805,"status":160,"phases":13806,"primaryCompletion":226,"completion":226,"start":4753,"enrollment":1654,"conditions":13807,"interventions":13809},"NCT01585831","Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY\u002FKlinefelter Syndrome",[95],[5155,13808],"XXY Syndrome",[13789],{"intervention":13811,"totalTrials":114,"cells":13812},"PI-2620 tracer",{"EARLY_PHASE1":13813,"PHASE1":13815,"PHASE2":13817,"PHASE3":13819,"PHASE4":13821,"NA":13823},{"trials":13814,"activeCount":117},[],{"trials":13816,"activeCount":117},[],{"trials":13818,"activeCount":117},[],{"trials":13820,"activeCount":117},[],{"trials":13822,"activeCount":117},[],{"trials":13824,"activeCount":117},[13825],{"nctId":13826,"briefTitle":13827,"status":160,"phases":13828,"primaryCompletion":1036,"completion":1036,"start":13829,"enrollment":11036,"conditions":13830,"interventions":13832},"NCT05350514","Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study",[],"2022-07-19",[1380,1925,13831],"Diabetes, Youth Onset",[13811],{"intervention":13834,"totalTrials":114,"cells":13835},"Platelet-rich plasma",{"EARLY_PHASE1":13836,"PHASE1":13838,"PHASE2":13840,"PHASE3":13842,"PHASE4":13844,"NA":13846},{"trials":13837,"activeCount":117},[],{"trials":13839,"activeCount":117},[],{"trials":13841,"activeCount":117},[],{"trials":13843,"activeCount":117},[],{"trials":13845,"activeCount":117},[],{"trials":13847,"activeCount":117},[13848],{"nctId":13849,"briefTitle":13850,"status":1622,"phases":13851,"primaryCompletion":840,"completion":840,"start":4226,"enrollment":117,"conditions":13852,"interventions":13855},"NCT02183896","Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip",[95],[13853,13854],"Femoroacetabular Impingement","Chondral Lesions",[13834,13856],"Saline",{"intervention":13856,"totalTrials":114,"cells":13858},{"EARLY_PHASE1":13859,"PHASE1":13861,"PHASE2":13863,"PHASE3":13865,"PHASE4":13867,"NA":13869},{"trials":13860,"activeCount":117},[],{"trials":13862,"activeCount":117},[],{"trials":13864,"activeCount":117},[],{"trials":13866,"activeCount":117},[],{"trials":13868,"activeCount":117},[],{"trials":13870,"activeCount":117},[13871],{"nctId":13849,"briefTitle":13850,"status":1622,"phases":13872,"primaryCompletion":840,"completion":840,"start":4226,"enrollment":117,"conditions":13873,"interventions":13874},[95],[13853,13854],[13834,13856],{"intervention":13876,"totalTrials":114,"cells":13877},"GnRH agonist",{"EARLY_PHASE1":13878,"PHASE1":13880,"PHASE2":13882,"PHASE3":13884,"PHASE4":13886,"NA":13888},{"trials":13879,"activeCount":117},[],{"trials":13881,"activeCount":117},[],{"trials":13883,"activeCount":117},[],{"trials":13885,"activeCount":117},[],{"trials":13887,"activeCount":117},[],{"trials":13889,"activeCount":117},[13890],{"nctId":13891,"briefTitle":13892,"status":160,"phases":13893,"primaryCompletion":226,"completion":226,"start":162,"enrollment":2173,"conditions":13894,"interventions":13895},"NCT01712230","Females, Aging, Metabolism, and Exercise",[95],[15],[13876],{"intervention":13897,"totalTrials":114,"cells":13898},"Sodium Fluorescein",{"EARLY_PHASE1":13899,"PHASE1":13901,"PHASE2":13903,"PHASE3":13905,"PHASE4":13907,"NA":13909},{"trials":13900,"activeCount":117},[],{"trials":13902,"activeCount":117},[],{"trials":13904,"activeCount":117},[],{"trials":13906,"activeCount":117},[],{"trials":13908,"activeCount":117},[],{"trials":13910,"activeCount":117},[13911],{"nctId":13912,"briefTitle":13913,"status":125,"phases":13914,"primaryCompletion":2098,"completion":2098,"start":13915,"enrollment":199,"conditions":13916,"interventions":13918},"NCT03752203","Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors",[95],"2021-08-11",[13917],"Pediatric Neurosurgical Tumors",[13897],{"intervention":13920,"totalTrials":114,"cells":13921},"Platelet rich plasma",{"EARLY_PHASE1":13922,"PHASE1":13924,"PHASE2":13926,"PHASE3":13928,"PHASE4":13930,"NA":13932},{"trials":13923,"activeCount":117},[],{"trials":13925,"activeCount":117},[],{"trials":13927,"activeCount":117},[],{"trials":13929,"activeCount":117},[],{"trials":13931,"activeCount":117},[],{"trials":13933,"activeCount":117},[13934],{"nctId":13935,"briefTitle":13936,"status":160,"phases":13937,"primaryCompletion":13938,"completion":13938,"start":13939,"enrollment":217,"conditions":13940,"interventions":13942},"NCT02397278","Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee",[95],"2020-01-08","2015-03",[13941],"Osteochondritis Dissecans",[13920],{"intervention":13944,"totalTrials":114,"cells":13945},"Pilocarpine",{"EARLY_PHASE1":13946,"PHASE1":13948,"PHASE2":13950,"PHASE3":13952,"PHASE4":13954,"NA":13956},{"trials":13947,"activeCount":117},[],{"trials":13949,"activeCount":117},[],{"trials":13951,"activeCount":117},[],{"trials":13953,"activeCount":117},[],{"trials":13955,"activeCount":117},[],{"trials":13957,"activeCount":117},[13958],{"nctId":13959,"briefTitle":13960,"status":160,"phases":13961,"primaryCompletion":9112,"completion":13962,"start":7332,"enrollment":13963,"conditions":13964,"interventions":13967},"NCT02754570","The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure",[95],"2018-02-21",27,[13965,13966],"Glaucoma, Open-angle","Hypertension, Ocular",[13944],{"intervention":13969,"totalTrials":114,"cells":13970},"Dolutegravir Sodium Monohydrate",{"EARLY_PHASE1":13971,"PHASE1":13973,"PHASE2":13975,"PHASE3":13977,"PHASE4":13979,"NA":13981},{"trials":13972,"activeCount":117},[],{"trials":13974,"activeCount":117},[],{"trials":13976,"activeCount":117},[],{"trials":13978,"activeCount":117},[],{"trials":13980,"activeCount":117},[],{"trials":13982,"activeCount":117},[13983],{"nctId":13984,"briefTitle":13985,"status":12371,"phases":13986,"primaryCompletion":7532,"completion":7532,"start":13987,"conditions":13988,"interventions":13989},"NCT02028819","Compassionate Use of Ibalizumab for the Treatment of HIV Infection",[],"2012-01",[9514],[13969,13990],"Ibalizumab",{"intervention":13990,"totalTrials":114,"cells":13992},{"EARLY_PHASE1":13993,"PHASE1":13995,"PHASE2":13997,"PHASE3":13999,"PHASE4":14001,"NA":14003},{"trials":13994,"activeCount":117},[],{"trials":13996,"activeCount":117},[],{"trials":13998,"activeCount":117},[],{"trials":14000,"activeCount":117},[],{"trials":14002,"activeCount":117},[],{"trials":14004,"activeCount":117},[14005],{"nctId":13984,"briefTitle":13985,"status":12371,"phases":14006,"primaryCompletion":7532,"completion":7532,"start":13987,"conditions":14007,"interventions":14008},[],[9514],[13969,13990],{"intervention":14010,"totalTrials":114,"cells":14011},"Oxycodone with Acetaminophen",{"EARLY_PHASE1":14012,"PHASE1":14014,"PHASE2":14016,"PHASE3":14018,"PHASE4":14020,"NA":14022},{"trials":14013,"activeCount":117},[],{"trials":14015,"activeCount":117},[],{"trials":14017,"activeCount":117},[],{"trials":14019,"activeCount":117},[],{"trials":14021,"activeCount":117},[],{"trials":14023,"activeCount":117},[14024],{"nctId":14025,"briefTitle":14026,"status":160,"phases":14027,"primaryCompletion":7670,"completion":965,"start":5058,"enrollment":8838,"conditions":14028,"interventions":14030},"NCT01328782","The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures",[95],[14029],"Elbow Fracture",[14010,14031,14032],"Bupivacaine 0.25%","Ropivacaine 0.20%",{"intervention":14031,"totalTrials":114,"cells":14034},{"EARLY_PHASE1":14035,"PHASE1":14037,"PHASE2":14039,"PHASE3":14041,"PHASE4":14043,"NA":14045},{"trials":14036,"activeCount":117},[],{"trials":14038,"activeCount":117},[],{"trials":14040,"activeCount":117},[],{"trials":14042,"activeCount":117},[],{"trials":14044,"activeCount":117},[],{"trials":14046,"activeCount":117},[14047],{"nctId":14025,"briefTitle":14026,"status":160,"phases":14048,"primaryCompletion":7670,"completion":965,"start":5058,"enrollment":8838,"conditions":14049,"interventions":14050},[95],[14029],[14010,14031,14032],{"intervention":14032,"totalTrials":114,"cells":14052},{"EARLY_PHASE1":14053,"PHASE1":14055,"PHASE2":14057,"PHASE3":14059,"PHASE4":14061,"NA":14063},{"trials":14054,"activeCount":117},[],{"trials":14056,"activeCount":117},[],{"trials":14058,"activeCount":117},[],{"trials":14060,"activeCount":117},[],{"trials":14062,"activeCount":117},[],{"trials":14064,"activeCount":117},[14065],{"nctId":14025,"briefTitle":14026,"status":160,"phases":14066,"primaryCompletion":7670,"completion":965,"start":5058,"enrollment":8838,"conditions":14067,"interventions":14068},[95],[14029],[14010,14031,14032],{"intervention":739,"totalTrials":114,"cells":14070},{"EARLY_PHASE1":14071,"PHASE1":14073,"PHASE2":14075,"PHASE3":14077,"PHASE4":14079,"NA":14081},{"trials":14072,"activeCount":117},[],{"trials":14074,"activeCount":117},[],{"trials":14076,"activeCount":117},[],{"trials":14078,"activeCount":117},[],{"trials":14080,"activeCount":117},[],{"trials":14082,"activeCount":117},[14083],{"nctId":728,"briefTitle":729,"status":160,"phases":14084,"primaryCompletion":731,"completion":732,"start":733,"enrollment":734,"conditions":14085,"interventions":14086},[95],[736,737],[88,739,740],{"intervention":14088,"totalTrials":114,"cells":14089},"dolutegravir",{"EARLY_PHASE1":14090,"PHASE1":14092,"PHASE2":14094,"PHASE3":14096,"PHASE4":14098,"NA":14100},{"trials":14091,"activeCount":117},[],{"trials":14093,"activeCount":117},[],{"trials":14095,"activeCount":117},[],{"trials":14097,"activeCount":117},[],{"trials":14099,"activeCount":117},[],{"trials":14101,"activeCount":117},[14102],{"nctId":14103,"briefTitle":14104,"status":160,"phases":14105,"primaryCompletion":1057,"completion":1057,"start":13023,"enrollment":4755,"conditions":14106,"interventions":14107},"NCT02404805","Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV\u002FHCV Seronegative Volunteers",[95],[5062,4630],[14088,14108],"simeprevir",{"intervention":14108,"totalTrials":114,"cells":14110},{"EARLY_PHASE1":14111,"PHASE1":14113,"PHASE2":14115,"PHASE3":14117,"PHASE4":14119,"NA":14121},{"trials":14112,"activeCount":117},[],{"trials":14114,"activeCount":117},[],{"trials":14116,"activeCount":117},[],{"trials":14118,"activeCount":117},[],{"trials":14120,"activeCount":117},[],{"trials":14122,"activeCount":117},[14123],{"nctId":14103,"briefTitle":14104,"status":160,"phases":14124,"primaryCompletion":1057,"completion":1057,"start":13023,"enrollment":4755,"conditions":14125,"interventions":14126},[95],[5062,4630],[14088,14108],{"intervention":4255,"totalTrials":114,"cells":14128},{"EARLY_PHASE1":14129,"PHASE1":14131,"PHASE2":14133,"PHASE3":14135,"PHASE4":14137,"NA":14139},{"trials":14130,"activeCount":117},[],{"trials":14132,"activeCount":117},[],{"trials":14134,"activeCount":117},[],{"trials":14136,"activeCount":117},[],{"trials":14138,"activeCount":117},[],{"trials":14140,"activeCount":117},[14141],{"nctId":4246,"briefTitle":4247,"status":160,"phases":14142,"primaryCompletion":4249,"completion":4249,"start":4250,"enrollment":1920,"conditions":14143,"interventions":14144},[95],[4252,4253],[4255,4231],{"intervention":14146,"totalTrials":114,"cells":14147},"TENOFOVIR DISOPROXIL FUMARATE 300 Mg \u002F EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]",{"EARLY_PHASE1":14148,"PHASE1":14150,"PHASE2":14152,"PHASE3":14154,"PHASE4":14156,"NA":14158},{"trials":14149,"activeCount":117},[],{"trials":14151,"activeCount":117},[],{"trials":14153,"activeCount":117},[],{"trials":14155,"activeCount":117},[],{"trials":14157,"activeCount":117},[],{"trials":14159,"activeCount":117},[14160],{"nctId":14161,"briefTitle":14162,"status":160,"phases":14163,"primaryCompletion":14164,"completion":14165,"start":9819,"enrollment":4755,"conditions":14166,"interventions":14167},"NCT02968576","Bioequivalence of Tenofovir and Emtricitabine Following Overencapsulation",[95],"2017-04","2017-06",[11190,11013],[14146],{"intervention":11552,"totalTrials":114,"cells":14169},{"EARLY_PHASE1":14170,"PHASE1":14172,"PHASE2":14174,"PHASE3":14176,"PHASE4":14178,"NA":14180},{"trials":14171,"activeCount":117},[],{"trials":14173,"activeCount":117},[],{"trials":14175,"activeCount":117},[],{"trials":14177,"activeCount":117},[],{"trials":14179,"activeCount":117},[],{"trials":14181,"activeCount":117},[14182],{"nctId":11539,"briefTitle":11540,"status":160,"phases":14183,"primaryCompletion":11542,"completion":11543,"start":11544,"enrollment":34,"conditions":14184,"interventions":14185},[95],[11546,11547,11548,11549],[11551,11500,11552],{"intervention":14187,"totalTrials":114,"cells":14188},"3 mg zinc sulfate supplement",{"EARLY_PHASE1":14189,"PHASE1":14191,"PHASE2":14193,"PHASE3":14195,"PHASE4":14197,"NA":14199},{"trials":14190,"activeCount":117},[],{"trials":14192,"activeCount":117},[],{"trials":14194,"activeCount":117},[],{"trials":14196,"activeCount":117},[],{"trials":14198,"activeCount":117},[],{"trials":14200,"activeCount":117},[14201],{"nctId":14202,"briefTitle":14203,"status":160,"phases":14204,"primaryCompletion":14165,"completion":14165,"start":11527,"enrollment":3515,"conditions":14205,"interventions":14209},"NCT02760095","Effects of EED on Zn Absorption and Retention in Children From a Standard Dose",[],[14206,14207,14208],"Environmental Enteric Dysfunction","Zinc Deficiency","Vitamin A Deficiency",[14187,14210],"0.5 mg of 13C10-retinyl-acetate",{"intervention":14210,"totalTrials":114,"cells":14212},{"EARLY_PHASE1":14213,"PHASE1":14215,"PHASE2":14217,"PHASE3":14219,"PHASE4":14221,"NA":14223},{"trials":14214,"activeCount":117},[],{"trials":14216,"activeCount":117},[],{"trials":14218,"activeCount":117},[],{"trials":14220,"activeCount":117},[],{"trials":14222,"activeCount":117},[],{"trials":14224,"activeCount":117},[14225],{"nctId":14202,"briefTitle":14203,"status":160,"phases":14226,"primaryCompletion":14165,"completion":14165,"start":11527,"enrollment":3515,"conditions":14227,"interventions":14228},[],[14206,14207,14208],[14187,14210],{"intervention":14230,"totalTrials":114,"cells":14231},"Colesevelam HCl",{"EARLY_PHASE1":14232,"PHASE1":14234,"PHASE2":14236,"PHASE3":14238,"PHASE4":14240,"NA":14242},{"trials":14233,"activeCount":117},[],{"trials":14235,"activeCount":117},[],{"trials":14237,"activeCount":117},[],{"trials":14239,"activeCount":117},[],{"trials":14241,"activeCount":117},[],{"trials":14243,"activeCount":117},[14244],{"nctId":14245,"briefTitle":14246,"status":160,"phases":14247,"primaryCompletion":2052,"completion":2052,"start":10234,"enrollment":649,"conditions":14248,"interventions":14250},"NCT00938405","Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus",[95],[1380,14249],"Hyperlipidemias",[14230],{"intervention":14252,"totalTrials":114,"cells":14253},"3% Nebulized Hypertonic Saline",{"EARLY_PHASE1":14254,"PHASE1":14256,"PHASE2":14258,"PHASE3":14260,"PHASE4":14262,"NA":14264},{"trials":14255,"activeCount":117},[],{"trials":14257,"activeCount":117},[],{"trials":14259,"activeCount":117},[],{"trials":14261,"activeCount":117},[],{"trials":14263,"activeCount":117},[],{"trials":14265,"activeCount":117},[14266],{"nctId":14267,"briefTitle":14268,"status":125,"phases":14269,"primaryCompletion":4250,"completion":4250,"start":7965,"enrollment":31,"conditions":14270,"interventions":14272},"NCT02834819","Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis",[95],[14271],"Bronchiolitis",[14252],{"intervention":845,"totalTrials":114,"cells":14274},{"EARLY_PHASE1":14275,"PHASE1":14277,"PHASE2":14279,"PHASE3":14281,"PHASE4":14283,"NA":14285},{"trials":14276,"activeCount":117},[],{"trials":14278,"activeCount":117},[],{"trials":14280,"activeCount":117},[],{"trials":14282,"activeCount":117},[],{"trials":14284,"activeCount":117},[],{"trials":14286,"activeCount":117},[14287],{"nctId":836,"briefTitle":837,"status":160,"phases":14288,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":14289,"interventions":14290},[95],[15,843],[790,845,846],{"intervention":14292,"totalTrials":114,"cells":14293},"Stiripentol",{"EARLY_PHASE1":14294,"PHASE1":14296,"PHASE2":14298,"PHASE3":14300,"PHASE4":14302,"NA":14304},{"trials":14295,"activeCount":117},[],{"trials":14297,"activeCount":117},[],{"trials":14299,"activeCount":117},[],{"trials":14301,"activeCount":117},[],{"trials":14303,"activeCount":117},[],{"trials":14305,"activeCount":117},[14306],{"nctId":14307,"briefTitle":14308,"status":12371,"phases":14309,"conditions":14310,"interventions":14312},"NCT01835314","Compassionate Use of Stiripentol in Dravet Syndrome",[],[14311],"Dravet Syndrome",[14292]]